<SEC-DOCUMENT>0001641489-23-000070.txt : 20231109
<SEC-HEADER>0001641489-23-000070.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109163031
ACCESSION NUMBER:		0001641489-23-000070
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			vTv Therapeutics Inc.
		CENTRAL INDEX KEY:			0001641489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473916571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37524
		FILM NUMBER:		231393066

	BUSINESS ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265
		BUSINESS PHONE:		336-841-0300

	MAIL ADDRESS:	
		STREET 1:		3980 PREMIER DR
		STREET 2:		SUITE 310
		CITY:			HIGH POINT
		STATE:			NC
		ZIP:			27265

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VTV Therapeutics Inc.
		DATE OF NAME CHANGE:	20150506
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtvt-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:2f86a218-254c-44f1-a495-2edc3c6776ab,g:2074b840-4080-4341-9c3d-403534345ba0,d:e4f163fa518047cf9584905c5271d2ff--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:vtvt="http://vtvtherapeutics.com/20230930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtvt-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001641489</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-112" decimals="1" name="vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones" scale="0" id="f-411">0.5</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtvt-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">vtvt:CinRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">vtvt:CinRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vtvt:LicenseAgreementObligationsAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-11</xbrli:startDate><xbrli:endDate>2020-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-30</xbrli:startDate><xbrli:endDate>2023-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SatisfactionOfMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-22</xbrli:startDate><xbrli:endDate>2022-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-22</xbrli:startDate><xbrli:endDate>2022-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-14</xbrli:startDate><xbrli:endDate>2021-01-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-25</xbrli:startDate><xbrli:endDate>2021-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-24</xbrli:startDate><xbrli:endDate>2020-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MasterServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MasterServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:CinRxPharmaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001641489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie4f163fa518047cf9584905c5271d2ff_1"></div><div style="min-height:18pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">____________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________________</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2023</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.140%"><tr><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37524</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">vTv Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">47-3916571</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3980 Premier Dr</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 310</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">High Point</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">27265</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">336</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">841-0300</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:41.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Class A common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">VTVT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-18">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:30.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.937%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Class of Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Outstanding as of November&#160;9, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class A common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">81,483,600</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Class B common stock, par value $0.01 per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">23,093,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.265%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv THERAPEUTICS INC. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED SEPTEMBER&#160;30, 2023</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE<br/>NUMBER</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_13">Condensed Consolidated Balance Sheets as of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_13"> September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_13"> 30, 2023 (Unaudited) and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_13">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_16">Unaudited Condensed Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_16">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_16"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_16"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_16">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_19">Unaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_19">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_19"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_19">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_25">Unaudited Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_25"> 30, 2023 and 202</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_25">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_28">Notes to Unaudited Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_28">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_79">25</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_118">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_118">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_118">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_121">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_121">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_121">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_124">PART II &#8211; OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_127">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_127">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_130">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_130">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_133">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_133">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_136">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_136">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_136">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_139">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_139">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_139">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_142">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_142">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_145">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_145">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.25pt;text-indent:-12.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_148">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ie4f163fa518047cf9584905c5271d2ff_148">37</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (&#8220;we&#8221;, the &#8220;Company&#8221; or the &#8220;Registrant&#8221;), which is the registrant, and those of vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to vTv Therapeutics Inc. and its consolidated subsidiaries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.363%"><tr><td style="width:1.0%"></td><td style="width:71.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">8,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">12,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-35">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G42 Promissory Note receivable</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtvt:NotesReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtvt:NotesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">12,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deposits</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-40">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-41">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">10,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">27,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-44">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-45">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-46">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-47">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-48">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-49">5,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">14,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">33,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#c9fcff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">9,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">7,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-54">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-55">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-56">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-57">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-58">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="f-59">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">10,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">7,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-64">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-65">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-66">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtvt:WarrantyLiability" scale="3" id="f-67">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-68">29,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-69">27,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-70"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-71"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-72">10,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-73">16,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-77">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-79">81,483,600</ix:nonFraction></ix:nonFraction> shares outstanding as of September&#160;30, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-80">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-81">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-82"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-85">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87">23,093,860</ix:nonFraction></ix:nonFraction> outstanding as of September&#160;30, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-88">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-89">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-90">254,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-91">253,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">281,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">265,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit attributable to vTv Therapeutics Inc.</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">25,233</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">10,740</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">14,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">33,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_16"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares and per share data)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-101">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">11,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">8,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">9,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">9,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-110">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-111">5,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-112">20,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-113">18,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">5,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">5,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">20,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">16,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">3,640</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-119">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">1,514</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">2,998</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense) &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-122">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-123">324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-124">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-125">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-126">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-127">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-128">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-129">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-130">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-131">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-132">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-133">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">8,540</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-135">5,468</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">21,525</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-137">18,783</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-141">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">8,540</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">5,468</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">21,525</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">18,983</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-146">1,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-147">1,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-148">4,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-149">4,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">6,654</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">4,261</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">16,772</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">14,419</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-154">6,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-155">4,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-156">16,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-157">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-158"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-159">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-160"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-161">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-162"><ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-163">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-165">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-166"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-167">81,483,600</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-168"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-169">80,490,121</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-170"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-171">81,483,600</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-172"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-173">72,649,531</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the three months ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at June 30, 2023</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-174">18,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-175">81,483,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-176">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-177">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-178">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-179">254,479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">280,809</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">25,283</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">1,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">6,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">6,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-185">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-186">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-187">6,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-188">6,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-189">6,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at September 30, 2023</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-190">10,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-191">81,483,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-192">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-193">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-194">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">254,912</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">281,192</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">25,233</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.348%"><tr><td style="width:1.0%"></td><td style="width:20.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the three months ended September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note Receivable for Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balances at June 30, 2022</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-198">15,916</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-199">77,329,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-200">773</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-201">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-202">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">243,772</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">253,303</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">8,526</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">1,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">4,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">4,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-210">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-211">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-212">4,154,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" scale="3" id="f-213">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-214">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-215">9,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-216">5,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">9,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-218">9,498</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-219">9,498</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-220">24,207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-221">81,483,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-222">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-223">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-224">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">253,446</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">267,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">16,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except number of shares)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit </span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-229">16,579</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-230">81,483,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-231">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-233">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">253,737</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">265,524</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">10,740</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-237">4,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">16,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">16,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-240">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-241">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-242">1,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-244">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at September 30, 2023</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-245">10,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-246">81,483,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-247">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-248">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-249">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">254,912</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">281,192</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">25,233</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="54" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the nine months ended September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable<br/>Noncontrolling<br/>Interest</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note Receivable for Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Deficit </span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balances at December 31, 2021</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-253">24,962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-254">66,942,777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-255">669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-256">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-257">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-258">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">238,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">248,834</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">9,740</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-262">4,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-263">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-265">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-266">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock to collaboration partner, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-267">10,386,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-268">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-269">4,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-270">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="0" name="vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-271">4,154,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" scale="3" id="f-272">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" sign="-" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-273">4,000</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-274">9,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="vtvt:StockIssuedDuringPeriodValuePurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-275">5,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="vtvt:TemporaryEquityChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-276">3,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-277">3,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-278">3,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balances at September 30, 2022</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-279">24,207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-280">81,483,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-281">815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-282">23,093,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-283">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">4,000</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-285">253,446</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-286">267,062</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">16,569</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows - Unaudited</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:66.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-288">21,525</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-289">18,983</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-290">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-291">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from G42 Promissory Note early redemption</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-292">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest income </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-294">100</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-295">200</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseOther" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpenseOther" scale="3" id="f-297">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-298">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-299">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-300">3,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-301">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of investments in Anteris Bio, Inc.</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-302">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants, related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="vtvt:ChangeInFairValueOfWarrantsRelatedParty" scale="3" id="f-304">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="vtvt:ChangeInFairValueOfWarrantsRelatedParty" scale="3" id="f-305">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-306">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-308">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-309">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-310">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-311">1,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-313">6,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-314">16,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-315">9,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-317">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-319">21</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-320">12,030</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Class A common stock to collaboration partner, net of offering costs</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-323">5,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of Class A common stock and warrants, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-325">5,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt issuance</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="f-326">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="f-327">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-328">317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-329">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-330">12,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-331">11,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-332">3,888</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-333">1,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-334">12,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-335">13,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents, end of period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-336">8,238</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-337">15,339</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c9fcff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td><td colspan="3" style="background-color:#c9fcff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in redemption value of noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-338">1,104</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-339">3,809</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable recorded at fair value from collaboration partner</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtvt:NotesReceivableFromCollaborators" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="vtvt:NotesReceivableFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="f-341">11,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes receivable for common stock from CinRx purchase agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="vtvt:NotesReceivableFromCollaborators" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="vtvt:NotesReceivableFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="f-343">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vTv Therapeutics Inc.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements &#8211; Unaudited</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollar amounts are in thousands, unless otherwise noted)</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_31"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1:  <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-344" continuedAt="f-344-1" escape="true">Description of Business, Basis of Presentation and Going Concern</ix:nonNumeric></span></div><ix:continuation id="f-344-1" continuedAt="f-344-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Condensed Consolidated Financial Statements. Various holders own nonvoting interests in vTv LLC, representing a <ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterest" scale="-2" id="f-345">22.1</ix:nonFraction>% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#8217;s interest to <ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterestByParent" scale="-2" id="f-346">77.9</ix:nonFraction>% of vTv LLC&#8217;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (&#8220;vTv Units&#8221;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company&#8217;s Class B common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-347">0.01</ix:nonFraction> (&#8220;Class B common stock&#8221;)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#8220;Lenders&#8221;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#8220;M&amp;F Group&#8221;), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates &#8220;MacAndrews&#8221;) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a &#8220;Letter Agreement&#8221; and collectively, the &#8220;Letter Agreements&#8221;).  In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor Fitzgerald&#8221;) (the &#8220;ATM Offering&#8221;), the purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) (the &#8220;LPC Purchase Agreement&#8221;), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#8220;G42 Investments&#8221;) (the &#8220;G42 Purchase Agreement&#8221;) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the &#8220;CinRx Purchase Agreement&#8221;). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern and Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September&#160;30, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September&#160;30, 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-348">281.2</ix:nonFraction>&#160;million and has generated net losses in each year of its existence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company&#8217;s liquidity sources included cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-349">8.2</ix:nonFraction> million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. To meet our future funding requirements into the third quarter of 2024, including </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-344-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funding the ongoing and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also use its remaining availability of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-350">37.3</ix:nonFraction> million under its Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company&#8217;s Class A common stock and the ability to sell an additional <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-351">9,437,376</ix:nonFraction> shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock. See Note 9 for further details. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on our financial condition. As such, these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_34"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-352" continuedAt="f-352-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-352-1" continuedAt="f-352-2"><ix:nonNumeric contextRef="c-1" name="vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock" id="f-353" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and nine months ended September&#160;30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2022, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2023, the results of operations for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the nine months ended September&#160;30, 2023 and 2022. The December&#160;31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-354" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-352-2" continuedAt="f-352-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-355" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One hundred percent (<ix:nonFraction unitRef="number" contextRef="c-86" decimals="0" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-356">100</ix:nonFraction>%) of the revenue earned during the nine months ended September&#160;30, 2022 was attributable  from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-357">not</ix:nonFraction> have any revenue during the three months ended September 30, 2022. The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-358"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-359">not</ix:nonFraction></ix:nonFraction> have any revenue during the three and nine months ended September&#160;30, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-360" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-361" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-362" continuedAt="f-362-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-362-1">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-363" continuedAt="f-363-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-352-3"><ix:continuation id="f-363-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-364" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_37"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3:  <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-365" continuedAt="f-365-1" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="f-365-1" continuedAt="f-365-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;) on May 31, 2022, pursuant to which the Company sold to G42 Investments <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-366">10,386,274</ix:nonFraction> shares of the Company&#8217;s Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-367">2.41</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="f-368">25.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-369">12.5</ix:nonFraction> million in cash at the closing and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-370">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the &#8220;G42 Promissory Note&#8221;). As part of the G42 Purchase Agreement, G42 Investments nominated a director as appointee and the Company&#8217;s board of directors approved appointing the new director to the Company&#8217;s board. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-371">12.0</ix:nonFraction> million, which reflected the original amount due under the G42 Promissory Note less a <ix:nonFraction unitRef="number" contextRef="c-92" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-372">3.75</ix:nonFraction>% discount, in full satisfaction of the note, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-373">0.3</ix:nonFraction> million and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024, (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#8220;Cogna Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#8220;Cogna&#8221;), which requires Cogna to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-365-2" continuedAt="f-365-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercializ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory, but will not have access to the various intellectual property (&#8220;IP&#8221;) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cogna Agreement, Cogna has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company will conduct its clinical trials for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the Partner Territory at its own cost. The results of each party&#8217;s clinical trials will be combined by the Company to seek FDA approval in the United States for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (&#8220;G42 Healthcare&#8221;), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of FDA approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" format="ixt:num-dot-decimal" scale="6" id="f-374">30.0</ix:nonFraction> million or (b) the payment by the Company of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="vtvt:CollaborateArrangementContingentConsiderationTransferredCash" format="ixt:num-dot-decimal" scale="6" id="f-375">30.0</ix:nonFraction> million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the FDA approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a period of at least <ix:nonNumeric contextRef="c-93" name="vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod" format="ixt-sec:durwordsen" id="f-376">ten years</ix:nonNumeric> after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#8220;Recently Issued Accounting Guidance&#8221; in this quarterly report on Form 10-Q for details of the ASU.  Accordingly, the Company determined that cash consideration of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-377">5.7</ix:nonFraction> million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-378">0.55</ix:nonFraction> at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-379">18.7</ix:nonFraction> million, net of a note receivable discount of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="vtvt:CollaborativeArrangementNoteReceivableDiscountPaid" format="ixt:num-dot-decimal" scale="6" id="f-380">0.6</ix:nonFraction> million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete R&amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#8220;JDC&#8221;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of September&#160;30, 2023, the clinical trials had not </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-365-3" continuedAt="f-365-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commenced. Accordingly, <ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-381"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-382">no</ix:nonFraction></ix:nonFraction> collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved by the FDA. The Company will recognize revenue from the material right related to Cogna&#8217;s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has <ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-383"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-384">no</ix:nonFraction></ix:nonFraction>t recognized any revenue under the ASC 606 unit of account during the three and nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-385">12.0</ix:nonFraction> million, which reflected the original amount due under the G42 Promissory Note less a <ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-386">3.75</ix:nonFraction>% discount, in full satisfaction of the note, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in a loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-387">0.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The G42 Promissory Note receivable was classified and accounted for under ASC 310 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 310&#8221;) and was initially measured at its fair value of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:ReceivablesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-388">11.9</ix:nonFraction> million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded the $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-389">18.7</ix:nonFraction> million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#8220;Huadong&#8221;) (the &#8220;Huadong License Agreement&#8221;), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s glucagon-like peptide-1 receptor agonist (&#8220;GLP-1r&#8221;) program, including the compound</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP273</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the &#8220;Huadong License Territory&#8221;). Additionally, under the Huadong License Agreement, the Company obtained a nonexclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company&#8217;s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the &#8220;First Huadong Amendment&#8221;) which eliminated the Company&#8217;s obligation to sponsor a multi-region clinical trial (the &#8220;Phase 2 MRCT&#8221;), and corresponding obligation to contribute up to $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="vtvt:MaximumSponsoringContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-390">3.0</ix:nonFraction> million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-391">3.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company&#8217;s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company&#8217;s obligation to participate on a joint development committee (the &#8220;JDC&#8221;), and (iv) other obligations considered to be immaterial in nature. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:num-dot-decimal" scale="6" id="f-392">2.0</ix:nonFraction> million due to the satisfaction of a development milestone under the license agreement.  This amount was fully recognized as revenue during the nine months ended </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-365-4"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 as the related performance obligation was fully satisfied. <ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="f-393">No</ix:nonFraction> revenue related to this combined performance obligation was recognized during the nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September&#160;30, 2023, and revenue will be recognized using the proportional performance model over the period of the Company&#8217;s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September&#160;30, 2023 was immaterial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An <ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="0" id="f-394">immaterial</ix:nonFraction> amount of revenue for this performance obligation was recognized during the nine months ended September&#160;30, 2022.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="vtvt:AdjustmentsToTransactionPriceForPerformanceObligations" format="ixt:fixed-zero" scale="6" id="f-395">No</ix:nonFraction> revenue for this performance obligation has been recognized during the nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anteris License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (&#8220;Anteris&#8221;) (the &#8220;Anteris License Agreement&#8221;), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company&#8217;s Nrf2 activator, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="vtvt:LicenseFeeReceived" format="ixt:num-dot-decimal" scale="6" id="f-396">2.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-397">151.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="vtvt:LicenseFeeReceived" format="ixt:num-dot-decimal" scale="6" id="f-398">2.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initial license payment as well as the fair value of the equity interest received in Anteris of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:ProceedsFromInterestAndDividendsReceived" format="ixt:num-dot-decimal" scale="6" id="f-399">4.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. <ix:nonFraction unitRef="usd" contextRef="c-108" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-400"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-401"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-402"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-403">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized related to the Anteris License Agreement during the three and nine months ended September 30, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement.  Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023.  The Company has begun the process of winding up the license, including obtaining all regulatory, manufacturing and other records generated by Anteris during the term of the Anteris License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company received a Section228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (&#8220;Plan of Dissolution&#8221;). (See Note 14).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-404" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company&#8217;s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-405">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-406">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-407">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-408">18,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-409">18,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-410">18,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_43"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-412" continuedAt="f-412-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-412-1" continuedAt="f-412-2">The Company has issued nonqualified stock option awards to management, other key employees, consultants, and nonemployee directors. These option awards generally vest ratably over a <ix:nonNumeric contextRef="c-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-413">three-year</ix:nonNumeric> period and the option awards expire after a term of <ix:nonNumeric contextRef="c-113" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-414">ten years</ix:nonNumeric> from the date of grant. As of September&#160;30, 2023, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-415">1.8</ix:nonFraction> million, which is expected to be </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-412-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized over a weighted average period of <ix:nonNumeric contextRef="c-113" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-416">2.2</ix:nonNumeric> years. The weighted average grant date fair value of options granted during the nine months ended September&#160;30, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-417">0.76</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-418">0.68</ix:nonFraction> per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September&#160;30, 2023 was immaterial.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-419" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-420">8,418,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-421">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-422">1,176,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-423">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-424">50,000</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-425">1.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-426">9,545,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-427">2.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-428">5,018,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-429">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-430">6.6</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-431">8,188,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-432">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-433">7.5</ix:nonNumeric> Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-434" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-435">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-436">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-437">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-438">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-439">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-440">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-441">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-442">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-443">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-444">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-445">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-446">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_46"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5:  <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-447" continuedAt="f-447-1" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="f-447-1" continuedAt="f-447-2"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Reneo Pharmaceuticals, Inc. (&#8220;Reneo&#8221;) and Anteris License Agreements, the Company received equity ownership interests of less than <ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="vtvt:InvestmentOwnershipPercentage" scale="-2" id="f-448">20</ix:nonFraction>% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company&#8217;s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo&#8217;s initial public offering, the Company&#8217;s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.</span></div><ix:nonNumeric contextRef="c-1" name="vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" id="f-449" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:68.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="vtvt:EquityInvestmentsWithReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-450">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="vtvt:EquityInvestmentsWithReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-451">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-453">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-454">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-455">5,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an unrealized gain on its investment in Reneo of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-456">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-457">3.0</ix:nonFraction> million for the three and nine months ended September&#160;30, 2023, respectively. The Company recognized an unrealized gain on its investment in Reneo of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-458">0.4</ix:nonFraction> million and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-459">3.0</ix:nonFraction> million for the three and nine months ended September&#160;30, 2022, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-447-2" continuedAt="f-447-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. These adjustments were recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company received a Section228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of a plan of Liquidation and Dissolution (&#8220;Plan of Dissolution&#8221;). The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="f-460"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="f-461">4.2</ix:nonFraction></ix:nonFraction> million impairment charge during the three and nine months ended September&#160;30, 2023. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-447-3">On October 30, 2023, the Company entered into a Common Stock Repurchase Agreement (the &#8220;Repurchase Agreement&#8221;) with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-462">4.4</ix:nonFraction> million.</ix:continuation> </span></div><div id="ie4f163fa518047cf9584905c5271d2ff_49"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6:  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-463" continuedAt="f-463-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-463-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the &#8220;Novo License Agreement&#8221;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo Nordisk&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and nonspecific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments payable totaling up to $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-464">9.0</ix:nonFraction> million for approval of a product for the treatment of type 1 diabetes, $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-465">50.5</ix:nonFraction> million for approval of a product for the treatment of type 2 diabetes, or $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-466">115.0</ix:nonFraction> million for approval of a product in any other indication. The Company may also be obligated to pay an additional $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-467">75.0</ix:nonFraction> million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="vtvt:PotentialMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-468">2.0</ix:nonFraction> million related to the satisfaction of the milestone to complete the phase 2 trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under this agreement.</span></div></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_52"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7:  <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-469" continuedAt="f-469-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-469-1" continuedAt="f-469-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-470">five-year</ix:nonNumeric> term as well as an option to terminate after <ix:nonNumeric contextRef="c-4" name="vtvt:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:durwordsen" id="f-471">three years</ix:nonNumeric>, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-472"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-473">0.1</ix:nonFraction></ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of September&#160;30, 2023 and December&#160;31, 2022, the weighted average incremental borrowing rate for the operating leases held by the Company was <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-474"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-475">9.5</ix:nonFraction></ix:nonFraction>%. At September&#160;30, 2023 and December&#160;31, 2022, the weighted average remaining lease terms for the operating leases held by the Company were <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-476">2.2</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-477">2.9</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-469-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-478" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating leases as of September&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-479">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-480">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-481">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-485">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtvt:OperatingLeasesImputedInterest" scale="3" id="f-486">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-487">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the nine months ended September&#160;30, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-488">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-489">0.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_55"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8:  <ix:nonNumeric contextRef="c-1" name="us-gaap:MinorityInterestDisclosureTextBlock" id="f-490" continuedAt="f-490-1" escape="true">Redeemable Noncontrolling Interest</ix:nonNumeric></span></div><ix:continuation id="f-490-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the <ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="vtvt:PercentageOfNonVotingEconomicInterest" scale="-2" id="f-491">22.1</ix:nonFraction>% noncontrolling interest in vTv LLC outstanding as of September&#160;30, 2023 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a <ix:nonFraction unitRef="number" contextRef="c-140" decimals="0" name="vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-492">one</ix:nonFraction>-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a <ix:nonNumeric contextRef="c-23" name="vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" format="ixt-sec:durday" id="f-493">20</ix:nonNumeric>-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September&#160;30, 2023 and December&#160;31, 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="f-494">10.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="f-495">16.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" id="f-496" continuedAt="f-496-1" escape="true">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="f-496-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-497">6,654</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-498">4,261</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-499">16,772</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-500">14,419</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-501">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-502">1,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" format="ixt:num-dot-decimal" scale="3" id="f-503">4,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" scale="3" id="f-504">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-505">5,062</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-506">5,435</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-507">12,560</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" format="ixt:num-dot-decimal" scale="3" id="f-508">14,522</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_58"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9:  <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-509" continuedAt="f-509-1" escape="true">Stockholders&#8217; Deficit</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-509-1" continuedAt="f-509-2">On May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to increase the number of shares of Class A common stock that the Company is authorized to issue from <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-510">100,000,000</ix:nonFraction> shares of Class A common stock to <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-511">200,000,000</ix:nonFraction> shares of Class A common stock, representing an increase of <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="vtvt:IncreaseInCommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-512">100,000,000</ix:nonFraction> shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-513">200,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-514">300,000,000</ix:nonFraction>, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="vtvt:CommonStockAndPreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-515">250,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="vtvt:CommonStockAndPreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-516">350,000,000</ix:nonFraction> shares.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-509-2" continuedAt="f-509-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-517">10,386,274</ix:nonFraction> shares of the Company's Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-518">2.41</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="f-519">25.0</ix:nonFraction> million, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-520">12.5</ix:nonFraction> million in cash at the closing of the transaction and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-521">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid at the <ix:nonNumeric contextRef="c-87" name="vtvt:SaleOfStockConsiderationReceivableTerm" format="ixt-sec:durwordsen" id="f-522">one-year</ix:nonNumeric> anniversary of the execution of the G42 Purchase Agreement (the &#8220;G42 Promissory Note&#8221;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-523">12.0</ix:nonFraction> million, which reflected the original amount due under the G42 Promissory Note less a <ix:nonFraction unitRef="number" contextRef="c-92" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-524">3.75</ix:nonFraction>% discount, in full satisfaction of the note, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-525">0.3</ix:nonFraction> million and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the &#8220;Transaction Date&#8221;), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (&#8220;CinPax&#8221;) and CinRx Pharma, LLC (&#8220;CinRx&#8221;), pursuant to which the Company agreed to sell to CinPax <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-526">4,154,549</ix:nonFraction> shares of the Company&#8217;s Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-527">2.41</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="f-528">10.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-529">6.0</ix:nonFraction> million in cash at the closing of the transaction and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-530">4.0</ix:nonFraction> million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement provides CinPax the right to nominate a director to be approved to sit on the Company&#8217;s Board of Directors and a board observer, which was subsequently approved by the Company&#8217;s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#8220;Recently Issued Accounting Guidance&#8221; in this quarterly report on Form 10-Q for details of the ASU.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company determined that cash consideration of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-531">3.0</ix:nonFraction> million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-532">0.72</ix:nonFraction> at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-533">1,200,000</ix:nonFraction> shares of common stock at an initial exercise of price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-534">0.72</ix:nonFraction> per share (the &#8220;CinRx Warrants&#8221;). The CinRx Warrants were initially measured at fair value of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-535">0.4</ix:nonFraction> million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (&#8220;FDA Approval&#8221;) to market and distribute the pharmaceutical product containing the Company&#8217;s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Product&#8221;), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within <ix:nonNumeric contextRef="c-149" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-536">five years</ix:nonNumeric> of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (&#8220;CinRx MSA&#8221;) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-537">0.01</ix:nonFraction> per share, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-538">13.0</ix:nonFraction> million by any method deemed to be an &#8220;at the market offering&#8221; as </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-509-3"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined in Rule 415(a)(4) under the Securities Act (the &#8220;ATM Offering&#8221;). The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021 and June&#160;25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company&#8217;s Class A common stock, by an aggregate offering price of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="vtvt:AggregateOfferingPriceOfShares" format="ixt:num-dot-decimal" scale="6" id="f-539">5.5</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="vtvt:AggregateOfferingPriceOfShares" format="ixt:num-dot-decimal" scale="6" id="f-540">50.0</ix:nonFraction> million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2023 and 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-541"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-542"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-543"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-544">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> sell any shares under the ATM Offering. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s Class A common stock having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-545">47.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park pursuant to the LPC Purchase Agreement. During the three and nine months ended September&#160;30, 2023 and 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-546"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-547"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-548"><ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-549">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> sell any shares under the LPC Purchase Agreement.</span></div></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_61"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10:  <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-550" continuedAt="f-550-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-550-1" continuedAt="f-550-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacAndrews directly or indirectly controls <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-551">23,084,267</ix:nonFraction> shares of Class B common stock. Further, as of September&#160;30, 2023, MacAndrews directly or indirectly holds <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-552">36,519,212</ix:nonFraction> shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately <ix:nonFraction unitRef="number" contextRef="c-168" decimals="3" name="vtvt:OwnershipPercentageOfMajorityOwner" scale="-2" id="f-553">57.0</ix:nonFraction>% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#8220;Letter Agreement Warrants&#8221;) to purchase additional shares of the Company&#8217;s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#8217;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#8217;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September&#160;30, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="f-554">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-550-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company entered into a common stock purchase agreement with G42 Investments pursuant to which the Company sold to G42 Investments <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-555">10,386,274</ix:nonFraction> shares of the Company&#8217;s Class A common stock at a price per share of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-556">2.41</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="vtvt:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="f-557">25.0</ix:nonFraction> million, which was paid (i) $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-558">12.5</ix:nonFraction> million in cash at the closing and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-559">12.5</ix:nonFraction> million in the form of a promissory note of G42 Investments to be paid on May 31, 2023 (the &#8220;G42 Promissory Note&#8221;). As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company&#8217;s board of directors appointed the new director to the Company&#8217;s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-560">12.0</ix:nonFraction> million from G42 Investments, which represented a <ix:nonFraction unitRef="number" contextRef="c-174" decimals="4" name="vtvt:NotesReceivableDiscountRate" scale="-2" id="f-561">3.75</ix:nonFraction>% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-562">0.3</ix:nonFraction> million and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinRx Pharma, LLC</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Services Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022, the Company entered into the CinRx MSA  with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="vtvt:DueToRelatedPartiesMonthlyAmount" format="ixt:num-dot-decimal" scale="6" id="f-563">0.2</ix:nonFraction> million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company&#8217;s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company&#8217;s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-564">4,154,549</ix:nonFraction> shares of the Company&#8217;s Class A common stock.</span></div></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_64"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11:  <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-565" continuedAt="f-565-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-565-1" continuedAt="f-565-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-566"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-567">not</ix:nonFraction></ix:nonFraction> record an income tax provision for the three and nine months ended September&#160;30, 2023. The Company&#8217;s income tax provision for the nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-568">0.2</ix:nonFraction> million representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-569">not</ix:nonFraction> record an income tax provision for the three months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September&#160;30, 2023 is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of <ix:nonFraction unitRef="number" contextRef="c-177" decimals="2" name="vtvt:PercentageOfAmountOfCashSavings" scale="-2" id="f-570">85</ix:nonFraction>% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-565-2">would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September&#160;30, 2023.</ix:continuation></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_67"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12:  <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-571" continuedAt="f-571-1" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="f-571-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-572" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-573">8,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-574">5,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-575">21,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-576">18,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-577">1,886</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-578">1,207</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-579">4,753</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-580">4,564</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-581"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-582">6,654</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-583"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-584">4,261</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-585"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-586">16,772</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-587"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-588">14,419</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-589"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-590">81,483,600</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-591"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-592">80,490,121</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-593"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-594">81,483,600</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-595"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-596">72,649,531</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-597"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-598">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-599"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-600">0.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-601"><ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-602">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-603"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-604">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-605" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-178" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-606">23,093,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-607">23,093,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-608">9,545,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-609">7,718,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-610">3,214,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-611">3,214,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-612">35,853,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-613">34,027,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie4f163fa518047cf9584905c5271d2ff_70"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13:  <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-614" continuedAt="f-614-1" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-614-1" continuedAt="f-614-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company&#8217;s investment in Reneo&#8217;s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-614-2" continuedAt="f-614-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-615" continuedAt="f-615-1" escape="true">The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-615-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-616">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-617">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-620">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-621">4,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-624">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-627">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-628">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-631">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-632">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-633">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-636">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-637">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-640">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-643">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-644">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-647">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-648">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-649">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-652">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-653">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-654">406</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-657">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-658">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-659">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="f-660">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-662">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-663">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="f-664">221</ix:nonFraction>)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="f-665">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:fixed-zero" scale="3" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-667">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September&#160;30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income &#8211; related party in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#8217;s current capitalization. Expected volatility is based on the historical volatility </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><ix:continuation id="f-614-3" continuedAt="f-614-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-668" continuedAt="f-668-1" escape="true">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2023 and December&#160;31, 2022 were:</ix:nonNumeric></span></div><ix:continuation id="f-668-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-204" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-669">68.37</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-205" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-670">77.01</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-206" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-671">76.06</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-207" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-672">76.94</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-208" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-673">85.88</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-209" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-674">82.17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-210" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-675">4.78</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-211" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-676">5.38</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-212" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-677">4.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-678">4.11</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-214" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-679">4.43</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-215" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-680">4.19</ix:nonFraction>%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2023 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-216" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-681">82.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-217" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-682">3.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-218" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-683">4.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-614-4">Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company&#8217;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.</ix:continuation> </span></div><div id="ie4f163fa518047cf9584905c5271d2ff_73"></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14:  <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-685" continuedAt="f-685-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-685-1" continuedAt="f-685-2">On October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (&#8220;Plan of Dissolution&#8221;) (See Note 5).</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-685-2">On October 30, 2023, vTv LLC, entered into a Common Stock Repurchase Agreement (the &#8220;Repurchase Agreement&#8221;) with Reneo pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC.  Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-686">4.4</ix:nonFraction> million, which was received by vTv LLC on October 30, 2023. vTv LLC had acquired the Reneo stock in connection with the December 21, 2017 License Agreement between vTv LLC and Reneo, which remains in effect.</ix:continuation>  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward Looking Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical financial information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws regarding, among other things, our intentions, plans, estimates, assumptions, predictions and beliefs. Although we believe that these forward-looking statements are based upon reasonable assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances, our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under &#8220;Part II, Other Information&#8212;Item 1A, Risk Factors&#8221; and under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or similar expressions and the negatives of those terms. Given the numerous uncertainties and factors to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, you should not place undue reliance on these forward-looking statements and understand that these statements are not guarantees of performance or results. Also, forward-looking statements represent our management&#8217;s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div><span><br/></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and preclinical drug candidates. Our lead program is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an orally administered, small molecule, liver-selective glucokinase activator (&#8220;GKA&#8221;) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (&#8220;T1D&#8221;).</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 6, 2023, the Board approved, and recommended that the stockholders of the Company entitled to vote thereon, approve, via written consent, the Amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding Class A common stock and Class B common stock, by a ratio of any whole number in the range of 1-for-10 to 1-for-40 (the &#8220;Reverse Stock Split&#8221;), with such ratio to be determined at the discretion of the Board and with such action to be effected at such time and date, if at all, as determined by the Board on or prior to December 31, 2023. On September 13, 2023, the holders of a majority of the voting power of the Company&#8217;s issued and outstanding capital stock entitled to vote thereon (the &#8220;Consenting Stockholders&#8221;) approved the Reverse Stock Split by means of a written consent. The same ratio will be used to effect a reverse stock split of both the Class A common stock and the Class B common stock. The Reverse Stock Split will not change the number of authorized shares of Class A common stock or Class B common stock.  </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Board has not yet determined the date on which the reverse stock split will occur or the ratio.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our drug candidates, their partnership status and their respective stages of development:</span></div><div style="text-align:justify"><img src="vtvt-20230930_g1.jpg" alt="Pipeline slide for 10-K 10-Q proxy_FINAL 11-02-2023.jpg" style="height:393px;margin-bottom:5pt;vertical-align:text-bottom;width:699px"/></div><div id="ie4f163fa518047cf9584905c5271d2ff_88"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Type 1 Diabetes Program &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cadisegliatin (TTP399)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has alignment with the FDA on trial designs that will support an efficient regulatory pathway to support registration of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an adjunctive therapy to insulin for the treatment of type 1 diabetes consistent with the breakthrough therapy designation granted by the FDA and expects to initiate studies as soon as possible. The FDA and the Company have agreed on the primary endpoint for the studies as the reduction in the number of hypoglycemic events between placebo and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treated groups. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we announced positive results of a mechanistic study of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with T1D. The study demonstrated that patients with T1D taking </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis. Consistent with previous clinical studies, improved fasting plasma glucose levels and fewer hypoglycemic events were observed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treated group during the week of treatment prior to the insulin withdrawal test. The results of the mechanistic study provided additional evidence to support the idea that treatment with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will not increase the risk of diabetic ketoacidosis (&#8220;DKA&#8221;) in patients with T1D. The data demonstrate that in contrast to agents such as SGLT2 inhibitors and GLP-1RAs, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> does not increase the risk of ketoacidosis when used as an adjunctive therapy to insulin in individuals with T1D. Moreover, these findings support prior studies that demonstrate that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> improves glucose control and reduces hypoglycemia and suggests a protective effect of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against acidosis in people with T1D. Full study results were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes Obesity and Metabolism</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> journal in conjunction with the 82nd American Diabetes Association Scientific Sessions on June 6, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we announced that the FDA granted Breakthrough Therapy Designation (&#8220;BTD) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an adjunctive therapy to insulin for the treatment of T1D. This designation provides a sponsor with added support and the potential to expedite development and review timelines for a promising new investigational medicine.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holding Company Structure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results under the VIE accounting model in its consolidated financial statements.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from milestone payments, up-front proceeds and research fees under collaboration and license agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception, including our predecessor companies, through September&#160;30, 2023, we have incurred approximately $623.9 million in research and development expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses by project for the three and nine months ended September&#160;30, 2023 and 2022 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cadisegliatin (TTP399)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other projects*</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,457&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,393&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">HPP737</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Azeliragon</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and further advance the development of our other drug candidates, subject to the availability of additional funding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the uncertainty of the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential benefits of our candidates over other therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">future clinical trial results;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and receipt of any regulatory approvals</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to secure sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">legislation and regulatory actions and changes in laws or regulations; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of doing so.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance, corporate development, human resources and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs and information systems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income represents noncash interest income related to the imputed interest from the G42 Promissory Note receivable, using the effective interest method and cash interest income represents dividends and interest from our money market account, all of which are recognized in our Condensed Consolidated Statement of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest expense is immaterial.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income/expense primarily consists of unrealized gains or losses attributable to the changes in fair value of the equity investment held, the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock held by related parties, the loss from the G42 Promissory Note early redemption on February 28, 2023 and the impairment charge from Anteris Bio, Inc. (&#8220;Anteris&#8221;) liquidation and dissolution.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_97"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended September&#160;30, 2023 and 2022</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,824</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,689</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,689)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,299)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,378)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,072)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,072)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,393)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no revenue for the three months ended September&#160;30, 2023 and September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $2.8 million and $3.1 million for the three months ended September&#160;30, 2023 and 2022, respectively. The decrease in research and development expenses during this period of $0.2 million, or 7.6%, was primarily driven by i) lower spending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $0.4 million, due to decreases in drug product related costs as well as lower spending on trial preparation costs, offset by ii) an increase in indirect costs and other projects of $0.2 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.5 million and $2.6 million for the three months ended September&#160;30, 2023 and 2022, respectively. The decrease in general and administrative expenses during this period of $0.1&#160;million, or 3.4%, was primarily driven by i) decreases of $0.4 million in legal expense, ii) decreases of $0.3 million in other general and administrative costs, partially offset by iii) increases of $0.5 million in payroll costs and iv) increases of $0.1 million in share-based expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended September&#160;30, 2023 of $0.1 million is related to dividend income from our money market account.  Interest income for the three months ended September&#160;30, 2022 of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is related to imputed interest on the promissory notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September&#160;30, 2023 and 2022 was insignificant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense was $3.3 million for the three months ended September&#160;30, 2023 and was driven by the recording of an impairment charge on a cost-method investment of $4.2 million and an unrealized gain related to our investment in Reneo, as well as gains</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ated to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties (&#8220;Related Party Warrants&#8221;). Other income was $0.1 million for the three months ended September&#160;30, 2022  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was driven by an unrealized gain related to our investment in Reneo as well as the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> losses rel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ated to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_100"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the nine months ended September&#160;30, 2023 and 2022</span></div><div style="margin-top:6pt;text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information concerning our results of operations for the periods shown:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:58.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of operations data:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,009)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,457</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,393</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,338</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,813</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,795</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,206</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,795)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,197)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,598)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,108)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,777)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,783)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,742)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,542)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:  net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,353)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no revenue for the nine months ended September&#160;30, 2023. Revenue for the nine months ended September&#160;30, 2022 relates to the increase in the transaction price for the license performance obligations under the amended license agreement with Huadong due to the satisfaction of a development milestone. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $11.5 million and $8.4 million for the nine months ended September&#160;30, 2023 and 2022, respectively. The increase in research and development expenses during the period of $3.1 million, or 36.5%, was primarily driven by i) higher spending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $2.5 million due to increases in drug product related costs as well as higher spending on trial preparation costs, and ii) an increase of $0.6 million in indirect costs and other projects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $9.3 million and $9.8 million for the nine months ended September&#160;30, 2023 and 2022, respectively. The decrease of $0.5 million has been primarily driven by i) decreases of $2.8 million in legal expense, ii) decreases of $0.8 million in severance costs, partially offset by iii) increases of $1.7 million in  payroll costs, iv) increases of $1.2 million in other general and administrative costs, and v) increases of $0.2 million share-based expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the nine months ended September&#160;30, 2023 of $0.4 million is related to imputed interest on the G42 Promissory Note and dividend income from our money market account. Interest income for the nine months ended September&#160;30, 2022 o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is related to imputed interest on the promissory note.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September&#160;30, 2023 and 2022 was insignificant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense was $1.1 million for the nine months ended September&#160;30, 2023, and is driven by the recording of a impairment charge on a cost-method investment of $4.2 million offset by an unrealized gain recognized related to the Company&#8217;s investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase shares of our own stock held by related parties. Other expense was $2.8 million for the nine months ended September&#160;30, 2022, and is driven by an unrealized loss recognized related to the Company&#8217;s investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we had an accumulated deficit of $281.2 million. Since our inception, we have experienced a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of September&#160;30, 2023, we had cash and cash equivalents of $8.2 million. The Company received proceeds of $4.4 million from the sale of Reneo Pharmaceuticals, Inc stock on October 30, 2023 (see Note 14).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we may rely on the remaining availability of $37.3 million under our Controlled Equity Offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor Fitzgerald&#8221;) pursuant to which we could offer and sell, from time to time, shares of our Class A common stock (the &#8220;ATM Offering&#8221;) and our ability to sell approximately 9.4 million shares of Class A common stock to Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) pursuant and subject to the limitations of the purchase agreement (the &#8220;LPC Purchase Agreement&#8221;). However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in our Class A common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n addition to available cash and cash equivalents and available funds discussed above, we are seeking possible additional partnering opportunities for our GKA, GLP-1r and other drug candidates, which we believe may provide additional cash for use in our operations and the continuation of the clinical trials for our drug candidates. We are evaluating several financing strategies to fund our planned and ongoing clinical trials, including direct equity investments and future public offerings of our common stock. The timing and availability of such financing are not yet known. We are currently in active discussions with respect to financing, partnering and licensing transactions for the future development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but we may not be successful in completing such transactions. These factors raise substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the Sales Agreement with Cantor Fitzgerald pursuant to which we may offer and sell, from time to time, through or to Cantor Fitzgerald, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $68.5 million. We are not obligated to sell any shares under the Sales Agreement. Under the terms of the Sales Agreement, we will pay Cantor Fitzgerald a commission of up to 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of September&#160;30, 2023, we have sold $31.2 million worth of Class A common stock under the ATM Offering for net proceeds of $30.3 million, leaving $37.3 million available to be sold. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Purchase Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the LPC Purchase Agreement, pursuant to which we have the right to sell to Lincoln Park shares of the Company&#8217;s Class A common stock having an aggregate value of up to $47.0 million. As of September&#160;30, 2023, we have issued 5,331,306 of these shares for gross proceeds of approximately $11.1 million, leaving $35.9 million available to be sold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the 36-month term of the LPC Purchase Agreement, we have the right, but not the obligation, from time to time, in our sole discretion, to direct Lincoln Park to purchase up to 250,000 shares per day (the &#8220;Regular Purchase Share Limit&#8221;) of the Class A common stock (each such purchase, a &#8220;Regular Purchase&#8221;). The Regular Purchase Share Limit will increase to 275,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $4.00 per share and will further increase to 300,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $5.00 per share. In any case, Lincoln Park&#8217;s maximum obligation under any single Regular Purchase will not exceed $2,000,000. The purchase price for shares of Class A common stock to be purchased by Lincoln Park under a Regular Purchase will be equal to the lower of (in each case, subject to the adjustments described in the LPC Purchase Agreement): (i) the lowest sale price for the Class A common stock on the applicable purchase date and (ii) the arithmetic average of the three lowest closing sales prices for the Class A common stock during the 10 consecutive trading days prior to the purchase date.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we direct Lincoln Park to purchase the maximum number of shares of Class A common stock that we may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the LPC Purchase Agreement, we may direct Lincoln Park to make an &#8220;accelerated purchase&#8221; and an &#8220;additional accelerated purchase&#8221;, each of an additional number of shares of Class A common stock which may not exceed the lesser of: (i) 300% of the number of shares purchased pursuant to the corresponding Regular Purchase and (ii) 30% of the total number of shares of the common stock traded during a specified period on the applicable purchase date as set forth in the LPC Purchase Agreement. The purchase price for such shares will be the lesser of (i) 97% of the volume weighted average price of the Class A common stock over a certain portion of the date of sale as set forth in the LPC Purchase Agreement and (ii) the closing sale price of the Class A common stock on the date of sale (an &#8220;Accelerated Purchase&#8221;). Under certain circumstances and in accordance with the LPC Purchase Agreement, we may direct Lincoln Park to purchase shares in multiple Accelerated Purchases on the same trading day.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LPC Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of its Class A common stock if those shares, when aggregated with all other shares of Class A common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of Class A common stock as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,167)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,142)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,279&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,087&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,888)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023, our net cash used in operating activities increased by $7.0 million from the nine months ended September&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The significant contributor to the change in cash used was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">driven by working capital changes, and offset by cash received of $6.8 million in excess of the fair value of the Class A common stock issued to G42 investments in 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no cash flows from investing activities for the nine months ended September&#160;30, 2023. For the nine months ended September&#160;30, 2022, net cash used in investing activities was insignificant. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2023, net cash provided by financing activities driven by the receipt of proceeds of $12.0 million from the G42 Promissory Note early redemption during the nine months ended September&#160;30, 2023. For the nine months ended September&#160;30, 2022, net cash provided by financing activities was driven by sales of our Class A common stock to a collaboration partner and from the CinRx Purchase Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. We plan to finance our operations into the first quarter of 2024 through the use of our cash and cash equivalents and, based on current operating plans, we are evaluating several financing strategies </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to fund the ongoing and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including direct equity investments and the potential licensing and monetization of other Company programs. The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, they may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, we may rely on our ability to sell shares of our Class A common stock pursuant to the ATM Offering and LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs, results and timing of our planned trials to evaluate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a potential adjunctive therapy for the treatment of type 1 diabetes;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of the FDA to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability of our drug candidates to progress through clinical development successfully;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to expand our research and development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with securing, establishing and maintaining commercialization capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need and ability to hire additional management, scientific, and medical personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of any payments we are required to make to M&amp;F TTP Holdings Two LLC in the future under the Tax Receivable Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. We currently have potential external source of funds available through the ATM Offering and LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring losses, accumulated deficit and our current levels of cash and cash equivalents raise substantial doubt about our ability to continue as a going concern as of the date of this Quarterly Report on Form 10-Q. If we are unable to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue as a going concern, we may have to liquidate our assets and it is likely that investors will lose all or a significant part of their investments. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all, and such additional funding may cause substantial dilution to our existing investors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate our research and development programs or commercialization efforts, or pursue one or more alternative strategies, such as restructuring, any of which could adversely affect our business prospects.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Critical Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. There have been no material changes to our critical accounting policies and estimates in 2023.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of recent accounting pronouncements in Note 2, &#8220;Summary of Significant Accounting Policies&#8221;, to the Condensed Consolidated Financial Statements in this Form 10-Q.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_118"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any material interest rate exposure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents in a financial institution that management believes to be of high credit quality. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the value of our investment portfolio.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any material foreign currency exposure.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_121"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of September&#160;30, 2023. Based upon that evaluation, our  Chief Executive Officer and Chief Financial Officer concluded that, as of September&#160;30, 2023, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes to Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Website Availability of Reports and other Corporate Governance Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC&#8217;s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_124"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_127"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_130"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are set forth under the heading &#8220;Risk Factors&#8221; under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. There have been no material changes to our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ie4f163fa518047cf9584905c5271d2ff_133"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of unregistered equity securities during the three months ended September&#160;30, 2023.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_136"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_139"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie4f163fa518047cf9584905c5271d2ff_142"></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended September 30, 2023, none of our directors or executive officers <ix:nonNumeric contextRef="c-10" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-687"><ix:nonNumeric contextRef="c-10" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-688">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-10" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-689"><ix:nonNumeric contextRef="c-10" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-690">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_145"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20230930xexx311.htm">Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20230930xexx312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20230930xexx321.htm">Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vtvt-20230930xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ie4f163fa518047cf9584905c5271d2ff_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie4f163fa518047cf9584905c5271d2ff_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;9, 2023</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VTV THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steven Tuch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Tuch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>vtvt-20230930xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i26e3fb1ce82f424ba11fb821c3e37c8f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Sekhri, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2023</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>vtvt-20230930xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2a00c82d33fc4620bac3ffba1cf8223f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Steven Tuch, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2023</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>vtvt-20230930xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib6688db9614f4082a13611d41dd54bd7_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2023</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Sekhri</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>vtvt-20230930xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4a95a57c538e49cb887588cc97c5af38_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of vTv Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Steven Tuch, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2023</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Tuch</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vtvt-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:2f86a218-254c-44f1-a495-2edc3c6776ab,g:2074b840-4080-4341-9c3d-403534345ba0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtvt="http://vtvtherapeutics.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vtvtherapeutics.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtvt-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://vtvtherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessBasisofPresentationandGoingConcern" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern">
        <link:definition>0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements">
        <link:definition>0000009 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation">
        <link:definition>0000010 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://vtvtherapeutics.com/role/Investments">
        <link:definition>0000011 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://vtvtherapeutics.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterest" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest">
        <link:definition>0000014 - Disclosure - Redeemable Noncontrolling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://vtvtherapeutics.com/role/StockholdersDeficit">
        <link:definition>0000015 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>0000016 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://vtvtherapeutics.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://vtvtherapeutics.com/role/NetLossperShare">
        <link:definition>0000018 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments">
        <link:definition>0000019 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vtvtherapeutics.com/role/SubsequentEvents">
        <link:definition>0000020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsTables">
        <link:definition>9954472 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>9954473 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://vtvtherapeutics.com/role/InvestmentsTables">
        <link:definition>9954474 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://vtvtherapeutics.com/role/LeasesTables">
        <link:definition>9954475 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestTables" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables">
        <link:definition>9954476 - Disclosure - Redeemable Noncontrolling Interest (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://vtvtherapeutics.com/role/NetLossperShareTables">
        <link:definition>9954477 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>9954478 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessBasisofPresentationandGoingConcernDetail" roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail">
        <link:definition>9954479 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail">
        <link:definition>9954481 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails" roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails">
        <link:definition>9954482 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail">
        <link:definition>9954483 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail">
        <link:definition>9954484 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail">
        <link:definition>9954485 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail">
        <link:definition>9954486 - Disclosure - Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" roleURI="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail">
        <link:definition>9954487 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>9954488 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954489 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail">
        <link:definition>9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1">
        <link:definition>9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail">
        <link:definition>9954491 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail">
        <link:definition>9954492 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail">
        <link:definition>9954493 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>9954494 - Disclosure - Related-Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>9954495 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail">
        <link:definition>9954496 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail">
        <link:definition>9954497 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail">
        <link:definition>9954498 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail">
        <link:definition>9954499 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://vtvtherapeutics.com/role/SubsequentEventsDetails">
        <link:definition>9954500 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtvt_CinRxPharmaLLCMember" abstract="true" name="CinRxPharmaLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_PhaseTwoMultiRegionalClinicalTrialMember" abstract="true" name="PhaseTwoMultiRegionalClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CinRxMember" abstract="true" name="CinRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_IncreaseInCommonStockSharesAuthorized" abstract="false" name="IncreaseInCommonStockSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" abstract="false" name="MaximumFundingPercentageOfResearchAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_WarrantyLiability" abstract="false" name="WarrantyLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CinRxWarrantsMember" abstract="true" name="CinRxWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" abstract="false" name="StockIssuedDuringPeriodValuePurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_MasterServiceAgreementMember" abstract="true" name="MasterServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_DueToRelatedPartiesMonthlyAmount" abstract="false" name="DueToRelatedPartiesMonthlyAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_JDRFInternationalMember" abstract="true" name="JDRFInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_NotesReceivableFromCollaborators" abstract="false" name="NotesReceivableFromCollaborators" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_WarrantLiabilityRelatedPartyMember" abstract="true" name="WarrantLiabilityRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_SatisfactionOfMilestonePaymentMember" abstract="true" name="SatisfactionOfMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" abstract="false" name="StockIssuedDuringPeriodSharesPurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_LicenseAgreementObligationsDomain" abstract="true" name="LicenseAgreementObligationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_MaximumSponsoringContributionAmount" abstract="false" name="MaximumSponsoringContributionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_TypeTwoDiabetesMember" abstract="true" name="TypeTwoDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_MacAndrewsAndForbesIncorporatedMember" abstract="true" name="MacAndrewsAndForbesIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_MFTTPHoldingsLLCMember" abstract="true" name="MFTTPHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CinRxInvestmentMember" abstract="true" name="CinRxInvestmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_SalesBasedMilestonesPaymentMember" abstract="true" name="SalesBasedMilestonesPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_LPCPurchaseAgreementMember" abstract="true" name="LPCPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterestByParent" abstract="false" name="PercentageOfNonVotingEconomicInterestByParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_LetterAgreementWarrantsMember" abstract="true" name="LetterAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_RedeemableNoncontrollingInterestsMember" abstract="true" name="RedeemableNoncontrollingInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_InvestmentOwnershipPercentage" abstract="false" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_OtherIndicationMember" abstract="true" name="OtherIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CollaborateArrangementContingentConsiderationTransferredCash" abstract="false" name="CollaborateArrangementContingentConsiderationTransferredCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_G42InvestmentsMember" abstract="true" name="G42InvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_TypeOneDiabetesMember" abstract="true" name="TypeOneDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_VTvLLCMember" abstract="true" name="VTvLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" abstract="true" name="DevelopmentalAndRegulatoryMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" abstract="false" name="CollaborativeArrangementNoteReceivableDiscountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_AnterisBioIncMember" abstract="true" name="AnterisBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" abstract="true" name="FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_AggregateOfferingPriceOfShares" abstract="false" name="AggregateOfferingPriceOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareLineItems" abstract="true" name="ScheduleOfEarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_SaleOfStockConsiderationReceivableTerm" abstract="false" name="SaleOfStockConsiderationReceivableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_PotentialMilestonePayment" abstract="false" name="PotentialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ChangeInFairValueOfWarrantsRelatedParty" abstract="false" name="ChangeInFairValueOfWarrantsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_NotesReceivableCurrent" abstract="false" name="NotesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" abstract="false" name="CollaborativeArrangementRoyaltiesReceivablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_PercentageOfAmountOfCashSavings" abstract="false" name="PercentageOfAmountOfCashSavings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" abstract="true" name="HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_OwnershipPercentageOfMajorityOwner" abstract="false" name="OwnershipPercentageOfMajorityOwner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" abstract="false" name="EquityInvestmentsWithReadilyDeterminableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_ScheduleOfEarningsPerShareTable" abstract="true" name="ScheduleOfEarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" abstract="false" name="AdjustmentsToTransactionPriceForPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CommonStockAndPreferredStockSharesAuthorized" abstract="false" name="CommonStockAndPreferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtvt_CantorFitzgeraldMember" abstract="true" name="CantorFitzgeraldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_OperatingLeasesImputedInterest" abstract="false" name="OperatingLeasesImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_PercentageOfNonVotingEconomicInterest" abstract="false" name="PercentageOfNonVotingEconomicInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_OneCustomerMember" abstract="true" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" abstract="true" name="FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" abstract="true" name="ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_NovoLicenseAgreementMember" abstract="true" name="NovoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" abstract="false" name="CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LicenseFeeReceived" abstract="false" name="LicenseFeeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_NotesReceivableDiscountRate" abstract="false" name="NotesReceivableDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtvt_ReneoPharmaceuticalsIncMember" abstract="true" name="ReneoPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CognaMember" abstract="true" name="CognaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" abstract="false" name="ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_LicenseAgreementObligationsAxis" abstract="true" name="LicenseAgreementObligationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" abstract="true" name="G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" abstract="false" name="RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" abstract="false" name="EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" abstract="false" name="PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" abstract="false" name="RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" abstract="true" name="LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtvt_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_TemporaryEquityChangeInRedemptionValue" abstract="false" name="TemporaryEquityChangeInRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtvt_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" abstract="false" name="RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vtvt-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:2f86a218-254c-44f1-a495-2edc3c6776ab,g:2074b840-4080-4341-9c3d-403534345ba0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3b701079-1e52-495f-860e-7330b21deeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_371f923b-f563-4305-bc84-9820bafd0aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b701079-1e52-495f-860e-7330b21deeb8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_371f923b-f563-4305-bc84-9820bafd0aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4ad39af-7935-402a-b738-f8dbbae26b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b701079-1e52-495f-860e-7330b21deeb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4ad39af-7935-402a-b738-f8dbbae26b6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f92867d4-916c-48fa-8f61-0aaa45b7b2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b701079-1e52-495f-860e-7330b21deeb8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f92867d4-916c-48fa-8f61-0aaa45b7b2cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_124ae07a-55cd-4b53-9a2b-9f934be6e049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b701079-1e52-495f-860e-7330b21deeb8" xlink:to="loc_us-gaap_NotesPayableCurrent_124ae07a-55cd-4b53-9a2b-9f934be6e049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_44ec23f7-a16a-4329-9f17-08da302fc3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5dd9af31-de45-42bf-9987-d831043b2d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ec23f7-a16a-4329-9f17-08da302fc3f8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5dd9af31-de45-42bf-9987-d831043b2d2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_07cc312b-9f65-429d-8f50-acdb3002f951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ec23f7-a16a-4329-9f17-08da302fc3f8" xlink:to="loc_us-gaap_CommonStockValue_07cc312b-9f65-429d-8f50-acdb3002f951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938685a2-e44a-40ad-a063-826161579a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_44ec23f7-a16a-4329-9f17-08da302fc3f8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938685a2-e44a-40ad-a063-826161579a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_12ab9350-63f9-44f2-a25d-de77d8579223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b84ec82a-ba0a-4f2c-94f2-69fbf8eb2ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_12ab9350-63f9-44f2-a25d-de77d8579223" xlink:to="loc_us-gaap_AssetsCurrent_b84ec82a-ba0a-4f2c-94f2-69fbf8eb2ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_efcc2caf-7bcb-4391-8d18-9246f795299b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_12ab9350-63f9-44f2-a25d-de77d8579223" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_efcc2caf-7bcb-4391-8d18-9246f795299b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe4a36ed-f799-4b4a-8d97-11232ff4af65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_12ab9350-63f9-44f2-a25d-de77d8579223" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe4a36ed-f799-4b4a-8d97-11232ff4af65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_8ece1c7c-dafd-47e1-a850-eb2417189545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_12ab9350-63f9-44f2-a25d-de77d8579223" xlink:to="loc_us-gaap_LongTermInvestments_8ece1c7c-dafd-47e1-a850-eb2417189545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_72931098-96dd-4e43-97ec-ff4a506daf41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ab618092-78de-4d9c-bbbc-1717778e2c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72931098-96dd-4e43-97ec-ff4a506daf41" xlink:to="loc_us-gaap_Liabilities_ab618092-78de-4d9c-bbbc-1717778e2c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_364b71b6-de5c-408c-802d-cd56962ccc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72931098-96dd-4e43-97ec-ff4a506daf41" xlink:to="loc_us-gaap_CommitmentsAndContingencies_364b71b6-de5c-408c-802d-cd56962ccc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3e99d477-790e-487c-b3f7-4aa0e3fc8f69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72931098-96dd-4e43-97ec-ff4a506daf41" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3e99d477-790e-487c-b3f7-4aa0e3fc8f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0cb26c80-546c-46c5-9012-2f05d2f6d567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72931098-96dd-4e43-97ec-ff4a506daf41" xlink:to="loc_us-gaap_StockholdersEquity_0cb26c80-546c-46c5-9012-2f05d2f6d567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ecc70753-60f5-476f-a650-7d4ce15cc49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_2b06b044-8338-4bec-a33b-950c463d79c0" xlink:href="vtvt-20230930.xsd#vtvt_WarrantyLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ecc70753-60f5-476f-a650-7d4ce15cc49b" xlink:to="loc_vtvt_WarrantyLiability_2b06b044-8338-4bec-a33b-950c463d79c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9f8ddac1-2ce3-4e95-8632-02ae59c47c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ecc70753-60f5-476f-a650-7d4ce15cc49b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9f8ddac1-2ce3-4e95-8632-02ae59c47c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a3188f0f-ca62-44f0-a9c3-e7297d8320c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ecc70753-60f5-476f-a650-7d4ce15cc49b" xlink:to="loc_us-gaap_LiabilitiesCurrent_a3188f0f-ca62-44f0-a9c3-e7297d8320c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4c27105c-6222-4da5-a68d-d2e8681206e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ecc70753-60f5-476f-a650-7d4ce15cc49b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4c27105c-6222-4da5-a68d-d2e8681206e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ecdc55e-8e34-47ad-b39c-0e4c9059653f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_ad3a90b6-3c2c-4cae-bf99-db8b2bcb4415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ecdc55e-8e34-47ad-b39c-0e4c9059653f" xlink:to="loc_us-gaap_DepositsAssetsCurrent_ad3a90b6-3c2c-4cae-bf99-db8b2bcb4415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_beeda58b-53c9-48ac-84b3-42c6d2612470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ecdc55e-8e34-47ad-b39c-0e4c9059653f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_beeda58b-53c9-48ac-84b3-42c6d2612470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80781e9f-97b8-40e5-8bca-5be74bceb349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ecdc55e-8e34-47ad-b39c-0e4c9059653f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80781e9f-97b8-40e5-8bca-5be74bceb349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c4877afe-64d3-4bbc-99e3-722de1549a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ecdc55e-8e34-47ad-b39c-0e4c9059653f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c4877afe-64d3-4bbc-99e3-722de1549a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent_32d5aff5-673f-4371-9bd7-99a8e4c31a49" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ecdc55e-8e34-47ad-b39c-0e4c9059653f" xlink:to="loc_vtvt_NotesReceivableCurrent_32d5aff5-673f-4371-9bd7-99a8e4c31a49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7dd0e032-e9c0-4f67-afd0-63687d51137c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98787800-c1dd-421b-ad9a-a817bc44874f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7dd0e032-e9c0-4f67-afd0-63687d51137c" xlink:to="loc_us-gaap_ProfitLoss_98787800-c1dd-421b-ad9a-a817bc44874f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6839f8d6-e2db-4d07-8818-c9493d8fb421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7dd0e032-e9c0-4f67-afd0-63687d51137c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6839f8d6-e2db-4d07-8818-c9493d8fb421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_faa5203c-8942-43c0-a561-1e2873612fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3b93d0c0-5965-4861-8236-8a4d99b81cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_faa5203c-8942-43c0-a561-1e2873612fda" xlink:to="loc_us-gaap_OperatingIncomeLoss_3b93d0c0-5965-4861-8236-8a4d99b81cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c8ca4f80-37c6-44aa-9872-5a31d8e2b03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_faa5203c-8942-43c0-a561-1e2873612fda" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c8ca4f80-37c6-44aa-9872-5a31d8e2b03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b55dc61b-ff9b-49e0-99dd-a5ba24082647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_faa5203c-8942-43c0-a561-1e2873612fda" xlink:to="loc_us-gaap_InterestExpense_b55dc61b-ff9b-49e0-99dd-a5ba24082647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b723bc17-f773-465e-b404-249dfcaf212f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_faa5203c-8942-43c0-a561-1e2873612fda" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b723bc17-f773-465e-b404-249dfcaf212f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6279f419-23bc-43e2-a1fe-7ea21461ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_930cbfca-9bac-4b5a-a905-0e19b3b2dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6279f419-23bc-43e2-a1fe-7ea21461ba5c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_930cbfca-9bac-4b5a-a905-0e19b3b2dddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_48426cc7-7d77-410b-ac9e-bef939bfe65a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6279f419-23bc-43e2-a1fe-7ea21461ba5c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_48426cc7-7d77-410b-ac9e-bef939bfe65a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c7bdb1b1-ad28-4102-b125-bc93211bf5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3424127d-e736-44d3-8885-a990c41b0d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c7bdb1b1-ad28-4102-b125-bc93211bf5d8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3424127d-e736-44d3-8885-a990c41b0d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e6624186-77f9-4e4a-9510-7e8ab094779b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c7bdb1b1-ad28-4102-b125-bc93211bf5d8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e6624186-77f9-4e4a-9510-7e8ab094779b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3a2a8fea-6c9d-4cd8-b841-f3ad98f293c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21dd0446-bdf6-4d8f-a090-5f7e47b07ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3a2a8fea-6c9d-4cd8-b841-f3ad98f293c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21dd0446-bdf6-4d8f-a090-5f7e47b07ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_93ceec8e-a97d-497a-96f3-a0ce1954bad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3a2a8fea-6c9d-4cd8-b841-f3ad98f293c9" xlink:to="loc_us-gaap_OperatingExpenses_93ceec8e-a97d-497a-96f3-a0ce1954bad7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a02fc44-49a8-4489-90c1-29402291d773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73cc0f68-0d86-4f7b-a4bd-bcc254d8ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a02fc44-49a8-4489-90c1-29402291d773" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73cc0f68-0d86-4f7b-a4bd-bcc254d8ac5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a00f0bfd-f4b4-4a4c-b856-d323b5712606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a02fc44-49a8-4489-90c1-29402291d773" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a00f0bfd-f4b4-4a4c-b856-d323b5712606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09f27be-62f2-4a06-954e-46de7aad8c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a02fc44-49a8-4489-90c1-29402291d773" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d09f27be-62f2-4a06-954e-46de7aad8c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583c46c9-85aa-41b2-8a49-d397ad01e816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8ce5027a-d08b-414b-ac60-0bad4136904d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583c46c9-85aa-41b2-8a49-d397ad01e816" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8ce5027a-d08b-414b-ac60-0bad4136904d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_4e247546-b314-4d7c-8867-302135dedec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583c46c9-85aa-41b2-8a49-d397ad01e816" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_4e247546-b314-4d7c-8867-302135dedec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_047c24fb-79b3-4749-ab21-1d10d1852f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583c46c9-85aa-41b2-8a49-d397ad01e816" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_047c24fb-79b3-4749-ab21-1d10d1852f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_ec1fbf27-b753-4368-aeed-f50c86a26848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583c46c9-85aa-41b2-8a49-d397ad01e816" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_ec1fbf27-b753-4368-aeed-f50c86a26848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_0991d87f-d1d8-4b26-b054-b84f4d95b45c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583c46c9-85aa-41b2-8a49-d397ad01e816" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_0991d87f-d1d8-4b26-b054-b84f4d95b45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dfc8b4f7-ddba-4489-8c0a-57effdafb137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_ProfitLoss_dfc8b4f7-ddba-4489-8c0a-57effdafb137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5689cab-bd02-467b-8679-dd1908511d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5689cab-bd02-467b-8679-dd1908511d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d9d3c909-2e5a-4626-a9d2-3987f6b40f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d9d3c909-2e5a-4626-a9d2-3987f6b40f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e9c866e1-45a6-4238-a1a1-324c242786a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e9c866e1-45a6-4238-a1a1-324c242786a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_ad08d33f-797e-4492-bd62-4f40ed8858b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_InterestIncomeOperating_ad08d33f-797e-4492-bd62-4f40ed8858b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_9ae84f9d-f3cf-45fd-8653-f854d4edf865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_9ae84f9d-f3cf-45fd-8653-f854d4edf865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23ae7dd1-4844-4b0c-8c83-40782d4cbcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_ShareBasedCompensation_23ae7dd1-4844-4b0c-8c83-40782d4cbcba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f83feb9b-392f-4d75-bce5-c7dedc7fb8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_Depreciation_f83feb9b-392f-4d75-bce5-c7dedc7fb8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_d6c1f8f6-db48-4421-b979-e07b141c2260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_d6c1f8f6-db48-4421-b979-e07b141c2260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_d2e82ac8-8288-46aa-9c22-25169c6588c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_InterestExpenseOther_d2e82ac8-8288-46aa-9c22-25169c6588c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6dfb4be2-63dc-4791-8e78-18eb9358df6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6dfb4be2-63dc-4791-8e78-18eb9358df6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_9f58ef00-c788-4c12-822c-a5841ffa81c6" xlink:href="vtvt-20230930.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_9f58ef00-c788-4c12-822c-a5841ffa81c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0c2209c9-d0c8-4305-bc0e-40fbf10e7d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f248832e-008b-4eaa-b725-4af8f643d665" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0c2209c9-d0c8-4305-bc0e-40fbf10e7d22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_318b49e7-22bf-477a-8112-91675a0eb8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d59344e9-b9f0-4b8d-8de4-85106c26c10e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_318b49e7-22bf-477a-8112-91675a0eb8fe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d59344e9-b9f0-4b8d-8de4-85106c26c10e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2fbe4755-52eb-41c9-82e9-2f34f7e333b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e974f99b-1c38-431f-a603-284449c8d8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_2fbe4755-52eb-41c9-82e9-2f34f7e333b6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e974f99b-1c38-431f-a603-284449c8d8f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_883d27fe-f4fb-49cc-afc2-ff3163752049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_2fbe4755-52eb-41c9-82e9-2f34f7e333b6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_883d27fe-f4fb-49cc-afc2-ff3163752049" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d791222b-3d72-48f7-a9a2-8dea8635e634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_79775fb6-6bd4-4696-ad8d-d0a84bc5d669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d791222b-3d72-48f7-a9a2-8dea8635e634" xlink:to="loc_us-gaap_OperatingLeaseLiability_79775fb6-6bd4-4696-ad8d-d0a84bc5d669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest_dcbde0e7-8e4a-41df-b603-2317510dd77f" xlink:href="vtvt-20230930.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d791222b-3d72-48f7-a9a2-8dea8635e634" xlink:to="loc_vtvt_OperatingLeasesImputedInterest_dcbde0e7-8e4a-41df-b603-2317510dd77f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="vtvt-20230930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2cd47b5c-03b8-4d69-8cbf-19f99d0c4f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2cd47b5c-03b8-4d69-8cbf-19f99d0c4f54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fdf0ccb6-f521-4410-9e62-dd53811cd70a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fdf0ccb6-f521-4410-9e62-dd53811cd70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c14654bf-95b2-4567-b605-77b04e530a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c14654bf-95b2-4567-b605-77b04e530a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_607684f3-c459-4e38-8428-19af76fe3797" xlink:href="vtvt-20230930.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:to="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_607684f3-c459-4e38-8428-19af76fe3797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_19b9609c-9e53-41bb-8b83-253a1b9fd04a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_19b9609c-9e53-41bb-8b83-253a1b9fd04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ea08d0b2-f733-4c82-b2dd-d91517932dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da6d2081-176e-4022-b1e3-e8743a30247a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ea08d0b2-f733-4c82-b2dd-d91517932dd4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_73893aa3-f6fe-4313-99ee-710036cf1fed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_dfcb4676-b478-4d0c-ad86-d3987defbda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_73893aa3-f6fe-4313-99ee-710036cf1fed" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_dfcb4676-b478-4d0c-ad86-d3987defbda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_7a9c2e19-1f86-4ec8-a2dd-b9af0946a93b" xlink:href="vtvt-20230930.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_73893aa3-f6fe-4313-99ee-710036cf1fed" xlink:to="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_7a9c2e19-1f86-4ec8-a2dd-b9af0946a93b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9aa6c2c7-3824-4a4b-af1b-38d322be8365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_71223682-0bf8-47cb-8025-dbcd62d9dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9aa6c2c7-3824-4a4b-af1b-38d322be8365" xlink:to="loc_us-gaap_ProfitLoss_71223682-0bf8-47cb-8025-dbcd62d9dbf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_49e934a9-3066-4551-96d7-6b10a47fed48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9aa6c2c7-3824-4a4b-af1b-38d322be8365" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_49e934a9-3066-4551-96d7-6b10a47fed48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d32de160-567c-4ba0-99e9-a90204dc9b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b58a6796-5263-4f5b-b171-c45758e05cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d32de160-567c-4ba0-99e9-a90204dc9b85" xlink:to="loc_us-gaap_ProfitLoss_b58a6796-5263-4f5b-b171-c45758e05cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3050b983-f22f-4c17-96a3-be8817c436ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d32de160-567c-4ba0-99e9-a90204dc9b85" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3050b983-f22f-4c17-96a3-be8817c436ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:calculationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9a3a8238-f73a-409d-a134-ef068e9c4ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_87e71df9-bceb-4e8c-8c69-bb5881e586f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9a3a8238-f73a-409d-a134-ef068e9c4ffa" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_87e71df9-bceb-4e8c-8c69-bb5881e586f6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vtvt-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:2f86a218-254c-44f1-a495-2edc3c6776ab,g:2074b840-4080-4341-9c3d-403534345ba0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20230930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_039a7583-dba1-4905-92bf-72f5e4c41740" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentType_039a7583-dba1-4905-92bf-72f5e4c41740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_62799749-151d-46b0-804b-940cea5deec7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentQuarterlyReport_62799749-151d-46b0-804b-940cea5deec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_11a0d656-4566-4dbb-a374-71af052ac740" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentPeriodEndDate_11a0d656-4566-4dbb-a374-71af052ac740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6b8b8c9c-a866-4f4e-a978-5556a5a505fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentTransitionReport_6b8b8c9c-a866-4f4e-a978-5556a5a505fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_79dac961-2b87-4d50-a0cf-e02c0a5c7917" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityFileNumber_79dac961-2b87-4d50-a0cf-e02c0a5c7917" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_229e67f9-7da3-49a3-9c39-d15c833e15f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityRegistrantName_229e67f9-7da3-49a3-9c39-d15c833e15f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a104d704-ba2d-4182-b588-3e0623b03b05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a104d704-ba2d-4182-b588-3e0623b03b05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_296ddfa1-e747-4f46-9fa0-2b712c50884a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityTaxIdentificationNumber_296ddfa1-e747-4f46-9fa0-2b712c50884a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a7fbd000-1144-4430-80f5-be81b6904262" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressAddressLine1_a7fbd000-1144-4430-80f5-be81b6904262" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b3b08601-607f-4883-bc43-c180777f8152" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressAddressLine2_b3b08601-607f-4883-bc43-c180777f8152" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e8f0dd05-98b2-495d-9cde-6ddaa030516c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressCityOrTown_e8f0dd05-98b2-495d-9cde-6ddaa030516c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_660859a3-c9ee-495a-b783-b7e532b025eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressStateOrProvince_660859a3-c9ee-495a-b783-b7e532b025eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_111391f2-9b53-44af-a0c3-10cc68143e51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressPostalZipCode_111391f2-9b53-44af-a0c3-10cc68143e51" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c76ce759-9d3d-4166-8aa5-697916f328ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_CityAreaCode_c76ce759-9d3d-4166-8aa5-697916f328ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86dfce61-e251-4653-8327-0339e81cebf3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_LocalPhoneNumber_86dfce61-e251-4653-8327-0339e81cebf3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ec90d438-ea9b-4c4c-a8e2-f3583aa36725" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_Security12bTitle_ec90d438-ea9b-4c4c-a8e2-f3583aa36725" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_49ea166e-b105-4070-acf8-06ebc4221ce8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_TradingSymbol_49ea166e-b105-4070-acf8-06ebc4221ce8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7ea2c3a6-bd92-488f-82be-2db6787a8dd2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_SecurityExchangeName_7ea2c3a6-bd92-488f-82be-2db6787a8dd2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d7e74a87-bf23-44cc-9cf4-307df715d3a6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityCurrentReportingStatus_d7e74a87-bf23-44cc-9cf4-307df715d3a6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_036828e3-7ca6-4175-9a0c-615edb0a8de8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityInteractiveDataCurrent_036828e3-7ca6-4175-9a0c-615edb0a8de8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2f502246-8217-41d0-ada7-ad04309e7a0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityFilerCategory_2f502246-8217-41d0-ada7-ad04309e7a0b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f79da69d-9a30-4eae-a094-33807afb475a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntitySmallBusiness_f79da69d-9a30-4eae-a094-33807afb475a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_738d72f9-2697-40b8-abc1-ccc9c674673b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityEmergingGrowthCompany_738d72f9-2697-40b8-abc1-ccc9c674673b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e6257f67-42f1-4ff5-8bdc-406105f00a1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityShellCompany_e6257f67-42f1-4ff5-8bdc-406105f00a1a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3c97a599-abb9-4c8d-92db-8dc1a059a45b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3c97a599-abb9-4c8d-92db-8dc1a059a45b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0522dc4d-3f79-46c4-87d3-ead1f085f6f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityCentralIndexKey_0522dc4d-3f79-46c4-87d3-ead1f085f6f7" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a4fa0207-d767-4d36-b69d-05762e3a9d9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_CurrentFiscalYearEndDate_a4fa0207-d767-4d36-b69d-05762e3a9d9c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b73a5590-780f-464f-adbf-a5b4f2231d1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentFiscalYearFocus_b73a5590-780f-464f-adbf-a5b4f2231d1f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_094477f9-d817-45f2-bb66-20c72e49793b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_094477f9-d817-45f2-bb66-20c72e49793b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3771bcd8-3006-49ad-9b4c-73fc215f5f0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_AmendmentFlag_3771bcd8-3006-49ad-9b4c-73fc215f5f0b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a4ab9b4-68bb-4add-8c6f-0a528fa41473_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:to="loc_us-gaap_ClassOfStockDomain_2a4ab9b4-68bb-4add-8c6f-0a528fa41473_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:to="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5dffad38-2686-44c1-af96-20c479d5535e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:to="loc_us-gaap_CommonClassAMember_5dffad38-2686-44c1-af96-20c479d5535e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0f9ae79e-8b42-430f-9efe-d791c4e851cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:to="loc_us-gaap_CommonClassBMember_0f9ae79e-8b42-430f-9efe-d791c4e851cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:to="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff82a17-8681-460f-9f02-1e02c8cc63b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff82a17-8681-460f-9f02-1e02c8cc63b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f927128e-586d-4f9b-a561-0cf14805c6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f927128e-586d-4f9b-a561-0cf14805c6e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent_3a440f99-030b-471c-9b6a-26e3d61384dd" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_vtvt_NotesReceivableCurrent_3a440f99-030b-471c-9b6a-26e3d61384dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ac5b92b-9cb7-4c23-aa42-b6b6a338169b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ac5b92b-9cb7-4c23-aa42-b6b6a338169b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_b11d42ea-4edb-42e9-a469-375afb8477a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_DepositsAssetsCurrent_b11d42ea-4edb-42e9-a469-375afb8477a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6e7e44b0-21ac-4530-a506-f321be249dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_AssetsCurrent_6e7e44b0-21ac-4530-a506-f321be249dd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_718fa9ce-80fd-416b-ac10-367aac486e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_718fa9ce-80fd-416b-ac10-367aac486e2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e41c918-174a-464f-85aa-b6bd0cd193dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e41c918-174a-464f-85aa-b6bd0cd193dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b7bb2102-ae9b-4c04-92ad-42031ff6613d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_LongTermInvestments_b7bb2102-ae9b-4c04-92ad-42031ff6613d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d8606d52-1c7a-4087-8512-db15e02b3570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_Assets_d8606d52-1c7a-4087-8512-db15e02b3570" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aecc5dfc-7dbc-4c16-aeca-bb6919389baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aecc5dfc-7dbc-4c16-aeca-bb6919389baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3b69c9ec-aabb-4688-82c4-d7d47c857517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3b69c9ec-aabb-4688-82c4-d7d47c857517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df873757-cd84-45d4-b8d3-9f4ded0f50e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df873757-cd84-45d4-b8d3-9f4ded0f50e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_a5f1c32c-9379-478a-9de3-b19831ec6e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_NotesPayableCurrent_a5f1c32c-9379-478a-9de3-b19831ec6e50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a729f1ee-88e7-497b-80dd-bf23b0c0571c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_LiabilitiesCurrent_a729f1ee-88e7-497b-80dd-bf23b0c0571c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c671e8f1-53a4-4281-a06b-6029ab787bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c671e8f1-53a4-4281-a06b-6029ab787bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42c27429-f6ef-4e2d-8f63-4520772fa6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42c27429-f6ef-4e2d-8f63-4520772fa6f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_eddf9747-5028-4698-9a9f-f7e1a657a1dc" xlink:href="vtvt-20230930.xsd#vtvt_WarrantyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_vtvt_WarrantyLiability_eddf9747-5028-4698-9a9f-f7e1a657a1dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ac1e69b-56ae-446d-8dae-bd58e78a0ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_Liabilities_5ac1e69b-56ae-446d-8dae-bd58e78a0ad4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a04a49dc-90d3-4554-acd3-777e8a63ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a04a49dc-90d3-4554-acd3-777e8a63ac59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d871da50-8a12-424a-beae-2f87347f3b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d871da50-8a12-424a-beae-2f87347f3b29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7faaccd8-9a20-4724-8161-e8cb3f63cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:to="loc_us-gaap_CommonStockValue_7faaccd8-9a20-4724-8161-e8cb3f63cbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_06694183-be8b-4892-9b8e-54979e124d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_06694183-be8b-4892-9b8e-54979e124d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_04dc9eec-30c7-45e5-a70c-e303d8ccefc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_04dc9eec-30c7-45e5-a70c-e303d8ccefc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_32480119-7439-40c2-bbbd-9a633dc5dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_StockholdersEquity_32480119-7439-40c2-bbbd-9a633dc5dda9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e60fe3a-ac36-43d9-92ce-ce4e1a0bfb82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e60fe3a-ac36-43d9-92ce-ce4e1a0bfb82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:to="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7e6a645-e332-4f8b-9b2b-fb950e12329b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:to="loc_us-gaap_ClassOfStockDomain_e7e6a645-e332-4f8b-9b2b-fb950e12329b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:to="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0e50ab85-cf0c-43ca-bd70-807e431f04d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:to="loc_us-gaap_CommonClassAMember_0e50ab85-cf0c-43ca-bd70-807e431f04d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_742eb62a-576c-496b-bed3-43f5ea70c0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:to="loc_us-gaap_CommonClassBMember_742eb62a-576c-496b-bed3-43f5ea70c0f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bb69f181-5a1b-427a-941e-7afbbc3571c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bb69f181-5a1b-427a-941e-7afbbc3571c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ec60cfaa-b291-4af5-8089-20dbca21ec23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ec60cfaa-b291-4af5-8089-20dbca21ec23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9e6aa35e-7ed4-4aac-bba1-6871765d0636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9e6aa35e-7ed4-4aac-bba1-6871765d0636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e33a62fe-9142-4bcd-adf8-5364e622feba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:to="loc_us-gaap_ClassOfStockDomain_e33a62fe-9142-4bcd-adf8-5364e622feba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:to="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_42e91849-b3d7-42de-9686-cdf60bf50a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:to="loc_us-gaap_CommonClassAMember_42e91849-b3d7-42de-9686-cdf60bf50a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_946dddb2-ba53-4be7-8faf-3b1a9db84f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:to="loc_us-gaap_CommonClassBMember_946dddb2-ba53-4be7-8faf-3b1a9db84f0f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29db10e7-45fe-4b04-89b4-d8ef0e878871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29db10e7-45fe-4b04-89b4-d8ef0e878871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_db6b16be-62ec-4026-a87f-41b97d5aed79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_db6b16be-62ec-4026-a87f-41b97d5aed79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1d774d06-198a-4493-b233-060380606a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1d774d06-198a-4493-b233-060380606a0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e1cf9ef-3e8c-408c-9de8-915076cc1a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:to="loc_us-gaap_OperatingExpenses_5e1cf9ef-3e8c-408c-9de8-915076cc1a9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79ca588a-543e-43ec-bb48-050b55e6e221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_79ca588a-543e-43ec-bb48-050b55e6e221" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_89e51a10-d78e-48c2-8b6b-b6743409a8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_89e51a10-d78e-48c2-8b6b-b6743409a8f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4bb19c13-fe47-43c0-8916-98268f3b20ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4bb19c13-fe47-43c0-8916-98268f3b20ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94e7e7c6-df28-450b-ac27-c3bae3cfe134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_InterestExpense_94e7e7c6-df28-450b-ac27-c3bae3cfe134" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7dbfc89-753d-48c6-8001-0b8062c85a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7dbfc89-753d-48c6-8001-0b8062c85a95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d5afc152-22f8-4031-9e5a-d8da064bc39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d5afc152-22f8-4031-9e5a-d8da064bc39b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1100f240-cee8-497e-aa55-02aa93bcccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_ProfitLoss_1100f240-cee8-497e-aa55-02aa93bcccf5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa08dbc2-b029-4580-aaa2-ad2ec4541ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa08dbc2-b029-4580-aaa2-ad2ec4541ad0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_598d1fa2-9776-4fa1-92a9-69f09188fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_NetIncomeLoss_598d1fa2-9776-4fa1-92a9-69f09188fbcc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b3bc2ae-89d4-45ad-8868-49e04322f2be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b3bc2ae-89d4-45ad-8868-49e04322f2be" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0f7ee383-6e01-43a1-a7c3-041acedae146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_EarningsPerShareBasic_0f7ee383-6e01-43a1-a7c3-041acedae146" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5dc0538f-fc79-42b8-b03a-869f1f4db7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5dc0538f-fc79-42b8-b03a-869f1f4db7c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c20d930b-9a71-44bb-bf20-d2eb2e1617b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c20d930b-9a71-44bb-bf20-d2eb2e1617b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e521866-dceb-4a5e-877d-5399a34ca1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e521866-dceb-4a5e-877d-5399a34ca1bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0be88566-38bf-4604-8487-1baf97b3af23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:to="loc_us-gaap_ClassOfStockDomain_0be88566-38bf-4604-8487-1baf97b3af23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_778aaeee-be10-430d-a6f9-27396bc36a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:to="loc_us-gaap_ClassOfStockDomain_778aaeee-be10-430d-a6f9-27396bc36a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5a3aa59f-09ab-4e35-b384-d653856be20d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_778aaeee-be10-430d-a6f9-27396bc36a8b" xlink:to="loc_us-gaap_CommonClassAMember_5a3aa59f-09ab-4e35-b384-d653856be20d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7819b70e-6ddf-4d7c-a153-815537a9a7c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:to="loc_us-gaap_RelatedPartyDomain_7819b70e-6ddf-4d7c-a153-815537a9a7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:to="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_7c07477f-c1f7-430d-a5fc-6f6415d72992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:to="loc_us-gaap_NonrelatedPartyMember_7c07477f-c1f7-430d-a5fc-6f6415d72992" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1eafac22-ab52-455a-831d-f2646e8c4630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:to="loc_us-gaap_RelatedPartyMember_1eafac22-ab52-455a-831d-f2646e8c4630" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f2e5110e-6b9c-48b7-a87e-cd53c2e9bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f2e5110e-6b9c-48b7-a87e-cd53c2e9bd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_fc596f7d-ce71-4b01-b18e-1372158dd4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_fc596f7d-ce71-4b01-b18e-1372158dd4b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TemporaryEquityChangeInRedemptionValue_1488e741-d2d5-4df1-995a-cfdc1471d452" xlink:href="vtvt-20230930.xsd#vtvt_TemporaryEquityChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_vtvt_TemporaryEquityChangeInRedemptionValue_1488e741-d2d5-4df1-995a-cfdc1471d452" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9653b5e2-e76a-49c6-9235-e630d328566a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02bc0943-1d33-4f97-9266-37a42d6f6562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_02bc0943-1d33-4f97-9266-37a42d6f6562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_914b9c76-5bdd-4fba-8643-b8eaf2a898a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockholdersEquity_914b9c76-5bdd-4fba-8643-b8eaf2a898a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_607437a1-4fb8-4667-8b02-341d236b132b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_NetIncomeLoss_607437a1-4fb8-4667-8b02-341d236b132b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e7fba0de-78f4-4e04-a2b8-1ed8e8c0c43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e7fba0de-78f4-4e04-a2b8-1ed8e8c0c43a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3df1668a-843c-42cd-8253-8fdbf0733bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3df1668a-843c-42cd-8253-8fdbf0733bc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_783d8984-e1f2-4382-9774-9b653214338b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_783d8984-e1f2-4382-9774-9b653214338b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_725397d5-bb89-49d0-a8d0-c17c6cd658cd" xlink:href="vtvt-20230930.xsd#vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_725397d5-bb89-49d0-a8d0-c17c6cd658cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_0d592aad-e6c6-4fa5-b034-296fbcea5cf6" xlink:href="vtvt-20230930.xsd#vtvt_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_0d592aad-e6c6-4fa5-b034-296fbcea5cf6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_fa034394-7ca9-4bbb-952b-ee1af0f6efa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_fa034394-7ca9-4bbb-952b-ee1af0f6efa4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce84c70a-b4ef-421b-9b5e-031689f563b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90d63918-db59-46f0-bee8-7a84aa75189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:to="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_572d0ef3-4034-492a-812b-b0c4f3a8e46a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:to="loc_us-gaap_EquityComponentDomain_572d0ef3-4034-492a-812b-b0c4f3a8e46a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:to="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7d3c32c6-95aa-4ccb-9fd1-78984b80cab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7d3c32c6-95aa-4ccb-9fd1-78984b80cab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f903a428-eb58-41f0-82a8-6000ad20b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_CommonStockMember_f903a428-eb58-41f0-82a8-6000ad20b34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_5e204427-dde4-483a-865e-f0484aca4676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_5e204427-dde4-483a-865e-f0484aca4676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f03a5650-9304-4407-aece-63065c28a3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f03a5650-9304-4407-aece-63065c28a3f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4765c247-d2b2-4bbb-8aed-b384008d6daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_RetainedEarningsMember_4765c247-d2b2-4bbb-8aed-b384008d6daa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6fd2aa01-95e0-4248-834f-eb202ee9585c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:to="loc_us-gaap_ClassOfStockDomain_6fd2aa01-95e0-4248-834f-eb202ee9585c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:to="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember_3541ac0e-96f3-4aa9-8eea-08ff496fb0eb" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestsMember_3541ac0e-96f3-4aa9-8eea-08ff496fb0eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_26593c14-93d6-478b-ae1b-3338b2890c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:to="loc_us-gaap_CommonClassAMember_26593c14-93d6-478b-ae1b-3338b2890c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_c5a332fd-11d3-4c78-adc3-fae92e7c9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:to="loc_us-gaap_CommonClassBMember_c5a332fd-11d3-4c78-adc3-fae92e7c9d31" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4618e28a-ae03-4a50-9d3a-067aef6fbeee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_ProfitLoss_4618e28a-ae03-4a50-9d3a-067aef6fbeee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1c65cf36-4e1d-4bf4-bbbd-4925af688b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_Depreciation_1c65cf36-4e1d-4bf4-bbbd-4925af688b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b135b77-c9ed-4415-86f5-107e44077c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b135b77-c9ed-4415-86f5-107e44077c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_4614e5bd-e672-4c0f-96d1-c894b97068f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_InterestIncomeOperating_4614e5bd-e672-4c0f-96d1-c894b97068f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_891fe151-3b6a-4a84-8105-59a77e567e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_InterestExpenseOther_891fe151-3b6a-4a84-8105-59a77e567e93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cb71bfbe-735c-4fb3-a3e4-924cefee94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_ShareBasedCompensation_cb71bfbe-735c-4fb3-a3e4-924cefee94ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_f2c75604-f97d-46d8-8c74-18a604a20d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_f2c75604-f97d-46d8-8c74-18a604a20d8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_6aae4665-6848-4137-984c-15d536473273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_6aae4665-6848-4137-984c-15d536473273" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_a6aef3c2-e0c5-4930-bbbe-afeb00ce6644" xlink:href="vtvt-20230930.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_a6aef3c2-e0c5-4930-bbbe-afeb00ce6644" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97220dff-e70d-460c-863b-d1680b3a04a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97220dff-e70d-460c-863b-d1680b3a04a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5936db14-3ebd-4ab7-ba57-dae74266c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5936db14-3ebd-4ab7-ba57-dae74266c2fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_27841ab1-501f-4e6c-a2e7-cf8beaf7f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_27841ab1-501f-4e6c-a2e7-cf8beaf7f9d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7ddd5b33-1db6-429b-9356-c038bc8dd3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7ddd5b33-1db6-429b-9356-c038bc8dd3c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c617d800-f55a-4827-90e0-e2f63112f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c617d800-f55a-4827-90e0-e2f63112f67e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9d854484-6f20-4151-9013-892593027248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9d854484-6f20-4151-9013-892593027248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6617328a-eed5-4075-b47c-809418e23e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6617328a-eed5-4075-b47c-809418e23e2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_17073d65-ea94-42f4-97d2-42142ccdc5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_17073d65-ea94-42f4-97d2-42142ccdc5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dc3bb50b-6a06-4f35-af52-e6ed45177b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dc3bb50b-6a06-4f35-af52-e6ed45177b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_fabb88f6-b939-461c-a360-b4eedabb0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_fabb88f6-b939-461c-a360-b4eedabb0ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9405c2ad-f251-46b9-8914-5c91a59a3a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9405c2ad-f251-46b9-8914-5c91a59a3a87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7c902ba5-0769-4719-bc9d-c6ae1adb4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7c902ba5-0769-4719-bc9d-c6ae1adb4eb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_926ddf98-03ea-414a-90a9-ac34b1b1649f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_926ddf98-03ea-414a-90a9-ac34b1b1649f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de86a938-84f5-4fa7-8886-c7f8ebb88ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de86a938-84f5-4fa7-8886-c7f8ebb88ada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e540ed09-787e-4e6a-ab11-6ceaa9ef9d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e540ed09-787e-4e6a-ab11-6ceaa9ef9d53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c87fa7e5-5bd6-4e4c-8017-5cd80ef02842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_3072beff-d616-43c4-b974-36fdcc54d751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_3072beff-d616-43c4-b974-36fdcc54d751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableFromCollaborators_511d201a-c4b9-4f48-af58-de439960f88b" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:to="loc_vtvt_NotesReceivableFromCollaborators_511d201a-c4b9-4f48-af58-de439960f88b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableFromCollaborators_00d86831-518b-4588-af60-db19e63bb3dc" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d25dc568-d66e-478e-90ca-55244f292ef9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d25dc568-d66e-478e-90ca-55244f292ef9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f0fdc342-fb81-462c-aaf1-f90fda427f65" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f0fdc342-fb81-462c-aaf1-f90fda427f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxMember_ddacc1f6-381f-400d-bd90-642b59853df8" xlink:href="vtvt-20230930.xsd#vtvt_CinRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0fdc342-fb81-462c-aaf1-f90fda427f65" xlink:to="loc_vtvt_CinRxMember_ddacc1f6-381f-400d-bd90-642b59853df8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#DescriptionofBusinessBasisofPresentationandGoingConcernDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:href="vtvt-20230930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_88f79136-425a-439b-a947-2f17609d4051" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_88f79136-425a-439b-a947-2f17609d4051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_ab3898c5-d450-425d-8695-7e6cdb1353b2" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_ab3898c5-d450-425d-8695-7e6cdb1353b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83844ae0-e32e-4b22-b0f4-0d4a19097aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83844ae0-e32e-4b22-b0f4-0d4a19097aa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1aff075-e092-4a8c-9b69-cf83618295e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1aff075-e092-4a8c-9b69-cf83618295e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6b32d58-a64f-4a5b-98d1-a7c7d8bf86e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6b32d58-a64f-4a5b-98d1-a7c7d8bf86e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_cd8b04bf-84c9-4dbb-b829-124730f04d6a" xlink:href="vtvt-20230930.xsd#vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_cd8b04bf-84c9-4dbb-b829-124730f04d6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_82412924-8604-4403-9204-5abefd33de47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_82412924-8604-4403-9204-5abefd33de47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:href="vtvt-20230930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_659a9881-f83a-422c-b7ce-e851f21413c5_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:to="loc_dei_EntityDomain_659a9881-f83a-422c-b7ce-e851f21413c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0bbe1ee6-762e-4202-bae8-d53ee8d54a70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:to="loc_dei_EntityDomain_0bbe1ee6-762e-4202-bae8-d53ee8d54a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_b3ed0485-ca72-4f21-b9c8-976d39f32988" xlink:href="vtvt-20230930.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0bbe1ee6-762e-4202-bae8-d53ee8d54a70" xlink:to="loc_vtvt_VTvLLCMember_b3ed0485-ca72-4f21-b9c8-976d39f32988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_adf703fb-7534-4fc9-b83c-337eabd09285_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:to="loc_us-gaap_ClassOfStockDomain_adf703fb-7534-4fc9-b83c-337eabd09285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:to="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_57e2519e-716e-4299-8409-33cb64370778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:to="loc_us-gaap_CommonClassAMember_57e2519e-716e-4299-8409-33cb64370778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_bb8c4f73-e51e-4863-ba15-3327706ef11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:to="loc_us-gaap_CommonClassBMember_bb8c4f73-e51e-4863-ba15-3327706ef11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6_default" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:to="loc_vtvt_LicenseAgreementObligationsDomain_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain_77114753-a030-45ce-81cb-678229512e16" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:to="loc_vtvt_LicenseAgreementObligationsDomain_77114753-a030-45ce-81cb-678229512e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_6cf49d4a-f2ec-4178-aba8-edd0b571e97b" xlink:href="vtvt-20230930.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_LicenseAgreementObligationsDomain_77114753-a030-45ce-81cb-678229512e16" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_6cf49d4a-f2ec-4178-aba8-edd0b571e97b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:to="loc_us-gaap_RelatedPartyDomain_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0a75a847-b453-4f45-a0ee-b219d7b8b383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:to="loc_us-gaap_RelatedPartyDomain_0a75a847-b453-4f45-a0ee-b219d7b8b383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_168f1460-b8bd-4fd6-a0db-ed24ec170857" xlink:href="vtvt-20230930.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0a75a847-b453-4f45-a0ee-b219d7b8b383" xlink:to="loc_vtvt_CantorFitzgeraldMember_168f1460-b8bd-4fd6-a0db-ed24ec170857" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:href="vtvt-20230930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_082efa6b-3f8d-4afb-9fbe-8ebb721743be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_082efa6b-3f8d-4afb-9fbe-8ebb721743be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6834afb-500c-4db1-9284-d7c73473176e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6834afb-500c-4db1-9284-d7c73473176e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:href="vtvt-20230930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d96c011-ff55-4561-a82b-275306e9f7fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d96c011-ff55-4561-a82b-275306e9f7fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e9d51a0a-eb83-4d53-a705-6a4db77a271a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e9d51a0a-eb83-4d53-a705-6a4db77a271a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_3f1356d5-fa92-4ddb-8ef6-c107a41633e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e9d51a0a-eb83-4d53-a705-6a4db77a271a" xlink:to="loc_us-gaap_SalesRevenueNetMember_3f1356d5-fa92-4ddb-8ef6-c107a41633e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_dec8e113-d4df-4cb9-8c80-3033b5df5537_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_dec8e113-d4df-4cb9-8c80-3033b5df5537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a37860f8-6ec4-4433-990b-9214a0727499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a37860f8-6ec4-4433-990b-9214a0727499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b3185b10-adc2-4ca4-9b18-419d5882925f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a37860f8-6ec4-4433-990b-9214a0727499" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b3185b10-adc2-4ca4-9b18-419d5882925f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d5de94f7-59a4-4701-bb53-49d8dcf077e0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:to="loc_srt_NameOfMajorCustomerDomain_d5de94f7-59a4-4701-bb53-49d8dcf077e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eaaba523-26ab-4945-bcf5-c46f080c331a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:to="loc_srt_NameOfMajorCustomerDomain_eaaba523-26ab-4945-bcf5-c46f080c331a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember_ac0076d9-adc7-491c-8538-92f6365b83d1" xlink:href="vtvt-20230930.xsd#vtvt_OneCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eaaba523-26ab-4945-bcf5-c46f080c331a" xlink:to="loc_vtvt_OneCustomerMember_ac0076d9-adc7-491c-8538-92f6365b83d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e2549ef-6588-4d41-9393-fba4ced3f459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e2549ef-6588-4d41-9393-fba4ced3f459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf94ecff-0624-45ac-825b-00f05b569cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf94ecff-0624-45ac-825b-00f05b569cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_2f7440f2-af0f-49de-80b4-138ffc5bb925" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_2f7440f2-af0f-49de-80b4-138ffc5bb925" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1c193ca-5a52-4eec-9316-62b86e93a139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1c193ca-5a52-4eec-9316-62b86e93a139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_edfb0932-076f-41ca-8ba2-b66e5fa029e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_edfb0932-076f-41ca-8ba2-b66e5fa029e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_1598ba9b-eb2e-4cce-8473-1ce8b9c9474c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_1598ba9b-eb2e-4cce-8473-1ce8b9c9474c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_79b6fcf7-6b2c-4cc2-952f-f682c88598a7" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_NotesReceivableDiscountRate_79b6fcf7-6b2c-4cc2-952f-f682c88598a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fde5f63a-2529-41c7-ad3f-9ea6dbb5f065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fde5f63a-2529-41c7-ad3f-9ea6dbb5f065" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_095aebfb-0b5b-4eb4-98a7-566e6377bf89" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_095aebfb-0b5b-4eb4-98a7-566e6377bf89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_a959503b-5da8-454b-b12a-3f2b9423658e" xlink:href="vtvt-20230930.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_a959503b-5da8-454b-b12a-3f2b9423658e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_bd313481-4f2a-4d0a-9e62-ebd574bf9a66" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_bd313481-4f2a-4d0a-9e62-ebd574bf9a66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_34f3174b-7151-402b-ac4b-2b242a0116d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_CommonStockValueOutstanding_34f3174b-7151-402b-ac4b-2b242a0116d3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d3e2919f-b90b-4fa4-9ace-2250d52df541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SharePrice_d3e2919f-b90b-4fa4-9ace-2250d52df541" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8d178bab-2886-41e4-b1ef-f0ec29905fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8d178bab-2886-41e4-b1ef-f0ec29905fee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_0bc9ae2e-f529-467e-a46d-a1e74bc10943" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_0bc9ae2e-f529-467e-a46d-a1e74bc10943" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6874b763-175b-4800-b4a8-574f59b2808b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6874b763-175b-4800-b4a8-574f59b2808b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184256fe-8fc5-48d6-b26c-3ed0e544cc41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184256fe-8fc5-48d6-b26c-3ed0e544cc41" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_21571110-87f7-4beb-8ebd-2cdc27c0d0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_21571110-87f7-4beb-8ebd-2cdc27c0d0dc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_e20132cd-a14b-4a39-ad82-a871d4813b8f" xlink:href="vtvt-20230930.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_e20132cd-a14b-4a39-ad82-a871d4813b8f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumSponsoringContributionAmount_295c5265-d225-4c83-b0f2-533e25c17308" xlink:href="vtvt-20230930.xsd#vtvt_MaximumSponsoringContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_MaximumSponsoringContributionAmount_295c5265-d225-4c83-b0f2-533e25c17308" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_ac4c06ed-bfd6-434f-8a59-aa5707dba2a8" xlink:href="vtvt-20230930.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_ac4c06ed-bfd6-434f-8a59-aa5707dba2a8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_94c4f6aa-f304-4a71-b926-4ffe030e23a7" xlink:href="vtvt-20230930.xsd#vtvt_AdjustmentsToTransactionPriceForPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_94c4f6aa-f304-4a71-b926-4ffe030e23a7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_cfb3248d-2854-42bb-8edc-d0c2626add19" xlink:href="vtvt-20230930.xsd#vtvt_LicenseFeeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_LicenseFeeReceived_cfb3248d-2854-42bb-8edc-d0c2626add19" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_8ff5cfd1-11a6-45bf-905e-c32e0f3caa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_8ff5cfd1-11a6-45bf-905e-c32e0f3caa0b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a6b6289-2bd3-4b45-a318-327f5f5bea31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a6b6289-2bd3-4b45-a318-327f5f5bea31" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_330b76bf-c55f-4fa4-84d7-69ab99a25e27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_330b76bf-c55f-4fa4-84d7-69ab99a25e27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_b3d403bb-e1aa-412c-8d5b-e201802863ac" xlink:href="vtvt-20230930.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_b3d403bb-e1aa-412c-8d5b-e201802863ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_907dd2e0-beaf-45b5-a8d4-c7b12af204b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:to="loc_us-gaap_CollaborativeArrangementMember_907dd2e0-beaf-45b5-a8d4-c7b12af204b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d9a12fe6-6066-4469-be17-886b957463f9_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:to="loc_dei_EntityDomain_d9a12fe6-6066-4469-be17-886b957463f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:to="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember_c3f641d1-9c2c-41ee-aa92-1339f7e83bd6" xlink:href="vtvt-20230930.xsd#vtvt_JDRFInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:to="loc_vtvt_JDRFInternationalMember_c3f641d1-9c2c-41ee-aa92-1339f7e83bd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_2c1d1238-4ffa-4b0c-aa0f-0756b6c37a3b" xlink:href="vtvt-20230930.xsd#vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:to="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_2c1d1238-4ffa-4b0c-aa0f-0756b6c37a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_125c4d39-87c6-422c-b927-c7fccfe02e80" xlink:href="vtvt-20230930.xsd#vtvt_AnterisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:to="loc_vtvt_AnterisBioIncMember_125c4d39-87c6-422c-b927-c7fccfe02e80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_ad352f49-9371-493f-bbb2-40e2926af1e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:to="loc_us-gaap_OtherCommitmentsDomain_ad352f49-9371-493f-bbb2-40e2926af1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6161ba41-7fd4-47dd-a568-1661da61ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6161ba41-7fd4-47dd-a568-1661da61ae93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_63bae855-da61-433e-b45a-9e3b297e4e74" xlink:href="vtvt-20230930.xsd#vtvt_PhaseTwoMultiRegionalClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_6161ba41-7fd4-47dd-a568-1661da61ae93" xlink:to="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_63bae855-da61-433e-b45a-9e3b297e4e74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1faf32d-b08d-4041-81d8-a7622b2b5fe6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:to="loc_srt_ProductsAndServicesDomain_e1faf32d-b08d-4041-81d8-a7622b2b5fe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd959262-b043-48a7-9068-e0c7852b5b6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:to="loc_srt_ProductsAndServicesDomain_fd959262-b043-48a7-9068-e0c7852b5b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_1101cf69-560e-4a39-b1b6-fbb3d39b24c3" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd959262-b043-48a7-9068-e0c7852b5b6d" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_1101cf69-560e-4a39-b1b6-fbb3d39b24c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30e07ecc-c187-412b-81c0-959b4bdc160d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30e07ecc-c187-412b-81c0-959b4bdc160d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_04c124ce-ba77-4a9d-bff3-da4e1357a574" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:to="loc_vtvt_G42InvestmentsMember_04c124ce-ba77-4a9d-bff3-da4e1357a574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_9e178783-b68c-468c-af53-e77a918f793c" xlink:href="vtvt-20230930.xsd#vtvt_CognaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:to="loc_vtvt_CognaMember_9e178783-b68c-468c-af53-e77a918f793c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2b04a047-7371-4f8f-ad80-da780300c55e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:to="loc_us-gaap_ClassOfStockDomain_2b04a047-7371-4f8f-ad80-da780300c55e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bbe52a6-4733-4e92-89ed-51e04c3a53e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:to="loc_us-gaap_ClassOfStockDomain_5bbe52a6-4733-4e92-89ed-51e04c3a53e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0174acfb-a73c-4ba8-b280-6fdbc6880760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bbe52a6-4733-4e92-89ed-51e04c3a53e8" xlink:to="loc_us-gaap_CommonClassAMember_0174acfb-a73c-4ba8-b280-6fdbc6880760" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3e1397b1-2c45-47a9-be7d-f0abc86d0d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3e1397b1-2c45-47a9-be7d-f0abc86d0d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68f81853-5331-4d55-933b-4f1ce626f08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68f81853-5331-4d55-933b-4f1ce626f08b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0baac68f-9cd8-4158-9238-63dab6c15315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0baac68f-9cd8-4158-9238-63dab6c15315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c9b4f31-5177-4b53-b0c6-72fc93484258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c9b4f31-5177-4b53-b0c6-72fc93484258" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfb01f89-4c2a-47af-b185-9e831361e85e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfb01f89-4c2a-47af-b185-9e831361e85e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:to="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_37e7f3dc-e324-43bc-90e5-c544c2158e43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_37e7f3dc-e324-43bc-90e5-c544c2158e43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814beb05-1cae-4698-a456-66d9fc0d5ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814beb05-1cae-4698-a456-66d9fc0d5ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71814907-8d3c-4442-b913-0ed4baf87453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814beb05-1cae-4698-a456-66d9fc0d5ba1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71814907-8d3c-4442-b913-0ed4baf87453" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c38993bf-a77e-4567-9d14-4bb28a8ef4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_743eb9a9-3e5a-456d-ae8e-174b9a9ca9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c38993bf-a77e-4567-9d14-4bb28a8ef4ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_743eb9a9-3e5a-456d-ae8e-174b9a9ca9e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c38993bf-a77e-4567-9d14-4bb28a8ef4ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_433d5e87-0832-4a73-9a30-555f35d83a0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_433d5e87-0832-4a73-9a30-555f35d83a0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f19b48fd-579d-400c-9d43-2f3b43db1bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f19b48fd-579d-400c-9d43-2f3b43db1bf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_866ce0fa-48a5-48b3-b5e6-b2d98ded007d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_866ce0fa-48a5-48b3-b5e6-b2d98ded007d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#InvestmentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_InvestmentOwnershipPercentage_c72e027b-4f4f-4f4c-9412-c86220b7baeb" xlink:href="vtvt-20230930.xsd#vtvt_InvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_vtvt_InvestmentOwnershipPercentage_c72e027b-4f4f-4f4c-9412-c86220b7baeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b417d6b3-af8e-485c-be25-e5cde8f51334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b417d6b3-af8e-485c-be25-e5cde8f51334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_70a94f76-662f-4e24-869a-d726fae3e9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_70a94f76-662f-4e24-869a-d726fae3e9d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_09990704-05d2-4812-b206-19721561748b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_09990704-05d2-4812-b206-19721561748b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:to="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9627ebb2-dcc0-4925-8bfb-88804a139b7b_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:to="loc_dei_EntityDomain_9627ebb2-dcc0-4925-8bfb-88804a139b7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4fd3eaf3-9fdb-4d49-8a6c-29032a505191" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:to="loc_dei_EntityDomain_4fd3eaf3-9fdb-4d49-8a6c-29032a505191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_390343e4-e22e-4722-8f02-b8e738934601" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4fd3eaf3-9fdb-4d49-8a6c-29032a505191" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_390343e4-e22e-4722-8f02-b8e738934601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4f401da4-cfe5-462e-b16b-be607516722c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4f401da4-cfe5-462e-b16b-be607516722c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_54799842-b019-4144-84ef-f0b4e50a71e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_54799842-b019-4144-84ef-f0b4e50a71e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4e38e977-fa19-4277-854b-372b63c1a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_54799842-b019-4144-84ef-f0b4e50a71e1" xlink:to="loc_us-gaap_SubsequentEventMember_4e38e977-fa19-4277-854b-372b63c1a36b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3339f246-690d-412e-84e0-0cb8814c3a4d" xlink:href="vtvt-20230930.xsd#vtvt_EquityInvestmentsWithReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:to="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3339f246-690d-412e-84e0-0cb8814c3a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_fc55903e-d14f-48aa-bfbb-7e5161eab0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_fc55903e-d14f-48aa-bfbb-7e5161eab0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:to="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e9db3f68-5759-4004-bb91-762b607d5f64_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:to="loc_dei_EntityDomain_e9db3f68-5759-4004-bb91-762b607d5f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:to="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_0316a2d4-51aa-4a6f-ab77-a377e03f3e97" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_0316a2d4-51aa-4a6f-ab77-a377e03f3e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_c1da07dd-17ac-4d34-9e1e-55cf30fe975f" xlink:href="vtvt-20230930.xsd#vtvt_AnterisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:to="loc_vtvt_AnterisBioIncMember_c1da07dd-17ac-4d34-9e1e-55cf30fe975f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cd6d8056-5101-4ae0-a59a-09d71b217b64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:to="loc_us-gaap_EquityComponentDomain_cd6d8056-5101-4ae0-a59a-09d71b217b64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:to="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_436aa79f-b31c-4f05-ac91-e65c2f67650c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:to="loc_us-gaap_CommonStockMember_436aa79f-b31c-4f05-ac91-e65c2f67650c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_dc68d0f5-813f-43f5-ba8e-644dc55464f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:to="loc_us-gaap_PreferredStockMember_dc68d0f5-813f-43f5-ba8e-644dc55464f3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_622fba21-b126-4bd9-8ea0-e4fde65868a0" xlink:href="vtvt-20230930.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_4c58a159-37d4-4362-9bf1-f5f38aae8719" xlink:href="vtvt-20230930.xsd#vtvt_PotentialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_622fba21-b126-4bd9-8ea0-e4fde65868a0" xlink:to="loc_vtvt_PotentialMilestonePayment_4c58a159-37d4-4362-9bf1-f5f38aae8719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:href="vtvt-20230930.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_622fba21-b126-4bd9-8ea0-e4fde65868a0" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_ccfa0cc4-838c-437c-bfc5-6fe459130e76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:to="loc_us-gaap_OtherCommitmentsDomain_ccfa0cc4-838c-437c-bfc5-6fe459130e76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_70d2928c-37e9-4061-b2a9-49db1849a45e" xlink:href="vtvt-20230930.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_70d2928c-37e9-4061-b2a9-49db1849a45e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_73c25fe3-4575-4c8a-ab1c-6b9850bf5b72" xlink:href="vtvt-20230930.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_73c25fe3-4575-4c8a-ab1c-6b9850bf5b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SatisfactionOfMilestonePaymentMember_fbff0eed-7055-41e5-835c-d5d0032a8b82" xlink:href="vtvt-20230930.xsd#vtvt_SatisfactionOfMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:to="loc_vtvt_SatisfactionOfMilestonePaymentMember_fbff0eed-7055-41e5-835c-d5d0032a8b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc7472f5-68ee-4489-8f2f-a8a91b528973_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc7472f5-68ee-4489-8f2f-a8a91b528973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1763777-c41f-4a25-a22c-0410a82a901e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1763777-c41f-4a25-a22c-0410a82a901e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_beb2c1f2-0cfe-435a-97fc-b04b061c13b9" xlink:href="vtvt-20230930.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1763777-c41f-4a25-a22c-0410a82a901e" xlink:to="loc_vtvt_NovoLicenseAgreementMember_beb2c1f2-0cfe-435a-97fc-b04b061c13b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_a835ccb0-52d3-4f92-a541-bafa5a5c1ffc" xlink:href="vtvt-20230930.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:to="loc_vtvt_TypeOneDiabetesMember_a835ccb0-52d3-4f92-a541-bafa5a5c1ffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_af6e4254-2336-4e0a-8e25-e2cdc58ed518" xlink:href="vtvt-20230930.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:to="loc_vtvt_TypeTwoDiabetesMember_af6e4254-2336-4e0a-8e25-e2cdc58ed518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_05af7412-1123-404f-9b56-bf4dafcde3e0" xlink:href="vtvt-20230930.xsd#vtvt_OtherIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:to="loc_vtvt_OtherIndicationMember_05af7412-1123-404f-9b56-bf4dafcde3e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bcc60cba-cda3-4b65-b235-12cda7e9775d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:to="loc_srt_RangeMember_bcc60cba-cda3-4b65-b235-12cda7e9775d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_151cc39a-52ac-4288-87d8-0d3c362d025c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:to="loc_srt_RangeMember_151cc39a-52ac-4288-87d8-0d3c362d025c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a20b87b-ec95-43d1-8d07-76be86d41506" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_151cc39a-52ac-4288-87d8-0d3c362d025c" xlink:to="loc_srt_MaximumMember_6a20b87b-ec95-43d1-8d07-76be86d41506" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RedeemableNoncontrollingInterestAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_5a46f812-2de3-4e44-9940-ff79d5dcb40c" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_5a46f812-2de3-4e44-9940-ff79d5dcb40c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_ec27dccf-d759-478b-b594-0808708b24a4" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_ec27dccf-d759-478b-b594-0808708b24a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_54a383dc-938c-4370-a860-261d30dc7d1b" xlink:href="vtvt-20230930.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_54a383dc-938c-4370-a860-261d30dc7d1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_3e169cfb-f46c-4650-9d6f-64f7665d7d7f" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_3e169cfb-f46c-4650-9d6f-64f7665d7d7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4d5158ed-5247-4926-8edd-4f8b7fc70497_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:to="loc_dei_EntityDomain_4d5158ed-5247-4926-8edd-4f8b7fc70497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_12927128-aa11-4441-b8e1-c3879919d605" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:to="loc_dei_EntityDomain_12927128-aa11-4441-b8e1-c3879919d605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_e71e0891-0cc7-49f8-8751-9a658d18d628" xlink:href="vtvt-20230930.xsd#vtvt_VTvLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12927128-aa11-4441-b8e1-c3879919d605" xlink:to="loc_vtvt_VTvLLCMember_e71e0891-0cc7-49f8-8751-9a658d18d628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34cf6366-456b-48e9-a2ce-663ec4bc3ffd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:to="loc_us-gaap_ClassOfStockDomain_34cf6366-456b-48e9-a2ce-663ec4bc3ffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_513526c3-8770-4174-9789-af4024eddac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:to="loc_us-gaap_ClassOfStockDomain_513526c3-8770-4174-9789-af4024eddac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_187b0d97-9e1c-4385-ada3-2954820d4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_513526c3-8770-4174-9789-af4024eddac4" xlink:to="loc_us-gaap_CommonClassAMember_187b0d97-9e1c-4385-ada3-2954820d4dd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_82a92275-1bad-43b9-9c75-9647fd796973_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_82a92275-1bad-43b9-9c75-9647fd796973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_70ed976d-0f3a-4e33-ad3d-e54cfbfcd5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_70ed976d-0f3a-4e33-ad3d-e54cfbfcd5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_d0f0ffb3-bc7a-4abb-9dc8-4757b0d1552e" xlink:href="vtvt-20230930.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_70ed976d-0f3a-4e33-ad3d-e54cfbfcd5fe" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_d0f0ffb3-bc7a-4abb-9dc8-4757b0d1552e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10583c18-9aae-48b9-8046-12f1a49a4126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10583c18-9aae-48b9-8046-12f1a49a4126" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized_4cb5a2b0-3294-4f39-87a6-bde11e6baac6" xlink:href="vtvt-20230930.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_IncreaseInCommonStockSharesAuthorized_4cb5a2b0-3294-4f39-87a6-bde11e6baac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_7176afdd-1609-4e8a-a263-a9ac2da414e2" xlink:href="vtvt-20230930.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_7176afdd-1609-4e8a-a263-a9ac2da414e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76161456-6b41-45a4-8976-bbccb2810828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76161456-6b41-45a4-8976-bbccb2810828" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_eaa5b0b1-bdab-4a99-b270-6fc9cb26f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_eaa5b0b1-bdab-4a99-b270-6fc9cb26f58a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_14f12498-55d9-4616-96df-f297344a1aaa" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_14f12498-55d9-4616-96df-f297344a1aaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf0ca9b0-1640-4d28-8167-8c5e36ba598c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf0ca9b0-1640-4d28-8167-8c5e36ba598c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_c67fadbb-1f57-4f3d-bdcb-f5a5aa8022ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_c67fadbb-1f57-4f3d-bdcb-f5a5aa8022ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivableTerm_f5113edc-ce91-4e46-939e-d12ea6eca7b1" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivableTerm_f5113edc-ce91-4e46-939e-d12ea6eca7b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_043105ec-a789-4f4d-9ef7-6e005ef8e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_043105ec-a789-4f4d-9ef7-6e005ef8e21b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_c9702ea4-e38f-44d2-a320-29d0e8c68145" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_NotesReceivableDiscountRate_c9702ea4-e38f-44d2-a320-29d0e8c68145" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5adbb302-cdee-47b9-8633-c80b3ec262a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5adbb302-cdee-47b9-8633-c80b3ec262a4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5b0adb41-c7a5-4f10-96e4-fc340655a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5b0adb41-c7a5-4f10-96e4-fc340655a4bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8242dd52-b8e6-42b6-8950-dea507e7272d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8242dd52-b8e6-42b6-8950-dea507e7272d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_f67b6fde-7d7c-407c-bc37-c45f0cfa73a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_f67b6fde-7d7c-407c-bc37-c45f0cfa73a1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8d9412fe-23ea-445e-b534-add6247ad6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8d9412fe-23ea-445e-b534-add6247ad6dd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd5aedca-6808-487f-ba0c-56315b56fb28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd5aedca-6808-487f-ba0c-56315b56fb28" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59692d8d-a3a9-4427-b462-c463e6f7603c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59692d8d-a3a9-4427-b462-c463e6f7603c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AggregateOfferingPriceOfShares_854b77bf-2e35-4e95-b860-cc26978ee6c3" xlink:href="vtvt-20230930.xsd#vtvt_AggregateOfferingPriceOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_AggregateOfferingPriceOfShares_854b77bf-2e35-4e95-b860-cc26978ee6c3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a83fe3db-72a3-49e9-9243-70206c190f04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:to="loc_us-gaap_ClassOfStockDomain_a83fe3db-72a3-49e9-9243-70206c190f04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:to="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ee15b35d-318e-499e-924f-0ea1be998f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:to="loc_us-gaap_CommonClassAMember_ee15b35d-318e-499e-924f-0ea1be998f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b639f1ed-bfd4-4eea-9a89-49c9ddd3803f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:to="loc_us-gaap_CommonStockMember_b639f1ed-bfd4-4eea-9a89-49c9ddd3803f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_843f79fd-6614-4f3f-adfb-4bad17496744_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:to="loc_us-gaap_RelatedPartyDomain_843f79fd-6614-4f3f-adfb-4bad17496744_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:to="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_6ae3cab7-aa8f-4ec6-a7fa-7215d235c96d" xlink:href="vtvt-20230930.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:to="loc_vtvt_CantorFitzgeraldMember_6ae3cab7-aa8f-4ec6-a7fa-7215d235c96d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_4c0f39b9-011b-42e4-b8bd-951a5f1fc63e" xlink:href="vtvt-20230930.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_4c0f39b9-011b-42e4-b8bd-951a5f1fc63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_499c07d8-f393-4c63-9943-d0c2273828e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:to="loc_us-gaap_TransactionDomain_499c07d8-f393-4c63-9943-d0c2273828e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_95789367-d677-47e0-825e-5c61395a1115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:to="loc_us-gaap_TransactionDomain_95789367-d677-47e0-825e-5c61395a1115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AtTheMarketOfferingMember_d167baee-e3a1-458b-908e-300cc9dd91c2" xlink:href="vtvt-20230930.xsd#vtvt_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_95789367-d677-47e0-825e-5c61395a1115" xlink:to="loc_vtvt_AtTheMarketOfferingMember_d167baee-e3a1-458b-908e-300cc9dd91c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58a7b625-7274-4d95-ab38-69e866fdc0d8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:to="loc_srt_RangeMember_58a7b625-7274-4d95-ab38-69e866fdc0d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5803f006-c80e-46fe-846f-067dfe390b91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:to="loc_srt_RangeMember_5803f006-c80e-46fe-846f-067dfe390b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c32802b-7f0b-4d0b-9355-be9eeea9901a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5803f006-c80e-46fe-846f-067dfe390b91" xlink:to="loc_srt_MaximumMember_5c32802b-7f0b-4d0b-9355-be9eeea9901a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_982bb31a-63d9-4f61-aa1a-bf5d382641f3" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:to="loc_vtvt_G42InvestmentsMember_982bb31a-63d9-4f61-aa1a-bf5d382641f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxInvestmentMember_b32c63e9-7769-4f8f-b3d4-a7294059d663" xlink:href="vtvt-20230930.xsd#vtvt_CinRxInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:to="loc_vtvt_CinRxInvestmentMember_b32c63e9-7769-4f8f-b3d4-a7294059d663" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3693148a-17e6-4c76-b5f6-229f21bef016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3693148a-17e6-4c76-b5f6-229f21bef016" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_4c70cc4b-67ca-4966-82fd-7c73d7102ff3" xlink:href="vtvt-20230930.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_4c70cc4b-67ca-4966-82fd-7c73d7102ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_07216093-af00-4dab-9fe4-e4835fb47042" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_07216093-af00-4dab-9fe4-e4835fb47042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_39886acd-3d06-48cb-a089-c1b430cb26cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_39886acd-3d06-48cb-a089-c1b430cb26cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99c3ffdf-64a6-43a0-8604-d82a7866d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_99c3ffdf-64a6-43a0-8604-d82a7866d2e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_8e887c64-48fe-493a-ad53-31083dd37323" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_8e887c64-48fe-493a-ad53-31083dd37323" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f47baf0-45a2-4cdb-a3bc-41320db73c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f47baf0-45a2-4cdb-a3bc-41320db73c0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_82ef036b-28a5-4e98-be3f-d52a4dddbe29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_82ef036b-28a5-4e98-be3f-d52a4dddbe29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_f30e62ba-1fc2-4512-9a84-cea043e314d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_f30e62ba-1fc2-4512-9a84-cea043e314d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_96ee2340-31d2-453a-9f57-a6044de85ce5" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_NotesReceivableDiscountRate_96ee2340-31d2-453a-9f57-a6044de85ce5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_336b0816-7f76-48c7-ba1d-87d393d8dc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_336b0816-7f76-48c7-ba1d-87d393d8dc2d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DueToRelatedPartiesMonthlyAmount_96f4b0be-354d-4a94-a25f-677ca8dda266" xlink:href="vtvt-20230930.xsd#vtvt_DueToRelatedPartiesMonthlyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_DueToRelatedPartiesMonthlyAmount_96f4b0be-354d-4a94-a25f-677ca8dda266" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_47555b3c-ca9c-45cf-88fa-0f5df6054648_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:to="loc_us-gaap_RelatedPartyDomain_47555b3c-ca9c-45cf-88fa-0f5df6054648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b5e1567-7ed8-4fd6-a663-cae6b8177701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:to="loc_us-gaap_RelatedPartyDomain_5b5e1567-7ed8-4fd6-a663-cae6b8177701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_40893918-2fb7-46b8-877f-3dfc9dc007f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5b5e1567-7ed8-4fd6-a663-cae6b8177701" xlink:to="loc_us-gaap_RelatedPartyMember_40893918-2fb7-46b8-877f-3dfc9dc007f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7b71e023-9874-44d8-ae3b-66ad13258c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:to="loc_us-gaap_ClassOfStockDomain_7b71e023-9874-44d8-ae3b-66ad13258c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:to="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_6198705a-acc4-41d8-a547-7a2ee75efab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:to="loc_us-gaap_CommonClassBMember_6198705a-acc4-41d8-a547-7a2ee75efab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ff888b74-2c5c-413a-b7a5-51760b0e0c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:to="loc_us-gaap_CommonClassAMember_ff888b74-2c5c-413a-b7a5-51760b0e0c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c65a64cd-44eb-474d-996b-eb98254529c3_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:to="loc_dei_EntityDomain_c65a64cd-44eb-474d-996b-eb98254529c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d57ae6ce-dab2-4fbc-b4a6-b26d8ce13ce9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:to="loc_dei_EntityDomain_d57ae6ce-dab2-4fbc-b4a6-b26d8ce13ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxPharmaLLCMember_76a66f1a-0d6b-448a-95d3-2cd663b446e8" xlink:href="vtvt-20230930.xsd#vtvt_CinRxPharmaLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d57ae6ce-dab2-4fbc-b4a6-b26d8ce13ce9" xlink:to="loc_vtvt_CinRxPharmaLLCMember_76a66f1a-0d6b-448a-95d3-2cd663b446e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_610194b0-1ed2-4032-a28e-636e0acaf663" xlink:href="vtvt-20230930.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_610194b0-1ed2-4032-a28e-636e0acaf663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_4d9bb301-4c5c-4161-955e-be362ef77865" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:to="loc_vtvt_G42InvestmentsMember_4d9bb301-4c5c-4161-955e-be362ef77865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MasterServiceAgreementMember_53a3e413-af6c-4177-b940-b68059bdd3b4" xlink:href="vtvt-20230930.xsd#vtvt_MasterServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:to="loc_vtvt_MasterServiceAgreementMember_53a3e413-af6c-4177-b940-b68059bdd3b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:href="vtvt-20230930.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_89013197-a63e-4cfd-a32b-3a425ae53d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_89013197-a63e-4cfd-a32b-3a425ae53d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_0dc04756-18ca-4189-8dde-e1a91f439b55" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_0dc04756-18ca-4189-8dde-e1a91f439b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:href="vtvt-20230930.xsd#vtvt_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:to="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:to="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3a37eea6-8180-4087-86fd-a78c1d86d59d_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:to="loc_dei_EntityDomain_3a37eea6-8180-4087-86fd-a78c1d86d59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8da81952-d420-4104-ac54-ea6f97b07997" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:to="loc_dei_EntityDomain_8da81952-d420-4104-ac54-ea6f97b07997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_79a0bec6-4f9f-4d39-aa3d-46a87e25390f" xlink:href="vtvt-20230930.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8da81952-d420-4104-ac54-ea6f97b07997" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_79a0bec6-4f9f-4d39-aa3d-46a87e25390f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:href="vtvt-20230930.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:to="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e888fe2-1a7a-4d71-b578-077108de587b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_ProfitLoss_5e888fe2-1a7a-4d71-b578-077108de587b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a3e70d5-3da4-4cc1-a5d3-b1c72716d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a3e70d5-3da4-4cc1-a5d3-b1c72716d3a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b348b747-429f-4709-8393-a0e3da21188e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b348b747-429f-4709-8393-a0e3da21188e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64bcd790-98cc-4c53-b96f-a527ea7cfbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64bcd790-98cc-4c53-b96f-a527ea7cfbcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48e38a09-25d6-4073-be83-bbe3df85b1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48e38a09-25d6-4073-be83-bbe3df85b1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0abadcf-0ee4-4d7f-b7f6-ebc47f889f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0abadcf-0ee4-4d7f-b7f6-ebc47f889f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78a75d1d-fe74-4d6c-b559-d6f434808a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_EarningsPerShareBasic_78a75d1d-fe74-4d6c-b559-d6f434808a63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_94aa6085-0594-4361-90e2-1eea9bdf0764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_94aa6085-0594-4361-90e2-1eea9bdf0764" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:href="vtvt-20230930.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:to="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_60103ba1-2aee-4ea6-9bb3-8c821919c6ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:to="loc_us-gaap_ClassOfStockDomain_60103ba1-2aee-4ea6-9bb3-8c821919c6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b3f59ca0-1001-48cd-81e7-c3e2589f9757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:to="loc_us-gaap_ClassOfStockDomain_b3f59ca0-1001-48cd-81e7-c3e2589f9757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_87499154-9944-420d-9cd4-48ecc13561e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b3f59ca0-1001-48cd-81e7-c3e2589f9757" xlink:to="loc_us-gaap_CommonClassAMember_87499154-9944-420d-9cd4-48ecc13561e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cda880bb-1181-4389-a512-7053599fc2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e66056bf-3305-44bc-98f3-0dd6646face9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cda880bb-1181-4389-a512-7053599fc2ec" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e66056bf-3305-44bc-98f3-0dd6646face9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cda880bb-1181-4389-a512-7053599fc2ec" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0cb2e30e-a36f-40a8-b390-470ca6039300_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0cb2e30e-a36f-40a8-b390-470ca6039300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0de5d705-a72d-4bd1-8fb5-0852ef350bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:to="loc_us-gaap_CommonClassBMember_0de5d705-a72d-4bd1-8fb5-0852ef350bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_52273679-4958-4833-b8f6-ef0049d34cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_52273679-4958-4833-b8f6-ef0049d34cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_28e6c948-058f-4a2c-b972-2a4c0db2b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:to="loc_us-gaap_WarrantMember_28e6c948-058f-4a2c-b972-2a4c0db2b38a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:href="vtvt-20230930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_81e950aa-8820-4456-980d-4fba0fc7ef27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_81e950aa-8820-4456-980d-4fba0fc7ef27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a5e3668a-ce50-4fe7-843e-9757f5e3dff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a5e3668a-ce50-4fe7-843e-9757f5e3dff7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_a623d42a-3086-4af6-bd3b-848d7f5597cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_a623d42a-3086-4af6-bd3b-848d7f5597cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5d965d93-58fc-4ee1-b6aa-8ecfffdb00f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_a623d42a-3086-4af6-bd3b-848d7f5597cc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5d965d93-58fc-4ee1-b6aa-8ecfffdb00f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66cde340-0e9d-4a27-99e0-456da41dcc07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66cde340-0e9d-4a27-99e0-456da41dcc07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_b1a719c9-9225-4b32-91dc-56caf1eaf657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_b1a719c9-9225-4b32-91dc-56caf1eaf657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_573b911a-aebb-4b08-8e9b-1afa4e9ce077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_573b911a-aebb-4b08-8e9b-1afa4e9ce077" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_ca457002-97e7-4bea-9ca3-06200636f7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_ca457002-97e7-4bea-9ca3-06200636f7d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_64630548-2fac-48e1-a4de-571feb10bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:href="vtvt-20230930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ed4a126c-036a-4de3-85f0-8e080dcd9256_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ed4a126c-036a-4de3-85f0-8e080dcd9256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca987fd3-d142-4046-aeba-d270f6764b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca987fd3-d142-4046-aeba-d270f6764b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a66f4dae-d04c-402b-88b3-bac3d7c9fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca987fd3-d142-4046-aeba-d270f6764b1b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a66f4dae-d04c-402b-88b3-bac3d7c9fd12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ecfe99-3e58-47f4-8020-ed43d70b1205_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0ecfe99-3e58-47f4-8020-ed43d70b1205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1f03a4e3-3733-4db2-8347-54b57c55a66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1f03a4e3-3733-4db2-8347-54b57c55a66c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_de15aeff-d5e8-468a-8df3-c49dd6060fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_de15aeff-d5e8-468a-8df3-c49dd6060fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1adaff22-f910-4023-b5f4-cc2233bacb42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1adaff22-f910-4023-b5f4-cc2233bacb42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93e6495a-b615-4ba5-a8d5-07eb503b25ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93e6495a-b615-4ba5-a8d5-07eb503b25ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_9dc0fb6a-0005-4f71-894c-447ae9302b91" xlink:href="vtvt-20230930.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93e6495a-b615-4ba5-a8d5-07eb503b25ff" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_9dc0fb6a-0005-4f71-894c-447ae9302b91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0855cc9-1f11-4249-9bf3-dad31278d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0855cc9-1f11-4249-9bf3-dad31278d33e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_112c2207-a530-493a-a7ca-8568b2bb9b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_112c2207-a530-493a-a7ca-8568b2bb9b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:to="loc_srt_RangeMember_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:to="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_249689af-eb92-49b6-af9d-2d05875d850e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:to="loc_srt_MinimumMember_249689af-eb92-49b6-af9d-2d05875d850e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3436915f-1f98-4855-8bcd-0b83b3fdeed7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:to="loc_srt_MaximumMember_3436915f-1f98-4855-8bcd-0b83b3fdeed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_e5ae42b8-3b5a-429e-ae5a-e94f0e329966" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:to="loc_srt_WeightedAverageMember_e5ae42b8-3b5a-429e-ae5a-e94f0e329966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_11d5e08e-531e-4552-af6c-c78b5b8e5ae3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_11d5e08e-531e-4552-af6c-c78b5b8e5ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7e49d17-5461-4ec8-9711-39bc3db9d4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7e49d17-5461-4ec8-9711-39bc3db9d4ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_421a657e-4259-422f-8ba2-902cc0c9b6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_421a657e-4259-422f-8ba2-902cc0c9b6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_92edd5f2-5ae8-4f6c-bb72-fc78c0969d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_92edd5f2-5ae8-4f6c-bb72-fc78c0969d39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember_f434e7ec-afe9-4c84-a650-d551d0ee983a" xlink:href="vtvt-20230930.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:to="loc_vtvt_LetterAgreementWarrantsMember_f434e7ec-afe9-4c84-a650-d551d0ee983a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxWarrantsMember_4b8a5b45-0aff-46ff-986a-74bbdaaa9fa6" xlink:href="vtvt-20230930.xsd#vtvt_CinRxWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:to="loc_vtvt_CinRxWarrantsMember_4b8a5b45-0aff-46ff-986a-74bbdaaa9fa6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0ae374f1-da03-45f6-9bb9-faf5b3a8bf12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_c1f35f0e-2869-4dd5-93db-0b1039a0f7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0ae374f1-da03-45f6-9bb9-faf5b3a8bf12" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_c1f35f0e-2869-4dd5-93db-0b1039a0f7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0ae374f1-da03-45f6-9bb9-faf5b3a8bf12" xlink:to="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83e97b9c-e748-412f-99ac-88816a4f94b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83e97b9c-e748-412f-99ac-88816a4f94b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9c13a981-ca77-442a-b834-f47f8a3a90a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9c13a981-ca77-442a-b834-f47f8a3a90a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9eb8b44e-16f7-4793-893f-a76c5b205373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9c13a981-ca77-442a-b834-f47f8a3a90a8" xlink:to="loc_us-gaap_SubsequentEventMember_9eb8b44e-16f7-4793-893f-a76c5b205373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:to="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_506b98a6-7988-4fc7-b19e-39ab06bd513f_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:to="loc_dei_EntityDomain_506b98a6-7988-4fc7-b19e-39ab06bd513f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_924ab423-7282-4da0-a456-0c82633fd477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:to="loc_dei_EntityDomain_924ab423-7282-4da0-a456-0c82633fd477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_8bf3b4c9-f8d9-41f7-9aca-a92a70485312" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_924ab423-7282-4da0-a456-0c82633fd477" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_8bf3b4c9-f8d9-41f7-9aca-a92a70485312" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vtvt-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:2f86a218-254c-44f1-a495-2edc3c6776ab,g:2074b840-4080-4341-9c3d-403534345ba0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_bbd3cc66-c4df-4b1f-88e7-4aba5c788de5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Class A common stock and warrants, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f531f73d-a411-496a-8120-e6b2621294d4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e25be3e6-2635-43ae-a8cf-86b98bf8a842_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_a66dca3d-7e4d-4bad-9345-67536ced9c45_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_label_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio</link:label>
    <link:label id="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_documentation_en-US" xlink:label="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable non controlling interest exchange agreement stock conversion ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:to="lab_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_VTvLLCMember_bdc3451b-e868-404b-b126-1be6c436e451_terseLabel_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">vTv Therapeutics LLC</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_label_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">V Tv L L C [Member]</link:label>
    <link:label id="lab_vtvt_VTvLLCMember_documentation_en-US" xlink:label="lab_vtvt_VTvLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">vTv LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember" xlink:href="vtvt-20230930.xsd#vtvt_VTvLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_VTvLLCMember" xlink:to="lab_vtvt_VTvLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a26d5b12-e3ad-4354-ab98-dd9a473d556c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_3c7ca125-72fe-4645-a094-a1d7ac108414_terseLabel_en-US" xlink:label="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonfinancial Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b98a1aaa-1102-4455-8abc-acecb66b1cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b55ad013-82ed-4d32-8409-7de7f52d3a01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a5e1541d-fc73-4218-81c4-823b96012ae4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAgreementObligationsDomain_9f759028-25bb-433a-bb30-47aad4c4be2f_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsDomain_label_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations [Domain]</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsDomain_documentation_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAgreementObligationsDomain" xlink:to="lab_vtvt_LicenseAgreementObligationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f1fc274c-db8a-4c50-afab-d33f8823f5fe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-qualified stock option awards expiration term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e041a4ac-f42b-4d0b-884c-bc9491b80625_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_93eb8a16-b41d-44f3-a2fd-81a817b9f18f_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c49027a3-f577-4784-b93b-51158133b342_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ebffae91-9daa-4c24-818f-18ea306c1506_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1cc0ddf8-43d5-46b0-8c2b-c22e26eeb99c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_a6b62c7d-c921-457f-b916-8a390652d6ee_terseLabel_en-US" xlink:label="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment with readily determinable fair value:</link:label>
    <link:label id="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_label_en-US" xlink:label="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments With Readily Determinable Fair Value</link:label>
    <link:label id="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_documentation_en-US" xlink:label="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments with readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:href="vtvt-20230930.xsd#vtvt_EquityInvestmentsWithReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:to="lab_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_7a47e990-3daa-4a7a-b7fd-1bcfa757ccfd_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6acc9a66-d90c-484b-8c0a-d5645ff16b1d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_931f0f51-f4d0-40b6-b99d-1e9534d4a63f_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, contingent consideration</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:to="lab_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_fa56c756-3ec7-4859-961f-bddaa8e90dbf_terseLabel_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</link:label>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_label_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent</link:label>
    <link:label id="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_documentation_en-US" xlink:label="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:href="vtvt-20230930.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:to="lab_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bfbafc7-bc3b-462a-9b47-8d6aa00f07a9_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2cc29b7c-d111-4b0a-87d2-081c4be7b3d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_3beca007-b18d-46bc-9eb6-6d306d8daadf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NotesReceivableDiscountRate_192d7c22-b874-49f0-894e-647d5db28bc9_terseLabel_en-US" xlink:label="lab_vtvt_NotesReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_vtvt_NotesReceivableDiscountRate_label_en-US" xlink:label="lab_vtvt_NotesReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Discount Rate</link:label>
    <link:label id="lab_vtvt_NotesReceivableDiscountRate_documentation_en-US" xlink:label="lab_vtvt_NotesReceivableDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NotesReceivableDiscountRate" xlink:to="lab_vtvt_NotesReceivableDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c127759-8d6c-472f-b2b1-de679bddcfba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CinRxMember_425d3120-bc1a-4110-957b-c1a0e4c97226_terseLabel_en-US" xlink:label="lab_vtvt_CinRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx</link:label>
    <link:label id="lab_vtvt_CinRxMember_label_en-US" xlink:label="lab_vtvt_CinRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx [Member]</link:label>
    <link:label id="lab_vtvt_CinRxMember_documentation_en-US" xlink:label="lab_vtvt_CinRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxMember" xlink:href="vtvt-20230930.xsd#vtvt_CinRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CinRxMember" xlink:to="lab_vtvt_CinRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1bd72e4-182d-48a4-ae68-d5b3735af548_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4abca63f-0433-42b5-a32c-9607d4696ed5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Class A common stock to collaboration partner, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_12c05832-ee83-4c97-81cb-f47cc9627c58_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_a6ba6572-b5ff-4826-8202-977c3571ffa3_terseLabel_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MacAndrews &amp; Forbes Incorporated</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_label_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mac Andrews And Forbes Incorporated [Member]</link:label>
    <link:label id="lab_vtvt_MacAndrewsAndForbesIncorporatedMember_documentation_en-US" xlink:label="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MacAndrews and Forbes Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:href="vtvt-20230930.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:to="lab_vtvt_MacAndrewsAndForbesIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4e9f0c1c-27df-4061-afeb-4135502944bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c6f7b4bf-b8e4-47ef-a888-ba97ac039ef5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business, Basis of Presentation and Going Concern</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_38f9f07c-0657-4380-8e58-8bfa6806dbf3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_1641b037-e270-4b92-8be2-5bb709c21793_terseLabel_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 2 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Two Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeTwoDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeTwoDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 2 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember" xlink:href="vtvt-20230930.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeTwoDiabetesMember" xlink:to="lab_vtvt_TypeTwoDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_ec2371a4-4709-42f1-920c-bbf7847207cd_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b2ba1d6d-c6dd-4cea-b7ce-0ae3c61c9d23_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7c16ea9c-2e59-4942-a8cd-0439c8714b5c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_85abde80-398d-47c6-bd89-35dfe36d08f9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_1d42b435-9213-432b-bd63-9f9527f0ffe1_terseLabel_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, termination period</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:href="vtvt-20230930.xsd#vtvt_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_vtvt_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3bf27c26-9662-498f-bf49-9e895bde7dac_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:href="vtvt-20230930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7924f51a-156a-4e68-a806-adbae50c21a7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e39a1f4a-fc8a-43b1-9691-078d37626a76_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_1def4a19-1ae3-4211-812d-a6baaa0f032f_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7a0ac632-d617-43d7-a3f0-5b7fe1cede5f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investment</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e37e97b4-3eb5-46ea-9d7d-6eb82d54065f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1d8595c4-7f63-40a8-9a14-841d7395a13b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82671f23-b26e-4e1f-b5c1-0d4283a92088_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c0aa7c5d-6cfd-4eaa-80af-cdf3a5685a9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_16cd66ed-3534-4f5b-a4b2-14ed19457d01_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_68e63023-706f-4a16-a374-092d866d6435_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_740f4a2f-03e8-4668-9160-5e943847b577_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9177285f-6a8b-4ba7-beba-dcc208e8c283_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_67870193-b734-4d32-8915-e9dea10777c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0c3bf0ad-93ed-4912-b258-2c360bf23c20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9bf55c21-fde1-49d0-be94-81d14a8a9ea3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_341ca89e-b39f-4720-bab0-e0bf8a38077a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_97b709c4-2f63-440a-b5ce-35465de0a4d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_43d29c85-5a67-4e24-a8dd-1b93af9d696e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5bc7f84b-9d61-46a0-bd1e-d87e2a3bb2c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_91ec7f27-bf83-499a-b247-1fe3938d2bcd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13840d0e-0313-485b-84d4-a2118854f583_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_7cd254d8-bf02-40f8-a63f-155c25079508_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change in fair value included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_3dd88ce6-3075-4d21-91f1-c11c526db0a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NotesReceivableFromCollaborators_628ca48d-a081-488d-a4e9-409d8f263e25_terseLabel_en-US" xlink:label="lab_vtvt_NotesReceivableFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable recorded at fair value from collaboration partner</link:label>
    <link:label id="lab_vtvt_NotesReceivableFromCollaborators_33de7dc8-7bce-4f77-95f2-1250dfdde0c6_verboseLabel_en-US" xlink:label="lab_vtvt_NotesReceivableFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable for common stock from CinRx purchase agreement</link:label>
    <link:label id="lab_vtvt_NotesReceivableFromCollaborators_label_en-US" xlink:label="lab_vtvt_NotesReceivableFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable from Collaborators</link:label>
    <link:label id="lab_vtvt_NotesReceivableFromCollaborators_documentation_en-US" xlink:label="lab_vtvt_NotesReceivableFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableFromCollaborators" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NotesReceivableFromCollaborators" xlink:to="lab_vtvt_NotesReceivableFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ac846163-28b4-49be-ab2c-4de17b0cb8c7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b062b7bb-c67a-4423-b7e9-f77ec9026b6b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_68976da6-40a3-41c2-8612-3222626321c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_040da252-689d-46eb-b9fd-ba2c7891bd61_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CantorFitzgeraldMember_67170991-352c-499f-bbe3-c77f6aa84e72_terseLabel_en-US" xlink:label="lab_vtvt_CantorFitzgeraldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Fitzgerald</link:label>
    <link:label id="lab_vtvt_CantorFitzgeraldMember_label_en-US" xlink:label="lab_vtvt_CantorFitzgeraldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
    <link:label id="lab_vtvt_CantorFitzgeraldMember_documentation_en-US" xlink:label="lab_vtvt_CantorFitzgeraldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor fitzgerald member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember" xlink:href="vtvt-20230930.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CantorFitzgeraldMember" xlink:to="lab_vtvt_CantorFitzgeraldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_9383fb13-1be4-4ef2-9949-5a6e445791b2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of investments in Anteris Bio, Inc.</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8c216be1-52cc-4445-acf7-058d01d56fee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b23d0ed8-1de0-410f-bc19-0eb56b067575_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-qualified stock option awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_123f56fb-5eb4-4793-af4c-16be0e204936_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_453634c3-563e-4c38-b12f-f0b7b3634e74_terseLabel_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novo License Agreement</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novo License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_NovoLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_NovoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novo license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember" xlink:href="vtvt-20230930.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NovoLicenseAgreementMember" xlink:to="lab_vtvt_NovoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c316e867-aefc-4a38-84ed-ba03291ceac6_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c2fa0ba6-ae0b-450c-afff-39c669332189_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3a1c070f-a24c-4520-b8f4-20921006454b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b91ae5f0-d3fc-4174-98d6-5dd628275da4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a85cd890-c5a1-499f-90a4-f1f1180e406f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_cdf0b4aa-187e-4692-b13a-200cb46c4060_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_label_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestsMember_documentation_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNoncontrollingInterestsMember" xlink:to="lab_vtvt_RedeemableNoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_340ac9eb-20f8-4106-b14a-edc9b7413ddc_terseLabel_en-US" xlink:label="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2 MRCT</link:label>
    <link:label id="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_label_en-US" xlink:label="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Two Multi Regional Clinical Trial [Member]</link:label>
    <link:label id="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_documentation_en-US" xlink:label="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase two multi-regional clinical trial.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:href="vtvt-20230930.xsd#vtvt_PhaseTwoMultiRegionalClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:to="lab_vtvt_PhaseTwoMultiRegionalClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8595ea7c-4855-4745-aced-3d1915890def_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fbc815e6-658e-4feb-ac6e-b06639542cfb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0dca6710-44f7-42ce-a90b-805b4eeaf132_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_eae41220-e8c6-4866-8d1f-061cac63da62_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_3d3bcea9-6828-47e5-ab14-69901e19bf01_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_629c6241-b736-4f19-80d7-bb2b8f8ddee1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_2df170e1-be76-4a16-bca3-66a2255b7a89_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4b0be192-b8e7-4d6f-b389-b2cfa7f6fb15_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3f357260-b2e3-45d4-abaa-baac55af7325_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8ba46b7f-52ad-49a9-a341-54df541f1a42_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_7d32244f-57e1-4378-ac2e-6528787f207b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Repayment of Loans to Purchase Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:to="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4d1583ab-7e55-4f77-b86d-59fb69eaf42f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_69a72b9b-d37b-447c-a8db-1c9c74fbf82e_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a9bffc5c-3c95-4c3b-994f-26891aa9a51d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_084c431a-6264-43ad-8680-cad68e9d1481_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_7c88b790-a068-4da2-a480-10732c35a507_terseLabel_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption amount of noncontrolling interest</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_label_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest Temporary Equity Redemption Value</link:label>
    <link:label id="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_documentation_en-US" xlink:label="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest temporary equity redemption value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:to="lab_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d465c029-4116-4043-b99c-56b02df5aa35_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_428dec1c-b0dc-49d9-baad-3e2a93c008b9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3316a596-81e9-44bb-95f1-1f1336aacc55_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_7d986ec1-af17-426b-9103-962ef5c50a4a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_50f20a03-5d4b-41d7-a066-fd28a8d5550a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fcec320c-4018-4c89-bcd8-86ebd7e21996_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_084705e0-b8cb-402c-a880-9c50be6cca02_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bf7adb9-f104-4013-89b0-f77e2b93135c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_152ab11f-dec1-47e2-afe0-0a688c32f7fd_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction, gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637c5a20-16c0-427e-b6fd-92641f5752df_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c1bb1d94-fdaf-4fdc-ac0a-17c46dd043d8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_22b7b82c-2bba-4fd6-8c10-a074ff2c9f50_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ceb78b7c-6c3c-43a5-8057-c621b94592c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0c2ce96c-9dd3-42ca-be3b-c2e34c475a71_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe2d59de-b6b4-4e1d-9f5f-811a140df6ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c61879df-65bb-44db-b6e3-f8272e637423_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from G42 Promissory Note early redemption</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5fed4b96-3e23-4bdc-8a6d-d9142ec2256d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_53e7917a-4c5b-4d54-b843-f5c7724fe71a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2a241ec5-e08c-4fef-9856-7e2272533ce0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TemporaryEquityChangeInRedemptionValue_d7303df3-7b6c-4d68-aa15-ca424eaf87fc_terseLabel_en-US" xlink:label="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_vtvt_TemporaryEquityChangeInRedemptionValue_label_en-US" xlink:label="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Change In Redemption Value</link:label>
    <link:label id="lab_vtvt_TemporaryEquityChangeInRedemptionValue_documentation_en-US" xlink:label="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Change In Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:href="vtvt-20230930.xsd#vtvt_TemporaryEquityChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:to="lab_vtvt_TemporaryEquityChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6680b0e7-b9c3-40f8-a86b-3f759de3e0df_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a970c426-4186-45d9-9e0c-b3f9aad267b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b1ba7a1f-05fc-43b5-9ebe-1880dc700923_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f3432b2b-e7aa-4bb5-86f7-905f9572fa5f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5aca3228-084a-466f-9595-2138aa56ff12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_4fe51fdf-07cb-4a32-b12d-373f5817f8cd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_45503722-cfca-4c5e-92fd-76562ad25077_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_ca55d42c-fff9-4ce3-a3f1-10b0834330c8_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:href="vtvt-20230930.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems" xlink:to="lab_vtvt_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CinRxWarrantsMember_87134918-dea3-41ad-9159-efc62628c3dc_terseLabel_en-US" xlink:label="lab_vtvt_CinRxWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Warrants</link:label>
    <link:label id="lab_vtvt_CinRxWarrantsMember_label_en-US" xlink:label="lab_vtvt_CinRxWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Warrants [Member]</link:label>
    <link:label id="lab_vtvt_CinRxWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_CinRxWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxWarrantsMember" xlink:href="vtvt-20230930.xsd#vtvt_CinRxWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CinRxWarrantsMember" xlink:to="lab_vtvt_CinRxWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a9b448d7-e4b2-4bac-8729-5e6550751f8c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0524665c-41ab-4313-a438-22b693c5f104_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d64f4fed-9084-4f11-a7e6-dbda26175a2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_daf29bf9-ce48-4f25-8395-537940534423_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_0a6f90e9-6f86-422a-8359-788777e2c76b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_40322a66-f8f4-40d5-b45b-d5ec1eda2795_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ae1edcc3-74e1-4843-972f-c8662b9445ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AnterisBioIncMember_1a74b749-9762-4361-a175-f18417f7b53e_terseLabel_en-US" xlink:label="lab_vtvt_AnterisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anteris Bio Inc</link:label>
    <link:label id="lab_vtvt_AnterisBioIncMember_label_en-US" xlink:label="lab_vtvt_AnterisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anteris Bio Inc [Member]</link:label>
    <link:label id="lab_vtvt_AnterisBioIncMember_documentation_en-US" xlink:label="lab_vtvt_AnterisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anteris Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember" xlink:href="vtvt-20230930.xsd#vtvt_AnterisBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AnterisBioIncMember" xlink:to="lab_vtvt_AnterisBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_923ffadd-2d05-4763-8d1a-4d2917e51e26_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of cash savings percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_label_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Amount Of Cash Savings</link:label>
    <link:label id="lab_vtvt_PercentageOfAmountOfCashSavings_documentation_en-US" xlink:label="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of amount of cash savings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfAmountOfCashSavings" xlink:to="lab_vtvt_PercentageOfAmountOfCashSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_5aa476f3-ee7e-44b6-833e-b02904c32b81_terseLabel_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborate arrangement, contingent consideration transferred, cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_label_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:label id="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_documentation_en-US" xlink:label="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborate Arrangement, Contingent Consideration Transferred, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:href="vtvt-20230930.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:to="lab_vtvt_CollaborateArrangementContingentConsiderationTransferredCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4f083afd-e634-4c7c-bd99-9a32721072d1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0ad5705d-fb60-47e5-b677-8a5898cdb194_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_ed0f579e-0a3f-4845-b80c-afd0afcc8fec_terseLabel_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 1 Diabetes</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_label_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type One Diabetes [Member]</link:label>
    <link:label id="lab_vtvt_TypeOneDiabetesMember_documentation_en-US" xlink:label="lab_vtvt_TypeOneDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type 1 diabetes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember" xlink:href="vtvt-20230930.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_TypeOneDiabetesMember" xlink:to="lab_vtvt_TypeOneDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d48de2e5-e9d9-4fe7-9b41-09b7d796d915_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_af31c803-9da7-40a5-bce5-001a86fcb12f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_69fce309-dbba-404f-8bf2-5b0048ddf367_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cb0ea256-013b-49c8-acbe-f96ed590d472_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_11c609dc-dc50-49f4-b20d-7a6df521fa56_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options granted under the Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_10f29edb-1277-4908-b3de-479d5782e2eb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AtTheMarketOfferingMember_e353bde9-7091-431e-a076-22f7c2bc219b_terseLabel_en-US" xlink:label="lab_vtvt_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering</link:label>
    <link:label id="lab_vtvt_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_vtvt_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_vtvt_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_vtvt_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AtTheMarketOfferingMember" xlink:href="vtvt-20230930.xsd#vtvt_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AtTheMarketOfferingMember" xlink:to="lab_vtvt_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G42InvestmentsMember_7253b921-a696-43b2-8f4a-9ff40c4c5ff4_terseLabel_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Investments</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_label_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Investments [Member]</link:label>
    <link:label id="lab_vtvt_G42InvestmentsMember_documentation_en-US" xlink:label="lab_vtvt_G42InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G42InvestmentsMember" xlink:to="lab_vtvt_G42InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_c5e4f151-c557-4e29-a406-dcc1d21b4fa1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a57d661b-bf74-41fc-99cb-d92752ab40ce_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize unrecognized share-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_508d48d9-2a95-4151-bf17-b6bba23e663f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_f1daa708-4281-48a5-8d24-f04fe590cbe8_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesTable_604de020-9399-43cd-b80e-063e4862a1b5_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_label_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesTable_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable" xlink:href="vtvt-20230930.xsd#vtvt_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesTable" xlink:to="lab_vtvt_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_484f6a5c-9378-4fae-8429-b79ea3c3b928_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_60ef0669-0c6e-4b73-854b-0c4777c809bc_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_b5ff1d30-09a5-4e58-b792-3c9c497251a6_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareLineItems_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:href="vtvt-20230930.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3f1de6e5-2667-4782-bea4-dccc1b6f2e90_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a74e742f-8a29-439e-85b2-da8962eca6d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ccc99d0c-168a-47ce-a706-52cee762c7f5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_48b2ee4b-4970-493d-be88-d43c8f83ff7c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1b3b7010-2edf-4795-9525-fed89192a643_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_caf0099e-d45c-40e7-83e5-8bcbdc8f38ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_e4ed7b68-0733-427a-b998-f098b08d0473_terseLabel_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_label_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase Agreement</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_documentation_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:href="vtvt-20230930.xsd#vtvt_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:to="lab_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d29d4b1f-f230-41e7-8726-7c2b71781934_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_5a8a61ba-cbfe-4109-b492-8bdbec649461_terseLabel_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:href="vtvt-20230930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_vtvt_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_9f15e356-b4c3-4bf9-865f-97c9135758d1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_9d391169-8353-45eb-a19e-8b0de4c8b060_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held by related party (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9c7e576b-1129-42c1-9cb1-0cce0900bd42_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_352cdf56-ffc0-4f1e-acfd-24d8b1054ecd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_7a3620e3-0e34-4a4f-8814-75edb44072a0_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3da833f-803e-41b4-abb1-8492609beaec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Common Stock to Collaboration Partner (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_85453fc7-36f6-4985-b12d-b08bfccf6255_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c89b459f-ea03-42c3-8cd4-b3dd213fac69_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_b84c59a3-fb55-452d-8a67-7b7001bd4085_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_9e084244-2f24-431e-9785-f3e9823f9a18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_33c28d95-213c-49b8-9bf9-6b3a95fbd925_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_67a7ed69-817e-4453-a06f-bdbaa7e70a18_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b7ef8e97-444d-4d71-8f0e-6589644b0396_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_6514ee03-c3e8-4957-a5d1-7261b89e3392_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bacff989-38ec-4268-bdba-b2eabb577134_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bc0612c2-7294-41e5-b091-0110070e21a7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CinRxPharmaLLCMember_51b959ab-7486-431c-916d-2e1fb945fd94_terseLabel_en-US" xlink:label="lab_vtvt_CinRxPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Pharma, LLC</link:label>
    <link:label id="lab_vtvt_CinRxPharmaLLCMember_label_en-US" xlink:label="lab_vtvt_CinRxPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Pharma, LLC [Member]</link:label>
    <link:label id="lab_vtvt_CinRxPharmaLLCMember_documentation_en-US" xlink:label="lab_vtvt_CinRxPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Pharma, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxPharmaLLCMember" xlink:href="vtvt-20230930.xsd#vtvt_CinRxPharmaLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CinRxPharmaLLCMember" xlink:to="lab_vtvt_CinRxPharmaLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_97b182a8-ee0e-4bb5-85e8-c2b6d20fabb5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_68ffd30c-786e-4676-9e3d-9408d5bf0db1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_59facf31-206f-4659-ba42-95449a15bc64_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0cdc5ac8-d063-4029-b1d0-6f067e3eb1cb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosure_57e7c4be-497d-47d0-adeb-cc4cbfce73d8_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_ReceivablesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFairValueDisclosure" xlink:to="lab_us-gaap_ReceivablesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4729d575-2f1a-46de-91e6-fbb837699251_terseLabel_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_label_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_documentation_en-US" xlink:label="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:href="vtvt-20230930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_a122a087-3480-4162-a1f3-fe92506e9934_terseLabel_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days used to determine exchange value based on weighted average price of Class A common stock</link:label>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_label_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock</link:label>
    <link:label id="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_documentation_en-US" xlink:label="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period used to determine exchange value based on weighted average price of Class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:href="vtvt-20230930.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:to="lab_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_88445da7-bab2-487d-9665-fe79048ef78d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4c6bb40a-5880-4327-9f2b-cf3feea96c3f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_2d2a606a-d2aa-421c-9297-33880ea7cf89_negatedLabel_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_label_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Imputed Interest</link:label>
    <link:label id="lab_vtvt_OperatingLeasesImputedInterest_documentation_en-US" xlink:label="lab_vtvt_OperatingLeasesImputedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases imputed interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest" xlink:href="vtvt-20230930.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OperatingLeasesImputedInterest" xlink:to="lab_vtvt_OperatingLeasesImputedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74a626cb-559f-4f4d-aeca-a1423bd8bd42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36ab07fa-c23a-4481-89fd-f453c4ca8ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b47650bd-216f-4dde-b5b8-8a00e0757a72_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_61d92a45-8cca-413d-8cf0-830e3019095f_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f10a1a1b-bd28-4a12-8389-dc43f89f989c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_131c7648-90b3-49da-ae9c-1bbd12a197d6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_JDRFInternationalMember_48ef4170-cf22-482b-858d-03c1472d3253_terseLabel_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JDRF</link:label>
    <link:label id="lab_vtvt_JDRFInternationalMember_label_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J D R F International [Member]</link:label>
    <link:label id="lab_vtvt_JDRFInternationalMember_documentation_en-US" xlink:label="lab_vtvt_JDRFInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JDRF international.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember" xlink:href="vtvt-20230930.xsd#vtvt_JDRFInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_JDRFInternationalMember" xlink:to="lab_vtvt_JDRFInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0709054a-14a7-477b-8c04-d0e8ee75d14f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c5d91e16-1423-4c8f-a722-39a2544622d9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_9e07b9b9-0964-4044-bd89-65b3066fa83f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Income Attributable to Vtv Therapeutics Inc</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_13c27ba0-e25e-4465-85b7-f8dbb07a0008_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f5b63610-5598-4513-9289-58c6c030ab9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f5e9dbfc-5a06-4a8c-baf6-1bc1e4d6c202_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_382a11bd-87c3-417f-a4c8-844a360b22e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eb88d8da-7851-4587-b371-92665879c808_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_b5f38834-febd-4745-9a05-5506c09c0925_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e52c2ff9-c354-460c-8ebf-d60f252fb431_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_39faec31-90c6-4e30-8157-4e3d15766e8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f05981fd-934f-4c52-8544-883869bcbc6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b3a0f0c1-aa60-49ad-801f-670ab28386bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_0f71331d-78d7-4c1b-9af0-dce83855705d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_6f06f440-7dc0-4af6-80d3-3fe2e2bd0ccd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in redemption value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_d7b982bc-0c86-401e-b046-cef5aa8f2b38_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_ee144353-677a-48bd-ab46-5c705b4b9e05_terseLabel_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M&amp;F TTP Holdings LLC</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_label_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M F T T P Holdings L L C [Member]</link:label>
    <link:label id="lab_vtvt_MFTTPHoldingsLLCMember_documentation_en-US" xlink:label="lab_vtvt_MFTTPHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M&amp;F TTP Holdings LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember" xlink:href="vtvt-20230930.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MFTTPHoldingsLLCMember" xlink:to="lab_vtvt_MFTTPHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_b1fa3d0b-187c-4f43-9b48-90054c2fd396_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_ad09cb54-b918-4e0f-b3ca-8be19f96af75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f65fded8-e638-4add-9fb6-1f682fef3246_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e19a09bc-3d3e-4632-804d-d145206c3b62_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_846311e3-760a-4b02-aba7-72f7d14dddaa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_4dec15d0-857f-4f35-83c5-fedf15fe43ac_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_a9b1e079-4e4e-4779-86c7-067f8f325eca_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_db9d4d89-ac4e-4863-a31a-b58fc6fb26c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to vTv Therapeutics Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_17aea37f-f2db-40a9-a18f-4874dd40705a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c16eb565-7fbd-4d41-b418-c6600ee20f35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_281d4e18-5e06-4ba7-95c1-7f878a15f742_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c749b418-ab94-4d31-8344-f706af486d5f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialMilestonePayment_875f4f06-cbaa-4f1f-ae7e-af9bf573ff6f_terseLabel_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_label_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment</link:label>
    <link:label id="lab_vtvt_PotentialMilestonePayment_documentation_en-US" xlink:label="lab_vtvt_PotentialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment" xlink:href="vtvt-20230930.xsd#vtvt_PotentialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialMilestonePayment" xlink:to="lab_vtvt_PotentialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4517846b-f6a9-4bf7-b154-66f0f041a64c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_febceb94-fa5f-41e7-8e25-035d617f71ee_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_InvestmentOwnershipPercentage_a5d948cd-ee10-4a15-90da-0f0a7e0b3577_terseLabel_en-US" xlink:label="lab_vtvt_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, ownership percentage</link:label>
    <link:label id="lab_vtvt_InvestmentOwnershipPercentage_label_en-US" xlink:label="lab_vtvt_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Ownership Percentage</link:label>
    <link:label id="lab_vtvt_InvestmentOwnershipPercentage_documentation_en-US" xlink:label="lab_vtvt_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment ownership percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_InvestmentOwnershipPercentage" xlink:href="vtvt-20230930.xsd#vtvt_InvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_InvestmentOwnershipPercentage" xlink:to="lab_vtvt_InvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bb3ef660-022f-4c11-af54-c49dc1137c84_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_b26aa722-e750-41a8-b88d-b2f64d309760_terseLabel_en-US" xlink:label="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed</link:label>
    <link:label id="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_label_en-US" xlink:label="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block]</link:label>
    <link:label id="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_documentation_en-US" xlink:label="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of investment in equity security with and without readily determinable fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:href="vtvt-20230930.xsd#vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:to="lab_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1df65757-306e-4e8f-9875-e3db3c3d1b24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_051bf62e-a1f8-4602-9021-fa539f5ea0de_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_350c1ae8-0340-4eb2-9593-3942a3660339_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8e0ec9ef-2c2c-4706-8ad7-66203578b55f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8f60389e-5662-42e9-b36b-c0c5e095af0f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_0b6f936a-1918-42cf-a498-5a4816491840_terseLabel_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_label_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_documentation_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:href="vtvt-20230930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_a2e72ddc-502f-4f83-bd43-515a4962ae4f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9b937f0e-bf49-49bc-a010-caf6f3bbd9bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_68293de5-4b73-4536-adce-ec32f44bdfd0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4108085f-db31-465e-96a5-f124321521da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock value</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4b75fec1-2ee4-47a7-a508-d17211b7d886_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_5261352f-9ff5-4dbb-ad85-8d9e5a3c33d5_terseLabel_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_label_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestone Payments Receivable</link:label>
    <link:label id="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:href="vtvt-20230930.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:to="lab_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_409444d8-fdeb-40fe-a6a4-2f27a669f4f1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_aee301ee-b796-4118-a838-572201c99270_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_640dbab5-07cb-4aa3-ac1b-f7cba8ed89f1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SatisfactionOfMilestonePaymentMember_917450fc-c0b1-428f-b3a4-83ca7a3be842_terseLabel_en-US" xlink:label="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfaction of Milestone Payment</link:label>
    <link:label id="lab_vtvt_SatisfactionOfMilestonePaymentMember_label_en-US" xlink:label="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfaction Of Milestone Payment [Member]</link:label>
    <link:label id="lab_vtvt_SatisfactionOfMilestonePaymentMember_documentation_en-US" xlink:label="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfaction of milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SatisfactionOfMilestonePaymentMember" xlink:href="vtvt-20230930.xsd#vtvt_SatisfactionOfMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SatisfactionOfMilestonePaymentMember" xlink:to="lab_vtvt_SatisfactionOfMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_25749e2d-640c-4dbc-8732-a56acb5b89a7_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on note receivable</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Note Receivable, Discount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:to="lab_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_f24b87c9-888f-4af3-986a-6ed7348164a8_terseLabel_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_label_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_vtvt_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_vtvt_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems" xlink:href="vtvt-20230930.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncomeTaxesLineItems" xlink:to="lab_vtvt_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_265a276f-c77c-47e3-9cbc-9da10816df8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0d22ad01-1271-498f-a1f3-fbd25c10c2bb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f325cc43-58b2-418d-a1ae-76d780c09c7b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2e37d205-a04c-47e4-986c-05c65b66c5ac_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_4fd93642-3b84-4910-8a27-d4ffcd3884b8_terseLabel_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_label_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Purchase Agreement</link:label>
    <link:label id="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_documentation_en-US" xlink:label="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A Common Stock under LPC agreement shares..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:href="vtvt-20230930.xsd#vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:to="lab_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b9aa91d-d326-466a-b2e2-397c51134d23_terseLabel_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_label_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label id="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_documentation_en-US" xlink:label="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:href="vtvt-20230930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="lab_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_aea49bf6-dbe7-47eb-91d4-cedd5519c28a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_59cf1731-4873-41be-ad4a-91955eef13c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_67c9cdf2-f3c0-4dfb-b5a9-4bc8060a853f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1af35711-0749-4e20-af11-4df9973d40a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantyLiability_e2625e90-3a03-4549-8ac3-a5bb34d9ff31_terseLabel_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_vtvt_WarrantyLiability_label_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty Liability</link:label>
    <link:label id="lab_vtvt_WarrantyLiability_documentation_en-US" xlink:label="lab_vtvt_WarrantyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability" xlink:href="vtvt-20230930.xsd#vtvt_WarrantyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantyLiability" xlink:to="lab_vtvt_WarrantyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2fd2739-b76a-4d18-9c0f-6418bada6c17_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8c106f11-7ea3-424a-9943-5ecc5984c08b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty_74bc2daf-e3d5-436d-8db8-ab2950f0dada_terseLabel_en-US" xlink:label="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants, related party</link:label>
    <link:label id="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty_label_en-US" xlink:label="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrants Related Party</link:label>
    <link:label id="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty_documentation_en-US" xlink:label="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:href="vtvt-20230930.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:to="lab_vtvt_ChangeInFairValueOfWarrantsRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseOther_2963578d-1040-457d-ab3e-4743121cd186_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOther_label_en-US" xlink:label="lab_us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther" xlink:to="lab_us-gaap_InterestExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_78529a08-7da1-43bd-ac08-e9385e97c6b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_adfe63e9-00d7-46d8-b1f9-e00479401343_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CinRxInvestmentMember_861765b1-849c-479b-864f-3aacba049641_terseLabel_en-US" xlink:label="lab_vtvt_CinRxInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Investment</link:label>
    <link:label id="lab_vtvt_CinRxInvestmentMember_label_en-US" xlink:label="lab_vtvt_CinRxInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Investment [Member]</link:label>
    <link:label id="lab_vtvt_CinRxInvestmentMember_documentation_en-US" xlink:label="lab_vtvt_CinRxInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CinRx Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxInvestmentMember" xlink:href="vtvt-20230930.xsd#vtvt_CinRxInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CinRxInvestmentMember" xlink:to="lab_vtvt_CinRxInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_676c1a98-b70f-45fb-ace0-682d5b70dbe6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit attributable to vTv Therapeutics Inc.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4820e1eb-85fe-4d34-b6c9-f6eb94c34bf6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7c1d60fc-ca3b-469c-a2eb-d67b60bc2681_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf6ee57d-c537-4462-a7df-f1bbad9187f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_25dfddd0-2f84-4263-9648-8b1752a67ad0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d3e49ae0-4cdb-491e-84bf-440cd32881fc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c3292be5-c5f6-4342-aa0d-9040d6b9cce6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6b11e703-029f-4341-8b93-21af3ed78782_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_7e3cb6ad-5065-4399-be29-8b7d837f7192_terseLabel_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental and Regulatory Milestone Payment</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_label_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental And Regulatory Milestone Payment [Member]</link:label>
    <link:label id="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_documentation_en-US" xlink:label="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental and regulatory milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:href="vtvt-20230930.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:to="lab_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_995dbbd2-eeff-46f2-8255-1580dc665145_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc04a288-119a-47d3-8db7-f74e0e7019f7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e1a84b88-ef97-4baa-9aad-13abe94fdc35_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inputs utilized in the valuation of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4072890f-f829-44f0-a761-b5952dc64595_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment without readily determinable fair values assessed under the measurement alternative:</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4da278c0-167a-43e1-9222-decc107984f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_af1f366d-18a3-4299-a4b2-3d98a6c155df_terseLabel_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties receivable, period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_label_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:label id="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_documentation_en-US" xlink:label="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalties Receivable, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:to="lab_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestAndDividendsReceived_c757b852-31d9-4078-bd53-a650a4efd9c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestAndDividendsReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest and Dividends Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:to="lab_us-gaap_ProceedsFromInterestAndDividendsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0481b0bc-58f6-4497-8f4b-01954d68429a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_359b6554-ab43-4376-bd70-64e6894d175c_terseLabel_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="vtvt-20230930.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d0084bf-0d05-405e-8d84-394351c2ff47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7ff6e593-5a2e-4602-b1f3-cf37e83cea77_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a1c7dc9a-be98-480f-b728-27c31bdc4d08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_87ada80a-aea6-422e-a030-0c085d238dfd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ca289f9b-01ef-44bf-b1cd-94144f102084_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OtherIndicationMember_4c5ae4a0-513b-4c61-8055-45739309095b_terseLabel_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indication</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_label_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indication [Member]</link:label>
    <link:label id="lab_vtvt_OtherIndicationMember_documentation_en-US" xlink:label="lab_vtvt_OtherIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember" xlink:href="vtvt-20230930.xsd#vtvt_OtherIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OtherIndicationMember" xlink:to="lab_vtvt_OtherIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9dcd4a2-9851-4676-b2f8-de79f01e7113_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec76beca-1bf3-4d8a-9654-5f3d42608236_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_90020f44-91dc-4d11-abb0-717c7c01e0dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_3e43b21f-122e-437e-8357-8c9d8d868742_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_efc7bc3e-d783-46d8-b8b4-ac0c1f63de0d_terseLabel_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital stock, shares authorized (in shares)</link:label>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_label_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Preferred Stock Shares Authorized</link:label>
    <link:label id="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and preferred stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:href="vtvt-20230930.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:to="lab_vtvt_CommonStockAndPreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_221f3835-a407-4fb8-bca6-622697b433c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_3cac4267-ce62-4df9-9d8e-d88f96847389_totalLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_92afd9ce-7d9a-4cb0-ba95-271e0bb28995_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non Voting Economic Interest By Parent</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non voting economic interest by parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e2591de0-9113-43ef-9363-6824af806215_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0ae3c488-4e0c-404f-bb40-901a04e62581_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_43007615-550f-4390-a11f-c5ac14e8f208_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_763193b0-7292-4ae2-a5f2-4dbee5c63e71_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9b128102-1521-41c7-ba86-44bcd9857cf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_6ce2f196-0881-4e6e-9117-581528289396_terseLabel_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding percentage of research and development milestones</link:label>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_label_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Funding Percentage Of Research And Development Milestones</link:label>
    <link:label id="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding percentage of research and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:href="vtvt-20230930.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:to="lab_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_ff6f902f-c876-41bf-8741-112bea54da9d_terseLabel_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement</link:label>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_label_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]</link:label>
    <link:label id="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:href="vtvt-20230930.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:to="lab_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_643a47a9-c717-4eb7-bac3-dc1685018c06_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_87ae4745-8375-4fe5-9b7c-8fe05933e1c4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3d10585e-c23e-4993-95c3-17844c41fd35_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f2f36df2-b0ce-4171-a41d-e2301fa6ce1e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_018ffa64-97b7-45da-8034-4f4faab7cdcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Award Activity for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_32a29857-e3ad-448d-a80b-9c838a6471e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2bf6fcc6-bb16-4a74-a67a-3eb7f7f40918_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_a51daf49-f10d-4b57-8f87-241fadd0496d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty liability, related party</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_b247a5f2-c9b5-42f3-a208-975465047591_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_7bf0d576-e1a8-496a-ab4c-5c6b232c3dd2_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_262e8f9d-f7c1-43a4-9ebe-f4474bd901be_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_fefda268-2b6f-4bbf-9b7f-0e8c6e1dd927_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf5e4fe9-1a17-4278-a2dd-49eae497bf07_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1bab9758-dc32-49f8-92f3-33fe5ca11d47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases / Issuance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bd0d97aa-6446-4d2e-a568-b82ef5f2ab61_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_882ea01f-0dec-4e43-8cd3-ac3a6ed13d3e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_f52a53d9-b91a-4ed7-a104-938241f7150f_terseLabel_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Redeemable Non controlling Interest To Class A Common Stock</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_label_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]</link:label>
    <link:label id="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_documentation_en-US" xlink:label="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of redeemable non controlling interest to class A common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:href="vtvt-20230930.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:to="lab_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9fd5ca94-7a49-4300-937f-ae9f6ce3efa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Compensation Expense Related to Grants of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e4a118d7-6df0-4f1e-8490-36e9c68b0d34_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b4f970ff-b08e-496e-ac45-b4ec806563d2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_39b72e90-a5a0-444c-b5ed-13df78dc4cc3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6b933463-9708-43c1-95dd-f87616cee1d1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ef5a1084-8528-4965-a8b3-1e710aaa14ce_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b342cc3e-4a09-4af4-8add-b8fdc76bb59b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_0c395200-f9ea-4d5f-82dd-62fc4516b7d9_terseLabel_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_label_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_vtvt_ScheduleOfEarningsPerShareTable_documentation_en-US" xlink:label="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:href="vtvt-20230930.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable" xlink:to="lab_vtvt_ScheduleOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_05ee7684-c243-44c1-a651-31b8ca4724f9_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_9f7ed5d9-96cf-4da8-985b-f8780e3ad0f6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options in years</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_4c533f57-5d14-41bb-b5be-ca834cd5360e_terseLabel_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestones Payment</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_label_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestones Payment [Member]</link:label>
    <link:label id="lab_vtvt_SalesBasedMilestonesPaymentMember_documentation_en-US" xlink:label="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:href="vtvt-20230930.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SalesBasedMilestonesPaymentMember" xlink:to="lab_vtvt_SalesBasedMilestonesPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_8d68492c-b93a-4920-b9a4-913a80885f9d_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Receivable for Common Stock</link:label>
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_label_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from Stockholder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFromStockholderMember" xlink:to="lab_us-gaap_ReceivablesFromStockholderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_db266149-832f-4c6c-9453-8e9036604da1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e98c00ae-9bba-4e58-845a-3bc888839bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a35f3726-0e40-4ca0-8a0c-7ecaf70423c7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8e91acb9-6703-4409-9020-b5e60b66bc6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_ebe45ee9-260f-46c0-934a-50d6b8f7b009_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MasterServiceAgreementMember_e49c5073-2fa7-489d-9228-83b9e5e197ec_terseLabel_en-US" xlink:label="lab_vtvt_MasterServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Service Agreement</link:label>
    <link:label id="lab_vtvt_MasterServiceAgreementMember_label_en-US" xlink:label="lab_vtvt_MasterServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Service Agreement [Member]</link:label>
    <link:label id="lab_vtvt_MasterServiceAgreementMember_documentation_en-US" xlink:label="lab_vtvt_MasterServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MasterServiceAgreementMember" xlink:href="vtvt-20230930.xsd#vtvt_MasterServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MasterServiceAgreementMember" xlink:to="lab_vtvt_MasterServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseFeeReceived_11551fba-9564-4542-b081-2db28febfafa_terseLabel_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee Received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_label_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee Received</link:label>
    <link:label id="lab_vtvt_LicenseFeeReceived_documentation_en-US" xlink:label="lab_vtvt_LicenseFeeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived" xlink:href="vtvt-20230930.xsd#vtvt_LicenseFeeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseFeeReceived" xlink:to="lab_vtvt_LicenseFeeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AggregateOfferingPriceOfShares_e92b732a-71df-4d61-a20d-f5318735c176_terseLabel_en-US" xlink:label="lab_vtvt_AggregateOfferingPriceOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_vtvt_AggregateOfferingPriceOfShares_label_en-US" xlink:label="lab_vtvt_AggregateOfferingPriceOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Offering Price Of Shares</link:label>
    <link:label id="lab_vtvt_AggregateOfferingPriceOfShares_documentation_en-US" xlink:label="lab_vtvt_AggregateOfferingPriceOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AggregateOfferingPriceOfShares" xlink:href="vtvt-20230930.xsd#vtvt_AggregateOfferingPriceOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AggregateOfferingPriceOfShares" xlink:to="lab_vtvt_AggregateOfferingPriceOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivableTerm_72a9bc0f-1de2-464a-afe5-92caa0a6b909_terseLabel_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration, receivables, payment term</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivableTerm_label_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration, Receivable, Term</link:label>
    <link:label id="lab_vtvt_SaleOfStockConsiderationReceivableTerm_documentation_en-US" xlink:label="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration, Receivable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:to="lab_vtvt_SaleOfStockConsiderationReceivableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a89271fe-67ed-430d-95e3-187be4a70c9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_df198c7a-2086-4663-987f-43f493e83b0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c655350a-53c6-430c-84fd-9ffd82cb67fe_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_b3921214-6330-4b37-8f43-930f9e3dffce_terseLabel_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="vtvt-20230930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_vtvt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4c6b4692-8073-48b0-85ea-8ba980a33c7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_ab0f9b84-859d-41dc-800b-b3007c7ef252_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collection of notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_8a82d9ed-0bbb-444b-b9fe-7954464a6bff_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_2418640a-ab7f-4fe8-b419-4f234a2cd9fc_terseLabel_en-US" xlink:label="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to transaction price for performance obligations</link:label>
    <link:label id="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_label_en-US" xlink:label="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Transaction Price For Performance Obligations</link:label>
    <link:label id="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_documentation_en-US" xlink:label="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to transaction price for performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:href="vtvt-20230930.xsd#vtvt_AdjustmentsToTransactionPriceForPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:to="lab_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_d775c9fc-2572-4f7b-be04-0479bd8c889e_terseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_10314c28-6924-45da-85d6-0ea578a4449a_verboseLabel_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_label_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non Voting Economic Interest</link:label>
    <link:label id="lab_vtvt_PercentageOfNonVotingEconomicInterest_documentation_en-US" xlink:label="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non voting economic interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_PercentageOfNonVotingEconomicInterest" xlink:to="lab_vtvt_PercentageOfNonVotingEconomicInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_50a63546-8fe2-4989-b3bf-a1fe759a3416_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e715965f-37ad-4cd5-9b31-99428fbd071c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3b51dfa2-0a8b-46c8-897f-c293d49695d8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d1899ce5-2029-44c5-a88f-add7752bb982_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_4fc52b02-f6d2-41b4-b700-98711aca5b2a_terseLabel_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Information Policy [Policy Text Block]</link:label>
    <link:label id="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited interim financial information policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="vtvt-20230930.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_fd983c1f-7306-4dfb-995b-7ef4bcbaf321_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_a0cf6883-fa8d-4d80-a89f-041d77b40ea4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, value</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LPCPurchaseAgreementMember_6f19f097-7f63-4a90-9203-7941f271537b_terseLabel_en-US" xlink:label="lab_vtvt_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LPC Purchase Agreement</link:label>
    <link:label id="lab_vtvt_LPCPurchaseAgreementMember_label_en-US" xlink:label="lab_vtvt_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">L P C Purchase Agreement [Member]</link:label>
    <link:label id="lab_vtvt_LPCPurchaseAgreementMember_documentation_en-US" xlink:label="lab_vtvt_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LPC purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember" xlink:href="vtvt-20230930.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LPCPurchaseAgreementMember" xlink:to="lab_vtvt_LPCPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_406bd93a-339d-477b-bf71-e018123d1466_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e233f4c0-3146-4a4c-a0da-c5ed140746a6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_a0ca104e-4c91-40b1-978d-0fc69980ebaf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_dcda4ea5-f898-4dc8-9a1f-01993d6ad1e4_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_01b95113-825a-4020-9f30-da7b803226ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f72d0275-16d7-4be9-b8d7-3f35f3b7bb53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ff78b08c-e7c2-4a91-b702-bbe4d033b21d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8a549547-ce15-4845-86a5-1c40bc904476_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_WarrantLiabilityRelatedPartyMember_f67dd1c1-d785-4559-949c-6ddaee94ea91_terseLabel_en-US" xlink:label="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, related party</link:label>
    <link:label id="lab_vtvt_WarrantLiabilityRelatedPartyMember_label_en-US" xlink:label="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability Related Party [Member]</link:label>
    <link:label id="lab_vtvt_WarrantLiabilityRelatedPartyMember_documentation_en-US" xlink:label="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember" xlink:href="vtvt-20230930.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_WarrantLiabilityRelatedPartyMember" xlink:to="lab_vtvt_WarrantLiabilityRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_11c54c97-b333-4cea-86fe-89ac65bc2c3a_terseLabel_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Agreement Warrants</link:label>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_label_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Agreement Warrants [Member]</link:label>
    <link:label id="lab_vtvt_LetterAgreementWarrantsMember_documentation_en-US" xlink:label="lab_vtvt_LetterAgreementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter agreement warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember" xlink:href="vtvt-20230930.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LetterAgreementWarrantsMember" xlink:to="lab_vtvt_LetterAgreementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_3c018928-d0e2-4fde-a2d4-ed880a2da5de_terseLabel_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares authorized (in shares)</link:label>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_label_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Common Stock Shares Authorized</link:label>
    <link:label id="lab_vtvt_IncreaseInCommonStockSharesAuthorized_documentation_en-US" xlink:label="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in common stock shares authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:href="vtvt-20230930.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:to="lab_vtvt_IncreaseInCommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_52f6ad1e-1970-465b-986d-8e13bfeffd14_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40f49c80-4f7b-43db-b9bc-9673dbd57c31_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_21abb1d2-e3c1-443e-b31a-92f31277bf1c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_MaximumSponsoringContributionAmount_f7c072d6-a2ed-42b3-8eef-bf63cdab7b40_terseLabel_en-US" xlink:label="lab_vtvt_MaximumSponsoringContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount to clinical trial</link:label>
    <link:label id="lab_vtvt_MaximumSponsoringContributionAmount_label_en-US" xlink:label="lab_vtvt_MaximumSponsoringContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Sponsoring Contribution Amount</link:label>
    <link:label id="lab_vtvt_MaximumSponsoringContributionAmount_documentation_en-US" xlink:label="lab_vtvt_MaximumSponsoringContributionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sponsoring contribution amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumSponsoringContributionAmount" xlink:href="vtvt-20230930.xsd#vtvt_MaximumSponsoringContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_MaximumSponsoringContributionAmount" xlink:to="lab_vtvt_MaximumSponsoringContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_c54ff31b-242d-4a5b-9412-934aafe085f5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, fair value</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_90bf433c-4df9-4d71-ac42-6549f6072964_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CognaMember_4127da9e-b30a-4c04-8131-f09c29bfedea_terseLabel_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cogna</link:label>
    <link:label id="lab_vtvt_CognaMember_label_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cogna [Member]</link:label>
    <link:label id="lab_vtvt_CognaMember_documentation_en-US" xlink:label="lab_vtvt_CognaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cogna</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember" xlink:href="vtvt-20230930.xsd#vtvt_CognaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CognaMember" xlink:to="lab_vtvt_CognaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8c172eae-d523-42fd-9a08-96c657ee6244_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ff41b727-1e52-4d54-8095-dc97951715a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarizes the Conclusions Reached Regarding Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b905ef3f-13a6-4abc-a45d-a3000bcf07cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ab90a012-760c-42db-b688-9262382597ff_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f241a8cb-0a36-4076-84d7-7d7262f741ab_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_26ce5d48-ebd3-4991-957c-256f7a075544_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_092d1a92-3ef7-44b3-9a4d-bea8bc058d78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OneCustomerMember_193a32b6-9347-427e-aab3-b75817b30c48_terseLabel_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:label id="lab_vtvt_OneCustomerMember_label_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer [Member]</link:label>
    <link:label id="lab_vtvt_OneCustomerMember_documentation_en-US" xlink:label="lab_vtvt_OneCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember" xlink:href="vtvt-20230930.xsd#vtvt_OneCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OneCustomerMember" xlink:to="lab_vtvt_OneCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_389e3e1a-3c84-44b5-a99f-ac142690d150_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_1262aa38-4aac-4d65-af90-39a2e91198e8_terseLabel_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_vtvt_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_vtvt_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable" xlink:href="vtvt-20230930.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable" xlink:to="lab_vtvt_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5626ddd7-45dd-449f-ba61-134c4529e431_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a6e0542-8755-4779-8ae5-7d280e8a95d9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A common stock to collaboration partner, net of offering cost</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_33366275-a49a-4f02-8b4f-f5a55070e230_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ac4a1f88-a1aa-4bdc-8a29-6d1fadc13f64_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_435155c5-304b-4b3a-8f0a-3eddab51f08f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining operating lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7ccfa099-bba4-4b54-9b51-e83774a468ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_1f4d0a76-f2f5-4c34-9c1b-c72bd1500235_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aaacb3fd-589b-4740-a499-3ad2b2518403_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_84912484-3c24-46f0-974d-561f9857d0e1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03cda2d1-8b2a-4149-b1f3-56ddc02454f6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8150fdaa-2937-4d15-ac70-fcbf83ba046d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_f6dedc96-3350-46f9-88b5-5857a635dffd_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3f85cc9d-0b60-4f8f-90b0-846d5098b298_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_9ffbd77d-e16c-4fed-94cc-40a713f42913_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales / Repurchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_db5aad16-a24f-4dab-94dc-9da21e6d31a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d2813680-8b92-4577-80c6-a38f9c065479_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contract Liabilities Related to Company's Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_05473898-4b77-4c11-bdbd-15c3eca04e11_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Technology Transfer Services of Chemistry and Manufacturing Know-How</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_label_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member]</link:label>
    <link:label id="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_documentation_en-US" xlink:label="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and technology transfer services of chemistry and manufacturing know-how.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:to="lab_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3ebf73d2-bc0e-471e-9964-ec73ec8f4b6d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_92a74327-26ad-4ba9-bc6f-920ec70cf847_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8d5d6245-3b8c-455d-865a-4971bc5ec9e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8219dd7e-ea58-4399-817e-201df70a1ddc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0d807758-f3cb-4bb4-a457-af1b1953a386_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_DueToRelatedPartiesMonthlyAmount_e4178607-2fed-40b5-923a-e597156c8eb4_terseLabel_en-US" xlink:label="lab_vtvt_DueToRelatedPartiesMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties, monthly amount</link:label>
    <link:label id="lab_vtvt_DueToRelatedPartiesMonthlyAmount_label_en-US" xlink:label="lab_vtvt_DueToRelatedPartiesMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due To Related Parties, Monthly Amount</link:label>
    <link:label id="lab_vtvt_DueToRelatedPartiesMonthlyAmount_documentation_en-US" xlink:label="lab_vtvt_DueToRelatedPartiesMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due To Related Parties, Monthly Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DueToRelatedPartiesMonthlyAmount" xlink:href="vtvt-20230930.xsd#vtvt_DueToRelatedPartiesMonthlyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_DueToRelatedPartiesMonthlyAmount" xlink:to="lab_vtvt_DueToRelatedPartiesMonthlyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_NotesReceivableCurrent_7ae27232-2ff4-4c6c-9f5e-1445dbe05cb5_terseLabel_en-US" xlink:label="lab_vtvt_NotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G42 Promissory Note receivable</link:label>
    <link:label id="lab_vtvt_NotesReceivableCurrent_label_en-US" xlink:label="lab_vtvt_NotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Current</link:label>
    <link:label id="lab_vtvt_NotesReceivableCurrent_documentation_en-US" xlink:label="lab_vtvt_NotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_NotesReceivableCurrent" xlink:to="lab_vtvt_NotesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b8910e3e-db51-4834-9e3c-7e3680ce5739_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_75c3ea50-0d3e-436e-831e-2c04ebdcb06c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2c5ab82f-86cd-4829-b7d1-190c4cdafa21_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c945987b-65ae-4bf6-84e7-0797a65dd571_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_04754104-acc8-420f-a6a3-edd02078bbd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4926ccd6-0851-425c-b9c6-d6664a62e361_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_eebbe5d4-ec69-44a8-bb4a-a58b7a0e302d_terseLabel_en-US" xlink:label="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining available stock value</link:label>
    <link:label id="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Availability Stock Issued During Period Value New Issues</link:label>
    <link:label id="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_documentation_en-US" xlink:label="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under our controlled equity offering sales agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:href="vtvt-20230930.xsd#vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee9acbce-d112-4875-a544-584180ce7ef4_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_LicenseAgreementObligationsAxis_05ea81ec-2602-4251-857c-23a11429ea85_terseLabel_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsAxis_label_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Obligations [Axis]</link:label>
    <link:label id="lab_vtvt_LicenseAgreementObligationsAxis_documentation_en-US" xlink:label="lab_vtvt_LicenseAgreementObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsAxis" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis" xlink:to="lab_vtvt_LicenseAgreementObligationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0b9fa95b-f117-4f3d-b59e-1fd75557a1c5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8f001567-836b-41ac-b3e9-61d1df728170_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c0f7a75-9252-426e-9e15-0a26e1ad7e5c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_664cb7ad-947d-4c3f-bd03-eb6293fcf0aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7c90ad39-b5ab-4363-ac2d-5be4d3617f41_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_5de806b2-95fc-4935-982c-f3f0993671b3_terseLabel_en-US" xlink:label="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hangzhou Zhongmei Huadong Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:href="vtvt-20230930.xsd#vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:to="lab_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_2baf795d-48df-45a1-8548-4fc6bb1f4b65_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and financing receivable, after allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_66f04784-ff1a-4a92-88bc-1c5a9f07236a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b707b18d-7654-4f02-b904-b55b009ddf58_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d784ded8-3d00-41fe-b161-4bff0a959bd6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e069672c-d5a7-4cec-b1b9-97da6e254f3e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_a4a591e5-b568-40d6-af9b-403333d252ce_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_d721ac6f-d26e-44b5-9822-8660e4a81614_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_673f0a85-6313-4863-a0cc-406d8e3b5025_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_86df1103-5b35-4ba8-88c0-8b6b76233fa3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_ec5ecbc5-d6b4-4df9-8a5a-4b36307db2c5_terseLabel_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of majority owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_label_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage Of Majority Owner</link:label>
    <link:label id="lab_vtvt_OwnershipPercentageOfMajorityOwner_documentation_en-US" xlink:label="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of majority owner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:href="vtvt-20230930.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_OwnershipPercentageOfMajorityOwner" xlink:to="lab_vtvt_OwnershipPercentageOfMajorityOwner" xlink:type="arc" order="1"/>
    <link:label id="lab_vtvt_ReneoPharmaceuticalsIncMember_9c529b05-7425-4a9a-ad94-2f395739f532_terseLabel_en-US" xlink:label="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reneo</link:label>
    <link:label id="lab_vtvt_ReneoPharmaceuticalsIncMember_label_en-US" xlink:label="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reneo Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_vtvt_ReneoPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reneo Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtvt_ReneoPharmaceuticalsIncMember" xlink:to="lab_vtvt_ReneoPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_aaffb570-4f6b-4011-91d5-b8ebe923ac47_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vtvt-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:2f86a218-254c-44f1-a495-2edc3c6776ab,g:2074b840-4080-4341-9c3d-403534345ba0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vtvt-20230930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b0e11a7c-74c1-43d8-8372-ed95b74b5099" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0e11a7c-74c1-43d8-8372-ed95b74b5099" xlink:to="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2a4ab9b4-68bb-4add-8c6f-0a528fa41473" xlink:to="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5dffad38-2686-44c1-af96-20c479d5535e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:to="loc_us-gaap_CommonClassAMember_5dffad38-2686-44c1-af96-20c479d5535e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0f9ae79e-8b42-430f-9efe-d791c4e851cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8e9c5281-4416-47fa-9582-03b24c665b8a" xlink:to="loc_us-gaap_CommonClassBMember_0f9ae79e-8b42-430f-9efe-d791c4e851cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_81889bc2-9166-45ce-a65f-439c5823074e" xlink:to="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_039a7583-dba1-4905-92bf-72f5e4c41740" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentType_039a7583-dba1-4905-92bf-72f5e4c41740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_62799749-151d-46b0-804b-940cea5deec7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentQuarterlyReport_62799749-151d-46b0-804b-940cea5deec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_11a0d656-4566-4dbb-a374-71af052ac740" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentPeriodEndDate_11a0d656-4566-4dbb-a374-71af052ac740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6b8b8c9c-a866-4f4e-a978-5556a5a505fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentTransitionReport_6b8b8c9c-a866-4f4e-a978-5556a5a505fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_79dac961-2b87-4d50-a0cf-e02c0a5c7917" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityFileNumber_79dac961-2b87-4d50-a0cf-e02c0a5c7917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_229e67f9-7da3-49a3-9c39-d15c833e15f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityRegistrantName_229e67f9-7da3-49a3-9c39-d15c833e15f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a104d704-ba2d-4182-b588-3e0623b03b05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a104d704-ba2d-4182-b588-3e0623b03b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_296ddfa1-e747-4f46-9fa0-2b712c50884a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityTaxIdentificationNumber_296ddfa1-e747-4f46-9fa0-2b712c50884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a7fbd000-1144-4430-80f5-be81b6904262" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressAddressLine1_a7fbd000-1144-4430-80f5-be81b6904262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b3b08601-607f-4883-bc43-c180777f8152" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressAddressLine2_b3b08601-607f-4883-bc43-c180777f8152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e8f0dd05-98b2-495d-9cde-6ddaa030516c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressCityOrTown_e8f0dd05-98b2-495d-9cde-6ddaa030516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_660859a3-c9ee-495a-b783-b7e532b025eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressStateOrProvince_660859a3-c9ee-495a-b783-b7e532b025eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_111391f2-9b53-44af-a0c3-10cc68143e51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityAddressPostalZipCode_111391f2-9b53-44af-a0c3-10cc68143e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c76ce759-9d3d-4166-8aa5-697916f328ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_CityAreaCode_c76ce759-9d3d-4166-8aa5-697916f328ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86dfce61-e251-4653-8327-0339e81cebf3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_LocalPhoneNumber_86dfce61-e251-4653-8327-0339e81cebf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ec90d438-ea9b-4c4c-a8e2-f3583aa36725" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_Security12bTitle_ec90d438-ea9b-4c4c-a8e2-f3583aa36725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_49ea166e-b105-4070-acf8-06ebc4221ce8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_TradingSymbol_49ea166e-b105-4070-acf8-06ebc4221ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7ea2c3a6-bd92-488f-82be-2db6787a8dd2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_SecurityExchangeName_7ea2c3a6-bd92-488f-82be-2db6787a8dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d7e74a87-bf23-44cc-9cf4-307df715d3a6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityCurrentReportingStatus_d7e74a87-bf23-44cc-9cf4-307df715d3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_036828e3-7ca6-4175-9a0c-615edb0a8de8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityInteractiveDataCurrent_036828e3-7ca6-4175-9a0c-615edb0a8de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2f502246-8217-41d0-ada7-ad04309e7a0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityFilerCategory_2f502246-8217-41d0-ada7-ad04309e7a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f79da69d-9a30-4eae-a094-33807afb475a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntitySmallBusiness_f79da69d-9a30-4eae-a094-33807afb475a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_738d72f9-2697-40b8-abc1-ccc9c674673b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityEmergingGrowthCompany_738d72f9-2697-40b8-abc1-ccc9c674673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e6257f67-42f1-4ff5-8bdc-406105f00a1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityShellCompany_e6257f67-42f1-4ff5-8bdc-406105f00a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3c97a599-abb9-4c8d-92db-8dc1a059a45b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3c97a599-abb9-4c8d-92db-8dc1a059a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0522dc4d-3f79-46c4-87d3-ead1f085f6f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_EntityCentralIndexKey_0522dc4d-3f79-46c4-87d3-ead1f085f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a4fa0207-d767-4d36-b69d-05762e3a9d9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_CurrentFiscalYearEndDate_a4fa0207-d767-4d36-b69d-05762e3a9d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b73a5590-780f-464f-adbf-a5b4f2231d1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentFiscalYearFocus_b73a5590-780f-464f-adbf-a5b4f2231d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_094477f9-d817-45f2-bb66-20c72e49793b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_094477f9-d817-45f2-bb66-20c72e49793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3771bcd8-3006-49ad-9b4c-73fc215f5f0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ec106a56-8e85-437f-b082-1d11ef777ae5" xlink:to="loc_dei_AmendmentFlag_3771bcd8-3006-49ad-9b4c-73fc215f5f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ba562e66-45f0-4d30-af2a-d74c3dedc861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ba562e66-45f0-4d30-af2a-d74c3dedc861" xlink:to="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e7e6a645-e332-4f8b-9b2b-fb950e12329b" xlink:to="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0e50ab85-cf0c-43ca-bd70-807e431f04d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:to="loc_us-gaap_CommonClassAMember_0e50ab85-cf0c-43ca-bd70-807e431f04d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_742eb62a-576c-496b-bed3-43f5ea70c0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e507d871-05b5-4290-a32e-adc23d716176" xlink:to="loc_us-gaap_CommonClassBMember_742eb62a-576c-496b-bed3-43f5ea70c0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_218f346c-9a7e-47db-b1df-05616ef2d3cf" xlink:to="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:to="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff82a17-8681-460f-9f02-1e02c8cc63b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff82a17-8681-460f-9f02-1e02c8cc63b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f927128e-586d-4f9b-a561-0cf14805c6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f927128e-586d-4f9b-a561-0cf14805c6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableCurrent_3a440f99-030b-471c-9b6a-26e3d61384dd" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_vtvt_NotesReceivableCurrent_3a440f99-030b-471c-9b6a-26e3d61384dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ac5b92b-9cb7-4c23-aa42-b6b6a338169b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ac5b92b-9cb7-4c23-aa42-b6b6a338169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_b11d42ea-4edb-42e9-a469-375afb8477a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_DepositsAssetsCurrent_b11d42ea-4edb-42e9-a469-375afb8477a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6e7e44b0-21ac-4530-a506-f321be249dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_611c17f2-b96b-4fdb-89a4-470ff03fccf7" xlink:to="loc_us-gaap_AssetsCurrent_6e7e44b0-21ac-4530-a506-f321be249dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_718fa9ce-80fd-416b-ac10-367aac486e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_718fa9ce-80fd-416b-ac10-367aac486e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e41c918-174a-464f-85aa-b6bd0cd193dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e41c918-174a-464f-85aa-b6bd0cd193dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b7bb2102-ae9b-4c04-92ad-42031ff6613d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_LongTermInvestments_b7bb2102-ae9b-4c04-92ad-42031ff6613d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d8606d52-1c7a-4087-8512-db15e02b3570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d218b7d4-5335-487f-ae4c-67c520fb1075" xlink:to="loc_us-gaap_Assets_d8606d52-1c7a-4087-8512-db15e02b3570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e33e3b57-d3b7-452e-a7be-5049659c3d82" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aecc5dfc-7dbc-4c16-aeca-bb6919389baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aecc5dfc-7dbc-4c16-aeca-bb6919389baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3b69c9ec-aabb-4688-82c4-d7d47c857517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3b69c9ec-aabb-4688-82c4-d7d47c857517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df873757-cd84-45d4-b8d3-9f4ded0f50e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_df873757-cd84-45d4-b8d3-9f4ded0f50e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_a5f1c32c-9379-478a-9de3-b19831ec6e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_NotesPayableCurrent_a5f1c32c-9379-478a-9de3-b19831ec6e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a729f1ee-88e7-497b-80dd-bf23b0c0571c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_11c91fc9-7319-452f-93f9-180651f2b5ac" xlink:to="loc_us-gaap_LiabilitiesCurrent_a729f1ee-88e7-497b-80dd-bf23b0c0571c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c671e8f1-53a4-4281-a06b-6029ab787bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c671e8f1-53a4-4281-a06b-6029ab787bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42c27429-f6ef-4e2d-8f63-4520772fa6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42c27429-f6ef-4e2d-8f63-4520772fa6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantyLiability_eddf9747-5028-4698-9a9f-f7e1a657a1dc" xlink:href="vtvt-20230930.xsd#vtvt_WarrantyLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_vtvt_WarrantyLiability_eddf9747-5028-4698-9a9f-f7e1a657a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ac1e69b-56ae-446d-8dae-bd58e78a0ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_Liabilities_5ac1e69b-56ae-446d-8dae-bd58e78a0ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a04a49dc-90d3-4554-acd3-777e8a63ac59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a04a49dc-90d3-4554-acd3-777e8a63ac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d871da50-8a12-424a-beae-2f87347f3b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d871da50-8a12-424a-beae-2f87347f3b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7faaccd8-9a20-4724-8161-e8cb3f63cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:to="loc_us-gaap_CommonStockValue_7faaccd8-9a20-4724-8161-e8cb3f63cbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_06694183-be8b-4892-9b8e-54979e124d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_06694183-be8b-4892-9b8e-54979e124d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_04dc9eec-30c7-45e5-a70c-e303d8ccefc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1eaf4c9-6f60-448e-8815-a40c5fa71807" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_04dc9eec-30c7-45e5-a70c-e303d8ccefc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_32480119-7439-40c2-bbbd-9a633dc5dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_StockholdersEquity_32480119-7439-40c2-bbbd-9a633dc5dda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e60fe3a-ac36-43d9-92ce-ce4e1a0bfb82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_28797088-3d31-443c-b204-3f2d861ecf6b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e60fe3a-ac36-43d9-92ce-ce4e1a0bfb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_06e1537f-bb73-40b5-9347-57a00c332f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_06e1537f-bb73-40b5-9347-57a00c332f91" xlink:to="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e33a62fe-9142-4bcd-adf8-5364e622feba" xlink:to="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_42e91849-b3d7-42de-9686-cdf60bf50a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:to="loc_us-gaap_CommonClassAMember_42e91849-b3d7-42de-9686-cdf60bf50a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_946dddb2-ba53-4be7-8faf-3b1a9db84f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d9feccf-56d7-4d2d-88c2-f72764f1ec3c" xlink:to="loc_us-gaap_CommonClassBMember_946dddb2-ba53-4be7-8faf-3b1a9db84f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5c3b981-d137-4e18-b540-298d5a33da07" xlink:to="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bb69f181-5a1b-427a-941e-7afbbc3571c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bb69f181-5a1b-427a-941e-7afbbc3571c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ec60cfaa-b291-4af5-8089-20dbca21ec23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ec60cfaa-b291-4af5-8089-20dbca21ec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9e6aa35e-7ed4-4aac-bba1-6871765d0636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49fd098b-aa8f-4786-af4c-bb72e86d7819" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9e6aa35e-7ed4-4aac-bba1-6871765d0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0044d6de-133c-4178-977d-f918f86a47e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0044d6de-133c-4178-977d-f918f86a47e8" xlink:to="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_778aaeee-be10-430d-a6f9-27396bc36a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0be88566-38bf-4604-8487-1baf97b3af23" xlink:to="loc_us-gaap_ClassOfStockDomain_778aaeee-be10-430d-a6f9-27396bc36a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5a3aa59f-09ab-4e35-b384-d653856be20d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_778aaeee-be10-430d-a6f9-27396bc36a8b" xlink:to="loc_us-gaap_CommonClassAMember_5a3aa59f-09ab-4e35-b384-d653856be20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7819b70e-6ddf-4d7c-a153-815537a9a7c4" xlink:to="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_7c07477f-c1f7-430d-a5fc-6f6415d72992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:to="loc_us-gaap_NonrelatedPartyMember_7c07477f-c1f7-430d-a5fc-6f6415d72992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1eafac22-ab52-455a-831d-f2646e8c4630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4db06cd3-0be0-4c2f-b143-a221155f2b6b" xlink:to="loc_us-gaap_RelatedPartyMember_1eafac22-ab52-455a-831d-f2646e8c4630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c9c1d2e-eb7a-49ce-b4ce-90eb0dd84844" xlink:to="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29db10e7-45fe-4b04-89b4-d8ef0e878871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29db10e7-45fe-4b04-89b4-d8ef0e878871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_db6b16be-62ec-4026-a87f-41b97d5aed79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_db6b16be-62ec-4026-a87f-41b97d5aed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1d774d06-198a-4493-b233-060380606a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1d774d06-198a-4493-b233-060380606a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e1cf9ef-3e8c-408c-9de8-915076cc1a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fd26d9d6-f0f4-4aad-b612-5f3126041270" xlink:to="loc_us-gaap_OperatingExpenses_5e1cf9ef-3e8c-408c-9de8-915076cc1a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79ca588a-543e-43ec-bb48-050b55e6e221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_79ca588a-543e-43ec-bb48-050b55e6e221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_89e51a10-d78e-48c2-8b6b-b6743409a8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_89e51a10-d78e-48c2-8b6b-b6743409a8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4bb19c13-fe47-43c0-8916-98268f3b20ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4bb19c13-fe47-43c0-8916-98268f3b20ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94e7e7c6-df28-450b-ac27-c3bae3cfe134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_InterestExpense_94e7e7c6-df28-450b-ac27-c3bae3cfe134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7dbfc89-753d-48c6-8001-0b8062c85a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7dbfc89-753d-48c6-8001-0b8062c85a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d5afc152-22f8-4031-9e5a-d8da064bc39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d5afc152-22f8-4031-9e5a-d8da064bc39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1100f240-cee8-497e-aa55-02aa93bcccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_ProfitLoss_1100f240-cee8-497e-aa55-02aa93bcccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa08dbc2-b029-4580-aaa2-ad2ec4541ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa08dbc2-b029-4580-aaa2-ad2ec4541ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_598d1fa2-9776-4fa1-92a9-69f09188fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_NetIncomeLoss_598d1fa2-9776-4fa1-92a9-69f09188fbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b3bc2ae-89d4-45ad-8868-49e04322f2be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6b3bc2ae-89d4-45ad-8868-49e04322f2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0f7ee383-6e01-43a1-a7c3-041acedae146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_EarningsPerShareBasic_0f7ee383-6e01-43a1-a7c3-041acedae146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5dc0538f-fc79-42b8-b03a-869f1f4db7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5dc0538f-fc79-42b8-b03a-869f1f4db7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c20d930b-9a71-44bb-bf20-d2eb2e1617b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c20d930b-9a71-44bb-bf20-d2eb2e1617b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e521866-dceb-4a5e-877d-5399a34ca1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c3b81b74-45e6-43d6-a738-c2206ed934d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e521866-dceb-4a5e-877d-5399a34ca1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb5dcd52-45dd-478c-be07-c1460ad7d765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb5dcd52-45dd-478c-be07-c1460ad7d765" xlink:to="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_572d0ef3-4034-492a-812b-b0c4f3a8e46a" xlink:to="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7d3c32c6-95aa-4ccb-9fd1-78984b80cab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7d3c32c6-95aa-4ccb-9fd1-78984b80cab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f903a428-eb58-41f0-82a8-6000ad20b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_CommonStockMember_f903a428-eb58-41f0-82a8-6000ad20b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_5e204427-dde4-483a-865e-f0484aca4676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesFromStockholderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_5e204427-dde4-483a-865e-f0484aca4676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f03a5650-9304-4407-aece-63065c28a3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f03a5650-9304-4407-aece-63065c28a3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4765c247-d2b2-4bbb-8aed-b384008d6daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43ce3329-b4fe-4b60-9fec-8612c5d69c7e" xlink:to="loc_us-gaap_RetainedEarningsMember_4765c247-d2b2-4bbb-8aed-b384008d6daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6fd2aa01-95e0-4248-834f-eb202ee9585c" xlink:to="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestsMember_3541ac0e-96f3-4aa9-8eea-08ff496fb0eb" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNoncontrollingInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestsMember_3541ac0e-96f3-4aa9-8eea-08ff496fb0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_26593c14-93d6-478b-ae1b-3338b2890c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:to="loc_us-gaap_CommonClassAMember_26593c14-93d6-478b-ae1b-3338b2890c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_c5a332fd-11d3-4c78-adc3-fae92e7c9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_07d096e5-0e22-49c1-8438-f17e5c5573eb" xlink:to="loc_us-gaap_CommonClassBMember_c5a332fd-11d3-4c78-adc3-fae92e7c9d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_211631b7-4154-46a4-9e8f-4c8210b77cc5" xlink:to="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f2e5110e-6b9c-48b7-a87e-cd53c2e9bd77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f2e5110e-6b9c-48b7-a87e-cd53c2e9bd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_fc596f7d-ce71-4b01-b18e-1372158dd4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_fc596f7d-ce71-4b01-b18e-1372158dd4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TemporaryEquityChangeInRedemptionValue_1488e741-d2d5-4df1-995a-cfdc1471d452" xlink:href="vtvt-20230930.xsd#vtvt_TemporaryEquityChangeInRedemptionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_vtvt_TemporaryEquityChangeInRedemptionValue_1488e741-d2d5-4df1-995a-cfdc1471d452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9653b5e2-e76a-49c6-9235-e630d328566a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0e4f3954-d565-44f8-ae2e-546fbac44c44" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9653b5e2-e76a-49c6-9235-e630d328566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0cb858e4-2ebf-4706-b88f-f2273c653890" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02bc0943-1d33-4f97-9266-37a42d6f6562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_02bc0943-1d33-4f97-9266-37a42d6f6562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_914b9c76-5bdd-4fba-8643-b8eaf2a898a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockholdersEquity_914b9c76-5bdd-4fba-8643-b8eaf2a898a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_607437a1-4fb8-4667-8b02-341d236b132b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_NetIncomeLoss_607437a1-4fb8-4667-8b02-341d236b132b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e7fba0de-78f4-4e04-a2b8-1ed8e8c0c43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e7fba0de-78f4-4e04-a2b8-1ed8e8c0c43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3df1668a-843c-42cd-8253-8fdbf0733bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3df1668a-843c-42cd-8253-8fdbf0733bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_783d8984-e1f2-4382-9774-9b653214338b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_783d8984-e1f2-4382-9774-9b653214338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_725397d5-bb89-49d0-a8d0-c17c6cd658cd" xlink:href="vtvt-20230930.xsd#vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement_725397d5-bb89-49d0-a8d0-c17c6cd658cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_0d592aad-e6c6-4fa5-b034-296fbcea5cf6" xlink:href="vtvt-20230930.xsd#vtvt_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement_0d592aad-e6c6-4fa5-b034-296fbcea5cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_fa034394-7ca9-4bbb-952b-ee1af0f6efa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_fa034394-7ca9-4bbb-952b-ee1af0f6efa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce84c70a-b4ef-421b-9b5e-031689f563b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ce84c70a-b4ef-421b-9b5e-031689f563b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90d63918-db59-46f0-bee8-7a84aa75189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8b3d6064-f92c-403a-8e68-3d853f789e94" xlink:to="loc_us-gaap_StockholdersEquity_90d63918-db59-46f0-bee8-7a84aa75189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a86e5cb6-ba5f-4b22-b130-a55c4a0d636c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a86e5cb6-ba5f-4b22-b130-a55c4a0d636c" xlink:to="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f0fdc342-fb81-462c-aaf1-f90fda427f65" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d25dc568-d66e-478e-90ca-55244f292ef9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f0fdc342-fb81-462c-aaf1-f90fda427f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxMember_ddacc1f6-381f-400d-bd90-642b59853df8" xlink:href="vtvt-20230930.xsd#vtvt_CinRxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f0fdc342-fb81-462c-aaf1-f90fda427f65" xlink:to="loc_vtvt_CinRxMember_ddacc1f6-381f-400d-bd90-642b59853df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5ca4ad7-3bf4-4bf6-b359-9ce3d2e4ca91" xlink:to="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4618e28a-ae03-4a50-9d3a-067aef6fbeee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_ProfitLoss_4618e28a-ae03-4a50-9d3a-067aef6fbeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1c65cf36-4e1d-4bf4-bbbd-4925af688b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_Depreciation_1c65cf36-4e1d-4bf4-bbbd-4925af688b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b135b77-c9ed-4415-86f5-107e44077c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b135b77-c9ed-4415-86f5-107e44077c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_4614e5bd-e672-4c0f-96d1-c894b97068f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_InterestIncomeOperating_4614e5bd-e672-4c0f-96d1-c894b97068f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_891fe151-3b6a-4a84-8105-59a77e567e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_InterestExpenseOther_891fe151-3b6a-4a84-8105-59a77e567e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cb71bfbe-735c-4fb3-a3e4-924cefee94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_ShareBasedCompensation_cb71bfbe-735c-4fb3-a3e4-924cefee94ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_f2c75604-f97d-46d8-8c74-18a604a20d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_f2c75604-f97d-46d8-8c74-18a604a20d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_6aae4665-6848-4137-984c-15d536473273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_6aae4665-6848-4137-984c-15d536473273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_a6aef3c2-e0c5-4930-bbbe-afeb00ce6644" xlink:href="vtvt-20230930.xsd#vtvt_ChangeInFairValueOfWarrantsRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35859f25-d282-4846-94bb-3acbf4860b12" xlink:to="loc_vtvt_ChangeInFairValueOfWarrantsRelatedParty_a6aef3c2-e0c5-4930-bbbe-afeb00ce6644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97220dff-e70d-460c-863b-d1680b3a04a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97220dff-e70d-460c-863b-d1680b3a04a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5936db14-3ebd-4ab7-ba57-dae74266c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5936db14-3ebd-4ab7-ba57-dae74266c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_27841ab1-501f-4e6c-a2e7-cf8beaf7f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_27841ab1-501f-4e6c-a2e7-cf8beaf7f9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7ddd5b33-1db6-429b-9356-c038bc8dd3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7179d449-5efd-4736-aea6-5e1d26612bb3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7ddd5b33-1db6-429b-9356-c038bc8dd3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c617d800-f55a-4827-90e0-e2f63112f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c617d800-f55a-4827-90e0-e2f63112f67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b6553f9-2cf7-4aca-b62f-2ab2ec491cac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9d854484-6f20-4151-9013-892593027248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9d854484-6f20-4151-9013-892593027248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6617328a-eed5-4075-b47c-809418e23e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2c680616-5853-455d-af64-682e9d7c5860" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6617328a-eed5-4075-b47c-809418e23e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_17073d65-ea94-42f4-97d2-42142ccdc5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_17073d65-ea94-42f4-97d2-42142ccdc5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dc3bb50b-6a06-4f35-af52-e6ed45177b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dc3bb50b-6a06-4f35-af52-e6ed45177b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_fabb88f6-b939-461c-a360-b4eedabb0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_fabb88f6-b939-461c-a360-b4eedabb0ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9405c2ad-f251-46b9-8914-5c91a59a3a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9405c2ad-f251-46b9-8914-5c91a59a3a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7c902ba5-0769-4719-bc9d-c6ae1adb4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7c902ba5-0769-4719-bc9d-c6ae1adb4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_926ddf98-03ea-414a-90a9-ac34b1b1649f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8dc8d3d9-b3e2-4f11-8c85-0c8f0f1dd8a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_926ddf98-03ea-414a-90a9-ac34b1b1649f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de86a938-84f5-4fa7-8886-c7f8ebb88ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de86a938-84f5-4fa7-8886-c7f8ebb88ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e540ed09-787e-4e6a-ab11-6ceaa9ef9d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e540ed09-787e-4e6a-ab11-6ceaa9ef9d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c87fa7e5-5bd6-4e4c-8017-5cd80ef02842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c87fa7e5-5bd6-4e4c-8017-5cd80ef02842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c818e6b5-90e5-42fe-b469-3c48a5d45900" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_3072beff-d616-43c4-b974-36fdcc54d751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_3072beff-d616-43c4-b974-36fdcc54d751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableFromCollaborators_511d201a-c4b9-4f48-af58-de439960f88b" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableFromCollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:to="loc_vtvt_NotesReceivableFromCollaborators_511d201a-c4b9-4f48-af58-de439960f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableFromCollaborators_00d86831-518b-4588-af60-db19e63bb3dc" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableFromCollaborators"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_51523344-0a3d-4475-9340-73871d417ee0" xlink:to="loc_vtvt_NotesReceivableFromCollaborators_00d86831-518b-4588-af60-db19e63bb3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" xlink:type="simple" xlink:href="vtvt-20230930.xsd#DescriptionofBusinessBasisofPresentationandGoingConcern"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c8409a3-e08a-4d61-9605-4dc55c48934f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9b37e612-4418-4c15-bd1f-532ff90c1cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c8409a3-e08a-4d61-9605-4dc55c48934f" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9b37e612-4418-4c15-bd1f-532ff90c1cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_14ef3dbe-8bc3-4cc8-91a4-8a979f8b696c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b35631e5-d57c-4848-9513-0dc93efcd993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14ef3dbe-8bc3-4cc8-91a4-8a979f8b696c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b35631e5-d57c-4848-9513-0dc93efcd993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6578881-b996-4fd7-8fc2-9060947c5ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_50a5ccda-705c-4fc0-8526-c5e5c6b61a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6578881-b996-4fd7-8fc2-9060947c5ec3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_50a5ccda-705c-4fc0-8526-c5e5c6b61a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_355367da-57c8-46c7-a00e-b4150c19d0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d841c0f-5c86-4fee-a9b9-915b6a58363a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_355367da-57c8-46c7-a00e-b4150c19d0bd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d841c0f-5c86-4fee-a9b9-915b6a58363a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Investments" xlink:type="simple" xlink:href="vtvt-20230930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c3831f8d-b647-4153-ac09-725183840048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f76e96da-1bd4-48e8-96e2-0fa6d5381f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c3831f8d-b647-4153-ac09-725183840048" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f76e96da-1bd4-48e8-96e2-0fa6d5381f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0bb53eb2-2e8e-46c3-af4b-c549fa042d79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb609fe0-4e4c-40d0-802e-bbfb37cb3fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0bb53eb2-2e8e-46c3-af4b-c549fa042d79" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb609fe0-4e4c-40d0-802e-bbfb37cb3fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/Leases" xlink:type="simple" xlink:href="vtvt-20230930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4ae14feb-a1f4-4178-b2e5-3c9ff6863676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ef1789fe-8d9e-4ffb-9d37-567fb1513302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ae14feb-a1f4-4178-b2e5-3c9ff6863676" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ef1789fe-8d9e-4ffb-9d37-567fb1513302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RedeemableNoncontrollingInterest"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_0900749f-ea31-4355-8ad2-f34c40a9eaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_cc2b56ba-f41f-44bb-94f5-c77a3cfc89d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_0900749f-ea31-4355-8ad2-f34c40a9eaa7" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_cc2b56ba-f41f-44bb-94f5-c77a3cfc89d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="vtvt-20230930.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6c21a450-a5cf-4386-85eb-5a15cfdf2766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_55c526fa-c46b-466b-bd1c-3c0ca916d283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c21a450-a5cf-4386-85eb-5a15cfdf2766" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_55c526fa-c46b-466b-bd1c-3c0ca916d283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c48859b1-fdc6-4c74-b7a2-00fde5ca4a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_389dd011-56f8-48aa-90b9-f6007203c399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c48859b1-fdc6-4c74-b7a2-00fde5ca4a5b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_389dd011-56f8-48aa-90b9-f6007203c399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vtvt-20230930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46f3359a-bd90-464f-a3cb-9559f01fc95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e02b5fb5-d43b-496e-80dd-a7df88ac8f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46f3359a-bd90-464f-a3cb-9559f01fc95c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e02b5fb5-d43b-496e-80dd-a7df88ac8f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShare" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c97ddd51-7f35-4ef4-a74e-faad40f9dc82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_794e90f5-75ea-4df4-8bc9-da29553ca601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c97ddd51-7f35-4ef4-a74e-faad40f9dc82" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_794e90f5-75ea-4df4-8bc9-da29553ca601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7b95fda1-09d8-47b4-9887-0e4229793932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7c5c213d-c730-40d2-b1c3-4990b796e4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7b95fda1-09d8-47b4-9887-0e4229793932" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7c5c213d-c730-40d2-b1c3-4990b796e4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b6cc4557-2ec2-479b-a088-bf8730bb9c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_47d93263-4ac2-4bf3-b6eb-a63f19664a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b6cc4557-2ec2-479b-a088-bf8730bb9c8b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_47d93263-4ac2-4bf3-b6eb-a63f19664a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_8479f774-33b5-415c-ba60-ef48fb29a494" xlink:href="vtvt-20230930.xsd#vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock_8479f774-33b5-415c-ba60-ef48fb29a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_76047c90-27f4-4c69-8a14-e4181469bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_UseOfEstimates_76047c90-27f4-4c69-8a14-e4181469bd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_181c4100-9172-4747-a6d7-e57514431202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_181c4100-9172-4747-a6d7-e57514431202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_02088840-4ea0-4168-b66e-e5e57ff7e956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_02088840-4ea0-4168-b66e-e5e57ff7e956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7a0a66f9-e144-4f6f-ae5f-834595a812d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7a0a66f9-e144-4f6f-ae5f-834595a812d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c4b44d7c-11b5-412c-8277-b70a5c45374e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c4b44d7c-11b5-412c-8277-b70a5c45374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_57d136a1-d7bb-4e6c-bba1-fb8fc9403d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_57d136a1-d7bb-4e6c-bba1-fb8fc9403d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79e2a2b8-4279-4c8c-877f-6d5de24c15c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a587af-de6b-4fbe-a6de-e99cff891329" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79e2a2b8-4279-4c8c-877f-6d5de24c15c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d5811c4-4e57-46ab-a9ca-aa55ab8ef525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4190f006-17c9-4f77-97f3-611e36e3410f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d5811c4-4e57-46ab-a9ca-aa55ab8ef525" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4190f006-17c9-4f77-97f3-611e36e3410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b0a958-bdcd-4eb4-84ae-2bd53b4f226f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7bc62291-b63b-4783-b705-830026cf6958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b0a958-bdcd-4eb4-84ae-2bd53b4f226f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7bc62291-b63b-4783-b705-830026cf6958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a1b6d6b1-d393-44d8-8f44-45d5b3a659df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19b0a958-bdcd-4eb4-84ae-2bd53b4f226f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a1b6d6b1-d393-44d8-8f44-45d5b3a659df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4de313b-851c-4850-97cc-ec69a2dffb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_c57c198c-7570-4c35-a6d1-aeacbfac4ddf" xlink:href="vtvt-20230930.xsd#vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4de313b-851c-4850-97cc-ec69a2dffb2a" xlink:to="loc_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock_c57c198c-7570-4c35-a6d1-aeacbfac4ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dbbbc9f1-714c-4d4f-99c3-d5c05ea85216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e35a72f8-ddb8-40cf-ae71-f77068819a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dbbbc9f1-714c-4d4f-99c3-d5c05ea85216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e35a72f8-ddb8-40cf-ae71-f77068819a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RedeemableNoncontrollingInterestTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_1aff283d-50ea-41c8-989d-9fca022719f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_7b82345f-15df-4fae-80cc-7b4e378f32ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_1aff283d-50ea-41c8-989d-9fca022719f3" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_7b82345f-15df-4fae-80cc-7b4e378f32ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_93ed59a2-8f0b-47cd-9ca3-a568eb388285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ac18c2c4-d241-44de-9e2e-276bca5c4616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93ed59a2-8f0b-47cd-9ca3-a568eb388285" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ac18c2c4-d241-44de-9e2e-276bca5c4616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a2973b66-4301-42ed-88b0-61d647ac8876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93ed59a2-8f0b-47cd-9ca3-a568eb388285" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a2973b66-4301-42ed-88b0-61d647ac8876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2955e2a7-0d41-4f5f-a917-5c0f6ea656bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0b111e85-56e0-4ddb-8d62-7923fee75b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2955e2a7-0d41-4f5f-a917-5c0f6ea656bc" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0b111e85-56e0-4ddb-8d62-7923fee75b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b68bca02-158e-4d75-92b9-3a64443e33a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2955e2a7-0d41-4f5f-a917-5c0f6ea656bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b68bca02-158e-4d75-92b9-3a64443e33a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#DescriptionofBusinessBasisofPresentationandGoingConcernDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d9111b7-4881-4ff7-93b8-ef9848efb372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:href="vtvt-20230930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d9111b7-4881-4ff7-93b8-ef9848efb372" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0bbe1ee6-762e-4202-bae8-d53ee8d54a70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_659a9881-f83a-422c-b7ce-e851f21413c5" xlink:to="loc_dei_EntityDomain_0bbe1ee6-762e-4202-bae8-d53ee8d54a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_b3ed0485-ca72-4f21-b9c8-976d39f32988" xlink:href="vtvt-20230930.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0bbe1ee6-762e-4202-bae8-d53ee8d54a70" xlink:to="loc_vtvt_VTvLLCMember_b3ed0485-ca72-4f21-b9c8-976d39f32988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_adf703fb-7534-4fc9-b83c-337eabd09285" xlink:to="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_57e2519e-716e-4299-8409-33cb64370778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:to="loc_us-gaap_CommonClassAMember_57e2519e-716e-4299-8409-33cb64370778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_bb8c4f73-e51e-4863-ba15-3327706ef11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_355a51af-c361-4b42-b993-cccbecf8df91" xlink:to="loc_us-gaap_CommonClassBMember_bb8c4f73-e51e-4863-ba15-3327706ef11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAgreementObligationsDomain_77114753-a030-45ce-81cb-678229512e16" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAgreementObligationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_LicenseAgreementObligationsAxis_fe23b21f-c7f7-4c05-a058-fcfb7d7e7fd6" xlink:to="loc_vtvt_LicenseAgreementObligationsDomain_77114753-a030-45ce-81cb-678229512e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_6cf49d4a-f2ec-4178-aba8-edd0b571e97b" xlink:href="vtvt-20230930.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_LicenseAgreementObligationsDomain_77114753-a030-45ce-81cb-678229512e16" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_6cf49d4a-f2ec-4178-aba8-edd0b571e97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0a75a847-b453-4f45-a0ee-b219d7b8b383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9c9d01fd-8e22-4b9c-a21e-32f68f7fb444" xlink:to="loc_us-gaap_RelatedPartyDomain_0a75a847-b453-4f45-a0ee-b219d7b8b383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_168f1460-b8bd-4fd6-a0db-ed24ec170857" xlink:href="vtvt-20230930.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0a75a847-b453-4f45-a0ee-b219d7b8b383" xlink:to="loc_vtvt_CantorFitzgeraldMember_168f1460-b8bd-4fd6-a0db-ed24ec170857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:href="vtvt-20230930.xsd#vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_f7f14d93-e353-4993-b5d1-1106501f206c" xlink:to="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_88f79136-425a-439b-a947-2f17609d4051" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_88f79136-425a-439b-a947-2f17609d4051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_ab3898c5-d450-425d-8695-7e6cdb1353b2" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterestByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterestByParent_ab3898c5-d450-425d-8695-7e6cdb1353b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83844ae0-e32e-4b22-b0f4-0d4a19097aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83844ae0-e32e-4b22-b0f4-0d4a19097aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1aff075-e092-4a8c-9b69-cf83618295e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1aff075-e092-4a8c-9b69-cf83618295e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6b32d58-a64f-4a5b-98d1-a7c7d8bf86e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6b32d58-a64f-4a5b-98d1-a7c7d8bf86e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_cd8b04bf-84c9-4dbb-b829-124730f04d6a" xlink:href="vtvt-20230930.xsd#vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues_cd8b04bf-84c9-4dbb-b829-124730f04d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_82412924-8604-4403-9204-5abefd33de47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_3dcb3b20-3be5-4a56-991e-6be543b7cd10" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_82412924-8604-4403-9204-5abefd33de47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f07bfd6-63d5-489e-9719-e0ee03aeef42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:href="vtvt-20230930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f07bfd6-63d5-489e-9719-e0ee03aeef42" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e9d51a0a-eb83-4d53-a705-6a4db77a271a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4d96c011-ff55-4561-a82b-275306e9f7fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e9d51a0a-eb83-4d53-a705-6a4db77a271a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_3f1356d5-fa92-4ddb-8ef6-c107a41633e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e9d51a0a-eb83-4d53-a705-6a4db77a271a" xlink:to="loc_us-gaap_SalesRevenueNetMember_3f1356d5-fa92-4ddb-8ef6-c107a41633e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a37860f8-6ec4-4433-990b-9214a0727499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dec8e113-d4df-4cb9-8c80-3033b5df5537" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a37860f8-6ec4-4433-990b-9214a0727499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b3185b10-adc2-4ca4-9b18-419d5882925f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a37860f8-6ec4-4433-990b-9214a0727499" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b3185b10-adc2-4ca4-9b18-419d5882925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eaaba523-26ab-4945-bcf5-c46f080c331a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d5de94f7-59a4-4701-bb53-49d8dcf077e0" xlink:to="loc_srt_NameOfMajorCustomerDomain_eaaba523-26ab-4945-bcf5-c46f080c331a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OneCustomerMember_ac0076d9-adc7-491c-8538-92f6365b83d1" xlink:href="vtvt-20230930.xsd#vtvt_OneCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eaaba523-26ab-4945-bcf5-c46f080c331a" xlink:to="loc_vtvt_OneCustomerMember_ac0076d9-adc7-491c-8538-92f6365b83d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:href="vtvt-20230930.xsd#vtvt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesTable_ebee8a25-ebca-4a19-a4f8-8c9e707f4937" xlink:to="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_082efa6b-3f8d-4afb-9fbe-8ebb721743be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_082efa6b-3f8d-4afb-9fbe-8ebb721743be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6834afb-500c-4db1-9284-d7c73473176e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_SummaryOfSignificantAccountingPoliciesLineItems_ae400e4a-9442-4969-acfe-64197b570d99" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6834afb-500c-4db1-9284-d7c73473176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6cbd33c0-54a7-4edd-9934-fe5f659201b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6cbd33c0-54a7-4edd-9934-fe5f659201b3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_330b76bf-c55f-4fa4-84d7-69ab99a25e27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_b3d403bb-e1aa-412c-8d5b-e201802863ac" xlink:href="vtvt-20230930.xsd#vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:to="loc_vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember_b3d403bb-e1aa-412c-8d5b-e201802863ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_907dd2e0-beaf-45b5-a8d4-c7b12af204b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de8509d7-9053-4dc4-b61b-ed06831a8c69" xlink:to="loc_us-gaap_CollaborativeArrangementMember_907dd2e0-beaf-45b5-a8d4-c7b12af204b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d9a12fe6-6066-4469-be17-886b957463f9" xlink:to="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_JDRFInternationalMember_c3f641d1-9c2c-41ee-aa92-1339f7e83bd6" xlink:href="vtvt-20230930.xsd#vtvt_JDRFInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:to="loc_vtvt_JDRFInternationalMember_c3f641d1-9c2c-41ee-aa92-1339f7e83bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_2c1d1238-4ffa-4b0c-aa0f-0756b6c37a3b" xlink:href="vtvt-20230930.xsd#vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:to="loc_vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember_2c1d1238-4ffa-4b0c-aa0f-0756b6c37a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_125c4d39-87c6-422c-b927-c7fccfe02e80" xlink:href="vtvt-20230930.xsd#vtvt_AnterisBioIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4780e511-4091-4bba-95a5-0c77f44a7a7b" xlink:to="loc_vtvt_AnterisBioIncMember_125c4d39-87c6-422c-b927-c7fccfe02e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6161ba41-7fd4-47dd-a568-1661da61ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ad352f49-9371-493f-bbb2-40e2926af1e1" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6161ba41-7fd4-47dd-a568-1661da61ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_63bae855-da61-433e-b45a-9e3b297e4e74" xlink:href="vtvt-20230930.xsd#vtvt_PhaseTwoMultiRegionalClinicalTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_6161ba41-7fd4-47dd-a568-1661da61ae93" xlink:to="loc_vtvt_PhaseTwoMultiRegionalClinicalTrialMember_63bae855-da61-433e-b45a-9e3b297e4e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd959262-b043-48a7-9068-e0c7852b5b6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e1faf32d-b08d-4041-81d8-a7622b2b5fe6" xlink:to="loc_srt_ProductsAndServicesDomain_fd959262-b043-48a7-9068-e0c7852b5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_1101cf69-560e-4a39-b1b6-fbb3d39b24c3" xlink:href="vtvt-20230930.xsd#vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd959262-b043-48a7-9068-e0c7852b5b6d" xlink:to="loc_vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember_1101cf69-560e-4a39-b1b6-fbb3d39b24c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_30e07ecc-c187-412b-81c0-959b4bdc160d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_04c124ce-ba77-4a9d-bff3-da4e1357a574" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:to="loc_vtvt_G42InvestmentsMember_04c124ce-ba77-4a9d-bff3-da4e1357a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CognaMember_9e178783-b68c-468c-af53-e77a918f793c" xlink:href="vtvt-20230930.xsd#vtvt_CognaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_56d0d6db-d980-4751-b64b-34d826ea19fe" xlink:to="loc_vtvt_CognaMember_9e178783-b68c-468c-af53-e77a918f793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bbe52a6-4733-4e92-89ed-51e04c3a53e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2b04a047-7371-4f8f-ad80-da780300c55e" xlink:to="loc_us-gaap_ClassOfStockDomain_5bbe52a6-4733-4e92-89ed-51e04c3a53e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0174acfb-a73c-4ba8-b280-6fdbc6880760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bbe52a6-4733-4e92-89ed-51e04c3a53e8" xlink:to="loc_us-gaap_CommonClassAMember_0174acfb-a73c-4ba8-b280-6fdbc6880760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6c61df0-0899-4999-9c8e-854806c9de4d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e2549ef-6588-4d41-9393-fba4ced3f459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e2549ef-6588-4d41-9393-fba4ced3f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf94ecff-0624-45ac-825b-00f05b569cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf94ecff-0624-45ac-825b-00f05b569cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_2f7440f2-af0f-49de-80b4-138ffc5bb925" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_2f7440f2-af0f-49de-80b4-138ffc5bb925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1c193ca-5a52-4eec-9316-62b86e93a139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f1c193ca-5a52-4eec-9316-62b86e93a139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_edfb0932-076f-41ca-8ba2-b66e5fa029e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_edfb0932-076f-41ca-8ba2-b66e5fa029e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_1598ba9b-eb2e-4cce-8473-1ce8b9c9474c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_1598ba9b-eb2e-4cce-8473-1ce8b9c9474c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_79b6fcf7-6b2c-4cc2-952f-f682c88598a7" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_NotesReceivableDiscountRate_79b6fcf7-6b2c-4cc2-952f-f682c88598a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fde5f63a-2529-41c7-ad3f-9ea6dbb5f065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fde5f63a-2529-41c7-ad3f-9ea6dbb5f065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_095aebfb-0b5b-4eb4-98a7-566e6377bf89" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue_095aebfb-0b5b-4eb4-98a7-566e6377bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_a959503b-5da8-454b-b12a-3f2b9423658e" xlink:href="vtvt-20230930.xsd#vtvt_CollaborateArrangementContingentConsiderationTransferredCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborateArrangementContingentConsiderationTransferredCash_a959503b-5da8-454b-b12a-3f2b9423658e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_bd313481-4f2a-4d0a-9e62-ebd574bf9a66" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod_bd313481-4f2a-4d0a-9e62-ebd574bf9a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_34f3174b-7151-402b-ac4b-2b242a0116d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_CommonStockValueOutstanding_34f3174b-7151-402b-ac4b-2b242a0116d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d3e2919f-b90b-4fa4-9ace-2250d52df541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_SharePrice_d3e2919f-b90b-4fa4-9ace-2250d52df541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8d178bab-2886-41e4-b1ef-f0ec29905fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8d178bab-2886-41e4-b1ef-f0ec29905fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_0bc9ae2e-f529-467e-a46d-a1e74bc10943" xlink:href="vtvt-20230930.xsd#vtvt_CollaborativeArrangementNoteReceivableDiscountPaid"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid_0bc9ae2e-f529-467e-a46d-a1e74bc10943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6874b763-175b-4800-b4a8-574f59b2808b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6874b763-175b-4800-b4a8-574f59b2808b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184256fe-8fc5-48d6-b26c-3ed0e544cc41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184256fe-8fc5-48d6-b26c-3ed0e544cc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesFairValueDisclosure_21571110-87f7-4beb-8ebd-2cdc27c0d0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesFairValueDisclosure"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ReceivablesFairValueDisclosure_21571110-87f7-4beb-8ebd-2cdc27c0d0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_e20132cd-a14b-4a39-ad82-a871d4813b8f" xlink:href="vtvt-20230930.xsd#vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones_e20132cd-a14b-4a39-ad82-a871d4813b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MaximumSponsoringContributionAmount_295c5265-d225-4c83-b0f2-533e25c17308" xlink:href="vtvt-20230930.xsd#vtvt_MaximumSponsoringContributionAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_MaximumSponsoringContributionAmount_295c5265-d225-4c83-b0f2-533e25c17308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_ac4c06ed-bfd6-434f-8a59-aa5707dba2a8" xlink:href="vtvt-20230930.xsd#vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable_ac4c06ed-bfd6-434f-8a59-aa5707dba2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_94c4f6aa-f304-4a71-b926-4ffe030e23a7" xlink:href="vtvt-20230930.xsd#vtvt_AdjustmentsToTransactionPriceForPerformanceObligations"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations_94c4f6aa-f304-4a71-b926-4ffe030e23a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LicenseFeeReceived_cfb3248d-2854-42bb-8edc-d0c2626add19" xlink:href="vtvt-20230930.xsd#vtvt_LicenseFeeReceived"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_vtvt_LicenseFeeReceived_cfb3248d-2854-42bb-8edc-d0c2626add19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_8ff5cfd1-11a6-45bf-905e-c32e0f3caa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInterestAndDividendsReceived"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ProceedsFromInterestAndDividendsReceived_8ff5cfd1-11a6-45bf-905e-c32e0f3caa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a6b6289-2bd3-4b45-a318-327f5f5bea31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f6a5930-132f-4610-821f-aca1aed60d33" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a6b6289-2bd3-4b45-a318-327f5f5bea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50ff7edf-5f2a-41eb-85cb-c304638cdc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ceeffd7-1e0c-4a6c-bc34-c34880bc7754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50ff7edf-5f2a-41eb-85cb-c304638cdc08" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ceeffd7-1e0c-4a6c-bc34-c34880bc7754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a4e8138f-1b09-48cf-b1a0-bf39f17f39b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50ff7edf-5f2a-41eb-85cb-c304638cdc08" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a4e8138f-1b09-48cf-b1a0-bf39f17f39b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d5fbbd65-5a60-403b-b452-9a0098ac48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50ff7edf-5f2a-41eb-85cb-c304638cdc08" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d5fbbd65-5a60-403b-b452-9a0098ac48e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8181f6ff-a222-48b8-abe5-3b0e184a3ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8181f6ff-a222-48b8-abe5-3b0e184a3ace" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:to="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814beb05-1cae-4698-a456-66d9fc0d5ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_37e7f3dc-e324-43bc-90e5-c544c2158e43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814beb05-1cae-4698-a456-66d9fc0d5ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_71814907-8d3c-4442-b913-0ed4baf87453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814beb05-1cae-4698-a456-66d9fc0d5ba1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_71814907-8d3c-4442-b913-0ed4baf87453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9562853-1f2d-4812-8f1b-b6162c1e5b8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3e1397b1-2c45-47a9-be7d-f0abc86d0d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3e1397b1-2c45-47a9-be7d-f0abc86d0d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68f81853-5331-4d55-933b-4f1ce626f08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68f81853-5331-4d55-933b-4f1ce626f08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0baac68f-9cd8-4158-9238-63dab6c15315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0baac68f-9cd8-4158-9238-63dab6c15315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c9b4f31-5177-4b53-b0c6-72fc93484258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4c9b4f31-5177-4b53-b0c6-72fc93484258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfb01f89-4c2a-47af-b185-9e831361e85e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12f0bfb2-339a-4b35-b543-ad5aa3e5bb7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfb01f89-4c2a-47af-b185-9e831361e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e0e3b7f-076e-424a-9579-f316197f7a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e0e3b7f-076e-424a-9579-f316197f7a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e2732ad-a3b5-4714-ae63-f9eb6be11c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e0e3b7f-076e-424a-9579-f316197f7a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e2732ad-a3b5-4714-ae63-f9eb6be11c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0bc24a3d-ecb1-4b6a-b285-0dc7dbf217e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e0e3b7f-076e-424a-9579-f316197f7a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0bc24a3d-ecb1-4b6a-b285-0dc7dbf217e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b2bc2d35-ae96-4833-b4e2-37b3ab665bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e0e3b7f-076e-424a-9579-f316197f7a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b2bc2d35-ae96-4833-b4e2-37b3ab665bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73761194-2ded-49aa-a853-2d4125c3d096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8e0e3b7f-076e-424a-9579-f316197f7a86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73761194-2ded-49aa-a853-2d4125c3d096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21200e0e-f3bf-49ab-854d-c426dc2b2a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21200e0e-f3bf-49ab-854d-c426dc2b2a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aa734bc7-f75a-4578-81a9-b779e3e7c2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aa734bc7-f75a-4578-81a9-b779e3e7c2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_bf008c1b-f13d-42eb-9cb6-128fbb2d4045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_bf008c1b-f13d-42eb-9cb6-128fbb2d4045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6f1b4440-3003-4f4d-b852-88ccf58d57c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6f1b4440-3003-4f4d-b852-88ccf58d57c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b06ef6de-905e-499d-a80d-7c7a1360a474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b06ef6de-905e-499d-a80d-7c7a1360a474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea461560-f38e-425f-8e33-b1af087e93dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b06ef6de-905e-499d-a80d-7c7a1360a474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea461560-f38e-425f-8e33-b1af087e93dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f85d749-80ea-4169-a212-4554954bb364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b06ef6de-905e-499d-a80d-7c7a1360a474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f85d749-80ea-4169-a212-4554954bb364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_311cf7b4-1ec2-4d05-9c08-905ee2f2e98d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b06ef6de-905e-499d-a80d-7c7a1360a474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_311cf7b4-1ec2-4d05-9c08-905ee2f2e98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16b8a412-31c8-4b6e-9d5e-e2c8b9c85806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b06ef6de-905e-499d-a80d-7c7a1360a474" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16b8a412-31c8-4b6e-9d5e-e2c8b9c85806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_119fc77e-4282-4e07-bee6-51f734efad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_119fc77e-4282-4e07-bee6-51f734efad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cd9a2299-4915-487c-8694-c2623f989472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3608c98c-4c5c-494f-ab9b-9b8db8cc9171" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cd9a2299-4915-487c-8694-c2623f989472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e6cb861-6aac-4f2a-8c4b-f5e11f4f6fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e6cb861-6aac-4f2a-8c4b-f5e11f4f6fca" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_433d5e87-0832-4a73-9a30-555f35d83a0d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f19b48fd-579d-400c-9d43-2f3b43db1bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f19b48fd-579d-400c-9d43-2f3b43db1bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_866ce0fa-48a5-48b3-b5e6-b2d98ded007d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_310412df-7a73-4bbd-bc0c-3b4d1c353a49" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_866ce0fa-48a5-48b3-b5e6-b2d98ded007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c38993bf-a77e-4567-9d14-4bb28a8ef4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d391df1c-93d5-4528-af75-b7b9494d0132" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c38993bf-a77e-4567-9d14-4bb28a8ef4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_743eb9a9-3e5a-456d-ae8e-174b9a9ca9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c38993bf-a77e-4567-9d14-4bb28a8ef4ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_743eb9a9-3e5a-456d-ae8e-174b9a9ca9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#InvestmentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1fd8feb4-7537-4d48-b54d-f3eefc01214a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1fd8feb4-7537-4d48-b54d-f3eefc01214a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:to="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4fd3eaf3-9fdb-4d49-8a6c-29032a505191" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9627ebb2-dcc0-4925-8bfb-88804a139b7b" xlink:to="loc_dei_EntityDomain_4fd3eaf3-9fdb-4d49-8a6c-29032a505191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_390343e4-e22e-4722-8f02-b8e738934601" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4fd3eaf3-9fdb-4d49-8a6c-29032a505191" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_390343e4-e22e-4722-8f02-b8e738934601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_54799842-b019-4144-84ef-f0b4e50a71e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4f401da4-cfe5-462e-b16b-be607516722c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_54799842-b019-4144-84ef-f0b4e50a71e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4e38e977-fa19-4277-854b-372b63c1a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_54799842-b019-4144-84ef-f0b4e50a71e1" xlink:to="loc_us-gaap_SubsequentEventMember_4e38e977-fa19-4277-854b-372b63c1a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_c5ba226f-6b98-4812-a95e-6f58d3a5967e" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_InvestmentOwnershipPercentage_c72e027b-4f4f-4f4c-9412-c86220b7baeb" xlink:href="vtvt-20230930.xsd#vtvt_InvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_vtvt_InvestmentOwnershipPercentage_c72e027b-4f4f-4f4c-9412-c86220b7baeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b417d6b3-af8e-485c-be25-e5cde8f51334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b417d6b3-af8e-485c-be25-e5cde8f51334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_70a94f76-662f-4e24-869a-d726fae3e9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_70a94f76-662f-4e24-869a-d726fae3e9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_09990704-05d2-4812-b206-19721561748b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_5b2fb771-2f27-4a97-800b-100b7cb268e6" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_09990704-05d2-4812-b206-19721561748b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d4f5c8-2fee-422c-8de6-3736b3e3d8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9d4f5c8-2fee-422c-8de6-3736b3e3d8ec" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:to="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e9db3f68-5759-4004-bb91-762b607d5f64" xlink:to="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_0316a2d4-51aa-4a6f-ab77-a377e03f3e97" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_0316a2d4-51aa-4a6f-ab77-a377e03f3e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AnterisBioIncMember_c1da07dd-17ac-4d34-9e1e-55cf30fe975f" xlink:href="vtvt-20230930.xsd#vtvt_AnterisBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e5d4bfaa-3ad2-4c02-8afb-fbbff5dcb344" xlink:to="loc_vtvt_AnterisBioIncMember_c1da07dd-17ac-4d34-9e1e-55cf30fe975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd6d8056-5101-4ae0-a59a-09d71b217b64" xlink:to="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_436aa79f-b31c-4f05-ac91-e65c2f67650c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:to="loc_us-gaap_CommonStockMember_436aa79f-b31c-4f05-ac91-e65c2f67650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_dc68d0f5-813f-43f5-ba8e-644dc55464f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1d169118-eba2-4c84-92c7-8c5ee752fcb0" xlink:to="loc_us-gaap_PreferredStockMember_dc68d0f5-813f-43f5-ba8e-644dc55464f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable_f0aee940-a0d0-48d0-8ed7-2a01b9571431" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3339f246-690d-412e-84e0-0cb8814c3a4d" xlink:href="vtvt-20230930.xsd#vtvt_EquityInvestmentsWithReadilyDeterminableFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:to="loc_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue_3339f246-690d-412e-84e0-0cb8814c3a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_fc55903e-d14f-48aa-bfbb-7e5161eab0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems_8c180cba-706c-49ba-b865-330328764eea" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_fc55903e-d14f-48aa-bfbb-7e5161eab0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f2bc31f5-7998-45b5-9594-172ce34ab551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:href="vtvt-20230930.xsd#vtvt_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f2bc31f5-7998-45b5-9594-172ce34ab551" xlink:to="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_ccfa0cc4-838c-437c-bfc5-6fe459130e76" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_70d2928c-37e9-4061-b2a9-49db1849a45e" xlink:href="vtvt-20230930.xsd#vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:to="loc_vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember_70d2928c-37e9-4061-b2a9-49db1849a45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SalesBasedMilestonesPaymentMember_73c25fe3-4575-4c8a-ab1c-6b9850bf5b72" xlink:href="vtvt-20230930.xsd#vtvt_SalesBasedMilestonesPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:to="loc_vtvt_SalesBasedMilestonesPaymentMember_73c25fe3-4575-4c8a-ab1c-6b9850bf5b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SatisfactionOfMilestonePaymentMember_fbff0eed-7055-41e5-835c-d5d0032a8b82" xlink:href="vtvt-20230930.xsd#vtvt_SatisfactionOfMilestonePaymentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_3d810810-d99c-4acd-a608-61c935ad1e15" xlink:to="loc_vtvt_SatisfactionOfMilestonePaymentMember_fbff0eed-7055-41e5-835c-d5d0032a8b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1763777-c41f-4a25-a22c-0410a82a901e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc7472f5-68ee-4489-8f2f-a8a91b528973" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1763777-c41f-4a25-a22c-0410a82a901e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NovoLicenseAgreementMember_beb2c1f2-0cfe-435a-97fc-b04b061c13b9" xlink:href="vtvt-20230930.xsd#vtvt_NovoLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1763777-c41f-4a25-a22c-0410a82a901e" xlink:to="loc_vtvt_NovoLicenseAgreementMember_beb2c1f2-0cfe-435a-97fc-b04b061c13b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0d2bb533-7bb7-4986-9a70-04a18e4ce9aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeOneDiabetesMember_a835ccb0-52d3-4f92-a541-bafa5a5c1ffc" xlink:href="vtvt-20230930.xsd#vtvt_TypeOneDiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:to="loc_vtvt_TypeOneDiabetesMember_a835ccb0-52d3-4f92-a541-bafa5a5c1ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_TypeTwoDiabetesMember_af6e4254-2336-4e0a-8e25-e2cdc58ed518" xlink:href="vtvt-20230930.xsd#vtvt_TypeTwoDiabetesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:to="loc_vtvt_TypeTwoDiabetesMember_af6e4254-2336-4e0a-8e25-e2cdc58ed518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OtherIndicationMember_05af7412-1123-404f-9b56-bf4dafcde3e0" xlink:href="vtvt-20230930.xsd#vtvt_OtherIndicationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_cfe0adf3-cfa5-44c0-b17f-52345dd2a64f" xlink:to="loc_vtvt_OtherIndicationMember_05af7412-1123-404f-9b56-bf4dafcde3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_151cc39a-52ac-4288-87d8-0d3c362d025c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bcc60cba-cda3-4b65-b235-12cda7e9775d" xlink:to="loc_srt_RangeMember_151cc39a-52ac-4288-87d8-0d3c362d025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a20b87b-ec95-43d1-8d07-76be86d41506" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_151cc39a-52ac-4288-87d8-0d3c362d025c" xlink:to="loc_srt_MaximumMember_6a20b87b-ec95-43d1-8d07-76be86d41506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommitmentsAndContingenciesLineItems_622fba21-b126-4bd9-8ea0-e4fde65868a0" xlink:href="vtvt-20230930.xsd#vtvt_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesTable_792329d6-09f0-49f2-a7dd-7a3945654f1b" xlink:to="loc_vtvt_CommitmentsAndContingenciesLineItems_622fba21-b126-4bd9-8ea0-e4fde65868a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PotentialMilestonePayment_4c58a159-37d4-4362-9bf1-f5f38aae8719" xlink:href="vtvt-20230930.xsd#vtvt_PotentialMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_CommitmentsAndContingenciesLineItems_622fba21-b126-4bd9-8ea0-e4fde65868a0" xlink:to="loc_vtvt_PotentialMilestonePayment_4c58a159-37d4-4362-9bf1-f5f38aae8719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtvt-20230930.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bb588a8b-4ee6-4784-b7dc-050da753eab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bb588a8b-4ee6-4784-b7dc-050da753eab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseTerminationPeriod_9b7e85c9-bd6d-44eb-b251-88a425d8eecf" xlink:href="vtvt-20230930.xsd#vtvt_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_vtvt_LesseeOperatingLeaseTerminationPeriod_9b7e85c9-bd6d-44eb-b251-88a425d8eecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aea36ad2-093f-4f3b-a5e3-a067da5bc260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_us-gaap_OperatingLeaseLiability_aea36ad2-093f-4f3b-a5e3-a067da5bc260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_835102b7-48f5-4807-aec7-58be27e68e57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_835102b7-48f5-4807-aec7-58be27e68e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1fac057f-f16f-45ec-be08-cb129b7a191d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1fac057f-f16f-45ec-be08-cb129b7a191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4ee6f905-4e53-49e2-9961-343c97c01626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4ee6f905-4e53-49e2-9961-343c97c01626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_be439a29-8b9c-4b22-9003-7f77012a6709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e4ebced-508b-43f0-b70a-4151b9dcdaaa" xlink:to="loc_us-gaap_OperatingLeaseCost_be439a29-8b9c-4b22-9003-7f77012a6709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_154bfa71-d124-432e-a390-229e33cac78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_154bfa71-d124-432e-a390-229e33cac78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_00851fbc-425c-4040-b0d9-c8b52c438d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_00851fbc-425c-4040-b0d9-c8b52c438d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_384c3006-2e19-4a13-a004-a78f3206b316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_384c3006-2e19-4a13-a004-a78f3206b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae60e544-e0c5-4625-8839-106ad7413a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae60e544-e0c5-4625-8839-106ad7413a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d9e54c7-868a-46cd-ad61-34abe4368267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d9e54c7-868a-46cd-ad61-34abe4368267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_34ed9d6c-4793-4fca-9d67-5956dc7c0113" xlink:href="vtvt-20230930.xsd#vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_34ed9d6c-4793-4fca-9d67-5956dc7c0113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_070f82c2-e936-4289-b346-9cd1f24a91bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_070f82c2-e936-4289-b346-9cd1f24a91bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OperatingLeasesImputedInterest_20b9137f-da13-4c21-bbfa-33c65a8d570b" xlink:href="vtvt-20230930.xsd#vtvt_OperatingLeasesImputedInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_vtvt_OperatingLeasesImputedInterest_20b9137f-da13-4c21-bbfa-33c65a8d570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_77f3f370-27ed-4e16-98f7-597e13757fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_92dcff31-4529-4b40-a8cc-134ce785149e" xlink:to="loc_us-gaap_OperatingLeaseLiability_77f3f370-27ed-4e16-98f7-597e13757fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="vtvt-20230930.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RedeemableNoncontrollingInterestAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_485a53cb-c935-4a30-9be5-3446952637d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_485a53cb-c935-4a30-9be5-3446952637d6" xlink:to="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_12927128-aa11-4441-b8e1-c3879919d605" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4d5158ed-5247-4926-8edd-4f8b7fc70497" xlink:to="loc_dei_EntityDomain_12927128-aa11-4441-b8e1-c3879919d605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_VTvLLCMember_e71e0891-0cc7-49f8-8751-9a658d18d628" xlink:href="vtvt-20230930.xsd#vtvt_VTvLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_12927128-aa11-4441-b8e1-c3879919d605" xlink:to="loc_vtvt_VTvLLCMember_e71e0891-0cc7-49f8-8751-9a658d18d628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_513526c3-8770-4174-9789-af4024eddac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34cf6366-456b-48e9-a2ce-663ec4bc3ffd" xlink:to="loc_us-gaap_ClassOfStockDomain_513526c3-8770-4174-9789-af4024eddac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_187b0d97-9e1c-4385-ada3-2954820d4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_513526c3-8770-4174-9789-af4024eddac4" xlink:to="loc_us-gaap_CommonClassAMember_187b0d97-9e1c-4385-ada3-2954820d4dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_70ed976d-0f3a-4e33-ad3d-e54cfbfcd5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_82a92275-1bad-43b9-9c75-9647fd796973" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_70ed976d-0f3a-4e33-ad3d-e54cfbfcd5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_d0f0ffb3-bc7a-4abb-9dc8-4757b0d1552e" xlink:href="vtvt-20230930.xsd#vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_70ed976d-0f3a-4e33-ad3d-e54cfbfcd5fe" xlink:to="loc_vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember_d0f0ffb3-bc7a-4abb-9dc8-4757b0d1552e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e3171dfb-13b8-4df3-87dd-bbc2074d5ba8" xlink:to="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfNonVotingEconomicInterest_5a46f812-2de3-4e44-9940-ff79d5dcb40c" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfNonVotingEconomicInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_PercentageOfNonVotingEconomicInterest_5a46f812-2de3-4e44-9940-ff79d5dcb40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_ec27dccf-d759-478b-b594-0808708b24a4" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio_ec27dccf-d759-478b-b594-0808708b24a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_54a383dc-938c-4370-a860-261d30dc7d1b" xlink:href="vtvt-20230930.xsd#vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock_54a383dc-938c-4370-a860-261d30dc7d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_3e169cfb-f46c-4650-9d6f-64f7665d7d7f" xlink:href="vtvt-20230930.xsd#vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cf722d56-eb77-4fe5-9de8-4a917904b2ca" xlink:to="loc_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue_3e169cfb-f46c-4650-9d6f-64f7665d7d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_1ced317e-b427-4d4b-9535-1aa5c2a9772b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2649a70d-aedb-4973-8b44-d1f1ffaca979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_1ced317e-b427-4d4b-9535-1aa5c2a9772b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2649a70d-aedb-4973-8b44-d1f1ffaca979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_211522b7-2152-4351-ab4c-684309d12676" xlink:href="vtvt-20230930.xsd#vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_1ced317e-b427-4d4b-9535-1aa5c2a9772b" xlink:to="loc_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_211522b7-2152-4351-ab4c-684309d12676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_f28839fa-e36b-44d2-944d-df07ca8d34de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_1ced317e-b427-4d4b-9535-1aa5c2a9772b" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet_f28839fa-e36b-44d2-944d-df07ca8d34de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d0534b7e-c989-4820-8188-7f5cfd930dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d0534b7e-c989-4820-8188-7f5cfd930dbc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a83fe3db-72a3-49e9-9243-70206c190f04" xlink:to="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ee15b35d-318e-499e-924f-0ea1be998f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:to="loc_us-gaap_CommonClassAMember_ee15b35d-318e-499e-924f-0ea1be998f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b639f1ed-bfd4-4eea-9a89-49c9ddd3803f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_97a11b39-2f9c-4992-a823-81b67ee4d325" xlink:to="loc_us-gaap_CommonStockMember_b639f1ed-bfd4-4eea-9a89-49c9ddd3803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_843f79fd-6614-4f3f-adfb-4bad17496744" xlink:to="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CantorFitzgeraldMember_6ae3cab7-aa8f-4ec6-a7fa-7215d235c96d" xlink:href="vtvt-20230930.xsd#vtvt_CantorFitzgeraldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:to="loc_vtvt_CantorFitzgeraldMember_6ae3cab7-aa8f-4ec6-a7fa-7215d235c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LPCPurchaseAgreementMember_4c0f39b9-011b-42e4-b8bd-951a5f1fc63e" xlink:href="vtvt-20230930.xsd#vtvt_LPCPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6e5b1ab2-e287-4bc8-86f5-6fc4cfbaa67a" xlink:to="loc_vtvt_LPCPurchaseAgreementMember_4c0f39b9-011b-42e4-b8bd-951a5f1fc63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_95789367-d677-47e0-825e-5c61395a1115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_499c07d8-f393-4c63-9943-d0c2273828e8" xlink:to="loc_us-gaap_TransactionDomain_95789367-d677-47e0-825e-5c61395a1115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AtTheMarketOfferingMember_d167baee-e3a1-458b-908e-300cc9dd91c2" xlink:href="vtvt-20230930.xsd#vtvt_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_95789367-d677-47e0-825e-5c61395a1115" xlink:to="loc_vtvt_AtTheMarketOfferingMember_d167baee-e3a1-458b-908e-300cc9dd91c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5803f006-c80e-46fe-846f-067dfe390b91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_58a7b625-7274-4d95-ab38-69e866fdc0d8" xlink:to="loc_srt_RangeMember_5803f006-c80e-46fe-846f-067dfe390b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c32802b-7f0b-4d0b-9355-be9eeea9901a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5803f006-c80e-46fe-846f-067dfe390b91" xlink:to="loc_srt_MaximumMember_5c32802b-7f0b-4d0b-9355-be9eeea9901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ea899034-1ec5-4e36-9d1b-ff1e7917a5a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_982bb31a-63d9-4f61-aa1a-bf5d382641f3" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:to="loc_vtvt_G42InvestmentsMember_982bb31a-63d9-4f61-aa1a-bf5d382641f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxInvestmentMember_b32c63e9-7769-4f8f-b3d4-a7294059d663" xlink:href="vtvt-20230930.xsd#vtvt_CinRxInvestmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4413b153-a5fb-4651-b866-9f6da5e8ffe0" xlink:to="loc_vtvt_CinRxInvestmentMember_b32c63e9-7769-4f8f-b3d4-a7294059d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f74404dd-8f75-40fc-867e-0d02f14aa9ec" xlink:to="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10583c18-9aae-48b9-8046-12f1a49a4126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10583c18-9aae-48b9-8046-12f1a49a4126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncreaseInCommonStockSharesAuthorized_4cb5a2b0-3294-4f39-87a6-bde11e6baac6" xlink:href="vtvt-20230930.xsd#vtvt_IncreaseInCommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_IncreaseInCommonStockSharesAuthorized_4cb5a2b0-3294-4f39-87a6-bde11e6baac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_7176afdd-1609-4e8a-a263-a9ac2da414e2" xlink:href="vtvt-20230930.xsd#vtvt_CommonStockAndPreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_CommonStockAndPreferredStockSharesAuthorized_7176afdd-1609-4e8a-a263-a9ac2da414e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76161456-6b41-45a4-8976-bbccb2810828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76161456-6b41-45a4-8976-bbccb2810828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_eaa5b0b1-bdab-4a99-b270-6fc9cb26f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_eaa5b0b1-bdab-4a99-b270-6fc9cb26f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_14f12498-55d9-4616-96df-f297344a1aaa" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_14f12498-55d9-4616-96df-f297344a1aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf0ca9b0-1640-4d28-8167-8c5e36ba598c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cf0ca9b0-1640-4d28-8167-8c5e36ba598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_c67fadbb-1f57-4f3d-bdcb-f5a5aa8022ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_c67fadbb-1f57-4f3d-bdcb-f5a5aa8022ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivableTerm_f5113edc-ce91-4e46-939e-d12ea6eca7b1" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivableTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivableTerm_f5113edc-ce91-4e46-939e-d12ea6eca7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_043105ec-a789-4f4d-9ef7-6e005ef8e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_043105ec-a789-4f4d-9ef7-6e005ef8e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_c9702ea4-e38f-44d2-a320-29d0e8c68145" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_NotesReceivableDiscountRate_c9702ea4-e38f-44d2-a320-29d0e8c68145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5adbb302-cdee-47b9-8633-c80b3ec262a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5adbb302-cdee-47b9-8633-c80b3ec262a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5b0adb41-c7a5-4f10-96e4-fc340655a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5b0adb41-c7a5-4f10-96e4-fc340655a4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8242dd52-b8e6-42b6-8950-dea507e7272d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8242dd52-b8e6-42b6-8950-dea507e7272d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_f67b6fde-7d7c-407c-bc37-c45f0cfa73a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_f67b6fde-7d7c-407c-bc37-c45f0cfa73a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8d9412fe-23ea-445e-b534-add6247ad6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_8d9412fe-23ea-445e-b534-add6247ad6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd5aedca-6808-487f-ba0c-56315b56fb28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd5aedca-6808-487f-ba0c-56315b56fb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59692d8d-a3a9-4427-b462-c463e6f7603c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59692d8d-a3a9-4427-b462-c463e6f7603c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_AggregateOfferingPriceOfShares_854b77bf-2e35-4e95-b860-cc26978ee6c3" xlink:href="vtvt-20230930.xsd#vtvt_AggregateOfferingPriceOfShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0b9672f-2524-49ef-8b12-e1ab6450c7b8" xlink:to="loc_vtvt_AggregateOfferingPriceOfShares_854b77bf-2e35-4e95-b860-cc26978ee6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_50804425-bf45-4448-92e3-2323a7b2725a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_50804425-bf45-4448-92e3-2323a7b2725a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b5e1567-7ed8-4fd6-a663-cae6b8177701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_47555b3c-ca9c-45cf-88fa-0f5df6054648" xlink:to="loc_us-gaap_RelatedPartyDomain_5b5e1567-7ed8-4fd6-a663-cae6b8177701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_40893918-2fb7-46b8-877f-3dfc9dc007f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5b5e1567-7ed8-4fd6-a663-cae6b8177701" xlink:to="loc_us-gaap_RelatedPartyMember_40893918-2fb7-46b8-877f-3dfc9dc007f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b71e023-9874-44d8-ae3b-66ad13258c89" xlink:to="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_6198705a-acc4-41d8-a547-7a2ee75efab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:to="loc_us-gaap_CommonClassBMember_6198705a-acc4-41d8-a547-7a2ee75efab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_ff888b74-2c5c-413a-b7a5-51760b0e0c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf6e77ef-6ca5-4339-b113-44ce3b027cd3" xlink:to="loc_us-gaap_CommonClassAMember_ff888b74-2c5c-413a-b7a5-51760b0e0c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d57ae6ce-dab2-4fbc-b4a6-b26d8ce13ce9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c65a64cd-44eb-474d-996b-eb98254529c3" xlink:to="loc_dei_EntityDomain_d57ae6ce-dab2-4fbc-b4a6-b26d8ce13ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxPharmaLLCMember_76a66f1a-0d6b-448a-95d3-2cd663b446e8" xlink:href="vtvt-20230930.xsd#vtvt_CinRxPharmaLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d57ae6ce-dab2-4fbc-b4a6-b26d8ce13ce9" xlink:to="loc_vtvt_CinRxPharmaLLCMember_76a66f1a-0d6b-448a-95d3-2cd663b446e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_296d7838-bd0e-4c1d-a6f8-eb1e6d2851f3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_610194b0-1ed2-4032-a28e-636e0acaf663" xlink:href="vtvt-20230930.xsd#vtvt_MacAndrewsAndForbesIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:to="loc_vtvt_MacAndrewsAndForbesIncorporatedMember_610194b0-1ed2-4032-a28e-636e0acaf663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_G42InvestmentsMember_4d9bb301-4c5c-4161-955e-be362ef77865" xlink:href="vtvt-20230930.xsd#vtvt_G42InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:to="loc_vtvt_G42InvestmentsMember_4d9bb301-4c5c-4161-955e-be362ef77865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MasterServiceAgreementMember_53a3e413-af6c-4177-b940-b68059bdd3b4" xlink:href="vtvt-20230930.xsd#vtvt_MasterServiceAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d56b5f68-c19e-4af0-87ba-af98b05965b7" xlink:to="loc_vtvt_MasterServiceAgreementMember_53a3e413-af6c-4177-b940-b68059bdd3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_773d951c-c8ca-4d62-8e1c-59f06a77fa31" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_3693148a-17e6-4c76-b5f6-229f21bef016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_3693148a-17e6-4c76-b5f6-229f21bef016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_OwnershipPercentageOfMajorityOwner_4c70cc4b-67ca-4966-82fd-7c73d7102ff3" xlink:href="vtvt-20230930.xsd#vtvt_OwnershipPercentageOfMajorityOwner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_OwnershipPercentageOfMajorityOwner_4c70cc4b-67ca-4966-82fd-7c73d7102ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_07216093-af00-4dab-9fe4-e4835fb47042" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_07216093-af00-4dab-9fe4-e4835fb47042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_39886acd-3d06-48cb-a089-c1b430cb26cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_39886acd-3d06-48cb-a089-c1b430cb26cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_99c3ffdf-64a6-43a0-8604-d82a7866d2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_99c3ffdf-64a6-43a0-8604-d82a7866d2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_8e887c64-48fe-493a-ad53-31083dd37323" xlink:href="vtvt-20230930.xsd#vtvt_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross_8e887c64-48fe-493a-ad53-31083dd37323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f47baf0-45a2-4cdb-a3bc-41320db73c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f47baf0-45a2-4cdb-a3bc-41320db73c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_82ef036b-28a5-4e98-be3f-d52a4dddbe29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_82ef036b-28a5-4e98-be3f-d52a4dddbe29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_f30e62ba-1fc2-4512-9a84-cea043e314d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_f30e62ba-1fc2-4512-9a84-cea043e314d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_NotesReceivableDiscountRate_96ee2340-31d2-453a-9f57-a6044de85ce5" xlink:href="vtvt-20230930.xsd#vtvt_NotesReceivableDiscountRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_NotesReceivableDiscountRate_96ee2340-31d2-453a-9f57-a6044de85ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_336b0816-7f76-48c7-ba1d-87d393d8dc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_336b0816-7f76-48c7-ba1d-87d393d8dc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_DueToRelatedPartiesMonthlyAmount_96f4b0be-354d-4a94-a25f-677ca8dda266" xlink:href="vtvt-20230930.xsd#vtvt_DueToRelatedPartiesMonthlyAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5dc7fe94-b6dd-433a-bb97-da0d8558cecf" xlink:to="loc_vtvt_DueToRelatedPartiesMonthlyAmount_96f4b0be-354d-4a94-a25f-677ca8dda266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_80c7ac0e-9679-43ea-8321-af01b64d118f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:href="vtvt-20230930.xsd#vtvt_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80c7ac0e-9679-43ea-8321-af01b64d118f" xlink:to="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:to="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8da81952-d420-4104-ac54-ea6f97b07997" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3a37eea6-8180-4087-86fd-a78c1d86d59d" xlink:to="loc_dei_EntityDomain_8da81952-d420-4104-ac54-ea6f97b07997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_MFTTPHoldingsLLCMember_79a0bec6-4f9f-4d39-aa3d-46a87e25390f" xlink:href="vtvt-20230930.xsd#vtvt_MFTTPHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8da81952-d420-4104-ac54-ea6f97b07997" xlink:to="loc_vtvt_MFTTPHoldingsLLCMember_79a0bec6-4f9f-4d39-aa3d-46a87e25390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:href="vtvt-20230930.xsd#vtvt_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesTable_1d5185a4-fe81-4172-a2f4-7bb56384387c" xlink:to="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_89013197-a63e-4cfd-a32b-3a425ae53d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_89013197-a63e-4cfd-a32b-3a425ae53d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_PercentageOfAmountOfCashSavings_0dc04756-18ca-4189-8dde-e1a91f439b55" xlink:href="vtvt-20230930.xsd#vtvt_PercentageOfAmountOfCashSavings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_IncomeTaxesLineItems_96a3781c-f0c6-44e1-8183-e994e82a8103" xlink:to="loc_vtvt_PercentageOfAmountOfCashSavings_0dc04756-18ca-4189-8dde-e1a91f439b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9d12363e-8868-4b9f-bb60-9ad2432e3a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:href="vtvt-20230930.xsd#vtvt_ScheduleOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9d12363e-8868-4b9f-bb60-9ad2432e3a2d" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:to="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b3f59ca0-1001-48cd-81e7-c3e2589f9757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_60103ba1-2aee-4ea6-9bb3-8c821919c6ae" xlink:to="loc_us-gaap_ClassOfStockDomain_b3f59ca0-1001-48cd-81e7-c3e2589f9757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_87499154-9944-420d-9cd4-48ecc13561e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b3f59ca0-1001-48cd-81e7-c3e2589f9757" xlink:to="loc_us-gaap_CommonClassAMember_87499154-9944-420d-9cd4-48ecc13561e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:href="vtvt-20230930.xsd#vtvt_ScheduleOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareTable_4cbc1481-6953-4a37-b0d7-03c5248c3099" xlink:to="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:to="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e888fe2-1a7a-4d71-b578-077108de587b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_ProfitLoss_5e888fe2-1a7a-4d71-b578-077108de587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a3e70d5-3da4-4cc1-a5d3-b1c72716d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a3e70d5-3da4-4cc1-a5d3-b1c72716d3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b348b747-429f-4709-8393-a0e3da21188e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b348b747-429f-4709-8393-a0e3da21188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64bcd790-98cc-4c53-b96f-a527ea7cfbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_87216ef4-0105-4772-b9c8-a5f5deb45022" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64bcd790-98cc-4c53-b96f-a527ea7cfbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_ScheduleOfEarningsPerShareLineItems_997458e2-596f-482d-a26d-ee8df4d587c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48e38a09-25d6-4073-be83-bbe3df85b1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_48e38a09-25d6-4073-be83-bbe3df85b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0abadcf-0ee4-4d7f-b7f6-ebc47f889f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0abadcf-0ee4-4d7f-b7f6-ebc47f889f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78a75d1d-fe74-4d6c-b559-d6f434808a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_EarningsPerShareBasic_78a75d1d-fe74-4d6c-b559-d6f434808a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_94aa6085-0594-4361-90e2-1eea9bdf0764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_35c531bc-971f-41d5-be3e-ec882e02661f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_94aa6085-0594-4361-90e2-1eea9bdf0764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e7b51a78-60fb-484c-b035-27b8badecf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e7b51a78-60fb-484c-b035-27b8badecf3b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb2e30e-a36f-40a8-b390-470ca6039300" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0de5d705-a72d-4bd1-8fb5-0852ef350bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:to="loc_us-gaap_CommonClassBMember_0de5d705-a72d-4bd1-8fb5-0852ef350bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_52273679-4958-4833-b8f6-ef0049d34cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_52273679-4958-4833-b8f6-ef0049d34cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_28e6c948-058f-4a2c-b972-2a4c0db2b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2bfd9659-4077-45bb-972c-b1c967dabd39" xlink:to="loc_us-gaap_WarrantMember_28e6c948-058f-4a2c-b972-2a4c0db2b38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cda880bb-1181-4389-a512-7053599fc2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cfde923d-d1e9-4af9-8702-3bf7aca7fac8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cda880bb-1181-4389-a512-7053599fc2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e66056bf-3305-44bc-98f3-0dd6646face9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cda880bb-1181-4389-a512-7053599fc2ec" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e66056bf-3305-44bc-98f3-0dd6646face9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_676fea08-47f7-4053-ba95-56926ccfb140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:href="vtvt-20230930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_676fea08-47f7-4053-ba95-56926ccfb140" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca987fd3-d142-4046-aeba-d270f6764b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed4a126c-036a-4de3-85f0-8e080dcd9256" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca987fd3-d142-4046-aeba-d270f6764b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a66f4dae-d04c-402b-88b3-bac3d7c9fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca987fd3-d142-4046-aeba-d270f6764b1b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a66f4dae-d04c-402b-88b3-bac3d7c9fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d0ecfe99-3e58-47f4-8020-ed43d70b1205" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1f03a4e3-3733-4db2-8347-54b57c55a66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1f03a4e3-3733-4db2-8347-54b57c55a66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_de15aeff-d5e8-468a-8df3-c49dd6060fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_de15aeff-d5e8-468a-8df3-c49dd6060fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1adaff22-f910-4023-b5f4-cc2233bacb42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc31159a-0d0a-4153-af6c-ddea73c9171e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1adaff22-f910-4023-b5f4-cc2233bacb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93e6495a-b615-4ba5-a8d5-07eb503b25ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d3b40b6f-254b-4b66-bad9-bd9cd6601dd5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93e6495a-b615-4ba5-a8d5-07eb503b25ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_WarrantLiabilityRelatedPartyMember_9dc0fb6a-0005-4f71-894c-447ae9302b91" xlink:href="vtvt-20230930.xsd#vtvt_WarrantLiabilityRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_93e6495a-b615-4ba5-a8d5-07eb503b25ff" xlink:to="loc_vtvt_WarrantLiabilityRelatedPartyMember_9dc0fb6a-0005-4f71-894c-447ae9302b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:href="vtvt-20230930.xsd#vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable_92403586-7c74-4fd5-bfba-0993f3c7c2e7" xlink:to="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_81e950aa-8820-4456-980d-4fba0fc7ef27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_81e950aa-8820-4456-980d-4fba0fc7ef27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a5e3668a-ce50-4fe7-843e-9757f5e3dff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_235d52c4-ef89-48c4-81fb-55c069f9ae71" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a5e3668a-ce50-4fe7-843e-9757f5e3dff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_a623d42a-3086-4af6-bd3b-848d7f5597cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_a623d42a-3086-4af6-bd3b-848d7f5597cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5d965d93-58fc-4ee1-b6aa-8ecfffdb00f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract_a623d42a-3086-4af6-bd3b-848d7f5597cc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5d965d93-58fc-4ee1-b6aa-8ecfffdb00f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems_8b7af9fd-2aad-4f3b-921e-49b728777224" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66cde340-0e9d-4a27-99e0-456da41dcc07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_66cde340-0e9d-4a27-99e0-456da41dcc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_b1a719c9-9225-4b32-91dc-56caf1eaf657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_b1a719c9-9225-4b32-91dc-56caf1eaf657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_573b911a-aebb-4b08-8e9b-1afa4e9ce077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_573b911a-aebb-4b08-8e9b-1afa4e9ce077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_ca457002-97e7-4bea-9ca3-06200636f7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_ca457002-97e7-4bea-9ca3-06200636f7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_64630548-2fac-48e1-a4de-571feb10bb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_167bf76e-a887-485a-b424-8052b14cafe8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_64630548-2fac-48e1-a4de-571feb10bb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="simple" xlink:href="vtvt-20230930.xsd#FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0478b428-2f10-4dda-96d1-1d453daf27a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0478b428-2f10-4dda-96d1-1d453daf27a9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7227ebc1-21a4-4b72-8971-5ae3a4d88bd2" xlink:to="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_249689af-eb92-49b6-af9d-2d05875d850e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:to="loc_srt_MinimumMember_249689af-eb92-49b6-af9d-2d05875d850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3436915f-1f98-4855-8bcd-0b83b3fdeed7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:to="loc_srt_MaximumMember_3436915f-1f98-4855-8bcd-0b83b3fdeed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_e5ae42b8-3b5a-429e-ae5a-e94f0e329966" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3aaee8df-f1e4-44bd-8e36-a5533c1787d1" xlink:to="loc_srt_WeightedAverageMember_e5ae42b8-3b5a-429e-ae5a-e94f0e329966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_11d5e08e-531e-4552-af6c-c78b5b8e5ae3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7e49d17-5461-4ec8-9711-39bc3db9d4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b7e49d17-5461-4ec8-9711-39bc3db9d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_421a657e-4259-422f-8ba2-902cc0c9b6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_421a657e-4259-422f-8ba2-902cc0c9b6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_92edd5f2-5ae8-4f6c-bb72-fc78c0969d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_25af9b95-147a-43d5-8d51-e50bb5bda6da" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_92edd5f2-5ae8-4f6c-bb72-fc78c0969d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dba6ef01-65b2-42e6-b83f-05a7fc3e6d29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_LetterAgreementWarrantsMember_f434e7ec-afe9-4c84-a650-d551d0ee983a" xlink:href="vtvt-20230930.xsd#vtvt_LetterAgreementWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:to="loc_vtvt_LetterAgreementWarrantsMember_f434e7ec-afe9-4c84-a650-d551d0ee983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_CinRxWarrantsMember_4b8a5b45-0aff-46ff-986a-74bbdaaa9fa6" xlink:href="vtvt-20230930.xsd#vtvt_CinRxWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7c3814a3-63a8-4027-88d6-9b528d351313" xlink:to="loc_vtvt_CinRxWarrantsMember_4b8a5b45-0aff-46ff-986a-74bbdaaa9fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6b9cfa1b-6db8-41e4-96e2-def261f07ad9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0855cc9-1f11-4249-9bf3-dad31278d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0855cc9-1f11-4249-9bf3-dad31278d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_112c2207-a530-493a-a7ca-8568b2bb9b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4e234910-7743-44d4-ba57-d1ea15866f92" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_112c2207-a530-493a-a7ca-8568b2bb9b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtvt-20230930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://vtvtherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_86a1ba84-c746-4fee-bdb5-92577fedce74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_86a1ba84-c746-4fee-bdb5-92577fedce74" xlink:to="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9c13a981-ca77-442a-b834-f47f8a3a90a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83e97b9c-e748-412f-99ac-88816a4f94b3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9c13a981-ca77-442a-b834-f47f8a3a90a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9eb8b44e-16f7-4793-893f-a76c5b205373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9c13a981-ca77-442a-b834-f47f8a3a90a8" xlink:to="loc_us-gaap_SubsequentEventMember_9eb8b44e-16f7-4793-893f-a76c5b205373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:to="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_924ab423-7282-4da0-a456-0c82633fd477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_506b98a6-7988-4fc7-b19e-39ab06bd513f" xlink:to="loc_dei_EntityDomain_924ab423-7282-4da0-a456-0c82633fd477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtvt_ReneoPharmaceuticalsIncMember_8bf3b4c9-f8d9-41f7-9aca-a92a70485312" xlink:href="vtvt-20230930.xsd#vtvt_ReneoPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_924ab423-7282-4da0-a456-0c82633fd477" xlink:to="loc_vtvt_ReneoPharmaceuticalsIncMember_8bf3b4c9-f8d9-41f7-9aca-a92a70485312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0ae374f1-da03-45f6-9bb9-faf5b3a8bf12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d8807bd6-54b5-48c1-8c9d-5a6103f4948c" xlink:to="loc_us-gaap_SubsequentEventLineItems_0ae374f1-da03-45f6-9bb9-faf5b3a8bf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_c1f35f0e-2869-4dd5-93db-0b1039a0f7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0ae374f1-da03-45f6-9bb9-faf5b3a8bf12" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_c1f35f0e-2869-4dd5-93db-0b1039a0f7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vtvt-20230930_g1.jpg
<DESCRIPTION>GRAHPIC
<TEXT>
begin 644 vtvt-20230930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>@[4 =#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3X6?]"+XP_[YM?\ X]1_P^T^%G_0B^,/^^;7_P"/4 ?HK17YU?\ #[3X6?\
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M_0B^,/\ OFU_^/4 ?HK17YU?\/M/A9_T(OC#_OFU_P#CU1Q?\%MOADTDPD\
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M** "BBB@ HHHH **** "G1QO-(L<:L\C$*JJ,DD] !3:T/#O_(P:7_U]1?\
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MWJ_AO7;G1-7TJ]TO6;:7R)].O;=X;B*3^XT; ,K<]",U])_M=2MX'^$_P#\
M:(QL_"]QX-M/%EU!"2%O=3O&D\ZXEQP[J%$:DY*J"HP.*ROV-/#]S\4/C_H_
MB#Q;<76M^&O .F/XAU)[^X,HBL=/BW00 N2 F\0QA.@4D 8% 'A/B[P5XA\
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M._L.^&=.T3]I^\TRS\6:/X@LF\)ZV#K6G17J6B;M/FR2L]O'-\O?$1Z?+NH
M^=/'/PH\;_#!K,>,O!WB#PD;S<;8:YI<]EY^W&[9YJ+NQN7..F1ZU8M_@K\0
MKSP6WC"#P'XFG\)+$TYUZ/1[AK 1J2K/YX3R]H(()S@$&OHOQCIL7PI_8*&B
M1ZY9_$;2?%WB]+RPUG1?-_LS2);6)EEB9;A(KB.ZE4CY6A53& P9JZKQEIFG
M_MF>-+#QY\&/B&WACXJQZ-#:_P#"M]0>33KB!+>U$+PZ5>(?*E1EW;824;:9
M&;&2  ?#%%/FADM9I(9HVBEC8H\;J0RL#@@@]"#7T_\ !W]E-O%/P8^*NN:J
MWA&ZU>STC3[K0;@>.=+46<DEY$LC3A;P+#F)F7%R%^8[0-^!0!\NUZ%<?LZ_
M%>T\./X@G^&/C*'04MOMK:I)H%VMJMOMW^<93'MV;?FW9QCG-<?XD\/77A37
M+K2;V6QGNK9@KR:;J$%];G*@_)/ [QN,$<JQP<CJ"*_32U\(K;_M@_#;QUIW
MC&SDU7PWX!TG5I_!>EB<:WJ5O#IJ^9#!YL<=K)O4G*"XW[ YV$C% 'YS^!_@
M_P"//B=#=S>#O!/B+Q9#:,J7,FAZ3/>K"S E0YB1MI(!QGK@U1\;?#OQ7\-=
M2AT[Q?X8UCPKJ$T0N([36["6SE>,DJ'5)%4E<JPR!C(/I7U?\(;72_B!^QO^
MT1)<:OI/@33;[Q9H]TDVI1W4EK:JTLS+%BV@FD/4*,1XXYQ6#^Q[X)T/PS\5
M_'WB&TUC1?'E]X%\$:CXIT2YL+>Y^RG4(53RI/+NX(68PER_S)C<JD9QD 'A
MM]^SY\4M+\,OXDO/AKXOM/#R6XO&U:?0;I+18" PE,ICV!""#NSC!KDIO#&L
M6WAZVUZ;2;Z+0KJ=[6#4WMG%M+,@!>-)2-K.H925!R 1GK7MWP1^%_C#X\>,
M;G7/#OQ?TO3_ (E7,-_?S07]WJT6K2(D3FX<W,=JT1+Q[^/.RP8@]2*]+\!^
M%=/\=?LO_L\^'-6)&EZO\6+FPN\-M/DRK9H_/;Y6/- 'S=X5^ OQ-\=:$FM^
M&OAUXL\0Z,Y95U'2M#NKFW8J<,!)'&5)!!!YXKG/"W@[7_'.NPZ)X;T/4O$&
MLS!C%IVEVDES</M!9ML: L< $G X ->P_M@_$3Q!J?[5'C&<7MQIG_"+:Q+I
M.A6]G(T*:3:V<S1V\5LJX\H)L##9CYB6ZFOK_P +7B7'[;'P?\<PB.S\4>*?
MA6WB'6)+:,1[M0;3;I6GP ,,XC1R>Y.: /S@L?!NOZIXH'AFST/4KOQ&;AK0
M:/!:2/>&920T7D@;]X((*XR,&KGA#X9^,/B%K%UI/A;PIKGB75+5#)<6.CZ=
M-=SPJ&"EG2-2R@,0,D=2!7WW\*=+MOC;^T-\!OVB-!MHXKC5M<CT;QM96R86
MSUN.%O\ 2,  +'<QA9!Z/N!))KQ'X=^/OAWXD^&?Q(^#/CCQ/=?#:75/%?\
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MY5E.01]=_P##DOXI_P#0]>#_ /OJZ_\ C-'_  Y+^*?_ $/7@_\ [ZNO_C-
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M'_\ ?5U_\9H_X<E_%/\ Z'KP?_WU=?\ QF@#\ZZ*_13_ (<E_%/_ *'KP?\
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MQAM^!@\'/'VY_P .2_BG_P!#UX/_ .^KK_XS1_PY+^*?_0]>#_\ OJZ_^,T
M?$7P;^,&O? _QQ!XG\/BUGG$,MI=6.H1&6UOK652DMO,@(+1NIP<$$<$$$ U
MN>*_&_PFNK36W\,?"W5])U+4 R6W]L>+3?V>FAF#;H(H[6"1G4#:IFFE7!.Y
M7."/L'_AR7\4_P#H>O!__?5U_P#&:/\ AR7\4_\ H>O!_P#WU=?_ !F@#YM^
M)OQ]^''QA'AR\\3?#SQ2FLZ-X>L= 6?2?&%M!;RK;1;%E,4FF2,"3DD>9[9[
MU#IO[5']GZU\!-0_X1CS/^%5HJ^7_:&/[4Q>-<]?*_<_>V_Q],^U?3'_  Y+
M^*?_ $/7@_\ [ZNO_C-'_#DOXI_]#UX/_P"^KK_XS0!\L?"#]J'4OA!^T-J7
MQ,LM(COK'5KJ\.J>'9I\17EG<R%Y+9I-AZ':0^SAD4X[5J:I^UA_:7B_X\:Y
M_P (MY?_  M*TEM?L_\ :.?[,WW,<^[=Y7[['E[<83KGMBOI/_AR7\4_^AZ\
M'_\ ?5U_\9H_X<E_%/\ Z'KP?_WU=?\ QF@#Y6M_CYH/B[X;>'_!_P 3O!]]
MXK7PROD:#K>B:TNE:A:VC%F>TE:2VN(YH0Q5DS&KIA@'*MM&OX<_:LM_A=X*
M\;Z+\+O"MY\/M5\2?8+9?$-EX@GDOK:TMB79?,"*?.F<YDDC,4>!M6%17TE_
MPY+^*?\ T/7@_P#[ZNO_ (S1_P .2_BG_P!#UX/_ .^KK_XS0!\T:+^V1XUO
M?AA\1/ WQ U/7/B5I/BJQAAMGUW79YI-*NX91)%<1&42<9^\@V[P%^88J7XF
M_'WX<?&$>'+SQ-\//%*:SHWAZQT!9])\86T%O*MM%L64Q2:9(P).21YGMGO7
MTE_PY+^*?_0]>#_^^KK_ .,T?\.2_BG_ -#UX/\ ^^KK_P",T ?G717Z*?\
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M#UX/_P"^KK_XS1_PY+^*?_0]>#_^^KK_ .,T ?G717Z*?\.2_BG_ -#UX/\
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MYNW8WF?ZO&W*]<YXQ7V3_P .2_BG_P!#UX/_ .^KK_XS1_PY+^*?_0]>#_\
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MX=T2UT:TT71/$5PBR>4#ON)6B\I7ED9F).P<8'.,U+X]_:DT'XT2>#[GXE^
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MQI#<)<(8B& !+H =P;@G@'FON+_AR7\4_P#H>O!__?5U_P#&:/\ AR7\4_\
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M* "BBB@ HHHH **** "BBB@ KX?_ ."K'_(@_!O_ +*-IO\ Z*N*^X*^'_\
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M^N_V:^=?\_Y_Z>:/\_Y_Z>:/J]+^4/[7Q_\ S]9]%?\ #<WCS_H$^'?O[O\
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M/-'^?\_]/-'U>E_*']KX_P#Y^L^BO^&YO'G_ $"?#OW]W_'M/]W_ )Y_Z_\
MUW^S1_PW-X\_Z!/AW[^[_CVG^[_SS_U_^N_V:^=?\_Y_Z>:/\_Y_Z>:/J]+^
M4/[7Q_\ S]9]%?\ #<WCS_H$^'?O[O\ CVG^[_SS_P!?_KO]FC_AN;QY_P!
MGP[]_=_Q[3_=_P">?^O_ -=_LU\Z_P"?\_\ 3S1_G_/_ $\T?5Z7\H?VOC_^
M?K/HK_AN;QY_T"?#OW]W_'M/]W_GG_K_ /7?[-'_  W-X\_Z!/AW[^[_ (]I
M_N_\\_\ 7_Z[_9KYU_S_ )_Z>:/\_P"?^GFCZO2_E#^U\?\ \_6?17_#<WCS
M_H$^'?O[O^/:?[O_ #S_ -?_ *[_ &:/^&YO'G_0)\._?W?\>T_W?^>?^O\
M]=_LU\Z_Y_S_ -/-'^?\_P#3S1]7I?RA_:^/_P"?K/HK_AN;QY_T"?#OW]W_
M ![3_=_YY_Z__7?[-'_#<WCS_H$^'?O[O^/:?[O_ #S_ -?_ *[_ &:^=?\
M/^?^GFC_ #_G_IYH^KTOY0_M?'_\_6?17_#<WCS_ *!/AW[^[_CVG^[_ ,\_
M]?\ Z[_9JM:_ML>.+6XO)DTKP^6NIQ,X:WGP%"*GE#]]_K<*/E^M<#X1_9_\
M>^/-!@UG0M!^W:;,6"3?;+>/.UBK$J\@83@@C<1CCK7(>*/#.I^#=>N]&UBV
M^R:E:L%FA\Q9-I*AA\RDJ;@@@Y!/6H5'#R?*DKG1/,,UIP52<Y*+V;6C^=CW
M;_AN;QY_T"?#OW]W_'M/]W_GG_K_ /7?[-'_  W-X\_Z!/AW[^[_ (]I_N_\
M\_\ 7_Z[_9KYU_S_ )_Z>:/\_P"?^GFK^KTOY3G_ +7Q_P#S]9]%?\-S>//^
M@3X=^_N_X]I_N_\ //\ U_\ KO\ 9H_X;F\>?] GP[]_=_Q[3_=_YY_Z_P#U
MW^S7SQ!!+=31PPQM--(P1(XU+,S$X  '6ZK8\6^"M;\"ZA!8Z]I\FFW<UNET
MD,I4L8VSM;@G%R<'@\\4O84;VY5<M9IF3BYJI*RZ]#V__AN;QY_T"?#OW]W_
M ![3_=_YY_Z__7?[-'_#<WCS_H$^'?O[O^/:?[O_ #S_ -?_ *[_ &:\Y\*?
ML^^/_&_A^WUO1- ^VZ9<;C'-]LMT)"L59MK2!A.&4C)&.*Y.^\)ZII4FJ17T
M$=C<::ZQW-M=7$<4P+'C9&S!I+COE P ()X(-2J.';LDC66/S6$5.4I)/9VW
MZZ:'N7_#<WCS_H$^'?O[O^/:?[O_ #S_ -?_ *[_ &:/^&YO'G_0)\._?W?\
M>T_W?^>?^O\ ]=_LU\Z]?\_Y_P!)K5\4>%M4\&:U-I.LVOV._B5'>+S%?"NH
M=3N4D&X*L#P>]5]7HWMRHQ_M;,&N;VKL>Z_\-S>//^@3X=^_N_X]I_N_\\_]
M?_KO]FC_ (;F\>?] GP[]_=_Q[3_ '?^>?\ K_\ 7?[-?.O^?\_]/-:<WAO4
M[;P_;:W-9R1:7<S-!!</@"1U&6"C.3<#U QGC.:?U>C_ "B6;9A+:JSW?_AN
M;QY_T"?#OW]W_'M/]W_GG_K_ /7?[-'_  W-X\_Z!/AW[^[_ (]I_N_\\_\
M7_Z[_9KYU_S_ )_Z>:/\_P"?^GFCZO2_E%_:^/\ ^?K/HK_AN;QY_P! GP[]
M_=_Q[3_=_P">?^O_ -=_LT?\-S>//^@3X=^_N_X]I_N_\\_]?_KO]FOG7_/^
M?^GFC_/^?^GFCZO2_E#^U\?_ ,_6?17_  W-X\_Z!/AW[^[_ (]I_N_\\_\
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MG_0)\._?W?\ 'M/]W_GG_K_]=_LT?\-S>//^@3X=^_N_X]I_N_\ //\ U_\
MKO\ 9KYU_P _Y_Z>:/\ /^?^GFCZO2_E#^U\?_S]9]%?\-S>//\ H$^'?O[O
M^/:?[O\ SS_U_P#KO]FC_AN;QY_T"?#OW]W_ ![3_=_YY_Z__7?[-?.O^?\
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M_33=UZK7E7Q4_P"2O?!;_L,ZA_Z:;N@#U6BBB@ HHHH **** "BBB@ HHHH
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MD4P1([=X3@1,Q=\$J.:Q?V'"1^RMX"B_Y9V\%Q;Q+_=CCNID11[!54?A5?\
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M_P!/-'^?\_\ 3S1_G_/_ $\T '^?\_\ 3S1_G_/_ $\T?Y_S_P!/-'^?\_\
M3S0 ?Y_S_P!/-'^?\_\ 3S1_G_/_ $\T?Y_S_P!/- !_G_/_ $\T?Y_S_P!/
M-'^?\_\ 3S1_G_/_ $\T '^?\_\ 3S1_G_/_ $\T?Y_S_P!/-'^?\_\ 3S0
M?Y_S_P!/-'^?\_\ 3S1_G_/_ $\T?Y_S_P!/- !_G_/_ $\T?Y_S_P!/-'^?
M\_\ 3S1_G_/_ $\T '^?\_\ 3S1_G_/_ $\T?Y_S_P!/-'^?\_\ 3S0 ?Y_S
M_P!/-'^?\_\ 3S1_G_/_ $\T?Y_S_P!/- !_G_/_ $\T?Y_S_P!/-'^?\_\
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M_P"1!^#?_91M-_\ 15Q0!]G:]X:TCQ1:Q6VM:59:O;12B:.&_MTG1) " X#
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M?>_O?<Z^]?E]_G_/_3S1_G_/_3S1]2E_S\_K[P_UCH_] J^]?_(GZ@_\*?\
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MZ^\/]8Z/_0*OO7_R)^H/_"G_  '_ -"3X=^_YG_()@^]_>^YU]Z/^%/^ _\
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M^'?O^9_R"8/O?WON=?>C_A3_ (#_ .A)\._?\S_D$P?>_O?<Z^]?E]_G_/\
MT\T?Y_S_ -/-'U*7_/S^OO#_ %CH_P#0*OO7_P B?J#_ ,*?\!_]"3X=^_YG
M_()@^]_>^YU]Z/\ A3_@/_H2?#OW_,_Y!,'WO[WW.OO7Y??Y_P _]/-'^?\
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M*_-/_/\ G_IYH_S_ )_Z>:/J4O\ GY_7WA_K'1_Z!5]Z_P#D3]0?^%/^ _\
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MH_X4_P" _P#H2?#OW_,_Y!,'WO[WW.OO7744<\NX?5Z/\B^Y'(_\*?\  ?\
MT)/AW[_F?\@F#[W][[G7WH_X4_X#_P"A)\._?\S_ )!,'WO[WW.OO7744<\N
MX?5Z/\B^Y'(_\*?\!_\ 0D^'?O\ F?\ ()@^]_>^YU]Z/^%/^ _^A)\._?\
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MKE((C(02%W,1SP>.O!KY=\0>&?#WB;7+C5[_ .+W@^2]FD\QF7580%/8*-W
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M.^51YDW/[M>>6^5OE'/RGTK*6KNCZG*:=7#X?V-6FH<NUG>_F_.Y>HHHJ#W
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M "O*O$?_ "=-\//^Q,\3?^EV@UZK7E7B/_DZ;X>?]B9XF_\ 2[0: /5:***
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M5YA]H%%%% !1110 4444 %%%% !1110 4444 %%%% !6/X/_ .17TS_K@O\
M*MBL?P?_ ,BOIG_7!?Y4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %8_@[_ )%'0_\ KQ@_]%K6Q6/X._Y%'0_^O&#_ -%K0!L4444
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MA+Q$&DUK1YM0CV?;-%W@)'=6YR3Y>#NP KY#;@4 /H.BO#\_&_\ Z'KX?_\
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M\N*,_&__ *'KX?\ _A#7W_RXH ]PHKP_/QO_ .AZ^'__ (0U]_\ +BC/QO\
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MO7U'GXW_ /0]?#__ ,(:^_\ EQ1GXW_]#U\/_P#PAK[_ .7%'U^KV7]?,/\
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MGRY_PR?\5?\ H5O?_D(VGW?[W^M_U_\ M=/>C_AD_P"*O_0K>_\ R$;3[O\
M>_UO^O\ ]KI[U]1Y^-__ $/7P_\ _"&OO_EQ1GXW_P#0]?#_ /\ "&OO_EQ1
M]?J]E_7S#_5?!_SR^]?_ ")\N?\ #)_Q5_Z%;W_Y"-I]W^]_K?\ 7_[73WH_
MX9/^*O\ T*WO_P A&T^[_>_UO^O_ -KI[U]1Y^-__0]?#_\ \(:^_P#EQ1GX
MW_\ 0]?#_P#\(:^_^7%'U^KV7]?,/]5\'_/+[U_\B?+G_#)_Q5_Z%;W_ .0C
M:?=_O?ZW_7_[73WH_P"&3_BK_P!"M[_\A&T^[_>_UO\ K_\ :Z>]?4>?C?\
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M\/\ _P (:^_^7%&?C?\ ]#U\/_\ PAK[_P"7%'U^KV7]?,/]5\'_ #R^]?\
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M=UM:L#D.0?\ 63>K]!V'&XZ^?C?_ -#U\/\ _P (:^_^7%&?C?\ ]#U\/_\
MPAK[_P"7%95,74J1Y7IZ';A,AP>#J>U5Y/I>SM^"/<**\/S\;_\ H>OA_P#^
M$-??_+BC/QO_ .AZ^'__ (0U]_\ +BN(^B/<**\/S\;_ /H>OA__ .$-??\
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M_EQ6=X<7XUQZ%8K%XY\ K&(E"A_!%ZQQ[G^V!G\J /H&BO#\_&__ *'KX?\
M_A#7W_RXHS\;_P#H>OA__P"$-??_ "XH ]PHKP_/QO\ ^AZ^'_\ X0U]_P#+
MBC/QO_Z'KX?_ /A#7W_RXH ]PHKP_/QO_P"AZ^'_ /X0U]_\N*,_&_\ Z'KX
M?_\ A#7W_P N* /<**\/S\;_ /H>OA__ .$-??\ RXHS\;_^AZ^'_P#X0U]_
M\N* /<**\/S\;_\ H>OA_P#^$-??_+BC/QO_ .AZ^'__ (0U]_\ +B@#W"BO
M#\_&_P#Z'KX?_P#A#7W_ ,N*,_&__H>OA_\ ^$-??_+B@#W"BO#\_&__ *'K
MX?\ _A#7W_RXHS\;_P#H>OA__P"$-??_ "XH ]PHKP_/QO\ ^AZ^'_\ X0U]
M_P#+BC/QO_Z'KX?_ /A#7W_RXH ]PHKP_/QO_P"AZ^'_ /X0U]_\N*,_&_\
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M )<49^-__0]?#_\ \(:^_P#EQ0![A17A^?C?_P!#U\/_ /PAK[_Y<49^-_\
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M?^_$W_QVC_AJKQ9_T#M%_P"_$W_QVO&:JZIJ4.CV,MW.EQ)%'C*VMM)<2')
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M8?X4]/U_$****^I/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "OC+_@IY_R(OPC_P"R@Z=_Z*GK[-KXR_X*>?\
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MT80^-1XE.J?\+*_M<"#_ (^/*-AYT>S'_+/R<=-W.=N*^V:*R_LO1KGW\O\
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MHHH *SM5_P"/K2O^OK_VE)6C6=JO_'UI7_7U_P"TI* -&BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.\._\@.Q_ZY+6C6=X=_Y
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M"T.\-WINBZ?I]T85MC/:VL<3^4N-L>Y0#M&!A>@P*\VO]7I\U/V=I>O7[_\
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M3Z@C(KPWQ#X3U7XN?';3=:T;6_&/@K0KGP7-;-JECI:V4[N;U?W#B^M':%\
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M6D:DXJT9-')4PF'K2YZM.,GW:3/H[_A7/A/_ *%?1?\ P7P__$T?\*Y\)_\
M0KZ+_P""^'_XFOG&BJ]M5_F?WF7]GX/_ )\Q_P# 5_D?1W_"N?"?_0KZ+_X+
MX?\ XFC_ (5SX3_Z%?1?_!?#_P#$U\XT4>VJ_P S^\/[/P?_ #YC_P" K_(^
MCO\ A7/A/_H5]%_\%\/_ ,31_P *Y\)_]"OHO_@OA_\ B:^<:*/;5?YG]X?V
M?@_^?,?_  %?Y'T=_P *Y\)_]"OHO_@OA_\ B:/^%<^$_P#H5]%_\%\/_P 3
M7SC11[:K_,_O#^S\'_SYC_X"O\CZ._X5SX3_ .A7T7_P7P__ !-'_"N?"?\
MT*^B_P#@OA_^)KYQHH]M5_F?WA_9^#_Y\Q_\!7^1]'?\*Y\)_P#0KZ+_ ."^
M'_XFC_A7/A/_ *%?1?\ P7P__$U\XT4>VJ_S/[P_L_!_\^8_^ K_ "/H[_A7
M/A/_ *%?1?\ P7P__$T?\*Y\)_\ 0KZ+_P""^'_XFOG&BCVU7^9_>']GX/\
MY\Q_\!7^1]'?\*Y\)_\ 0KZ+_P""^'_XFC_A7/A/_H5]%_\ !?#_ /$U\XT4
M>VJ_S/[P_L_!_P#/F/\ X"O\CZ._X5SX3_Z%?1?_  7P_P#Q-'_"N?"?_0KZ
M+_X+X?\ XFOG&BCVU7^9_>']GX/_ )\Q_P# 5_D?1W_"N?"?_0KZ+_X+X?\
MXFC_ (5SX3_Z%?1?_!?#_P#$U\XT4>VJ_P S^\/[/P?_ #YC_P" K_(^CO\
MA7/A/_H5]%_\%\/_ ,31_P *Y\)_]"OHO_@OA_\ B:^<:*/;5?YG]X?V?@_^
M?,?_  %?Y'T=_P *Y\)_]"OHO_@OA_\ B:/^%<^$_P#H5]%_\%\/_P 37SC1
M1[:K_,_O#^S\'_SYC_X"O\CZ._X5SX3_ .A7T7_P7P__ !-'_"N?"?\ T*^B
M_P#@OA_^)KYQHH]M5_F?WA_9^#_Y\Q_\!7^1]'?\*Y\)_P#0KZ+_ ."^'_XF
MC_A7/A/_ *%?1?\ P7P__$U\XT4>VJ_S/[P_L_!_\^8_^ K_ "/H[_A7/A/_
M *%?1?\ P7P__$U7T+P5X>L=8OY[;0=,MY[>X7R98K.-6C_=(?E(7(Y)Z>M?
M/D,SV\BR1.T<BG*NIP0?4&O4? /Q3CBFEMM<<AYW#"\QQD*% <=N%'/Y^M+V
MU1Z.3^\J. PD6I1HQ37]U?Y'KE%)'(LL:NC!T89#*<@CU%+61W!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %9VJ_\ 'UI7_7U_[2DK1K.U7_CZ
MTK_KZ_\ :4E &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5G>'?^0'8_P#7):T:SO#O_(#L?^N2T :-%%% !1110 4444 %%%%
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M -%3T ?1?QN_Y%2T_P"OU/\ T7)7B->W?&[_ )%2T_Z_4_\ 1<E>(T %%%%
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MY\8O^2D:S_O1_P#HI*]O\<:+?ZWI_A2/3Y)K>2'4H9GN8$1FA00R OA@1C)
MY'>O$/C%_P E(UG_ 'H__125[QXS\<1_#_PO8ZG-:FZ@,D44P$@0QQ;2TDG(
MYV(K-M[XQD5RT.?VBY%=G15Y>1\[LCB]/T?6?!_BP:U>VNH:U FH7T4DUO;J
MTS)-#:E)?+0#*[K<I\HX)!/&36%_PA/B];71M3334CG\,VT=W;VCG=/)-),9
M[J*(J=I8PA8,GC+O@CK7:>(/C/#H^J>(;..RMVCTF6QA%Y=WP@@D:XE\MBS;
M&V+&2N3SDY&!BK?_  L;5;FXNHM-T73]7^QZ9!J<[66K%UE65[A52!O)Q(?]
M&;EB@RP'O7K*>(BE+D73M_GU4K/UL><XT6W'F?\ 7_#?@<W!X?O=2CCTN+1[
MVTU6U\5S:FNJ/#Y4<-O]O>9F60XW^9"6CVKG(D(;C-9G_"(ZM=>#O"^BPZ#<
MVNNZ-#<?VE?,H"3,;2:*0I)G]Z9Y75\=NK8*@5V=E\74UZZ6TT331?75Q<(E
MGYUQY4<D)LX+IIG8(Q0 7"+@!B21V)VL\0?%R;PI<-;ZIHP,MN]M]K-E<F98
MDDCGD=US&K.$6W8XV@MG@9X(IXF]E#7??OIWVUV_X(W&C:[EY;?UKI_6AQ=Q
M\.O$UK]ETFULGN=(MM'E-LOF*AV27-C)/IQR0!E8)E0DA0LBKD!":]'\$7U]
M=>(-;3^R6TW15@M6M/.L/LLGFDS"6,\G>$58<,!CYR.<5E:U\8XM/UB*PABT
MJ-9)YXDO-4U86ENXCCMW!5Q&^2PN!@?[!.:](&<<]:YL15J^S2JQ6NWWZO\
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M_"D?&7_18_$'_@HTO_Y&H_X4CXR_Z+'X@_\ !1I?_P C4 =;17)?\*1\9?\
M18_$'_@HTO\ ^1J/^%(^,O\ HL?B#_P4:7_\C4 =;17)?\*1\9?]%C\0?^"C
M2_\ Y&H_X4CXR_Z+'X@_\%&E_P#R-0!UM%<E_P *1\9?]%C\0?\ @HTO_P"1
MJ/\ A2/C+_HL?B#_ ,%&E_\ R-0!UM%<E_PI'QE_T6/Q!_X*-+_^1J/^%(^,
MO^BQ^(/_  4:7_\ (U '6T5R7_"D?&7_ $6/Q!_X*-+_ /D:C_A2/C+_ *+'
MX@_\%&E__(U '6T5R7_"D?&7_18_$'_@HTO_ .1J/^%(^,O^BQ^(/_!1I?\
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M ,F(O_BJ]7_X4CXR_P"BQ^(/_!1I?_R-1_PI'QE_T6/Q!_X*-+_^1J /*/\
MA5?BG_H%_P#DQ%_\51_PJOQ3_P! O_R8B_\ BJ]7_P"%(^,O^BQ^(/\ P4:7
M_P#(U'_"D?&7_18_$'_@HTO_ .1J /*/^%5^*?\ H%_^3$7_ ,51_P *K\4_
M] O_ ,F(O_BJ]7_X4CXR_P"BQ^(/_!1I?_R-1_PI'QE_T6/Q!_X*-+_^1J /
M*/\ A5?BG_H%_P#DQ%_\51_PJOQ3_P! O_R8B_\ BJ]7_P"%(^,O^BQ^(/\
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M /D:@#K:*Y+_ (4CXR_Z+'X@_P#!1I?_ ,C4?\*1\9?]%C\0?^"C2_\ Y&H
MZVBN2_X4CXR_Z+'X@_\ !1I?_P C4?\ "D?&7_18_$'_ (*-+_\ D:@#K:*Y
M+_A2/C+_ *+'X@_\%&E__(U'_"D?&7_18_$'_@HTO_Y&H ZVBN2_X4CXR_Z+
M'X@_\%&E_P#R-1_PI'QE_P!%C\0?^"C2_P#Y&H ZVBN2_P"%(^,O^BQ^(/\
MP4:7_P#(U'_"D?&7_18_$'_@HTO_ .1J .MHKDO^%(^,O^BQ^(/_  4:7_\
M(U'_  I'QE_T6/Q!_P""C2__ )&H ZVL[5?^/K2O^OK_ -I25A_\*1\9?]%C
M\0?^"C2__D:LS6/@OXQBO-'4_&#7V\R[V@G2-,^7]S(<_P#'M[8_&@#T"BN2
M_P"%(^,O^BQ^(/\ P4:7_P#(U'_"D?&7_18_$'_@HTO_ .1J .MHKDO^%(^,
MO^BQ^(/_  4:7_\ (U'_  I'QE_T6/Q!_P""C2__ )&H ZVBN2_X4CXR_P"B
MQ^(/_!1I?_R-1_PI'QE_T6/Q!_X*-+_^1J .MHKDO^%(^,O^BQ^(/_!1I?\
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M2_X4CXR_Z+'X@_\ !1I?_P C4?\ "D?&7_18_$'_ (*-+_\ D:@#K:SO#O\
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MYN7O;]4?,5\IJU*\ZU.KR\WK_F?F7XJ\6:OXVUJ75M<OY-2U*555[B;&Y@H
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MC+_HL?B#_P %&E__ "-1_P *1\9?]%C\0?\ @HTO_P"1J .MHKDO^%(^,O\
MHL?B#_P4:7_\C4?\*1\9?]%C\0?^"C2__D:@#K:*Y+_A2/C+_HL?B#_P4:7_
M /(U'_"D?&7_ $6/Q!_X*-+_ /D:@#K:*Y+_ (4CXR_Z+'X@_P#!1I?_ ,C4
M?\*1\9?]%C\0?^"C2_\ Y&H ZVBN2_X4CXR_Z+'X@_\ !1I?_P C4?\ "D?&
M7_18_$'_ (*-+_\ D:@#K:*Y+_A2/C+_ *+'X@_\%&E__(U'_"D?&7_18_$'
M_@HTO_Y&H ZVBN2_X4CXR_Z+'X@_\%&E_P#R-1_PI'QE_P!%C\0?^"C2_P#Y
M&H ZVN \9?\ ):/@U_V%M0_]-5W6E_PI'QE_T6/Q!_X*-+_^1JX[7/ASXA\*
M_'#X-7.I_$'5?$D#:O?J+:[L+*%0?[+NSG,4*MVQU[T ?2E%%% !1110 444
M4 %%%% !1110 5Y5XC_Y.F^'G_8F>)O_ $NT&O5:\J\1_P#)TWP\_P"Q,\3?
M^EV@T >JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?#_P#P58_Y$'X-_P#91M-_]%7%?<%?#_\ P58_Y$'X-_\ 91M-_P#15Q0!
M]"?M,^.M<^'O@.PU'0+[[!>2ZE';O)Y,<F8S%*Q&'4CJJ\XSQ7S/_P -.?$O
M_H9?_)"V_P#C=>]?MF?\DOTO_L,1?^B)Z^,Z^XRC#T:F%4IP3=WND?S-Q[F^
M8X/.I4L-B9PCRQTC.27W)GJ7_#3GQ+_Z&7_R0MO_ (W1_P -.?$O_H9?_)"V
M_P#C=>6T5[7U/#?\^H_<C\Z_UASG_H,J_P#@R?\ F>I?\-.?$O\ Z&7_ ,D+
M;_XW1_PTY\2_^AE_\D+;_P"-UY;11]3PW_/J/W(/]8<Y_P"@RK_X,G_F>I?\
M-.?$O_H9?_)"V_\ C='_  TY\2_^AE_\D+;_ .-UY;11]3PW_/J/W(/]8<Y_
MZ#*O_@R?^9ZE_P -.?$O_H9?_)"V_P#C='_#3GQ+_P"AE_\ )"V_^-UY;11]
M3PW_ #ZC]R#_ %ASG_H,J_\ @R?^9ZE_PTY\2_\ H9?_ "0MO_C='_#3GQ+_
M .AE_P#)"V_^-UY;11]3PW_/J/W(/]8<Y_Z#*O\ X,G_ )GJ7_#3GQ+_ .AE
M_P#)"V_^-T?\-.?$O_H9?_)"V_\ C=>6T4?4\-_SZC]R#_6'.?\ H,J_^#)_
MYGJ7_#3GQ+_Z&7_R0MO_ (W1_P -.?$O_H9?_)"V_P#C=>6T4?4\-_SZC]R#
M_6'.?^@RK_X,G_F>I?\ #3GQ+_Z&7_R0MO\ XW1_PTY\2_\ H9?_ "0MO_C=
M>6UQOQ2^(P^&^BV5U'IK:M?7]Y'86EH)T@5Y7R1ND?A!\IYYYQ]1G/#82G%S
ME3C9?W5_D=.&SC/L76C0HXNJY2V_>27XN5EZO0^A/^&G/B7_ -#+_P"2%M_\
M;H_X:<^)?_0R_P#DA;?_ !NOF^#XIS6OPYUCQ/KGAZ]\/W6E"59]-NV^^Z ;
M1'+C$B,2 ' P3GTK*F^.7D_!N_\ &[:&R7EA*;:ZT=[K#13+.(F0R;.V0WW>
MXK%PP*WA':_P]/N_#<]&.(XGF[0Q-5^^J?\ %=N=[*_-:WG\.JUU1]2_\-.?
M$O\ Z&7_ ,D+;_XW1_PTY\2_^AE_\D+;_P"-U\O^&_BYK,GBC3-#\7>#)_"<
MVJAQI]P-0BO(9G1=S(S(!L;'0'K6)X[_ &CG\%Z?!>Q>&FU.VFU&]LD9+S83
M';'$DV#&>X?C_8Z\\3)8",7.4$DO[NO3I:_5&].7%56O'#T\34E*6JM6NGOM
M)3Y7\,MGT9]=_P##3GQ+_P"AE_\ )"V_^-T?\-.?$O\ Z&7_ ,D+;_XW7RUX
MO^/%IX;\=^$_#EGIIU5==\EFO%N-BVZ3-B,XV'<2 YQD<+5_6/C';:1\5M/\
M&G3FEBN%C2;4Q, EO/(LC11%-O)81'G(ZCBJY<!=KDCH[?"MW\C%5^*7&,OK
M%6THN:_>/X8Z-_%WV3U>ED[H^EO^&G/B7_T,O_DA;?\ QNC_ (:<^)?_ $,O
M_DA;?_&Z^5=<^,'B>'QUKWAWP[X";Q(NC+ US=+J\5L<2Q[UPCIR?O# )Z=L
MUW'@/QI9?$'PM9ZY8QRP13[E>WN%VR0R*Q5T8>H8&JA2P523A&FKJ_V>VCMI
MK;R,L1C>(\+1CB*N*J<LN7:LVUS+FC=*;<;K5<R5SW+_ (:<^)?_ $,O_DA;
M?_&Z/^&G/B7_ -#+_P"2%M_\;KY2\0_'+5+74-9/AWP3>>)=$T25H-1U2.\C
MA"2( 9%BC(+2[1UQCD>G-='X@^-/A#PEH^E:CKVJ'1UU.%9X+:Y@D-QM(S\T
M2JS+CH21C/>I4,!K[D5;O%)?>U9_(UE7XHCR)5ZLG/91J2E+:]G&,G).VMFD
M['T5_P -.?$O_H9?_)"V_P#C='_#3GQ+_P"AE_\ )"V_^-U\[:[\;/!'ANQT
MV\U#Q!;PVFHPO<6DR(\J3(F V"BGD$@;>N>,<4_0OC/X*\3:]:Z-I?B&UO=2
MNH/M$4$8;YDV[L9Q@-CDH3N&#D5?LL!S<O+"_HC#Z[Q1[-UO:XCE5];U+:;Z
M[:=>W4^AO^&G/B7_ -#+_P"2%M_\;J&']I'XC6\UQ+'XBVO<.'D/V&V.Y@H4
M'_5\<*!QZ5\Z:1\>_ .NZY::-9>(X)=2NF*10-%*F6#%=I+* K$J< D$\8SD
M9;I/QFTB32?%.IZV8M!T_0M7FTIII9C)YQCVX8 *#EMWW &/'4U*IX![1A]R
M+EBN*8W4ZM=/31RFF[NRLF[N[TT3/I/_ (:<^)?_ $,O_DA;?_&Z/^&G/B7_
M -#+_P"2%M_\;KYCU;]H7P78^ ;OQ99:E_:UC#)]G6*WC=96F()6,JP!3."<
ML ,#/-6+SX^>!M)\-Z/K6I:[%9VNJQ>9;+Y4KNP!(8[%3=@,"-Q4#BER9?VA
MM?9;%>WXKLK5,1K)QMS5+\R5VK7O>VNWY'TI_P -.?$O_H9?_)"V_P#C='_#
M3GQ+_P"AE_\ )"V_^-UX!XB^+/A#PKX?LM<U/7K6'2[['V6>/=+YWNBH"Q [
MX''?%-^&OQ%MOB5I^JWUG"B6EGJ,UC#-'-YJW")M(E!VC 8-TYQZUI['!.:I
MJ$;]K(YWF'$D:#Q4L165-.UW.:5]K:O5KJEMU/H'_AISXE_]#+_Y(6W_ ,;H
M_P"&G/B7_P!#+_Y(6W_QNO+:*V^IX;_GU'[D>=_K#G/_ $&5?_!D_P#,]2_X
M:<^)?_0R_P#DA;?_ !NC_AISXE_]#+_Y(6W_ ,;KRVBCZGAO^?4?N0?ZPYS_
M -!E7_P9/_,]2_X:<^)?_0R_^2%M_P#&Z/\ AISXE_\ 0R_^2%M_\;KRVBCZ
MGAO^?4?N0?ZPYS_T&5?_  9/_,]2_P"&G/B7_P!#+_Y(6W_QNC_AISXE_P#0
MR_\ DA;?_&Z\MHH^IX;_ )]1^Y!_K#G/_095_P#!D_\ ,]2_X:<^)?\ T,O_
M )(6W_QNC_AISXE_]#+_ .2%M_\ &Z\MHH^IX;_GU'[D'^L.<_\ 095_\&3_
M ,SU+_AISXE_]#+_ .2%M_\ &Z/^&G/B7_T,O_DA;?\ QNO+:*/J>&_Y]1^Y
M!_K#G/\ T&5?_!D_\SU+_AISXE_]#+_Y(6W_ ,;H_P"&G/B7_P!#+_Y(6W_Q
MNO+:*/J>&_Y]1^Y!_K#G/_095_\ !D_\SU+_ (:<^)?_ $,O_DA;?_&ZAN/V
MD?B-=20/+XBW-!)YL9^PVPVMM*Y_U?/#'\Z\SHH^IX;_ )]1^Y!_K#G/_095
M_P#!D_\ ,^B_A?\ M<:MI^H_9?&K?VI83-Q?0PI'+;_54 #+^&[KUZ5]7:/K
M5CXATV#4--NXKVRG7='-"VY6'^/MVK\QJ[;X9?%S7_A9J7GZ7/YME(P-QI\Q
M)AE]\?PM_M#GZCBO&QV3PK+GP_NR[='_ )'Z'PSX@XG 26'S5NI3?VMY1_\
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MO?!;_L,ZA_Z:;NO5:\J^*G_)7O@M_P!AG4/_ $TW= 'JM%%% !1110 4444
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M]IWQ?XK\<^ M!\4>&YO#FE6.EW6N6-K?!;B*:[:=420,T9VR0Y;: V1@G!P
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MBB@ HHHH **** "BBB@ HHHH *Q_!W_(HZ'_ ->,'_HM:V*Q_!W_ "*.A_\
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M9J4336-[/K=LD-U&'5"\3E\.H=U4E21E@.I% '<UY5\5/^2O?!;_ +#.H?\
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M&O\ H8M)_P# V+_XJC_A//#7_0Q:3_X&Q?\ Q5?&U% 'V3_PGGAK_H8M)_\
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MB_\ BJ^-J* /LG_A//#7_0Q:3_X&Q?\ Q5'_  GGAK_H8M)_\#8O_BJ^-J*
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M5F"%Y/.^4X.%7-3_ !4_Y*]\%O\ L,ZA_P"FF[KU6O*OBI_R5[X+?]AG4/\
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ML8!&* -77?C)-X>^)ES87EEJ:6EKX+D\1S6$<MO(H9)<% JQEFEP"-PG\O\
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M??:L=:N_#MI B/)<,P9U6Z4B1(F(&4 Y&1GG-;7QB^#^M?$;Q!X2UWP_XO\
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M?7'[2'CR'P[\6M1UKP[)HUKX;O(;:VDTW4+7S;=S+"GD9>&568JY<R%"N#M
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MPCAO(U+R@G@!U'+?4<_6O,/"/@O5?&VH"UTV#<%_UD[\1Q#U8_TZFOI7X?\
MPNTKP';B2-?M>ILN)+R1>?<(/X1^I[F@#LZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K'\'?\ (HZ'_P!>,'_HM:V*Q_!W_(HZ'_UXP?\ HM:
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M#GX^_P#"OU#_ ..T >^45X'_ ,*1M/\ H<_'W_A7ZA_\=H_X4C:?]#GX^_\
M"OU#_P".T >^45X'_P *1M/^AS\??^%?J'_QVC_A2-I_T.?C[_PK]0_^.T >
M^5\/_P#!5C_D0?@W_P!E&TW_ -%7%>R?\*1M/^AS\??^%?J'_P =KY)_X*,_
M#6W\->"_A=+'XB\5:B;CQS86Y75?$%W=K&#',=Z"1R$<8X<<C)YYH ^\?C9X
M5U3Q=X5M;/2;7[7<I>I,R>8B841R G+$#JP_.O%/^%(^-?\ H"_^34'_ ,77
M8?\ "D;3_H<_'W_A7ZA_\=H_X4C:?]#GX^_\*_4/_CM ''_\*1\:_P#0%_\
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M1M/^AS\??^%?J'_QVC_A2-I_T.?C[_PK]0_^.T <?_PI'QK_ - 7_P FH/\
MXNC_ (4CXU_Z O\ Y-0?_%UV'_"D;3_H<_'W_A7ZA_\ ':/^%(VG_0Y^/O\
MPK]0_P#CM ''_P#"D?&O_0%_\FH/_BZ/^%(^-?\ H"_^34'_ ,778?\ "D;3
M_H<_'W_A7ZA_\=H_X4C:?]#GX^_\*_4/_CM ''_\*1\:_P#0%_\ )J#_ .+H
M_P"%(^-?^@+_ .34'_Q==A_PI&T_Z'/Q]_X5^H?_ !VC_A2-I_T.?C[_ ,*_
M4/\ X[0!Q_\ PI'QK_T!?_)J#_XNC_A2/C7_ * O_DU!_P#%UV'_  I&T_Z'
M/Q]_X5^H?_':/^%(VG_0Y^/O_"OU#_X[0!Q__"D?&O\ T!?_ ":@_P#BZ/\
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M$0?J3U)]SS5ZO _^%(VG_0Y^/O\ PK]0_P#CM'_"D;3_ *'/Q]_X5^H?_':
M/?**\#_X4C:?]#GX^_\ "OU#_P".T?\ "D;3_H<_'W_A7ZA_\=H ]\HKP/\
MX4C:?]#GX^_\*_4/_CM'_"D;3_H<_'W_ (5^H?\ QV@#WRBO _\ A2-I_P!#
MGX^_\*_4/_CM'_"D;3_H<_'W_A7ZA_\ ': /?**\#_X4C:?]#GX^_P#"OU#_
M ..T?\*1M/\ H<_'W_A7ZA_\=H ]\HKP/_A2-I_T.?C[_P *_4/_ ([1_P *
M1M/^AS\??^%?J'_QV@#WRBO _P#A2-I_T.?C[_PK]0_^.T?\*1M/^AS\??\
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MHGN_VKO"<>BZ5=V6D^)-8U34+B>T'A[3M,,FI030JK3)+"6&TH'7/)ZY&1G
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M^0'8_P#7): -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L[PW_R+NE_]>L7_ * *T:SO#?\ R+NE_P#7K%_Z * -&BBB@ HHHH ****
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M//B#XJ^.&O>#?"FK>&M!TK2M"T[5O/UK0;G4)YGN9+A2OR7MN$"B <8)^8T
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MT5K?\(CKO_0%U#_P%D_PH_X1'7?^@+J'_@+)_A0!DT5K?\(CKO\ T!=0_P#
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M'_BCI_B3Q%JGA/7/#%L/&%M NNQ:E!.WV2X2$1/):%1\P(+$+)QTSZU],_\
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M_ 63_"C_ (1'7?\ H"ZA_P" LG^% &316M_PB.N_] 74/_ 63_"C_A$==_Z
MNH?^ LG^% &316M_PB.N_P#0%U#_ ,!9/\*/^$1UW_H"ZA_X"R?X4 9-%:W_
M  B.N_\ 0%U#_P !9/\ "C_A$==_Z NH?^ LG^% &32@%B !DUM6O@G7[NXC
MA71[U&<X#2P,BCZL1@5Z_P""?AC9^&1'=7>V\U+KO(^2(_[(]?<_I0!R/@CX
M1S7_ )=[K:M;VW5;7H[_ .]_='MU^E>OVMK#96\<%O$L,,8VI&@P /85+10
M5G>'?^0'8_\ 7):T:SO#O_(#L?\ KDM &C1110 4444 %%%% !1110 4444
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M@=5D4'*$HRL <9# ]#0!<HJGJVM:?H-JMSJ=];:=;-+' )KN98D,DCA(TRQ
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M-<>697E9I)9&DD=G<LS,SNS$L2>: -NBBL3P7XH_X3/PS9ZS_9&J:%]IW_\
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M_P"@I_Y+R_\ Q-?/=% 'T)_PM3PM_P!!3_R7E_\ B:/^%J>%O^@I_P"2\O\
M\37SW10!]"?\+4\+?]!3_P EY?\ XFC_ (6IX6_Z"G_DO+_\37SW10!]"?\
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M?P:/@>3X Z[IOA*[TOQ'-=W=OXFU+[)*+LVSV%TRQWDC#<(A,EN$1SM0K&J
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MHH'!'4YS61J7[-.BZSX9TK3;_P 3^+;S5-*N)+FQ\2RZL3JMN9,!U6?;]T@
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M]FEK90);P)T1!^I]3[FK5 !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %9WAW_D!V/_ %R6M&L[P[_R ['_ *Y+0!HT444 %%%% !1110 4444
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M1C(5!]2-Z]>.*LT5SQR^A%WM?;\"?9Q,B/16L=/BCL1!;W*6L\#,(P Y>5'
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M ,+[7/\ Y94?V7\(_P"]\4/_  OM<_\ EE0!TG_"A_\ J.?^2G_V='_"A_\
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MV7\(_P"]\4/_  OM<_\ EE1_9?PC_O?%#_POM<_^65 '2?\ "A_^HY_Y*?\
MV='_  H?_J.?^2G_ -G7-_V7\(_[WQ0_\+[7/_EE1_9?PC_O?%#_ ,+[7/\
MY94 =)_PH?\ ZCG_ )*?_9U7NO@G]EFM$_MG=Y\OE9^RXV_(S9^_S]W]:P_[
M+^$?][XH?^%]KG_RRJUI/@/X6>+-:TNRM-0^(5G*;GG[=X_UU0RF.085AJ#8
M.[:.Q.<#O0!VWA?X1:?H-W]JO)O[4F4YC#Q[$3WVY.3]?RKO*YG_ (9;\$?]
M!#QW_P"'$\0?_)U'_#+?@C_H(>.__#B>(/\ Y.H Z:BN9_X9;\$?]!#QW_X<
M3Q!_\G4?\,M^"/\ H(>._P#PXGB#_P"3J .FHKF?^&6_!'_00\=_^'$\0?\
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MKF?^&6_!'_00\=_^'$\0?_)U'_#+?@C_ *"'CO\ \.)X@_\ DZ@#IJSO#O\
MR ['_KDM97_#+?@C_H(>._\ PXGB#_Y.K+\+_LQ>"[KP]I\LFH>.=[PJ3M^(
M6OJ/R%]@4 =U17,_\,M^"/\ H(>._P#PXGB#_P"3J/\ AEOP1_T$/'?_ (<3
MQ!_\G4 =-17,_P##+?@C_H(>._\ PXGB#_Y.H_X9;\$?]!#QW_X<3Q!_\G4
M=-17,_\ #+?@C_H(>.__  XGB#_Y.H_X9;\$?]!#QW_X<3Q!_P#)U '345S/
M_#+?@C_H(>.__#B>(/\ Y.H_X9;\$?\ 00\=_P#AQ/$'_P G4 =-17,_\,M^
M"/\ H(>._P#PXGB#_P"3J/\ AEOP1_T$/'?_ (<3Q!_\G4 =-17,_P##+?@C
M_H(>._\ PXGB#_Y.H_X9;\$?]!#QW_X<3Q!_\G4 =-17,_\ #+?@C_H(>.__
M  XGB#_Y.H_X9;\$?]!#QW_X<3Q!_P#)U '345S/_#+?@C_H(>.__#B>(/\
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M9;\$?]!#QW_X<3Q!_P#)U'_#+?@C_H(>._\ PXGB#_Y.H Z:BN9_X9;\$?\
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M#B\QKO0KGQ4NH6=PQ@,:+!;Q(%C ;#G>QY''-8WPU^!_C+1;?X*0ZCI)L_\
MA'Y->_M5ENH6-J+D.(3\KG?NW#[F<=\4 >QZ7^T5\-]:\;GPC9>++*XU_P P
MPBW4/L>0?P)*5\MFSQM5B<Y%<]IO[5O@B+Q9K/ASQ'J5KX:U2SUF;2;:*>5Y
M!<*@3$S,$"PJQ<@;SCY3\QYQYEX;^#?Q(C\.^%?AG?>%-'LM \/ZU%J9\91W
MZ,;B..8R_N[<#S%F8':6;CJ.^:C\4?"KXG:A;_$WPI8^"=+GT?QGK\EU'X@N
MM2B5K2',9$CQ#+,/E.T#YE.XE>F0#VU/CEI5GXN^(6EZVD.BZ5X/BLII]6FN
M-RS"XC+CY-ORD$!0 6+$C SQ4WA_]H;X=^*/"6K^)M-\46TVB:3M%]<R12Q&
M#=PN4=0WS'@8')X&37F6L?#OXF^&_$/Q8U;P? J7NIPZ+'I=S)<0![Q+>+9<
M*N\D1OC(#2 #G(]:QO#?P@\8W2_%*\\2^ DOT\3VVG36^CW'B<N[/#O#1M=X
M++*IVN"%"9( 8 < 'HVL?M;?#BT^'.J^,-,UDZW96,JVWV>W@ECF>=P3'&5D
M52H;:WS$;?E/)(Q6EJ'[3OPWT/PCH'B'5O$L&GV6M1>;:)Y,TDK@$JQ\M4+A
M0P*[BH&17E>G_#7XL>)OA!\2M#UNVO+:/4K..+1-%UO6XM3NTD4EI,W:JHVM
M\H4.3@CD@<G0G\-?$S0/&&@_$+3_ (?6>MZE-X=70K[P[/K$$<U@R2,PD2<C
MRV5AC('/./>@#U'Q+^T1\.?".G:3?ZKXIM8+'5K>2ZL;B..29)XT(#E2BD9!
M(&W[V<@#@U)X:_:"^'?C#Q-9>']%\56>H:Q>6WVJ"VA#_.FW?C<5VAPO)0D,
M #D<5Y/\.?@'XF\)^,/AA=ZCI]E<6^EPZS<:BUHZ?9[&:Z;='%&K$,0,E<J"
M!@]N34\!_ WQ=X;TGX+(-$ALKWP]=:M/J;-/"PMS.LGELVU_G#$IPF< #.,4
M >P^$_VA/AWXZ\73>&-!\46NHZW'O_T>..0*^S[VR0J$DP,GY6/ )Z5OZOXR
M_L[QUX?\,PV?VF;4X+JZEF\PK]GAA"#=C:=V7D1<9'7//2OGGP1\/_BWJ_Q4
M^'WB7QMH3"30;B]AO]0.M13_ &@2PNJS1VZ[8X8P=J[5&\YR1QQ[EIOAK4)O
MC)K?B.]MO*L(=)MM,TZ0NI\W,CRSM@,2.?*7Y@/N\<4 <WXV^-^N6/C:]\*^
M!O ESX[U73(HYM48:C%806GF#,:>9("&<CG:.Q[\XP=8_;$\)^'?!-MK6KV%
M_IFJ-J;:3<Z+<1GSK6>,KYV]E!&U5<-D<L" !G(#]<T'XA_"SXH^*?$O@SPI
M:>.M(\4?9YKFQ;4X["XM+B*/R\AY 59"N.!SD]@.>4U[X)>.Y/A=JVHMIUGJ
M?C?5?%=MXFN-&M+M8HD6-UQ DLF%R%4$L>.N,X&0#N;[]K+P/X?\5:QIGB#4
M(=&T^UM["XL;^1I)'OEN8FD!$"Q[T"@+DG/WAG;76^/?COX"^&-IIUSXD\2V
MMA%J*"6T\M'N&FC(R'58E8[#_>QCWKSR\^&?B77M7^,FKW?AY+:Y\3>&K6ST
MZ%KF&0FX%K*)(=V[C;(4&Y@H. 1Q7GGQ$^ /Q!6]\%Z]H=KKEU<6_ABUT6^L
M/#_B2'2+JWEB&3F9U=)(R21A>XSTH ^A?%7QY\ ^"M%T?6-8\26]OI>L([V%
MW%')/'.%4,V#&K=B.#C)X'/%4/'7QRM?#^C^&)/#>CW7C#6?%"[]&TN!OLIN
M(P@D:5WE \I I!)89Y''4CSKPY\!=6\-M\$[6#2)&T_P[>WU[J,=WJ,-XUF9
MD9D_>>7%YA$A'W(^#ZXW'N?C)X2\5?\ "5^%/'/@VPMM;U?05N;>;1KFY%O]
MLMYU4,$E8;4=2BD$\=?H0!W@SX])?:1XHN/''A^Z^'EUX;9/[16_F%Q;!7&4
M,=P@"R$\?*HSEE SFK^B_M&?#KQ%X.UCQ3IWB6.YT/2"HOK@6TX>#<0%)C*!
M\$G@A<<'T-<7>W7QZU[P+XMU%=.TWP[K4\]N=&T&&ZAFN(85($ZM<D>46< E
M21P2>G&/.YO@K\1-8\,_&-KOPNUGJ'BVRTUK&S?6X[YP\3$21R3R,/G PW9.
M<*>,4 ?0?@KX\> ?B)<:O!X?\36E^^DH9;TX>)(HP2#)N=5#(,?>4D=.>13/
M OQ^^'WQ)O-2M?#OB>UOY].C::Y1EDAV1J<-(#(J[D'&67(&1SR*X;QU\%M7
M\4>/_$+:?:1:=I.I> G\/Q7^] J71F8JC*#OP$QSMQCC.>*Q-!^'_P 0O&WA
M.Z\+^(?!'ASP9#:>&9M!@UM)H[JZN)&0(IA,>/(@."S(P)/&.^ #TKPS^TE\
M-?&-UJUMH_BNUO9]+@DN;F-8I5/E1@EWCW(/-  )_=[N,>HJE;_M4_"NZT'4
M-9B\6PG3+!H4N+@VEP 'E#&-%!CR[$(QVJ"1M.0,5\_^ _V</'AF \0:/XC6
M?1M)O+;3I]0\96][:/));/"$@MA!NC5MPX:1 !C).,'U;4OA;K%M^SCX*\/K
MX+_MK7M&AMI38VFN+I5S:7*(<S0W"*R&0,S=2 =Q.2: /7_ ?Q"\._$[P^FM
M^&-4CU;3'=H_.C5D*N.JLK ,IY'! X(/>NBKS#]GW2?'>D^$+Q/'DLXNI+UW
ML;2]O8[VZM;;:H6.:XC55E;<&.<9P1D]AZ?0 4444 %%%% !1110 4444 %%
M%% !1110!ZW\-_CI=:'Y6GZ^TE[IXPJ77WI81[_WE_4>_2OH+3M2M=6LXKNR
MGCN;:4;DEC;(-?$5=/X(^(6K>!+WS;&7S+9SF:TD),<GO['W'Z]* /K^BN7\
M#_$32?'EGOLI/*NT&9K.4CS$]_\ :7W'Z=*ZB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L?P?\ \BOIG_7!?Y5L5C^#_P#D5],_ZX+_ "H
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MP0\5^'K/X+6>KZ,@'A;4=7FU%Q<Q2)&)?-,$B_/N8,S*1@;A_$!0![#'\?/
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MX/\ ^17TS_K@O\J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM8JVV1,J<,I!P>"".U &7_PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\
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M%G_12_!__@^M?_CE=5_PB>A_] ;3_P#P%C_PH_X1/0_^@-I__@+'_A0!RO\
MPT)\+/\ HI?@_P#\'UK_ /'*/^&A/A9_T4OP?_X/K7_XY75?\(GH?_0&T_\
M\!8_\*/^$3T/_H#:?_X"Q_X4 <K_ ,-"?"S_ **7X/\ _!]:_P#QROC;_@IM
M\5O!/B_P/\)8=!\8Z!K<MKX_T^ZN(].U2"X:&%8IPTCA&.U 2,L>!D5]Y_\
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MWV/PC_T5GX=?^%)#1]C\(_\ 16?AU_X4D-?2/_"4?"[_ *"_A'_P)M?\:/\
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M4-E?4?-CZ@U]0:?K'PXU:\BM+*]\+WEU*=L<%O+;.[GT"@Y)JSHWA31#JVO
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M?_0&T_\ \!8_\*/^$3T/_H#:?_X"Q_X4 ?(WV/PC_P!%9^'7_A20T?8_"/\
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M_P#P?6O_ ,<H_P"&A/A9_P!%+\'_ /@^M?\ XY75?\(GH?\ T!M/_P# 6/\
MPH_X1/0_^@-I_P#X"Q_X4 <K_P -"?"S_HI?@_\ \'UK_P#'*/\ AH3X6?\
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M_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'*ZK_ (1/0_\ H#:?_P" L?\
MA1_PB>A_] ;3_P#P%C_PH Y7_AH3X6?]%+\'_P#@^M?_ (Y1_P -"?"S_HI?
M@_\ \'UK_P#'*ZK_ (1/0_\ H#:?_P" L?\ A1_PB>A_] ;3_P#P%C_PH Y7
M_AH3X6?]%+\'_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'*ZK_ (1/0_\
MH#:?_P" L?\ A1_PB>A_] ;3_P#P%C_PH Y7_AH3X6?]%+\'_P#@^M?_ (Y1
M_P -"?"S_HI?@_\ \'UK_P#'*ZK_ (1/0_\ H#:?_P" L?\ A1_PB>A_] ;3
M_P#P%C_PH Y7_AH3X6?]%+\'_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'
M*ZK_ (1/0_\ H#:?_P" L?\ A1_PB>A_] ;3_P#P%C_PH Y7_AH3X6?]%+\'
M_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'*ZK_ (1/0_\ H#:?_P" L?\
MA1_PB>A_] ;3_P#P%C_PH Y7_AH3X6?]%+\'_P#@^M?_ (Y1_P -"?"S_HI?
M@_\ \'UK_P#'*ZK_ (1/0_\ H#:?_P" L?\ A1_PB>A_] ;3_P#P%C_PH Y7
M_AH3X6?]%+\'_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'*ZK_ (1/0_\
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ML),?DRUB77P ^$;L3;_M!^$XE])+JT<_F+H5]R?\(GH?_0&T_P#\!8_\*/\
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M*X#T3E?^&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KJO\
MA$]#_P"@-I__ ("Q_P"%'_")Z'_T!M/_ / 6/_"@#E?^&A/A9_T4OP?_ .#Z
MU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KJO\ A$]#_P"@-I__ ("Q_P"%'_")
MZ'_T!M/_ / 6/_"@#E?^&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P
M?6O_ ,<KJO\ A$]#_P"@-I__ ("Q_P"%'_")Z'_T!M/_ / 6/_"@#E?^&A/A
M9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KJO\ A$]#_P"@-I__
M ("Q_P"%'_")Z'_T!M/_ / 6/_"@#E?^&A/A9_T4OP?_ .#ZU_\ CE'_  T)
M\+/^BE^#_P#P?6O_ ,<KJO\ A$]#_P"@-I__ ("Q_P"%'_")Z'_T!M/_ / 6
M/_"@#E?^&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KJO\
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MSQ;A.(H<D5R5DKN/ZI]5^*_$Z&BBBO*/N@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Q]>_X_M"_P"OX_\ HB:MBL?7O^/[0O\ K^/_ *(FH V****
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M>3Y'@<BH>PP<+=V_BEYM_ILNB"BBBN0]\**** "BBB@ HHHH **** "BBB@
MHHHH **** "L?7O^/[0O^OX_^B)JV*Q]>_X_M"_Z_C_Z(FH V**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P?_ ,BOIG_7!?Y5
ML5C^#_\ D5],_P"N"_RH V**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *Q_!W_ "*.A_\ 7C!_Z+6MBL?P=_R*.A_]>,'_ *+6@#8HHHH
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M_P"&DK3_ *)_X^_\$?\ ]G1_PTE:?]$_\??^"/\ ^SKJJ* .5_X:2M/^B?\
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M $#M:_[\0_\ QVC_ (:J\)_] [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\
M([S_ (:2M/\ HG_C[_P1_P#V='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M
M:_[\0_\ QVC_ (:J\)_] [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_
M (:2M/\ HG_C[_P1_P#V='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\
M0_\ QVC_ (:J\)_] [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2
MM/\ HG_C[_P1_P#V='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\
MQVC_ (:J\)_] [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\
MHG_C[_P1_P#V='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_
M (:J\)_] [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C
M[_P1_P#V='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J
M\)_] [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1
M_P#V='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_]
M [6O^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V
M='_#25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_] [6O
M^_$/_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V='_#
M25I_T3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_] [6O^_$/
M_P =H_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V='_#25I_
MT3_Q]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_] [6O^_$/_P =
MH_L[%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V='_#25I_T3_Q
M]_X(_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_] [6O^_$/_P =H_L[
M%_\ /MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V='_#25I_T3_Q]_X(
M_P#[.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_] [6O^_$/_P =H_L[%_\
M/MA_K?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V='_#25I_T3_Q]_X(_P#[
M.N#_ .&JO"?_ $#M:_[\0_\ QVC_ (:J\)_] [6O^_$/_P =H_L[%_\ /MA_
MK?D/_07'\?\ ([S_ (:2M/\ HG_C[_P1_P#V=9FE?M%6T6I:TY\ >/")+E&
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ME:?]$_\ 'W_@C_\ LZ/^&DK3_HG_ (^_\$?_ -G7544 <K_PTE:?]$_\??\
M@C_^SH_X:2M/^B?^/O\ P1__ &==510!RO\ PTE:?]$_\??^"/\ ^SH_X:2M
M/^B?^/O_  1__9UU5% '*_\ #25I_P!$_P#'W_@C_P#LZ/\ AI*T_P"B?^/O
M_!'_ /9UU5% '*_\-)6G_1/_ !]_X(__ +.C_AI*T_Z)_P"/O_!'_P#9UU5%
M '*_\-)6G_1/_'W_ ((__LZ/^&DK3_HG_C[_ ,$?_P!G7544 <K_ ,-)6G_1
M/_'W_@C_ /LZ/^&DK3_HG_C[_P $?_V==510!RO_  TE:?\ 1/\ Q]_X(_\
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MKZ;]GC/_ !*[L8#;CSSFO7:X#QE_R6CX-?\ 86U#_P!-5W0![K1110 4444
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ML[PW_P B[I?_ %ZQ?^@"@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\7K7Q;?QV4-II=C):6*P3/)-*SGEY 454 !8!06^]G/:OL7_ (9'_P"IK_\
M*=_]MH_X9'_ZFO\ \IW_ -MK*698";NY]4]GTVZ'?1X/XJP\7&&'WBX_'#12
M^*WOVUZ^O<^'-#_9[T&X\2:YK?B?2;#5KZXUF;4+&4/(=D+!-J2+PK$%6.TA
M@,\=373>,/@OX*\?:M%J>O:##?7\:A1-YDD98#H&V, P'^UGTKZ]_P"&1_\
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MLUF&6IMIJ[_NOU[=SMEPIQC.$:<X3<8JR7M8V2:LTESZ*VEETTV/CSP_\"_
MOA35(-2TGP_#8W\$[7$=Q'-+N5F4J0"6^[AB-GW>>E,T?X#^ M URVUBQ\-V
M\6I6Q+13O)))M8L6W89B"P).&(R.,$8%?8W_  R/_P!37_Y3O_MM'_#(_P#U
M-?\ Y3O_ +;4K'98K6MI_=?^1I+AGC2;DY*;YE9_O8ZK71^_JM7IYON?'NK_
M  -\"Z]XH_X2&_\ #EM<ZL7$C3,[A'8=WC#;&/\ O*<]ZUKOX;^&[[Q:OB:X
MTJ.76UMS:?:2[X:(@J59,[&X8CD$XXKZL_X9'_ZFO_RG?_;:/^&1_P#J:_\
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M/C7_ ,]O /Y7M'_".?&O_GMX!_*]KVVB@#Q+_A'/C7_SV\ _E>T?\(Y\:_\
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M?_9J]VHH \2_X1SXU_\ /;P#^5[1_P (Y\:_^>W@'\KVO;:* /$O^$<^-?\
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M>VT4 >)?\(Y\:_\ GMX!_*]H_P"$<^-?_/;P#^5[7MM% 'B7_".?&O\ Y[>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728557703792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">vTv Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3916571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3980 Premier Dr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">High Point<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">841-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VTVT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001641489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728558662688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="nump">$ 12,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableCurrent', window );">G42 Promissory Note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Current deposits</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,125<span></span>
</td>
<td class="nump">27,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="nump">5,588<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,924<span></span>
</td>
<td class="nump">33,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">9,620<span></span>
</td>
<td class="nump">7,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,275<span></span>
</td>
<td class="nump">7,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">18,669<span></span>
</td>
<td class="nump">18,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_WarrantyLiability', window );">Warrant liability, related party</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,435<span></span>
</td>
<td class="nump">27,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">10,722<span></span>
</td>
<td class="nump">16,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">254,912<span></span>
</td>
<td class="nump">253,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(281,192)<span></span>
</td>
<td class="num">(265,524)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(25,233)<span></span>
</td>
<td class="num">(10,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable noncontrolling interest and stockholders&#8217; deficit</a></td>
<td class="nump">14,924<span></span>
</td>
<td class="nump">33,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_WarrantyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warranty Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_WarrantyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728553420288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">23,093,860<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728557846672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">11,457<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">9,338<span></span>
</td>
<td class="nump">9,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,368<span></span>
</td>
<td class="nump">5,689<span></span>
</td>
<td class="nump">20,795<span></span>
</td>
<td class="nump">18,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,368)<span></span>
</td>
<td class="num">(5,689)<span></span>
</td>
<td class="num">(20,795)<span></span>
</td>
<td class="num">(16,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interest</a></td>
<td class="num">(8,540)<span></span>
</td>
<td class="num">(5,468)<span></span>
</td>
<td class="num">(21,525)<span></span>
</td>
<td class="num">(18,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before noncontrolling interest</a></td>
<td class="num">(8,540)<span></span>
</td>
<td class="num">(5,468)<span></span>
</td>
<td class="num">(21,525)<span></span>
</td>
<td class="num">(18,983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interest</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
<td class="num">(4,753)<span></span>
</td>
<td class="num">(4,564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to vTv Therapeutics Inc.</a></td>
<td class="num">(6,654)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(16,772)<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="num">(6,654)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(16,772)<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(3,640)<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="num">(1,514)<span></span>
</td>
<td class="num">(2,998)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="num">$ (324)<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares)</a></td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">80,490,121<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">72,649,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares)</a></td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">80,490,121<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">72,649,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552667840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class A Common Stock</div></th>
<th class="th"><div>Class B Common Stock</div></th>
<th class="th">
<div>Redeemable Noncontrolling Interest </div>
<div>Redeemable Noncontrolling Interest</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class B Common Stock</div>
</th>
<th class="th"><div>Note Receivable for Common Stock</div></th>
<th class="th">
<div>Note Receivable for Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,942,777<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">$ (9,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (248,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Common Stock to Collaboration Partner (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A common stock to collaboration partner, net of offering cost</a></td>
<td class="nump">5,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement', window );">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement', window );">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs</a></td>
<td class="nump">5,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(3,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="num">(16,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267,062)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,329,051<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="num">(8,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement', window );">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement', window );">Issuance of Class A common stock under CinRx purchase agreement, net of offering costs</a></td>
<td class="nump">5,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(9,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,498)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="num">(16,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267,062)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">16,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">10,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(10,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="num">(25,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281,192)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_TemporaryEquityChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">10,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="num">(25,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="nump">6,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,271<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="num">$ (25,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (281,192)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Class A Common Stock under LPC agreement shares..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_StockIssuedDuringPeriodValuePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_StockIssuedDuringPeriodValuePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_TemporaryEquityChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Change In Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_TemporaryEquityChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728553541552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss before noncontrolling interest</a></td>
<td class="num">$ (21,525)<span></span>
</td>
<td class="num">$ (18,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Non-cash interest income</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="num">(3,044)<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment of investments in Anteris Bio, Inc.</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ChangeInFairValueOfWarrantsRelatedParty', window );">Change in fair value of warrants, related party</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,167)<span></span>
</td>
<td class="num">(9,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock', window );">Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner</a></td>
<td class="nump">12,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of Class A common stock to collaboration partner, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from sale of Class A common stock and warrants, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,279<span></span>
</td>
<td class="nump">11,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(3,888)<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, beginning of period</a></td>
<td class="nump">12,126<span></span>
</td>
<td class="nump">13,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, end of period</a></td>
<td class="nump">8,238<span></span>
</td>
<td class="nump">15,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in redemption value of noncontrolling interest</a></td>
<td class="num">(1,104)<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableFromCollaborators', window );">Notes receivable recorded at fair value from collaboration partner</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableFromCollaborators', window );">Notes receivable for common stock from CinRx purchase agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=vtvt_CinRxMember', window );">CinRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableFromCollaborators', window );">Notes receivable recorded at fair value from collaboration partner</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableFromCollaborators', window );">Notes receivable for common stock from CinRx purchase agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480228/946-830-45-39<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from repayment of loans for purchasing common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ChangeInFairValueOfWarrantsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrants related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ChangeInFairValueOfWarrantsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable from Collaborators</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=vtvt_CinRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=vtvt_CinRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728561662528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Basis of Presentation and Going Concern</a></td>
<td class="text">Description of Business, Basis of Presentation and Going Concern<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#8220;vTv LLC&#8221;), the Company&#8217;s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (&#8220;VIE&#8221;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#8217;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#8217;s results pursuant to Accounting Standards Codification Topic 810, &#8220;Consolidation&#8221; in its Condensed Consolidated Financial Statements. Various holders own nonvoting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#8217;s interest to 77.9% of vTv LLC&#8217;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (&#8220;vTv Units&#8221;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company&#8217;s Class B common stock, par value $0.01 (&#8220;Class B common stock&#8221;)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#8220;Lenders&#8221;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#8220;M&amp;F Group&#8221;), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates &#8220;MacAndrews&#8221;) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a &#8220;Letter Agreement&#8221; and collectively, the &#8220;Letter Agreements&#8221;).  In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&#8220;Cantor Fitzgerald&#8221;) (the &#8220;ATM Offering&#8221;), the purchase agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) (the &#8220;LPC Purchase Agreement&#8221;), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#8220;G42 Investments&#8221;) (the &#8220;G42 Purchase Agreement&#8221;) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the &#8220;CinRx Purchase Agreement&#8221;). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern and Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September&#160;30, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September&#160;30, 2023, the Company had an accumulated deficit of $281.2&#160;million and has generated net losses in each year of its existence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company&#8217;s liquidity sources included cash and cash equivalents of $8.2 million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. To meet our future funding requirements into the third quarter of 2024, including </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funding the ongoing and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also use its remaining availability of $37.3 million under its Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company&#8217;s Class A common stock and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#8217;s Class A common stock. See Note 9 for further details. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on our financial condition. As such, these conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728560811216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and nine months ended September&#160;30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2022, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2023, the results of operations for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the nine months ended September&#160;30, 2023 and 2022. The December&#160;31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One hundred percent (100%) of the revenue earned during the nine months ended September&#160;30, 2022 was attributable  from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728560894240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#8220;G42 Investments&#8221;), entered into a Common Stock Purchase Agreement (the &#8220;G42 Purchase Agreement&#8221;) on May 31, 2022, pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company&#8217;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the &#8220;G42 Promissory Note&#8221;). As part of the G42 Purchase Agreement, G42 Investments nominated a director as appointee and the Company&#8217;s board of directors approved appointing the new director to the Company&#8217;s board. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024, (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#8220;Cogna Agreement&#8221;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#8220;Cogna&#8221;), which requires Cogna to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the &#8220;Partner Territory&#8221;). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercializ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory, but will not have access to the various intellectual property (&#8220;IP&#8221;) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cogna Agreement, Cogna has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company will conduct its clinical trials for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the Partner Territory at its own cost. The results of each party&#8217;s clinical trials will be combined by the Company to seek FDA approval in the United States for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (&#8220;G42 Healthcare&#8221;), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of FDA approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at the option of G42 Investments, either (a) the issuance of the Company&#8217;s Class A common stock (the &#8220;Milestone Shares&#8221;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#8220;Milestone Cash Payment&#8221;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the FDA approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a period of at least ten years after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#8220;Recently Issued Accounting Guidance&#8221; in this quarterly report on Form 10-Q for details of the ASU.  Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#8217;s behalf to complete R&amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#8220;JDC&#8221;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of September&#160;30, 2023, the clinical trials had not </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#8217;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved by the FDA. The Company will recognize revenue from the material right related to Cogna&#8217;s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in a loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The G42 Promissory Note receivable was classified and accounted for under ASC 310 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 310&#8221;) and was initially measured at its fair value of $11.9 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#8220;Huadong&#8221;) (the &#8220;Huadong License Agreement&#8221;), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company&#8217;s glucagon-like peptide-1 receptor agonist (&#8220;GLP-1r&#8221;) program, including the compound</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP273</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the &#8220;Huadong License Territory&#8221;). Additionally, under the Huadong License Agreement, the Company obtained a nonexclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company&#8217;s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the &#8220;First Huadong Amendment&#8221;) which eliminated the Company&#8217;s obligation to sponsor a multi-region clinical trial (the &#8220;Phase 2 MRCT&#8221;), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company&#8217;s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company&#8217;s obligation to participate on a joint development committee (the &#8220;JDC&#8221;), and (iv) other obligations considered to be immaterial in nature. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement.  This amount was fully recognized as revenue during the nine months ended </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the nine months ended September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September&#160;30, 2023, and revenue will be recognized using the proportional performance model over the period of the Company&#8217;s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September&#160;30, 2023 was immaterial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An immaterial amount of revenue for this performance obligation was recognized during the nine months ended September&#160;30, 2022.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No revenue for this performance obligation has been recognized during the nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anteris License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (&#8220;Anteris&#8221;) (the &#8220;Anteris License Agreement&#8221;), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company&#8217;s Nrf2 activator, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$151.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initial license payment as well as the fair value of the equity interest received in Anteris of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. No revenue was recognized related to the Anteris License Agreement during the three and nine months ended September 30, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement.  Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023.  The Company has begun the process of winding up the license, including obtaining all regulatory, manufacturing and other records generated by Anteris during the term of the Anteris License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company received a Section228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (&#8220;Plan of Dissolution&#8221;). (See Note 14).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company&#8217;s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728652800544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based CompensationThe Company has issued nonqualified stock option awards to management, other key employees, consultants, and nonemployee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September&#160;30, 2023, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.8 million, which is expected to be <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized over a weighted average period of 2.2 years. The weighted average grant date fair value of options granted during the nine months ended September&#160;30, 2023 and 2022 was $0.76 and $0.68 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September&#160;30, 2023 was immaterial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,418,571&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,000)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018,072&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,188,444&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728560819968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Reneo Pharmaceuticals, Inc. (&#8220;Reneo&#8221;) and Anteris License Agreements, the Company received equity ownership interests of less than 20% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company&#8217;s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo&#8217;s initial public offering, the Company&#8217;s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:68.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an unrealized gain on its investment in Reneo of $0.6&#160;million and $3.0 million for the three and nine months ended September&#160;30, 2023, respectively. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September&#160;30, 2022, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. These adjustments were recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company received a Section228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of a plan of Liquidation and Dissolution (&#8220;Plan of Dissolution&#8221;). The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $4.2 million impairment charge during the three and nine months ended September&#160;30, 2023. </span></div>On October 30, 2023, the Company entered into a Common Stock Repurchase Agreement (the &#8220;Repurchase Agreement&#8221;) with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $4.4 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728652800544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the &#8220;Novo License Agreement&#8221;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#8220;Novo Nordisk&#8221;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#8217;s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and nonspecific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments payable totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728562270848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of September&#160;30, 2023 and December&#160;31, 2022, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At September&#160;30, 2023 and December&#160;31, 2022, the weighted average remaining lease terms for the operating leases held by the Company were 2.2 years and 2.9 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating leases as of September&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the nine months ended September&#160;30, 2023 and 2022 was $0.2 million and $0.1 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728659931904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">Redeemable Noncontrolling Interest<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September&#160;30, 2023 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September&#160;30, 2023 and December&#160;31, 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $10.7 million and $16.6 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company&#8217;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,435)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,560)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552598640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">Stockholders&#8217; DeficitOn May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the &#8220;G42 Promissory Note&#8221;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the &#8220;Transaction Date&#8221;), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (&#8220;CinPax&#8221;) and CinRx Pharma, LLC (&#8220;CinRx&#8221;), pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company&#8217;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement provides CinPax the right to nominate a director to be approved to sit on the Company&#8217;s Board of Directors and a board observer, which was subsequently approved by the Company&#8217;s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#8220;Recently Issued Accounting Guidance&#8221; in this quarterly report on Form 10-Q for details of the ASU.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of common stock at an initial exercise of price of approximately $0.72 per share (the &#8220;CinRx Warrants&#8221;). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (&#8220;FDA Approval&#8221;) to market and distribute the pharmaceutical product containing the Company&#8217;s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Product&#8221;), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (&#8220;CinRx MSA&#8221;) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an &#8220;at the market offering&#8221; as </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined in Rule 415(a)(4) under the Securities Act (the &#8220;ATM Offering&#8221;). The shares are offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;14, 2021 and June&#160;25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company&#8217;s Class A common stock, by an aggregate offering price of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $50.0 million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2023 and 2022, the Company did not sell any shares under the ATM Offering. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park pursuant to the LPC Purchase Agreement. During the three and nine months ended September&#160;30, 2023 and 2022, the Company did not sell any shares under the LPC Purchase Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728553507216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacAndrews directly or indirectly controls 23,084,267 shares of Class B common stock. Further, as of September&#160;30, 2023, MacAndrews directly or indirectly holds 36,519,212 shares of the Company&#8217;s Class A common stock. As a result, MacAndrews&#8217; holdings represent approximately 57.0% of the combined voting power of the Company&#8217;s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#8220;Letter Agreement Warrants&#8221;) to purchase additional shares of the Company&#8217;s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#8217;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#8217;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#8217;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#8217;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September&#160;30, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the &#8220;Tax Receivable Agreement&#8221;), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (&#8220;M&amp;F&#8221;), as successor in interest to vTv Therapeutics Holdings, LLC (&#8220;vTv Therapeutics Holdings&#8221;), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#8217;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the &#8220;Investor Rights Agreement&#8221;). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company entered into a common stock purchase agreement with G42 Investments pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company&#8217;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid on May 31, 2023 (the &#8220;G42 Promissory Note&#8221;). As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company&#8217;s board of directors appointed the new director to the Company&#8217;s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $12.0 million from G42 Investments, which represented a 3.75% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinRx Pharma, LLC</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Services Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022, the Company entered into the CinRx MSA  with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company&#8217;s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company&#8217;s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company&#8217;s Class A common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728562235488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and nine months ended September&#160;30, 2023. The Company&#8217;s income tax provision for the nine months ended September&#160;30, 2022 was $0.2 million representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#8217;s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September&#160;30, 2023 is due to the valuation allowance against the Company&#8217;s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which </span></div>would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September&#160;30, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728560844192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,490,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,649,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,853,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,027,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728657339648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company&#8217;s investment in Reneo&#8217;s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September&#160;30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income &#8211; related party in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#8217;s current capitalization. Expected volatility is based on the historical volatility </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2023 and December&#160;31, 2022 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.37% - 77.01%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.06%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.94% - 85.88%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78% - 5.38%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11% - 4.43%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2023 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.38&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div>Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company&#8217;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728561712272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (&#8220;Plan of Dissolution&#8221;) (See Note 5).On October 30, 2023, vTv LLC, entered into a Common Stock Repurchase Agreement (the &#8220;Repurchase Agreement&#8221;) with Reneo pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC.  Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million, which was received by vTv LLC on October 30, 2023. vTv LLC had acquired the Reneo stock in connection with the December 21, 2017 License Agreement between vTv LLC and Reneo, which remains in effect.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728557831904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,654)<span></span>
</td>
<td class="num">$ (4,261)<span></span>
</td>
<td class="num">$ (16,772)<span></span>
</td>
<td class="num">$ (14,419)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728562238512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552589936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#8217; Deficit for the three and nine months ended September&#160;30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2022, contained in the Company&#8217;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of September&#160;30, 2023, the results of operations for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the nine months ended September&#160;30, 2023 and 2022. The December&#160;31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company&#8217;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One hundred percent (100%) of the revenue earned during the nine months ended September&#160;30, 2022 was attributable  from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September&#160;30, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.</span></div>The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#8217;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#8217;s transaction price is allocated to each performance obligation using the Company&#8217;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#8217;s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728562248032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Liabilities Related to Company's Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company&#8217;s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728561720928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Award Activity for the Period</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,418,571&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,000)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018,072&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,188,444&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Expense Related to Grants of Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728561050128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock', window );">Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:68.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in equity security with and without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728561671632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities for Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company&#8217;s operating leases as of September&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728561715216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock', window );">Summary of Net Income Attributable to Vtv Therapeutics Inc</a></td>
<td class="text">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,435)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,560)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4M<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728560837760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,490,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,649,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,853,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,027,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company&#8217;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728562388464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summarizes the Conclusions Reached Regarding Fair Value Measurements</a></td>
<td class="text">The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2023 and December&#160;31, 2022 were:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.37% - 77.01%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.06%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.94% - 85.88%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78% - 5.38%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11% - 4.43%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#8217;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2023 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.38&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73&#160;</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552606336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Going Concern (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="num">$ (281,192)<span></span>
</td>
<td class="num">$ (265,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
<td class="nump">$ 8,238<span></span>
</td>
<td class="nump">$ 12,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Cantor Fitzgerald</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues', window );">Remaining available stock value</a></td>
<td class="nump">$ 37,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | LPC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">9,437,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterest', window );">Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterestByParent', window );">Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC</a></td>
<td class="nump">77.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC | Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining availability under our controlled equity offering sales agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseAgreementObligationsAxis=vtvt_LPCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseAgreementObligationsAxis=vtvt_LPCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728553580608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vtvt_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vtvt_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728551497232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue', window );">Collaborative arrangement, contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash', window );">Collaborate arrangement, contingent consideration transferred, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid', window );">Discount on note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Receivables, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember', window );">G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod', window );">Royalties receivable, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | JDRF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones', window );">Maximum funding percentage of research and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | JDRF | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations', window );">Adjustments to transaction price for performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_MaximumSponsoringContributionAmount', window );">Maximum contribution amount to clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations', window );">Adjustments to transaction price for performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Anteris Bio Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License Fee Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements | Anteris Bio Inc | License and Technology Transfer Services of Chemistry and Manufacturing Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LicenseFeeReceived', window );">License Fee Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestAndDividendsReceived', window );">Equity interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestAndDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for dividends and interest on the entity's equity and debt investments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestAndDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_AdjustmentsToTransactionPriceForPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to transaction price for performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_AdjustmentsToTransactionPriceForPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborateArrangementContingentConsiderationTransferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborate Arrangement, Contingent Consideration Transferred, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborateArrangementContingentConsiderationTransferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementNoteReceivableDiscountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Note Receivable, Discount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementNoteReceivableDiscountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalties Receivable, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LicenseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Fee Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LicenseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum funding percentage of research and development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_MaximumSponsoringContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum sponsoring contribution amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_MaximumSponsoringContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_CognaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_CognaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_JDRFInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_JDRFInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_PhaseTwoMultiRegionalClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_PhaseTwoMultiRegionalClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_AnterisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_AnterisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728555056864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">18,669<span></span>
</td>
<td class="nump">18,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, net of current portion</a></td>
<td class="nump">$ 18,686<span></span>
</td>
<td class="nump">$ 18,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552941312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - Stock Option - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Non-qualified stock option awards vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Non-qualified stock option awards expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested share-based compensation arrangements</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize unrecognized share-based compensation cost</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728549971280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Beginning balance (in shares) | shares</a></td>
<td class="nump">8,418,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,176,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Ending balance (in shares) | shares</a></td>
<td class="nump">9,545,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">5,018,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">8,188,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, weighted average remaining contractual term</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">1.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Awards outstanding, Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">2.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and expected to vest (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728557475344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728553457328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,044<span></span>
</td>
<td class="num">$ (2,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Impairment of investments in Anteris Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember', window );">Reneo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_InvestmentOwnershipPercentage', window );">Equity method investments, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember', window );">Reneo | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552534240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investment without readily determinable fair values assessed under the measurement alternative:</a></td>
<td class="nump">$ 4,387<span></span>
</td>
<td class="nump">$ 5,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember', window );">Reneo | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue', window );">Equity investment with readily determinable fair value:</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_AnterisBioIncMember', window );">Anteris Bio Inc | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems', window );"><strong>Equity Securities Without Readily Determinable Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investment without readily determinable fair values assessed under the measurement alternative:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_EquityInvestmentsWithReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity investments with readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_EquityInvestmentsWithReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_AnterisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_AnterisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728562167808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2007</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Type 1 Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Type 2 Diabetes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember', window );">Developmental and Regulatory Milestone Payment | Other Indication | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember', window );">Sales-based Milestones Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=vtvt_SatisfactionOfMilestonePaymentMember', window );">Satisfaction of Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vtvt_NovoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeOneDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_TypeTwoDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vtvt_OtherIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_SalesBasedMilestonesPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=vtvt_SatisfactionOfMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=vtvt_SatisfactionOfMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728549771072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LesseeOperatingLeaseTerminationPeriod', window );">Lessee, operating lease, termination period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining operating lease term</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728552537072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining three months)</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OperatingLeasesImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728558662896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue', window );">Redemption amount of noncontrolling interest</a></td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock', window );">Number of days used to determine exchange value based on weighted average price of Class A common stock</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_VTvLLCMember', window );">vTv Therapeutics LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfNonVotingEconomicInterest', window );">Noncontrolling interest ownership percentage</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfNonVotingEconomicInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non voting economic interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfNonVotingEconomicInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period used to determine exchange value based on weighted average price of Class A common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest exchange agreement stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest temporary equity redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_VTvLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_VTvLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728555129360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to vTv Therapeutics Inc. common shareholders</a></td>
<td class="num">$ (6,654)<span></span>
</td>
<td class="num">$ (4,261)<span></span>
</td>
<td class="num">$ (16,772)<span></span>
</td>
<td class="num">$ (14,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent', window );">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet', window );">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</a></td>
<td class="num">$ (5,062)<span></span>
</td>
<td class="num">$ (5,435)<span></span>
</td>
<td class="num">$ (12,560)<span></span>
</td>
<td class="num">$ (14,522)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4M<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728551318112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jul. 22, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 25, 2021</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Nov. 24, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_CommonStockAndPreferredStockSharesAuthorized', window );">Capital stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember', window );">G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivableTerm', window );">Sale of stock, consideration, receivables, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember', window );">CinRx Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncreaseInCommonStockSharesAuthorized', window );">Increase in shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | CinRx Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Cantor Fitzgerald | ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_AggregateOfferingPriceOfShares', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | LPC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | LPC Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | CinRx Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_AggregateOfferingPriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_AggregateOfferingPriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_CommonStockAndPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and preferred stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_CommonStockAndPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncreaseInCommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncreaseInCommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration, Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtvt_CinRxInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=vtvt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=vtvt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_LPCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vtvt_LPCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728558685712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | MacAndrews &amp; Forbes Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_OwnershipPercentageOfMajorityOwner', window );">Ownership percentage of majority owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Accounts and financing receivable, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_NotesReceivableDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from G42 Promissory Note early redemption</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Master Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_DueToRelatedPartiesMonthlyAmount', window );">Due to related parties, monthly amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class B Common Stock | MacAndrews &amp; Forbes Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares held by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,084,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Common Stock | MacAndrews &amp; Forbes Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares held by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,519,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Common Stock | G42 Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,386,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Common Stock | CinRx Pharma, LLC | Master Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares held by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_DueToRelatedPartiesMonthlyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due To Related Parties, Monthly Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_DueToRelatedPartiesMonthlyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_NotesReceivableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_NotesReceivableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_OwnershipPercentageOfMajorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage of majority owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_OwnershipPercentageOfMajorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtvt_MacAndrewsAndForbesIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtvt_G42InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtvt_G42InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtvt_MasterServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtvt_MasterServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_CinRxPharmaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_CinRxPharmaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728555124128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember', window );">M&amp;F TTP Holdings LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtvt_PercentageOfAmountOfCashSavings', window );">Amount of cash savings percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtvt_PercentageOfAmountOfCashSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount of cash savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtvt_PercentageOfAmountOfCashSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtvt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_MFTTPHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728557851296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,540)<span></span>
</td>
<td class="num">$ (5,468)<span></span>
</td>
<td class="num">$ (21,525)<span></span>
</td>
<td class="num">$ (18,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net loss attributable to noncontrolling interests</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
<td class="num">(4,753)<span></span>
</td>
<td class="num">(4,564)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted</a></td>
<td class="num">(6,654)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(16,772)<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic</a></td>
<td class="num">$ (6,654)<span></span>
</td>
<td class="num">$ (4,261)<span></span>
</td>
<td class="num">$ (16,772)<span></span>
</td>
<td class="num">$ (14,419)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares)</a></td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">80,490,121<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">72,649,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares)</a></td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">80,490,121<span></span>
</td>
<td class="nump">81,483,600<span></span>
</td>
<td class="nump">72,649,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728557480976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">35,853,802<span></span>
</td>
<td class="nump">34,027,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">23,093,860<span></span>
</td>
<td class="nump">23,093,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">9,545,439<span></span>
</td>
<td class="nump">7,718,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)</a></td>
<td class="nump">3,214,503<span></span>
</td>
<td class="nump">3,214,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728550032512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net Change in fair value included in earnings</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Purchases / Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Sales / Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warranty liability, related party</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=vtvt_WarrantLiabilityRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=vtvt_WarrantLiabilityRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728551301808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember', window );">CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life of options in years</a></td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.8238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield | CinRx Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Expected volatility | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.6837<span></span>
</td>
<td class="nump">0.7694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Risk-free interest rate | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0478<span></span>
</td>
<td class="nump">0.0411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Expected volatility | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.7701<span></span>
</td>
<td class="nump">0.8588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Risk-free interest rate | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0538<span></span>
</td>
<td class="nump">0.0443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Expected volatility | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.7606<span></span>
</td>
<td class="nump">0.8217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Risk-free interest rate | Letter Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Inputs utilized in the valuation of warrants</a></td>
<td class="nump">0.0488<span></span>
</td>
<td class="nump">0.0419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_CinRxWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vtvt_LetterAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vtvt_LetterAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139728554885536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Reneo</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period</a></td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>vtvt-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:vtvt="http://vtvtherapeutics.com/20230930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtvt-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-09</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-09</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtvt:RedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">vtvt:CinRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">vtvt:CinRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:VTvLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vtvt:LicenseAgreementObligationsAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vtvt:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CognaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-14</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:PhaseTwoMultiRegionalClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:JDRFInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:AnterisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:ReneoPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-30</startDate>
            <endDate>2023-10-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:TypeTwoDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vtvt:OtherIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SalesBasedMilestonesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-02-28</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">vtvt:SatisfactionOfMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vtvt:NovoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-22</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-22</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtvt:CinRxInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-14</startDate>
            <endDate>2021-01-14</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-25</startDate>
            <endDate>2021-06-25</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">vtvt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-24</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vtvt:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MacAndrewsAndForbesIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:G42InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MasterServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtvt:MasterServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:CinRxPharmaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtvt:MFTTPHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">vtvt:WarrantLiabilityRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:LetterAgreementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001641489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vtvt:CinRxWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001641489</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones contextRef="c-112" decimals="1" id="f-411" unitRef="number">0.5</vtvt:MaximumFundingPercentageOfResearchAndDevelopmentMilestones>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37524</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">vTv Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">47-3916571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3980 Premier Dr</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">High Point</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">27265</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">841-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Class A common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">VTVT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="0" id="f-25" unitRef="shares">81483600</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-26" unitRef="shares">23093860</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">8238000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-33" unitRef="usd">12126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-35" unitRef="usd">173000</us-gaap:AccountsReceivableNetCurrent>
    <vtvt:NotesReceivableCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">0</vtvt:NotesReceivableCurrent>
    <vtvt:NotesReceivableCurrent contextRef="c-5" decimals="-3" id="f-37" unitRef="usd">12243000</vtvt:NotesReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">1872000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">2537000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">15000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">15000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">10125000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">27094000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">140000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">207000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">272000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">349000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">4387000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">5588000</us-gaap:LongTermInvestments>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">14924000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">33238000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">9620000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">7313000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">154000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">17000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">17000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">473000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">224000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">10275000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">7708000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">213000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <vtvt:WarrantyLiability contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">278000</vtvt:WarrantyLiability>
    <vtvt:WarrantyLiability contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">684000</vtvt:WarrantyLiability>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">29435000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">27399000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-70" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-71" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">10722000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">16579000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-75"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-76" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-77" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-78" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-79" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">815000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-81" unitRef="usd">815000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-83"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-84" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-85" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-86" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-87" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-9" decimals="-3" id="f-88" unitRef="usd">232000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-89" unitRef="usd">232000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">254912000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">253737000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">-281192000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">-265524000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">-25233000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">-10740000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">14924000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">33238000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-99" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-101" unitRef="usd">2009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-10" decimals="-3" id="f-102" unitRef="usd">2824000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="-3" id="f-103" unitRef="usd">3055000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">11457000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-3" id="f-105" unitRef="usd">8393000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-10" decimals="-3" id="f-106" unitRef="usd">2544000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-11" decimals="-3" id="f-107" unitRef="usd">2634000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">9338000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-109" unitRef="usd">9813000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-10" decimals="-3" id="f-110" unitRef="usd">5368000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-11" decimals="-3" id="f-111" unitRef="usd">5689000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">20795000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="-3" id="f-113" unitRef="usd">18206000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="-3" id="f-114" unitRef="usd">-5368000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-3" id="f-115" unitRef="usd">-5689000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-20795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-117" unitRef="usd">-16197000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-118" unitRef="usd">-3640000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-119" unitRef="usd">403000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-120" unitRef="usd">-1514000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-121" unitRef="usd">-2998000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-122" unitRef="usd">341000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-123" unitRef="usd">-324000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-19" decimals="-3" id="f-124" unitRef="usd">406000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-20" decimals="-3" id="f-125" unitRef="usd">221000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-10" decimals="-3" id="f-126" unitRef="usd">131000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-11" decimals="-3" id="f-127" unitRef="usd">150000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">384000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-12" decimals="-3" id="f-129" unitRef="usd">200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-10" decimals="-3" id="f-130" unitRef="usd">4000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-11" decimals="-3" id="f-131" unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">6000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="-3" id="f-133" unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-134" unitRef="usd">-8540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-135" unitRef="usd">-5468000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-21525000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-137" unitRef="usd">-18783000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-138" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-139" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-141" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-10" decimals="-3" id="f-142" unitRef="usd">-8540000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-3" id="f-143" unitRef="usd">-5468000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-21525000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">-18983000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-146" unitRef="usd">-1886000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-147" unitRef="usd">-1207000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-4753000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">-4564000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-150" unitRef="usd">-6654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-151" unitRef="usd">-4261000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-16772000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-153" unitRef="usd">-14419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-10" decimals="-3" id="f-154" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-11" decimals="-3" id="f-155" unitRef="usd">-4261000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-12" decimals="-3" id="f-157" unitRef="usd">-14419000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-21"
      decimals="2"
      id="f-158"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-23"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-23"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-24"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-24"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="0" id="f-166" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-21" decimals="0" id="f-167" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="0" id="f-168" unitRef="shares">80490121</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="0" id="f-169" unitRef="shares">80490121</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-23" decimals="0" id="f-170" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-23" decimals="0" id="f-171" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-24" decimals="0" id="f-172" unitRef="shares">72649531</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-24" decimals="0" id="f-173" unitRef="shares">72649531</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-25" decimals="-3" id="f-174" unitRef="usd">18879000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="0" id="f-175" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-176" unitRef="usd">815000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="0" id="f-177" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-178" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-179" unitRef="usd">254479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-180" unitRef="usd">-280809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-181" unitRef="usd">-25283000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-182" unitRef="usd">-1886000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-183" unitRef="usd">-6654000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-184" unitRef="usd">-6654000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-185" unitRef="usd">433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-10" decimals="-3" id="f-186" unitRef="usd">433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <vtvt:TemporaryEquityChangeInRedemptionValue contextRef="c-31" decimals="-3" id="f-187" unitRef="usd">-6271000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-32" decimals="-3" id="f-188" unitRef="usd">6271000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-10" decimals="-3" id="f-189" unitRef="usd">6271000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-34" decimals="-3" id="f-190" unitRef="usd">10722000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-35" decimals="0" id="f-191" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-192" unitRef="usd">815000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-36" decimals="0" id="f-193" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-194" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-195" unitRef="usd">254912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-196" unitRef="usd">-281192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-197" unitRef="usd">-25233000</us-gaap:StockholdersEquity>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-39" decimals="-3" id="f-198" unitRef="usd">15916000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-40" decimals="0" id="f-199" unitRef="shares">77329051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-200" unitRef="usd">773000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="0" id="f-201" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-202" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-204" unitRef="usd">243772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-205" unitRef="usd">-253303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-206" unitRef="usd">-8526000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-207" unitRef="usd">-1207000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="-3" id="f-208" unitRef="usd">-4261000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-209" unitRef="usd">-4261000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-48" decimals="-3" id="f-210" unitRef="usd">338000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-211" unitRef="usd">338000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement contextRef="c-49" decimals="0" id="f-212" unitRef="shares">4154549</vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-49" decimals="-3" id="f-213" unitRef="usd">42000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-50" decimals="-3" id="f-214" unitRef="usd">-4000000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-51" decimals="-3" id="f-215" unitRef="usd">9336000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-11" decimals="-3" id="f-216" unitRef="usd">5378000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:TemporaryEquityChangeInRedemptionValue contextRef="c-46" decimals="-3" id="f-217" unitRef="usd">9498000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-47" decimals="-3" id="f-218" unitRef="usd">-9498000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-11" decimals="-3" id="f-219" unitRef="usd">-9498000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-52" decimals="-3" id="f-220" unitRef="usd">24207000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-53" decimals="0" id="f-221" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-222" unitRef="usd">815000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-54" decimals="0" id="f-223" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-224" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-225" unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-226" unitRef="usd">253446000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-227" unitRef="usd">-267062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-228" unitRef="usd">-16569000</us-gaap:StockholdersEquity>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-59" decimals="-3" id="f-229" unitRef="usd">16579000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-60" decimals="0" id="f-230" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-231" unitRef="usd">815000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-61" decimals="0" id="f-232" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-233" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-234" unitRef="usd">253737000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-235" unitRef="usd">-265524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-236" unitRef="usd">-10740000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-237" unitRef="usd">-4753000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-65" decimals="-3" id="f-238" unitRef="usd">-16772000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">-16772000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-240" unitRef="usd">1175000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">1175000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <vtvt:TemporaryEquityChangeInRedemptionValue contextRef="c-64" decimals="-3" id="f-242" unitRef="usd">-1104000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-65" decimals="-3" id="f-243" unitRef="usd">1104000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">1104000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-34" decimals="-3" id="f-245" unitRef="usd">10722000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-35" decimals="0" id="f-246" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-247" unitRef="usd">815000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-36" decimals="0" id="f-248" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-249" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-250" unitRef="usd">254912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-251" unitRef="usd">-281192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-252" unitRef="usd">-25233000</us-gaap:StockholdersEquity>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-67" decimals="-3" id="f-253" unitRef="usd">24962000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-68" decimals="0" id="f-254" unitRef="shares">66942777</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-3" id="f-255" unitRef="usd">669000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-69" decimals="0" id="f-256" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-3" id="f-257" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-3" id="f-258" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-3" id="f-259" unitRef="usd">238193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-260" unitRef="usd">-248834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-3" id="f-261" unitRef="usd">-9740000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-74" decimals="-3" id="f-262" unitRef="usd">-4564000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-75" decimals="-3" id="f-263" unitRef="usd">-14419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-264" unitRef="usd">-14419000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-76" decimals="-3" id="f-265" unitRef="usd">981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-266" unitRef="usd">981000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-77" decimals="0" id="f-267" unitRef="shares">10386274</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-77" decimals="-3" id="f-268" unitRef="usd">104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-78" decimals="-3" id="f-269" unitRef="usd">4936000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-12" decimals="-3" id="f-270" unitRef="usd">5040000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement contextRef="c-77" decimals="0" id="f-271" unitRef="shares">4154549</vtvt:StockIssuedDuringPeriodSharesPurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-77" decimals="-3" id="f-272" unitRef="usd">42000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-79" decimals="-3" id="f-273" unitRef="usd">-4000000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-78" decimals="-3" id="f-274" unitRef="usd">9336000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:StockIssuedDuringPeriodValuePurchaseAgreement contextRef="c-12" decimals="-3" id="f-275" unitRef="usd">5378000</vtvt:StockIssuedDuringPeriodValuePurchaseAgreement>
    <vtvt:TemporaryEquityChangeInRedemptionValue contextRef="c-74" decimals="-3" id="f-276" unitRef="usd">3809000</vtvt:TemporaryEquityChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-75" decimals="-3" id="f-277" unitRef="usd">-3809000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-12" decimals="-3" id="f-278" unitRef="usd">-3809000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-52" decimals="-3" id="f-279" unitRef="usd">24207000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-53" decimals="0" id="f-280" unitRef="shares">81483600</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-281" unitRef="usd">815000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-54" decimals="0" id="f-282" unitRef="shares">23093860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-283" unitRef="usd">232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-284" unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-285" unitRef="usd">253446000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-286" unitRef="usd">-267062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-287" unitRef="usd">-16569000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-21525000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-289" unitRef="usd">-18983000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">67000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-3" id="f-291" unitRef="usd">69000</us-gaap:Depreciation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-313000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-12" decimals="-3" id="f-293" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeOperating contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">100000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-12" decimals="-3" id="f-295" unitRef="usd">200000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpenseOther contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">0</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c-12" decimals="-3" id="f-297" unitRef="usd">9000</us-gaap:InterestExpenseOther>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">1175000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-299" unitRef="usd">981000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">3044000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-12" decimals="-3" id="f-301" unitRef="usd">-2998000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">4245000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-12" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <vtvt:ChangeInFairValueOfWarrantsRelatedParty contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">-406000</vtvt:ChangeInFairValueOfWarrantsRelatedParty>
    <vtvt:ChangeInFairValueOfWarrantsRelatedParty contextRef="c-12" decimals="-3" id="f-305" unitRef="usd">-221000</vtvt:ChangeInFairValueOfWarrantsRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">-173000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">-665000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-309" unitRef="usd">-853000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">2270000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="-3" id="f-311" unitRef="usd">-1417000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-12" decimals="-3" id="f-313" unitRef="usd">6769000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">-16167000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-315" unitRef="usd">-9142000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-317" unitRef="usd">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-319" unitRef="usd">-21000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">12030000</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
    <us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock contextRef="c-12" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-323" unitRef="usd">5040000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="c-12" decimals="-3" id="f-325" unitRef="usd">5746000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">566000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-12" decimals="-3" id="f-327" unitRef="usd">776000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">317000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-12" decimals="-3" id="f-329" unitRef="usd">475000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">12279000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-331" unitRef="usd">11087000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">-3888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-333" unitRef="usd">1924000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-334" unitRef="usd">12126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-73" decimals="-3" id="f-335" unitRef="usd">13415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-336" unitRef="usd">8238000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-58" decimals="-3" id="f-337" unitRef="usd">15339000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">1104000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-12" decimals="-3" id="f-339" unitRef="usd">-3809000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <vtvt:NotesReceivableFromCollaborators contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">0</vtvt:NotesReceivableFromCollaborators>
    <vtvt:NotesReceivableFromCollaborators contextRef="c-12" decimals="-3" id="f-341" unitRef="usd">11891000</vtvt:NotesReceivableFromCollaborators>
    <vtvt:NotesReceivableFromCollaborators contextRef="c-80" decimals="-3" id="f-342" unitRef="usd">0</vtvt:NotesReceivableFromCollaborators>
    <vtvt:NotesReceivableFromCollaborators contextRef="c-81" decimals="-3" id="f-343" unitRef="usd">4000000</vtvt:NotesReceivableFromCollaborators>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-344">Description of Business, Basis of Presentation and Going Concern&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. (the &#x201c;Company,&#x201d; the &#x201c;Registrant,&#x201d; &#x201c;we&#x201d; or &#x201c;us&#x201d;) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (&#x201c;vTv LLC&#x201d;), the Company&#x2019;s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that vTv LLC is a variable-interest entity (&#x201c;VIE&#x201d;) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC&#x2019;s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC&#x2019;s results pursuant to Accounting Standards Codification Topic 810, &#x201c;Consolidation&#x201d; in its Condensed Consolidated Financial Statements. Various holders own nonvoting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.&#x2019;s interest to 77.9% of vTv LLC&#x2019;s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (&#x201c;vTv Units&#x201d;) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company&#x2019;s Class B common stock, par value $0.01 (&#x201c;Class B common stock&#x201d;)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the &#x201c;Lenders&#x201d;) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (&#x201c;M&amp;amp;F Group&#x201d;), a related party and an affiliate of MacAndrews &amp;amp; Forbes Incorporated (together with its affiliates &#x201c;MacAndrews&#x201d;) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a &#x201c;Letter Agreement&#x201d; and collectively, the &#x201c;Letter Agreements&#x201d;).  In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor Fitzgerald&#x201d;) (the &#x201c;ATM Offering&#x201d;), the purchase agreement with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) (the &#x201c;LPC Purchase Agreement&#x201d;), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (&#x201c;G42 Investments&#x201d;) (the &#x201c;G42 Purchase Agreement&#x201d;) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the &#x201c;CinRx Purchase Agreement&#x201d;). v&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September&#160;30, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September&#160;30, 2023, the Company had an accumulated deficit of $281.2&#160;million and has generated net losses in each year of its existence. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the Company&#x2019;s liquidity sources included cash and cash equivalents of $8.2 million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. To meet our future funding requirements into the third quarter of 2024, including &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;funding the ongoing and future clinical trials of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TTP399),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may also use its remaining availability of $37.3 million under its Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company&#x2019;s Class A common stock and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company&#x2019;s Class A common stock. See Note 9 for further details. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;impact on our financial condition. As such, these conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <vtvt:PercentageOfNonVotingEconomicInterest contextRef="c-82" decimals="3" id="f-345" unitRef="number">0.221</vtvt:PercentageOfNonVotingEconomicInterest>
    <vtvt:PercentageOfNonVotingEconomicInterestByParent contextRef="c-82" decimals="3" id="f-346" unitRef="number">0.779</vtvt:PercentageOfNonVotingEconomicInterestByParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-83"
      decimals="INF"
      id="f-347"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-348" unitRef="usd">-281200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-349" unitRef="usd">8200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues contextRef="c-84" decimals="-5" id="f-350" unitRef="usd">37300000</vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-85" decimals="0" id="f-351" unitRef="shares">9437376</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-352">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#x2019; Deficit for the three and nine months ended September&#160;30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2022, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September&#160;30, 2023, the results of operations for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the nine months ended September&#160;30, 2023 and 2022. The December&#160;31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company&#x2019;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One hundred percent (100%) of the revenue earned during the nine months ended September&#160;30, 2022 was attributable  from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the revenue recognition guidance established by ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#x2019;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#x2019;s transaction price is allocated to each performance obligation using the Company&#x2019;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying Condensed Consolidated Balance Sheet as of September&#160;30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September&#160;30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders&#x2019; Deficit for the three and nine months ended September&#160;30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&#160;31, 2022, contained in the Company&#x2019;s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September&#160;30, 2023, the results of operations for the three and nine months ended September&#160;30, 2023 and 2022 and cash flows for the nine months ended September&#160;30, 2023 and 2022. The December&#160;31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September&#160;30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-354">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company&#x2019;s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-355">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One hundred percent (100%) of the revenue earned during the nine months ended September&#160;30, 2022 was attributable  from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="0" id="f-356" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-360">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-361">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-362">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the revenue recognition guidance established by ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). When an agreement falls under the scope of other standards, such as ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.&lt;/span&gt;&lt;/div&gt;The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company&#x2019;s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract&#x2019;s transaction price is allocated to each performance obligation using the Company&#x2019;s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-363">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company&#x2019;s behalf. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-364">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-365">Collaboration Agreements&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Purchase Agreement and Cogna Collaborative and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and G42 Investments AI Holding RSC Ltd, a private limited company (&#x201c;G42 Investments&#x201d;), entered into a Common Stock Purchase Agreement (the &#x201c;G42 Purchase Agreement&#x201d;) on May 31, 2022, pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company&#x2019;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the &#x201c;G42 Promissory Note&#x201d;). As part of the G42 Purchase Agreement, G42 Investments nominated a director as appointee and the Company&#x2019;s board of directors approved appointing the new director to the Company&#x2019;s board. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024, (or if earlier, the date of receipt of U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval in the U.S. for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the &#x201c;Cogna Agreement&#x201d;) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (&#x201c;Cogna&#x201d;), which requires Cogna to work with the Company in performing clinical trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as jointly creating a global development plan to develop, market, and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in certain countries in the Middle East, Africa, and Central Asia (the &#x201c;Partner Territory&#x201d;). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercializ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;e cadisegliatin (TTP399) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Partner Territory, but will not have access to the various intellectual property (&#x201c;IP&#x201d;) related to the license and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;needed to conduct the trials. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Cogna Agreement, Cogna has the right to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for commercial sale under terms to be agreed upon by the parties at a later date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company will conduct its clinical trials for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; outside of the Partner Territory at its own cost. The results of each party&#x2019;s clinical trials will be combined by the Company to seek FDA approval in the United States for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (&#x201c;G42 Healthcare&#x201d;), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The G42 Purchase Agreement also provides for, following the receipt of FDA approval of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, at the option of G42 Investments, either (a) the issuance of the Company&#x2019;s Class A common stock (the &#x201c;Milestone Shares&#x201d;) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the &#x201c;Milestone Cash Payment&#x201d;). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the FDA approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA approval will be granted or as to the timing thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a period of at least ten years after the first commercial sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Partner Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#x201c;Recently Issued Accounting Guidance&#x201d; in this quarterly report on Form 10-Q for details of the ASU.  Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company&#x2019;s behalf to complete R&amp;amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (&#x201c;JDC&#x201d;) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services.  The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of September&#160;30, 2023, the clinical trials had not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified certain commitments that are in the scope of ASC 606 as Cogna&#x2019;s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is approved by the FDA. The Company will recognize revenue from the material right related to Cogna&#x2019;s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;resulting in a loss of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and was recognized as a component of other income/(expense) in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The G42 Promissory Note receivable was classified and accounted for under ASC 310 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 310&#x201d;) and was initially measured at its fair value of $11.9 million. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Huadong License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (&#x201c;Huadong&#x201d;) (the &#x201c;Huadong License Agreement&#x201d;), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company&#x2019;s glucagon-like peptide-1 receptor agonist (&#x201c;GLP-1r&#x201d;) program, including the compound&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; TTP273&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the &#x201c;Huadong License Territory&#x201d;). Additionally, under the Huadong License Agreement, the Company obtained a nonexclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company&#x2019;s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the &#x201c;First Huadong Amendment&#x201d;) which eliminated the Company&#x2019;s obligation to sponsor a multi-region clinical trial (the &#x201c;Phase 2 MRCT&#x201d;), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company&#x2019;s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company&#x2019;s obligation to participate on a joint development committee (the &#x201c;JDC&#x201d;), and (iv) other obligations considered to be immaterial in nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement.  This amount was fully recognized as revenue during the nine months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the nine months ended September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September&#160;30, 2023, and revenue will be recognized using the proportional performance model over the period of the Company&#x2019;s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September&#160;30, 2023 was immaterial. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An immaterial amount of revenue for this performance obligation was recognized during the nine months ended September&#160;30, 2022.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No revenue for this performance obligation has been recognized during the nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Anteris License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (&#x201c;Anteris&#x201d;) (the &#x201c;Anteris License Agreement&#x201d;), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company&#x2019;s Nrf2 activator, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HPP971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$151.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; initial license payment as well as the fair value of the equity interest received in Anteris of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. No revenue was recognized related to the Anteris License Agreement during the three and nine months ended September 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement.  Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023.  The Company has begun the process of winding up the license, including obtaining all regulatory, manufacturing and other records generated by Anteris during the term of the Anteris License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2023, the Company received a Section228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (&#x201c;Plan of Dissolution&#x201d;). (See Note 14).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities related to the Company&#x2019;s collaboration agreements consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-87" decimals="0" id="f-366" unitRef="shares">10386274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-88"
      decimals="2"
      id="f-367"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-89" decimals="-5" id="f-368" unitRef="usd">25000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-87" decimals="-5" id="f-369" unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-90" decimals="-5" id="f-370" unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-91" decimals="-5" id="f-371" unitRef="usd">12000000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-92" decimals="4" id="f-372" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-91" decimals="-5" id="f-373" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue contextRef="c-90" decimals="-5" id="f-374" unitRef="usd">30000000</vtvt:CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue>
    <vtvt:CollaborateArrangementContingentConsiderationTransferredCash contextRef="c-89" decimals="-5" id="f-375" unitRef="usd">30000000</vtvt:CollaborateArrangementContingentConsiderationTransferredCash>
    <vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod contextRef="c-93" id="f-376">P10Y</vtvt:CollaborativeArrangementRoyaltiesReceivablePeriod>
    <us-gaap:CommonStockValueOutstanding contextRef="c-94" decimals="-5" id="f-377" unitRef="usd">5700000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:SharePrice
      contextRef="c-94"
      decimals="INF"
      id="f-378"
      unitRef="usdPerShare">0.55</us-gaap:SharePrice>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-95" decimals="-5" id="f-379" unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:CollaborativeArrangementNoteReceivableDiscountPaid contextRef="c-96" decimals="-5" id="f-380" unitRef="usd">600000</vtvt:CollaborativeArrangementNoteReceivableDiscountPaid>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-96" decimals="-5" id="f-381" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-97" decimals="-5" id="f-382" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-5" id="f-383" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-5" id="f-384" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-98" decimals="-5" id="f-385" unitRef="usd">12000000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-99" decimals="4" id="f-386" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-98" decimals="-5" id="f-387" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ReceivablesFairValueDisclosure contextRef="c-95" decimals="-5" id="f-388" unitRef="usd">11900000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-95" decimals="-5" id="f-389" unitRef="usd">18700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vtvt:MaximumSponsoringContributionAmount contextRef="c-100" decimals="-5" id="f-390" unitRef="usd">3000000</vtvt:MaximumSponsoringContributionAmount>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable contextRef="c-100" decimals="-5" id="f-391" unitRef="usd">3000000</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations contextRef="c-101" decimals="-5" id="f-392" unitRef="usd">2000000</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations contextRef="c-102" decimals="-5" id="f-393" unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations contextRef="c-103" decimals="-5" id="f-394" unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:AdjustmentsToTransactionPriceForPerformanceObligations contextRef="c-104" decimals="-5" id="f-395" unitRef="usd">0</vtvt:AdjustmentsToTransactionPriceForPerformanceObligations>
    <vtvt:LicenseFeeReceived contextRef="c-105" decimals="-5" id="f-396" unitRef="usd">2000000</vtvt:LicenseFeeReceived>
    <vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable contextRef="c-106" decimals="-5" id="f-397" unitRef="usd">151000000</vtvt:PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable>
    <vtvt:LicenseFeeReceived contextRef="c-107" decimals="-5" id="f-398" unitRef="usd">2000000</vtvt:LicenseFeeReceived>
    <us-gaap:ProceedsFromInterestAndDividendsReceived contextRef="c-107" decimals="-5" id="f-399" unitRef="usd">4200000</us-gaap:ProceedsFromInterestAndDividendsReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-108" decimals="INF" id="f-400" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-109" decimals="INF" id="f-401" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-110" decimals="INF" id="f-402" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-111" decimals="INF" id="f-403" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities related to the Company&#x2019;s collaboration agreements consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-405" unitRef="usd">17000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-406" unitRef="usd">17000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-407" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-408" unitRef="usd">18669000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-409" unitRef="usd">18686000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-410" unitRef="usd">18686000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-412">Share-Based CompensationThe Company has issued nonqualified stock option awards to management, other key employees, consultants, and nonemployee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September&#160;30, 2023, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.8 million, which is expected to be &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized over a weighted average period of 2.2 years. The weighted average grant date fair value of options granted during the nine months ended September&#160;30, 2023 and 2022 was $0.76 and $0.68 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September&#160;30, 2023 was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,418,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,545,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,188,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-113" id="f-413">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-113" id="f-414">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-114" decimals="-5" id="f-415" unitRef="usd">1800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-113" id="f-416">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-113"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-418"
      unitRef="usdPerShare">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the stock option awards for the nine months ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted &lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,418,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,545,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,018,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,188,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="0" id="f-420" unitRef="shares">8418571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-421"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="0" id="f-422" unitRef="shares">1176868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-423"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="0" id="f-424" unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-425"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="0" id="f-426" unitRef="shares">9545439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-427"
      unitRef="usdPerShare">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="0" id="f-428" unitRef="shares">5018072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-429"
      unitRef="usdPerShare">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-430">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="0" id="f-431" unitRef="shares">8188444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-432"
      unitRef="usdPerShare">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-433">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-434">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-3" id="f-435" unitRef="usd">113000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-3" id="f-436" unitRef="usd">109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-437" unitRef="usd">316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-438" unitRef="usd">289000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-439" unitRef="usd">320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-3" id="f-440" unitRef="usd">229000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-3" id="f-441" unitRef="usd">859000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-442" unitRef="usd">692000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="-3" id="f-443" unitRef="usd">433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-444" unitRef="usd">338000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">1175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-446" unitRef="usd">981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-447">Investments&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the Reneo Pharmaceuticals, Inc. (&#x201c;Reneo&#x201d;) and Anteris License Agreements, the Company received equity ownership interests of less than 20% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company&#x2019;s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo&#x2019;s initial public offering, the Company&#x2019;s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment with readily determinable fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reneo common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment without readily determinable fair values assessed under the measurement alternative:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anteris preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized an unrealized gain on its investment in Reneo of $0.6&#160;million and $3.0 million for the three and nine months ended September&#160;30, 2023, respectively. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September&#160;30, 2022, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. These adjustments were recognized as a component of other income/(expense) in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2023, the Company received a Section228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of a plan of Liquidation and Dissolution (&#x201c;Plan of Dissolution&#x201d;). The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $4.2 million impairment charge during the three and nine months ended September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;On October 30, 2023, the Company entered into a Common Stock Repurchase Agreement (the &#x201c;Repurchase Agreement&#x201d;) with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $4.4 million.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <vtvt:InvestmentOwnershipPercentage contextRef="c-124" decimals="2" id="f-448" unitRef="number">0.20</vtvt:InvestmentOwnershipPercentage>
    <vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock contextRef="c-1" id="f-449">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment with readily determinable fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reneo common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment without readily determinable fair values assessed under the measurement alternative:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anteris preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock>
    <vtvt:EquityInvestmentsWithReadilyDeterminableFairValue contextRef="c-125" decimals="-3" id="f-450" unitRef="usd">4387000</vtvt:EquityInvestmentsWithReadilyDeterminableFairValue>
    <vtvt:EquityInvestmentsWithReadilyDeterminableFairValue contextRef="c-126" decimals="-3" id="f-451" unitRef="usd">1343000</vtvt:EquityInvestmentsWithReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-127" decimals="-3" id="f-452" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-128" decimals="-3" id="f-453" unitRef="usd">4245000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">4387000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-5" decimals="-3" id="f-455" unitRef="usd">5588000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-129" decimals="-5" id="f-456" unitRef="usd">600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-130" decimals="-5" id="f-457" unitRef="usd">3000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-131" decimals="-5" id="f-458" unitRef="usd">400000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-132" decimals="-5" id="f-459" unitRef="usd">-3000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-1" decimals="-5" id="f-460" unitRef="usd">4200000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-10" decimals="-5" id="f-461" unitRef="usd">4200000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-133" decimals="-5" id="f-462" unitRef="usd">4400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-463">Commitments and Contingencies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novo Nordisk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2007, the Company entered into an Agreement (the &#x201c;Novo License Agreement&#x201d;) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the &#x201c;Novo Nordisk&#x201d;) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk&#x2019;s GKA program, including rights to preclinical and clinical compounds such as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and nonspecific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments payable totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vtvt:PotentialMilestonePayment contextRef="c-134" decimals="-5" id="f-464" unitRef="usd">9000000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-135" decimals="-5" id="f-465" unitRef="usd">50500000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-136" decimals="-5" id="f-466" unitRef="usd">115000000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-137" decimals="-5" id="f-467" unitRef="usd">75000000</vtvt:PotentialMilestonePayment>
    <vtvt:PotentialMilestonePayment contextRef="c-138" decimals="-5" id="f-468" unitRef="usd">2000000</vtvt:PotentialMilestonePayment>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-469">Leases&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.1 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Further, th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each of September&#160;30, 2023 and December&#160;31, 2022, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At September&#160;30, 2023 and December&#160;31, 2022, the weighted average remaining lease terms for the operating leases held by the Company were 2.2 years and 2.9 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for the Company&#x2019;s operating leases as of September&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost and the related operating cash flows for the nine months ended September&#160;30, 2023 and 2022 was $0.2 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-470">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtvt:LesseeOperatingLeaseTerminationPeriod contextRef="c-4" id="f-471">P3Y</vtvt:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-139" decimals="-5" id="f-472" unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-139" decimals="-5" id="f-473" unitRef="usd">100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-474" unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-475" unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-476">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-477">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-478">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities for the Company&#x2019;s operating leases as of September&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-4" decimals="-3" id="f-479" unitRef="usd">48000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-480" unitRef="usd">194000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-481" unitRef="usd">177000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-482" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-483" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-4" decimals="-3" id="f-484" unitRef="usd">0</vtvt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-485" unitRef="usd">419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <vtvt:OperatingLeasesImputedInterest contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">41000</vtvt:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-487" unitRef="usd">378000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-488" unitRef="usd">200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-5" id="f-489" unitRef="usd">100000</us-gaap:OperatingLeaseCost>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="c-1" id="f-490">Redeemable Noncontrolling Interest&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September&#160;30, 2023 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September&#160;30, 2023 and December&#160;31, 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $10.7 million and $16.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company&#x2019;s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to vTv Therapeutics Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <vtvt:PercentageOfNonVotingEconomicInterest contextRef="c-82" decimals="3" id="f-491" unitRef="number">0.221</vtvt:PercentageOfNonVotingEconomicInterest>
    <vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio contextRef="c-140" decimals="0" id="f-492" unitRef="number">1</vtvt:RedeemableNonControllingInterestExchangeAgreementStockConversionRatio>
    <vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock contextRef="c-23" id="f-493">P20D</vtvt:PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock>
    <vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue contextRef="c-4" decimals="-5" id="f-494" unitRef="usd">10700000</vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue>
    <vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue contextRef="c-5" decimals="-5" id="f-495" unitRef="usd">16600000</vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock contextRef="c-1" id="f-496">The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to vTv Therapeutics Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-10" decimals="-3" id="f-497" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-11" decimals="-3" id="f-498" unitRef="usd">-4261000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-499" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-12" decimals="-3" id="f-500" unitRef="usd">-14419000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-10" decimals="-3" id="f-501" unitRef="usd">1592000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-11" decimals="-3" id="f-502" unitRef="usd">-1174000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-1" decimals="-3" id="f-503" unitRef="usd">4212000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent contextRef="c-12" decimals="-3" id="f-504" unitRef="usd">-103000</vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-10" decimals="-3" id="f-505" unitRef="usd">-5062000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-11" decimals="-3" id="f-506" unitRef="usd">-5435000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-1" decimals="-3" id="f-507" unitRef="usd">-12560000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="c-12" decimals="-3" id="f-508" unitRef="usd">-14522000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-509">Stockholders&#x2019; DeficitOn May&#160;4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Investments Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the &#x201c;G42 Promissory Note&#x201d;). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company&#x2019;s Condensed Consolidated Statements of Operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CinPax and CinRx Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 22, 2022 (the &#x201c;Transaction Date&#x201d;), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (&#x201c;CinPax&#x201d;) and CinRx Pharma, LLC (&#x201c;CinRx&#x201d;), pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company&#x2019;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement provides CinPax the right to nominate a director to be approved to sit on the Company&#x2019;s Board of Directors and a board observer, which was subsequently approved by the Company&#x2019;s board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the &#x201c;Recently Issued Accounting Guidance&#x201d; in this quarterly report on Form 10-Q for details of the ASU.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of common stock at an initial exercise of price of approximately $0.72 per share (the &#x201c;CinRx Warrants&#x201d;). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (&#x201c;FDA Approval&#x201d;) to market and distribute the pharmaceutical product containing the Company&#x2019;s proprietary candidate, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;cadisegliatin (TTP399)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Product&#x201d;), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (&#x201c;CinRx MSA&#x201d;) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an &#x201c;at the market offering&#x201d; as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defined in Rule 415(a)(4) under the Securities Act (the &#x201c;ATM Offering&#x201d;). The shares are offered and sold pursuant to the Company&#x2019;s shelf registration statement on Form S-3. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;14, 2021 and June&#160;25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company&#x2019;s Class A common stock, by an aggregate offering price of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.5 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $50.0 million, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2023 and 2022, the Company did not sell any shares under the ATM Offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lincoln Park Capital Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#x2019;s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park pursuant to the LPC Purchase Agreement. During the three and nine months ended September&#160;30, 2023 and 2022, the Company did not sell any shares under the LPC Purchase Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-141"
      decimals="INF"
      id="f-510"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-142"
      decimals="INF"
      id="f-511"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <vtvt:IncreaseInCommonStockSharesAuthorized
      contextRef="c-143"
      decimals="INF"
      id="f-512"
      unitRef="shares">100000000</vtvt:IncreaseInCommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-144"
      decimals="INF"
      id="f-513"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-145"
      decimals="INF"
      id="f-514"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <vtvt:CommonStockAndPreferredStockSharesAuthorized
      contextRef="c-146"
      decimals="INF"
      id="f-515"
      unitRef="shares">250000000</vtvt:CommonStockAndPreferredStockSharesAuthorized>
    <vtvt:CommonStockAndPreferredStockSharesAuthorized
      contextRef="c-147"
      decimals="INF"
      id="f-516"
      unitRef="shares">350000000</vtvt:CommonStockAndPreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-87" decimals="0" id="f-517" unitRef="shares">10386274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-88"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-87" decimals="-5" id="f-519" unitRef="usd">25000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-87" decimals="-5" id="f-520" unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-88" decimals="-5" id="f-521" unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <vtvt:SaleOfStockConsiderationReceivableTerm contextRef="c-87" id="f-522">P1Y</vtvt:SaleOfStockConsiderationReceivableTerm>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-91" decimals="-5" id="f-523" unitRef="usd">12000000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-92" decimals="4" id="f-524" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-91" decimals="-5" id="f-525" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-148" decimals="0" id="f-526" unitRef="shares">4154549</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-149"
      decimals="2"
      id="f-527"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-148" decimals="-5" id="f-528" unitRef="usd">10000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-148" decimals="-5" id="f-529" unitRef="usd">6000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-149" decimals="-5" id="f-530" unitRef="usd">4000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-150" decimals="-5" id="f-531" unitRef="usd">3000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-151"
      decimals="2"
      id="f-532"
      unitRef="usdPerShare">0.72</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-152"
      decimals="INF"
      id="f-533"
      unitRef="shares">1200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-152"
      decimals="2"
      id="f-534"
      unitRef="usdPerShare">0.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-152" decimals="-5" id="f-535" unitRef="usd">400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-149" id="f-536">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-153"
      decimals="INF"
      id="f-537"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-154" decimals="-5" id="f-538" unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vtvt:AggregateOfferingPriceOfShares contextRef="c-155" decimals="-5" id="f-539" unitRef="usd">5500000</vtvt:AggregateOfferingPriceOfShares>
    <vtvt:AggregateOfferingPriceOfShares contextRef="c-156" decimals="-5" id="f-540" unitRef="usd">50000000</vtvt:AggregateOfferingPriceOfShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-157"
      decimals="INF"
      id="f-541"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-158"
      decimals="INF"
      id="f-542"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-159"
      decimals="INF"
      id="f-543"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-160"
      decimals="INF"
      id="f-544"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-161" decimals="-5" id="f-545" unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-162"
      decimals="INF"
      id="f-546"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-163"
      decimals="INF"
      id="f-547"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-164"
      decimals="INF"
      id="f-548"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-165"
      decimals="INF"
      id="f-549"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-550">Related-Party Transactions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MacAndrews &amp;amp; Forbes Incorporated&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacAndrews directly or indirectly controls 23,084,267 shares of Class B common stock. Further, as of September&#160;30, 2023, MacAndrews directly or indirectly holds 36,519,212 shares of the Company&#x2019;s Class A common stock. As a result, MacAndrews&#x2019; holdings represent approximately 57.0% of the combined voting power of the Company&#x2019;s outstanding common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letter Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the &#x201c;Letter Agreement Warrants&#x201d;) to purchase additional shares of the Company&#x2019;s Class A common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company&#x2019;s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company&#x2019;s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company&#x2019;s Class A common stock as determined pursuant to the Exchange Agreement), at the Company&#x2019;s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September&#160;30, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and MacAndrews are party to a tax receivable agreement (the &#x201c;Tax Receivable Agreement&#x201d;), which provides for the payment by the Company to M&amp;amp;F TTP Holdings Two LLC (&#x201c;M&amp;amp;F&#x201d;), as successor in interest to vTv Therapeutics Holdings, LLC (&#x201c;vTv Therapeutics Holdings&#x201d;), and M&amp;amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company&#x2019;s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investor Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an investor rights agreement with M&amp;amp;F, as successor in interest to vTv Therapeutics Holdings (the &#x201c;Investor Rights Agreement&#x201d;). The Investor Rights Agreement provides M&amp;amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;G42 Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 31, 2022, the Company entered into a common stock purchase agreement with G42 Investments pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company&#x2019;s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid on May 31, 2023 (the &#x201c;G42 Promissory Note&#x201d;). As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company&#x2019;s board of directors appointed the new director to the Company&#x2019;s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $12.0 million from G42 Investments, which represented a 3.75% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CinRx Pharma, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 22, 2022, the Company entered into the CinRx MSA  with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company&#x2019;s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company&#x2019;s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company&#x2019;s Class A common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="c-166" decimals="0" id="f-551" unitRef="shares">23084267</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="c-167" decimals="0" id="f-552" unitRef="shares">36519212</us-gaap:InvestmentOwnedBalanceShares>
    <vtvt:OwnershipPercentageOfMajorityOwner contextRef="c-168" decimals="3" id="f-553" unitRef="number">0.570</vtvt:OwnershipPercentageOfMajorityOwner>
    <vtvt:PercentageOfAmountOfCashSavings contextRef="c-168" decimals="2" id="f-554" unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-169"
      decimals="INF"
      id="f-555"
      unitRef="shares">10386274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-170"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">2.41</us-gaap:SaleOfStockPricePerShare>
    <vtvt:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="c-171" decimals="-5" id="f-557" unitRef="usd">25000000</vtvt:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-171" decimals="-5" id="f-558" unitRef="usd">12500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="c-172" decimals="-5" id="f-559" unitRef="usd">12500000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-173" decimals="-5" id="f-560" unitRef="usd">12000000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <vtvt:NotesReceivableDiscountRate contextRef="c-174" decimals="4" id="f-561" unitRef="number">0.0375</vtvt:NotesReceivableDiscountRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-173" decimals="-5" id="f-562" unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vtvt:DueToRelatedPartiesMonthlyAmount contextRef="c-175" decimals="-5" id="f-563" unitRef="usd">200000</vtvt:DueToRelatedPartiesMonthlyAmount>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="c-176" decimals="0" id="f-564" unitRef="shares">4154549</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-565">Income Taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and nine months ended September&#160;30, 2023. The Company&#x2019;s income tax provision for the nine months ended September&#160;30, 2022 was $0.2 million representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company&#x2019;s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September&#160;30, 2023 is due to the valuation allowance against the Company&#x2019;s expected net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which &lt;/span&gt;&lt;/div&gt;would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September&#160;30, 2023.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-566" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-5" id="f-567" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-5" id="f-568" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-5" id="f-569" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <vtvt:PercentageOfAmountOfCashSavings contextRef="c-177" decimals="2" id="f-570" unitRef="number">0.85</vtvt:PercentageOfAmountOfCashSavings>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-571">Net Loss per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,483,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,490,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,483,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,649,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,545,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,718,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,853,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,027,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;__________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-572">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.145%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,483,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,490,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,483,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,649,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-10" decimals="-3" id="f-573" unitRef="usd">-8540000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-3" id="f-574" unitRef="usd">-5468000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-575" unitRef="usd">-21525000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-576" unitRef="usd">-18983000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-577" unitRef="usd">-1886000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-578" unitRef="usd">-1207000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-579" unitRef="usd">-4753000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-580" unitRef="usd">-4564000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-10" decimals="-3" id="f-581" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-10" decimals="-3" id="f-582" unitRef="usd">-6654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-11" decimals="-3" id="f-583" unitRef="usd">-4261000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-11" decimals="-3" id="f-584" unitRef="usd">-4261000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-585" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-586" unitRef="usd">-16772000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-12" decimals="-3" id="f-587" unitRef="usd">-14419000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-12" decimals="-3" id="f-588" unitRef="usd">-14419000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="0" id="f-589" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-21" decimals="0" id="f-590" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="0" id="f-591" unitRef="shares">80490121</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="0" id="f-592" unitRef="shares">80490121</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-23" decimals="0" id="f-593" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-23" decimals="0" id="f-594" unitRef="shares">81483600</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-24" decimals="0" id="f-595" unitRef="shares">72649531</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-24" decimals="0" id="f-596" unitRef="shares">72649531</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-21"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-598"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-599"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-600"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-23"
      decimals="2"
      id="f-601"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-23"
      decimals="2"
      id="f-602"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-24"
      decimals="2"
      id="f-603"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-24"
      decimals="2"
      id="f-604"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-605">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.865%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class B common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,093,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options granted under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,545,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,718,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,853,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,027,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;__________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:90.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares of Class B common stock do not share in the Company&#x2019;s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-178" decimals="0" id="f-606" unitRef="shares">23093860</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-179" decimals="0" id="f-607" unitRef="shares">23093860</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-180" decimals="0" id="f-608" unitRef="shares">9545439</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-181" decimals="0" id="f-609" unitRef="shares">7718944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-182" decimals="0" id="f-610" unitRef="shares">3214503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-183" decimals="0" id="f-611" unitRef="shares">3214503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-612" unitRef="shares">35853802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="0" id="f-613" unitRef="shares">34027307</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-614">Fair Value of Financial Instruments&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company&#x2019;s investment in Reneo&#x2019;s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Changes in Level 3 instruments for the three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in&lt;br/&gt;fair value included in &lt;br/&gt;earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases /&lt;br/&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales /&lt;br/&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September&#160;30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income &#x2013; related party in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company&#x2019;s current capitalization. Expected volatility is based on the historical volatility &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2023 and December&#160;31, 2022 were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.37% - 77.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.06%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.94% - 85.88%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78% - 5.38%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11% - 4.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2023 were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.&lt;/span&gt;&lt;/div&gt;Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company&#x2019;s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-615">The following table summarizes the conclusions reached regarding fair value measurements as of September&#160;30, 2023 and December&#160;31, 2022 (in thousands):&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active &lt;br/&gt;Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable &lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:93.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Changes in Level 3 instruments for the three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Change in&lt;br/&gt;fair value included in &lt;br/&gt;earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases /&lt;br/&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales /&lt;br/&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability, related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-184" decimals="-3" id="f-616" unitRef="usd">4387000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-185" decimals="-3" id="f-617" unitRef="usd">4387000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-186" decimals="-3" id="f-618" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-187" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-184" decimals="-3" id="f-620" unitRef="usd">4387000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-185" decimals="-3" id="f-621" unitRef="usd">4387000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-186" decimals="-3" id="f-622" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-187" decimals="-3" id="f-623" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-184" decimals="-3" id="f-624" unitRef="usd">278000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-188" decimals="-3" id="f-625" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-189" decimals="-3" id="f-626" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-190" decimals="-3" id="f-627" unitRef="usd">278000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-184" decimals="-3" id="f-628" unitRef="usd">278000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-185" decimals="-3" id="f-629" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-186" decimals="-3" id="f-630" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-187" decimals="-3" id="f-631" unitRef="usd">278000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-191" decimals="-3" id="f-632" unitRef="usd">1343000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-192" decimals="-3" id="f-633" unitRef="usd">1343000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-193" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-194" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-191" decimals="-3" id="f-636" unitRef="usd">1343000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-192" decimals="-3" id="f-637" unitRef="usd">1343000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-193" decimals="-3" id="f-638" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-194" decimals="-3" id="f-639" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-191" decimals="-3" id="f-640" unitRef="usd">684000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-195" decimals="-3" id="f-641" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-196" decimals="-3" id="f-642" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-197" decimals="-3" id="f-643" unitRef="usd">684000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-191" decimals="-3" id="f-644" unitRef="usd">684000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-192" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-193" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-194" decimals="-3" id="f-647" unitRef="usd">684000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-198" decimals="-3" id="f-648" unitRef="usd">684000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-199" decimals="-3" id="f-649" unitRef="usd">-406000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-199" decimals="-3" id="f-650" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-199" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-200" decimals="-3" id="f-652" unitRef="usd">278000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-198" decimals="-3" id="f-653" unitRef="usd">684000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-199" decimals="-3" id="f-654" unitRef="usd">-406000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-199" decimals="-3" id="f-655" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-199" decimals="-3" id="f-656" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-200" decimals="-3" id="f-657" unitRef="usd">278000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-201" decimals="-3" id="f-658" unitRef="usd">1262000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-202" decimals="-3" id="f-659" unitRef="usd">-221000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-202" decimals="-3" id="f-660" unitRef="usd">368000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-202" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-203" decimals="-3" id="f-662" unitRef="usd">1409000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-201" decimals="-3" id="f-663" unitRef="usd">1262000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c-202" decimals="-3" id="f-664" unitRef="usd">-221000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-202" decimals="-3" id="f-665" unitRef="usd">368000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales contextRef="c-202" decimals="-3" id="f-666" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-203" decimals="-3" id="f-667" unitRef="usd">1409000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-668">Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September&#160;30, 2023 and December&#160;31, 2022 were:&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.790%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.37% - 77.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.06%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.94% - 85.88%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78% - 5.38%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11% - 4.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September&#160;30, 2023 were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life of options in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-204" decimals="4" id="f-669" unitRef="number">0.6837</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-205" decimals="4" id="f-670" unitRef="number">0.7701</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-206" decimals="4" id="f-671" unitRef="number">0.7606</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-207" decimals="4" id="f-672" unitRef="number">0.7694</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-208" decimals="4" id="f-673" unitRef="number">0.8588</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-209" decimals="4" id="f-674" unitRef="number">0.8217</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-210" decimals="4" id="f-675" unitRef="number">0.0478</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-211" decimals="4" id="f-676" unitRef="number">0.0538</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-212" decimals="4" id="f-677" unitRef="number">0.0488</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-213" decimals="4" id="f-678" unitRef="number">0.0411</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-214" decimals="4" id="f-679" unitRef="number">0.0443</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-215" decimals="4" id="f-680" unitRef="number">0.0419</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-216" decimals="4" id="f-681" unitRef="number">0.8238</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-217" id="f-682">P3Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-218" decimals="4" id="f-683" unitRef="number">0.0473</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-219" decimals="4" id="f-684" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-685">Subsequent EventsOn October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (&#x201c;Plan of Dissolution&#x201d;) (See Note 5).On October 30, 2023, vTv LLC, entered into a Common Stock Repurchase Agreement (the &#x201c;Repurchase Agreement&#x201d;) with Reneo pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC.  Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million, which was received by vTv LLC on October 30, 2023. vTv LLC had acquired the Reneo stock in connection with the December 21, 2017 License Agreement between vTv LLC and Reneo, which remains in effect.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-133" decimals="-5" id="f-686" unitRef="usd">4400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-10" id="f-687">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-10" id="f-688">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-10" id="f-689">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-10" id="f-690">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,R#:5<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #,@VE7S'QT6NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VE!-'1S43PI""XHWD(RNQMLFI",M/OVMG&WB^@#>,S,GV^^
M@>E,E"8D?$XA8B*'^6KR_9"EB1MV((H2()L#>IWK.3',S5U(7M/\3'N(VGSH
M/4+#^35X)&TU:5B 55R)3'762)-04T@GO#4K/GZFOL"L >S1XT 91"V J65B
M/$Y]!Q?  B-,/G\7T*[$4OT36SK 3LDINS4UCF,]MB4W[R#@[>GQI:Q;N2&3
M'@S.O[*3=(RX8>?)K^W=_?:!J88W;25$Q6^WC9 ME_SF?7']X7<1]L&ZG?O'
MQF=!U<&ONU!?4$L#!!0    ( ,R#:5>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M"%,/R/LK2L7^1+W@L%-I^B]02P,$%     @ S(-I5^I(X@\A!@  !AT  !@
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MB8Z5$=#_/W ])+<+\RIL_^IS]1]02P,$%     @ S(-I5SWMI6DE P  + \
M !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RUEUUOVC 4AO^*E4U3*W7D
MDZ\.(A7"M%U40D7;KMWD0*PZ<68;:/?K9R=I1 JD04JY -LY[^OCQ^9$GNP9
M?Q(Q@$3/"4W%U(BES&Y-4X0Q)%CT6 :I>K)F/,%2=?G&%!D''.6BA)J.90W,
M!)/4\"?YV)+[$[:5E*2PY$ALDP3SEQE0MI\:MO$Z\$ VL=0#IC_)\ 96(']E
M2ZYZ9N42D01205B*.*RGQIU]NQCK^#S@-X&].&@CO9)'QIYTYV<T-2R=$% (
MI7; ZF<'<Z!4&ZDT_I:>1C6E%AZV7]V_YVM7:WG$ N:,_B&1C*?&R$ 1K/&6
MR@>V_P'E>OK:+V14Y-]H7\0.A@8*MT*RI!2K#!*2%K_XN>1P(+"],P*G%#AM
M!6XI<-\*W#,"KQ1X;6?HEX)\Z6:Q]AQ<@"7V)YSM$=?1RDTW<OJY6O$BJ3XG
M*\G54Z)TTI^S-%*[#A%2+<$HB;!4G1FF. T!K;2Q0%=+S"&5,4@28GJ-OJ+/
MR$0B5J-B8DJ5AW8SPW+.63&G<V;.%60]Y%HWR+$<]X1\WBP/(%1R.Y<[)^1!
ML_P>OR#+R]7V"?6B_>1676XJ]!5_I^+OY'[>.?X4"X'N%/TD4?^;E63ATRFB
MC2ZZF-R*#(<P-52U$,!W8/A?/MD#Z]LIOEV:!5V:+3HRJVV%6VV%V[P5Q18(
MO04HPQSM,-T"NB(IVHH(9<"+$W]]:G\*ZV%NK6OSSK=ZECI?NT/N;8*"QB0O
MY=F168VG5_'T6O.\*8L%PEL9,T[^J1JCP1:C)XD6YOT#6.K=5WS>8&T=&;2.
M7!Q'VD>1-2K]BDK_<BKJ!2XD3B.2;M[#TC]*;&1[(W=P1*5M8-"8[Z4'KB.S
M&MI!A7;0HI;.WJVEC2Z7UM(NS8(NS18=F=6V8EAMQ?#C:NFP32UM$Q0T)GDI
MSX[,:CQ'%<_11];248MJ5F!M'1DT)GPIVX[,:FS'%=OQAU;D\?%+Q;7&[FCP
MEFW;P* QWTO1=F16H#4/;AKZ'GF/^8:D E%8*WNK-U2KX\7=K.A(EN67CT<F
MU54F;\;J.@M<!ZCG:\;D:T??9ZH+LO\?4$L#!!0    ( ,R#:5=&Y_<$>@8
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MVGGG:0?#&MJ!L*9V,*Q%NWID(]TCV_?RU3J+K^A&2?7,4+[.YHK]+Z=>*9N
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M^S=GYIEQ7=1UL=Z]O,NS15YN&S3_?U,4]9=?+AK^8U%^VL6X^C]02P,$%
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M OQXT- "U^0M-F[_8A*6W#I,L88\JM'OC3*#J.0M.J!:[ 0^8J6AJ/6:P$]
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M+\Z_6 RKOZ)37)-1(6%0OY"-K_FV@V PM\'2M+%1^PM*(D) O0'8L<!K$(6
M:,*9)0T58']C90<QVE(H:N@!8; J+?KX_#$U3>L:#,E+47E%='63W'XJ ,9F
M 18SQZ0.3->EILE$#XOL+V+:5.1I^6E6BPPJ@^G2>3/Y1N!QN<Y<!MK<).:4
MZJM!"8&<1^C[L2D$#ID])#6/IDZ2_R:VTL@L;F-_XYSG1M/9,,*+IJIDT!Y?
MS\E2N>FU@R!N@B#D2E/^<XB CYZ5BGQR%HJ\&JX.N))<MK/_1!<3[C8T&:=4
MA H*=OBD'.J2^)YJ6E?V19SA0*)>J=,@. 27148T5(XS3L '@%M81^1JP/W$
M-TGN%1Q1H=RF5)JHO.!>.GSZB2TDT4G)#4ZCM[P( <G^K\QKLRP5FZ.!3:4P
M[5?D]L6H)\"8,/QM8K*3/ .S0OH58<DI-3_!#(MJ7+LQ)B;V \47,!LJ&[T;
M"(-@X0ZW3=VSU%"9G@%%[Y%Y)* F$1O+X#XU L5)HM;$-[GYB=<;YTK&-V D
M@6,*I]'QIP:.9,@A D;G$TC958;.R"<U\L>"3>BP33<.NY@Q['8DB&3KA#VT
MJ18<>T#I93O5S3B28,/=$ C:9L)92-Q<I9:IP<!%\BBZ"#CE&I)21DP=SF_#
MD-D(*Z:;[%34NQY&U"/G4:YL"\,=4^*8^0YD: WG2HE!ABO4T9 (S:_'0%[D
M&Q?GI=8/FOI10Z4Q<;@CO?_C$.+',PQR4PG/&7?G=*E>Y'X/'?_PJ.,ZV)=R
MWQ(9:U:&N-P8KT*=:,Y87K&#K8C,1@GG8DBRC(:)DQZ-TEUH&52U+Q2%95V[
M(G>+.%*.A' ?<@$U-\&*[AJS@V;WD:1=TW&"D7M)V9/Z3K3-T4C?0Y6?)F4'
M5%)A>!^2P'G7H]M9"??!=LS<F)]AO0U!$0$_!!I3:4J2*9M*0.XB!@<@O=^O
MJ60CV32[?'*81(S+I$H&1&X;<OZ:JKUQI6%V1Z#A->6:!S47JW)\;DF.C(V9
M@_%&ZC0F)L:WEIDE"GT\SZ4=),NNEF4C+02C?2'%YB14U?>4\6>M=S\=/$W0
M4NKD>H%K5IJ)S)\85&G J"C%Y\@B3L#X>63%PRW!1=J)>X:F@)*8&(?8EYRK
MAS<1(5WG2UXQY/ ;E-Y3UX-[!),5F5*44[0:?B*G&U<,?4<E(O;#,KGW3&,7
MK/B*[DYYZA[>\4609:.G 7R?:P@AM"U3RXTHE,Y-:B'%0V7/^($QQ'L4[$Y7
MI<>UR-6M3'2' 75E*EVO9WZP;UJ"UV0VII(P=4^(OYLJA6P&8F"^)VT-^6;2
M=EWONF3&U84R:T0$%6NT#U/6=M*6OZ58['WHJ8B,;@Z2*-.-IW;MD/EVE+)C
M<X3:1B/<,\']3E23KE]!'KU<P:PH<DV8]>5G&X,7^7*@A-0YE\@>^L<[7KJ=
MFB1?&J<[@!GC';JS,YH[=E&%9XI"@YEG0W#*=T885VLV+MKQ P+.>-(4);X[
M)6<C<6*M;1.C)UG[EA!S8+E\HWNJ7LN?X0#Y(.I!IB0'(.4[U(FYI)-/!"KJ
MGP\W:,F;:9?)#4VZ/$T-EH2@@Q_-M#LID2E([*2$<:R.=!EY*!22UV(+%"U;
M3B5TP143B(ISIZOZX58HW? =O&-*)%;+W=">QPNTS9P>K%J4M!A@<HBFR47/
M'/J&5E(N"J=$;W[0>?(N#7E.OL0<=<V9](:MX[-5 O*=]/*2]Z87Q<P2AX&A
M=:TW:W@*<R%=WC 4=MF%0)CH0E$JMW4?>S[4W=BF@UR0VO&Z#HXY>S-7D0X[
M5OR$YEKVX\DI#5]I3?D#\9T9([X#:^72E(6US8K J$S!I7G$ [J28THQ]C_2
M^'5J?W$! GCNA][^434F'9!4A5RR?!="CS6F'Q)ZU^*Y2$IX1=VQG[EZ^'YL
MFH0G!*3_ DJD#WGDQB#'Q62Y9>[PJ!<._ZA[KZZ6+^XCX.;[C@/?=GRA>>]J
M^?:^^L&=\A8/SA\>DT7=^\EU<,K'E^?WGQP9Q+?LTAB<?.>U'&$S-[LH>I>H
M5,AP(!;%""H4G?D6A) >=EEODP$'&$P7PWGF^)51+;=Z;6Y/!I%BFQOPDWJ&
M\DL.26Y=T\1TQ90C=;;(_%N&_47A]=+TXB;E3JL=@\<N5R"42MA)D=GUJ!.*
M(3V.Y(3#%G04!Z;O.G;NJO.W6,*GP]A1</PUVG32RH"IM^SA:TP:/_VY^#S?
MTKS4U"_5I>N&C@C5N#'.*0DW>ZC93E$$[QD<A\%W7,5(LAD./;E!@D:!"^I#
M#QO(3<!X$S5(L'L5-1!&[A<7<8;$__ACGX0<^A#Y;/+].)C/AK^2YP\/VBB?
MD@]OAP_QK^3[\W&X?,7_/5=&0=5FC:GGIU]^?B(-K_Q'=!U_C;YR,;J&'XGC
M&D\#\#M]CYC_H V&_SWA^?\!4$L#!!0    ( ,R#:5?LK$;A/A<  -I.   8
M    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL[5Q;<]LXEOXK*$^VRZZ294EV
M;MU)JAQG,LEL,NV-D]VJW=H'B(0D="B"#9!VU+]^SP4 08J4G6S/T^Y+(E,D
M<.[G.P>'>G%G[%>W4:H6W[9%Z5X>;>JZ^OGLS&4;M95N:BI5PC<K8[>RAC_M
M^LQ55LF<'MH69XO9[,G95NKRZ-4+NG9M7[TP35WH4EU;X9KM5MK=:U68NY='
M\Z-PX9->;VJ\</;J1277ZD;57ZIK"W^=Q55RO56ETZ845JU>'EW.?WY]@??3
M#?^NU9U+/@OD9&G,5_SC??[R:(8$J4)E-:X@X;];=:6* A<",G[W:Q[%+?'!
M]'-8_2WQ#KPLI5-7IO@/G=>;ET?/CD2N5K(IZD_F[IWR_#S&]3)3./I7W/E[
M9T<B:UQMMOYAH&"K2_Y??O-R>,@#"__ @NCFC8C*-[*6KUY8<R<LW@VKX0=B
ME9X&XG2)2KFI+7RKX;GZ%7!3R*6QDF1TN;9*@<AK]^*LAM7QGK/,K_2:5UJ,
MK/1<?#1EO7'BKV6N\N[S9T!5)&T12'N].+C@C:JFXGPV$8O9XOS >N>1U7-:
M[WQDO5_M6I;Z#^)T(JY,Z4RA<V9<EKFXMLH!ZWS!K,1;7<HRT[(0-W"1Q2+^
MZW+I:@NV]-]#$F("+H8)0/_ZV54R4R^/*MS+WJJC5S_]9?YD]LL!]BXB>Q>'
M5O\N31Y<:9C.L>7%WRX6XKJQV09\H[U.$KTRZU**Y,E;1=<_Z S<.KW[\T;!
M?=M*ECNZ Q=]7]XJ5_,FE^_%.U/DNER+3S=7XD.=3X04E=6WH!E1Z*VN52XR
MO\+Q3W]YMEC,?NFM0E?GOYQ,!/RE+#R@R]H(I'"[!:9N:I-]'>+EN ;RDC7W
M;PE+"UCFH]R)\SF9[6(BJL:Z1L(BL-/=1F<;42>\@@GF^$V?W_EL<O[LR63Q
M]$*XC00EH$$F#^)^\Z>_.'%52 ?B0=:1!4<LR)J%DRE1*<LKX *RJJSYIB&6
MJ6(G'BVF%T F!'80N9!KX&6-TJP"=[P"//=H\7@Z@^A3%.0ZS,:==**2.A?'
M^D0\FB^FC\,=(%:12;=!.I#FK# .-8>*/=9#=^-=F&"(2-C7;+5SQNY$:6JB
MH"\?$-E2\?:P22+Q\WUEM:O] U8+FIJ*2Z3?UD&RPXJ=[&U=PG*E1'.3(M<6
ML@L*T*%P#=B38A,?TM722)OC=N$QQQJYQ;7X:103/EI".HN+ [.CRTW%KZ5X
MJY:V@90J%L]8")..D0TYE(3_($P?X)P>VYI<KW1Z7U>:2)O,,DBR%DT'[ZKD
MCA[/&R4:V,,R0W#S%'>)SH!7B0H6L[F7#9"&TB@K-)\]<X1DCIG>DVJL7H.6
M"MC!-'O$##%2*/ C*<ZG3Q__"XC>9?C<!(USU12%<!"]W$IF(3D$GB:PL0,$
M@(J#>Z4 6R=G?32;GD<31U&BOP +$!+U'ZAPW T#EBE16O"$@34M+ (7U=FQ
M^E9AC#P)[K'G^ ;8@1OR))/!'TFJ@B5_K10';#?=LX -4H#*I@"4*5M+W,K*
MTJV #F"K!O^GA\%KRZQH*/QVKF/$V1CP(2<+C%$0:R 4%]+R.BPN=T+\]Q]<
M-988EMGOC7;:7U_Y>$>25Q(4FZ%5NF;Y&V@7*765RM@FU;=,59Z[MY!DS%UP
M'Q">MC&1HU(@*C851D-M('6L0/ELK'2A$[+!3FI=B#=@;=LET.>O7TS$,?"G
M5T"5+;2R;)PH==R#C+,B/7Z9WB ]L"RR_<8V:W&90\S0"!R(II"?WKZYC(F#
M(P%8K-<WK8*Q.9-@C6I=:'@6'OW\^?K\^?,3T?4-5.8:1%ZKP702M LXL5@1
M695>KW=+"6*!J-]29A'$.L"@-7H4BMK[JD$EQ$PTF'7 FYKA[:N>VX^%VM;*
M*#@L=:'K'5DG&'N384AB+[ZSNJX5*A=,E>XW2*Y"1VW 9CRE[/&!^4S;K-FZ
M&D"= HM!R#'$.Q.A//C&<)09$_QH I?K4Y3;1'@/A47T=@D<>B90NAHVWI9@
MI1DOC:K5CBT5W!4\M (\5"K3.$C$).U#<E' )E4O^_ B-8(>JLDZB W)*CSN
MDH/(AM':/J0A\OC+SRK;E*8PZYVX,47#/OOAP]6$$,1JI=%*!Q/V<;I)"\1"
M[(80@ KC71 I02G7RB4P"$H$12!00)UG@%M!P 7$&@#I[I"S@'?<H7' _[]A
MF@6A9U#"4M268EV8)2R3JUNH42N22U4 0T"'OS:!DLM^55Z[:/7*8F4 D7QL
M2S2X8'B82JQ6+OCV1YWGA1)_E0Y6O%Q!5)2\\A7L;8&42Z=E1S?7 %1*L.7/
MRH+I0])J8<R7F-9 ^]L$*':T.?$7[B C";,DNF0TB*ZC((HI,)DV0 J8+LB\
M1B\ VL"DP,"6NXY:0$ZJE$O@2).+0\)<X38:D]"RT&M.0<2A^H:2<XJ^]![7
M)F:F40Y&A*B,/1V(0TK 9?>D-Q'+IF990!*'Z(F%"< 8YT*(NI60&!HW(HM@
MS>^OHY=854@???'YZ&I(ZS!Q4W'#J0QLN-AU79E(8]P>*('-(<Q"N9\Z9+*K
MCY$A>O:]@R (KDJQ* ]8K=:$U8R3:\4W@>EG:FG0CD8(+P$S=/9DZZ-]4GL<
M,4',5?@U:?^07K];K5@+D-'=H=,YR,80ZO> !S[:.!4<Y?TUZW^I(*$4>E7O
M&?C4EZ<=;H!J]#<HG7,?Q3PPR?;]?9_0>@.D\HI;B.>4(%4G O6%T49QKT#7
M,Q@?*Y.L&2D$ H$WWBZ#P+94I5J!KWH8I!T*H=Y8TZQYD<K<*=M!%#U_]W4+
M71X)GX"!&.%U+1O9=4U5%:0MU-($<6,KBZTL&P3:C05P/6( %.JC< A]ABA"
M,9#+0X]N&X#80:-8\*%BJ$)&U[&$X, 5%7Q%=?& (P8S1]OZCJQCFMJAIWE#
MN]=< R;!>H+B..%?)+F%_?WMB3[@%:2Q)%O<C\U.J:\"H.8^Q"QU+!D.,D)%
M9@3$BP@^,,F_4[*H-QE&JC%T((XQ92L+*O]:(K/2W8,G(,:86PIL29I VV_3
MR7C6" @TH>P38$,)N"K=$ I +"D\A4G#H'VNQ2GWP!MJ)DBONK8\O/68$>([
MUJ< SC > 7D^$,(% N62=9@C_3EC62S!]OA@ QDKUPMGVM@ $L?63EH4)25*
MQQK& _TD='!,%6JI'N. 3355<<?RA.[$(@ !]G?UJU*D\U%#)5E#42QN",3'
M! M!FIM(2:L*R(>P">@1'<*(1^>SMC& 4>5X>=+I2?2< \OTSB.A<35,T!5^
M=<U+M?CK\P#7?2:0EI2.O=O2I2>^FP00 D$5@"!'$8A*Y!#/$F7B2AV%HJ,D
M!7. ==0E3:!87--!B*C18B"%^- P;&/$K%4^AX"! Z6NL<0Y9;0]4D)X"IF$
M6V4^G]1ZZVW3*K/"().I@9Q7RZ\@08(E!P#=7M#V[2)AS0[\)\G&V(N$?)'K
M-087RH'LCQX;E"KV,T8]@YJFH7N +89:% K@O,"J= >Q!D2\JGU\6FGKZKU\
M-;[X&)/3T*@.];980R*WB!ZILV01E0$E*ZFM=PVOD]"E"'8Z!1^.\"#$A^2Q
MX+S?5>9W=0#6A<G/^H9<Z ''GC)=3-?UTF]K74[,Z<E KG/"ZUNP" H$^6\-
M;QY,*N$!542"'L)_GA4\%42YD043A%HWFO]"\Z%"4>80_:BJ%I<W7RCSG<[.
M$3$P_/%AXE.X_SW+YS(C&(@\_\VOZ6,&ZQ>T!V'+UI06K:JPBX8]4.R"SV>G
M_T;T@XJD+F)-!_M/:6&+)5$?JB2 E)R1(EE00VR&/7H\?1KCG=N8ILC105O[
M<0\U!&];785-!&1Q<-U@5(-/[AG#H]GT\>/A!8%AN$]M=;-MCQR\%@<7AQC?
M;S[@#O-G+=\3\G'J#-(! X<*JF!#Y]=3]20\@H:H7:0$/J;B)KC)15!L>WKN
M*%)0.,(C<N0Z+8E;$!/ABXL'+#YV2K8DV ?7XB<N;Z[$L]DSC*?X\<GL"9U-
MDV0"83+M53> ]8AC7JSG5WW+B8V++:0,EN$0I0*Q58BJ&=3&N$,@3>()1:^!
MTQX*XI-\(L^8/--P0QUC=!_F'L0HL"CMA&NJ;Y5QK!*GU]R" VU:[;XZWX:^
MDS9WK;B(^(:+_Q"7!FIG2*@.@ ;&FC3#33T_0P8AQ:TJ<U!1%PN)O+'#5;JH
M,-].J/M%EC+<^E\J0(PKKK^W50';BD\_R6WURQL6J<9LQW+!:$F='NYF8I-'
M5C*# K%K 5T;"[$YZ+[7V^B))]BK;YRZ]@P!^6:^0N]B$FH_5&B7=]^#""VV
MM'?IY4"MNTZ=R43BF5L \']_<]6VU%%ST1Y['C AB+5+P#&>S,0B>PO9'"I0
MKF9!76"?'A%$?T-SEEA*=$49P <?]/0XL4!\Z9,3HH].Q1]UUW?R6_0\O55=
MHX7P1D>Y>8)#?'N4<_SK79='SP=:M"X'^.BF$\@:D+[BX5^R<EJ%>2"9IGH/
MZ_ H9^#0+'F6SPXIVJXB0 9MVI)/5%A4B68(MF":LEPD'93QI$5'/73H<]X:
M:R^BD"2$ZCC I&^?TK.E:GT<DP9\;'ROK]-:R54! <[N N^0K53-QV3*WNIX
M##&R[6#(I0"]PHR">,6'RQ$;IXB881,,V\H>Q QX,)6O\-B- J3#AUZS] 2V
M'P\WDB,+05I8/>^ADM*,F'WO##1H?8S\)%#6&^M/UDML:&UYU(C/L/?)[GID
M8LE#F8TD.I;)T$-"NR(&8(J'F+\WNL+(3RL0G(AAUK/F.H&4R4KSTK#F'T(3
M?'<\Y^HV"2*3D9YAVU1#@8;F=-L!_7,:I3SAL3C!T@AP%0@=; 9#% 7XV.^5
MG5K(]P([->98,(WA,YS?CK!^@&>>C:%,@K+%J$K=T90-T"^$?]]AO5<J,?\Y
M.A+,ZC8X4 DX5N4ETQ]>C  LOH_]GFR3/-TUV*0I'*=[0I+OZ8%[LFV++MSO
M1AZ(M'B:.^C59%ECDTK8XY4D'6B,[+!:/\0<ZY4G(%<9=[O[M(<G1@@YZ33E
M]H_+,8"E\QBD=Y9O&WB#N_V)D>G_VKR.^/^!G1\;V/D\PGA2K2*)&1;!K'2D
M>JQ:/)_/Q*?X9'L@[[]K0;/GW#LF.):'PGDXKNBV!Q[-Y]/G:96<V#%VI&-C
M 672J<)1HCDVNG'MX'I1>(/">BT+2I4W.._LJ%%:8OLT%KDYME.HM3"26!&Z
M4 )C^]"L6,-#,0&/?*]+OVMD;F#3PW.MFN<-^?QL8!:#^D_O9+G^8V,:\9\;
M6'&K=%S\>B.!GTPU-46]*S.=X!SL-&K2WQ@UF3:Q1RELCSC85-@WP^T\*$"6
MA=-61>/"""^4P\P!V6%@YN!A[I!3K(LFDVM3GA;Z*^+@JH98?SHG&Z]HL!*^
MU)"/X@'-A^O3N8T\0OY<6[GMCPZ1FP)# I+MXNFYF 356EF1 #&#4Q6T:<!&
M")++$JJI@@?/K@!82V;! T;V]6O))[R?]+8]Y4TWOVQPG A2/3U\8QI0Z;\:
MJZ0X1D3,?:U0D(SH9F#&XS+G3CT7,VU<'%5K-Q*W:B1W"8J<=+4X\:WRW>D*
MS?]!.@WB"81 _::HW1)/[/#$[W2#H^S=)D+?$EBQ0:$/UU?_E'54FI1Y_PZ8
M$#/6_()\=WY@@*KMW,>L%V@?]_?C5+%OZ>EP\V58I1VL(E]3>"[# \5#<NG6
MRZ["<(AG#UO,8:<XP ;?]%HIG<DA0@D+\?'3U>?T/!,U:7'$#T^!.EU)/]@!
M2RT;2#=-Q4=KW6,R!%V&AZ=IXHXVYO#?BLLG@+S)0FO U-@-BK5!?^ !V&G
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M(P:$X8_:5/3K94M3UV9+'S=*@A7B#?#]RH#:_1^X0?PYNU?_ U!+ P04
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M]Y09VDBN@&8I9J.G)_\0F78IS4L($*L:,>*06]PJ@B=ZCO9$1.Q0@04B@@!
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MZJQZ8(]^8TV]W@CD!N(D#EE)"M:6D\52HCX?=9J1R>QPT*)A52IU&C_*)>@
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M<6B7F\%8'W\V(;N]03^S8AGN[X#S![MF>]5XE$S/GR>3%Z<_0[!\RMXZ6Y.
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MT.7+@?JWAU&Q]V4]K]$<OFS]K",T;N %NKR(G?_U0JL<K;9*:WK;*3[E.<#
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MHE\#J)T"?5\I:K[^Q6VP^WVQ^!M02P,$%     @ S(-I5UR]*C.[!P  ?Q<
M !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL[5AM;]NV%OXKA'<SM$ J
MVY+KN&D2($G;K4.[YB;K^N'BXH*6:)L+)6HD9<?]]7L.*<MR8CM9[_UP,:Q
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MM3,@?:ZHHSO!!1AF]_I_4$L#!!0    ( ,R#:5>I$G>$>P(  +@'   9
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M:"DEY@688]<J]K79P<;Y64=;M;3P"BU"CX+K4J$OG #Y-]\W9KU>>-);A8/
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M-52PXFELT+O\+%$OMVK6N"S[UQT"KA$P\F^^-PH\-?I&8&3W5@+E$;8D7>.
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MTKL?'CZ8?ROM@KK I9ICZOCPZ>.]4-:G/[QI^+MO5/^H.?F1.+BR- #OZ>/
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M:03H_48(?=P8 ]V7U.PK4$L#!!0    ( ,R#:5?@V1K0UP(  %\&   9
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M\YY&ZP/8OS*&=HHOT&S^R5]02P,$%     @ S(-I5UA8D,LK P  8 <  !D
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M 3%-']H?W7QJSMSI+^J&AJZA?5-?6@GP&Y,5W7$@A-_I8E4K</*O*YWFA-Q
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M1K^GLF\16</(.'V=_R"-D5%ZN 06@+(=\/I<2O/4L ,47X0F_P%02P,$%
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M5A9DA!;_^+&,PQ9 \=0#W!+@/@6TGP%X)< [5D.[!+2/U= I <9UN_#=!"[
M$OL#SM:(:VG%IA<F^@:MXD6HKI.9Y.HI43CISXKZ0&R.9F1!R9Q$F$HTBB*V
MI)+0!9JRE$0$!'J+1G%,='IQBJYH4:,ZV:<!2$S2,R5Q-PO0Z<D9.D&$HD\)
M6PI,8S&PI3)5*[2CTJQQ89;[C%D>NF94)@*%-(:X!A_LQU_LP=LJ1%6<W$V<
MQNY>PAGDY\ASWB#7<;T:>R;'P]TZ=_Y->_C7VG>"X55%XQD^[T#1W!PNFJ\?
M%19=2<C$M[HR*!2UZQ7I)MD7.8Y@:*DN*("OP/)?OVIUG?=U.6B2+&B2+&R(
M;"=;[2I;[7WL_BVL@"ZA+OH%L&N ^D99^<[ 7FV']*!$<% B_%-"W6(7E=".
M4YW*J<XQ3J&?:&*:)'"UO%&EMMG6N;N7\J7%UB19T"19V!#93EZZ55ZZ_ZLU
M=)O,5I-D09-D84-D.]GJ5=GJ[7V+)HQ&0"4O[G%.Q /*@>LC-2/6Y60OW4MS
MTB19T"196)!=;'6LUI-V96^-7*K;+,RL*Y"I\N(BK4ZK<7IDIL@GY^-6?]*J
M.0_4^%U,R[_IB]G]&O,%H0*E,%>JG/.>>M]Y,0\7&\ER,_#=,ZE:H5DFZA,"
MN!90S^>,R<U&*Z@^2OQ?4$L#!!0    ( ,R#:5??2IIE?P\  %+<   9
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;,W=;6^CV &&X;^"TJK:2MG$8#LO
MTYE(F? .4T4SNZW4JA^(?6+3Q9 %G&Q6^^-[P"0$FQS;RKW;[(>=Q.%<!\=^
M#(8G^.-#EO]4S(4HM5\625I\.IB7Y=V'X^-B,A>+J#C*[D0J?W*;Y8NHE-_F
ML^/B+A?1M!ZT2(Z-P>#D>!'%Z<'%Q_JVZ_SB8[8LDS@5U[E6+!>+*'_\+)+L
MX=.!?O!TP]=X-B^K&XXO/MY%,_%-E#_>7>?RN^-G91HO1%K$6:KEXO;3P:7^
M(1R?5P/J)?X1BX?BQ==:=5=NLNRGZAMO^NE@4*V12,2DK(A(_G,OKD225))<
MCY\;].!YSFK@RZ^?=+N^\_+.W$2%N,J2?\;3<O[IX.Q FXK;:)F47[,'5S1W
M:%QYDRPIZO]K#\VR@P-MLBS*;-$,EFNPB-/5O]$OS2_BQ0!]],H HQE@K \8
MOC)@V P8[CK#J!DP6A\P?F7 N!DPWG7 23/@9-=5.FT&G.XZPUDSX&S7&<Z;
M >?K TY>>^ &3X_<8-<Y].<'>^='6W]ZN/7Z\3Y>/;'J9Z49E='%QSQ[T/)J
M>>E57]1/[7J\?#+&:97";V4N?QK+<>6%?/8FT4V61W4F+F>Y$#)C9:%]KUU.
MIW%U:Y1H7KK*>[7,=Z8HHSCYJUSBQV^F]MV?__KQN)1K4GG'DV96:S6K\<JL
MNO8E2\MYH5GI5$Q[QMOJ\<-MXUWU^/-MX_TMZV\H@&/Y$#P_#L;3X_#94(JV
MN#G2C+-#S1@8PYX5NE(/_Q(]:D.]'FWTC#;5HTTQ.=+TU?!!WZ.I'GZYG!TU
ML^NG?0^F>O@W<2>'#UZ]Z\[NP_ONN_NVV;VWS>[O\)L?OOZ;#W8?WC=[J![N
M1ZE\W$?U<%WQ)!X^OY@,:V^X_<7D7FB7>1ZEL^;EY#*=:G_/TLEK2V@_R"^+
MJ-XT%]J_0REK7BD6Q7]Z[M;GU6J,^E>CVG'Y4-Q%$_'I0.Z9%"*_%P<7?_F3
M?C+X6U^R2,PD,8O$;!)S2,PE,8_$?!(+2"R$L$[,1\\Q'ZGTBS K"NTVSQ::
M,S*T:_E%7!19_B@#7@I-1'GR*'?0IV)Q5Z6Y+[]*?]_\DIA)8A:)V23FD)B[
MPDYJK'K7=W\QU(>#@=R>W;],YN9B:TOXY%H%)!9"6"=NX^>XC95QNY)[FKG<
M,FI)'-W$B=PG%\6AELIWZ-FM?).0Y]7F\R[+7PN;4M\W;"1FDIA%8O9XX[FJ
MGYV<G&\\J1UR5G>%C;?.ZI&S^B06[/J+"Z%9.XDZ>4[4B3)17\6]2)>B+RS*
M@?N&A<1,$K-(S#[9>-JNI^1DVTN_N]7P-I<P!H/-)Y9/WK6 Q$((ZSSE3Y^?
M\J?*IWRUI^:E]Z(HZ_=C?4]]);#O4Y_$3!*S2,PF,8?$7!+S2,PGL8#$0@CK
M!/3L.:!G[^/8R1D9<Q(S2<PB,9O$'!)S2<PC,9_$ A(+(:P3\_/GF)\KM\/?
MYI%$M2)+IMIW<:H5]?=]IU ^*Z%]@WJ^^=9B,#P[,4Y'W=TGDYS5(C&;Q!P2
M<TG,(S&?Q (2"R&L$T)]T)[U'*AC&"6B.GQ2E-GDIT/M+H\G0KL3^2J/=3*7
MQ;2]I3^AZDGVC6BCG;Y\AW,TTM?RB<YIH9J-:@ZJN:CFH9J/:@&JA936#>J+
M>H*^3U G<@\WGHJFKI"+B9#[PE--?EVV^\"'VBS/BM[WN.K9]DZLOG%<PQ@/
MZO_64TO.:Z&:C6H.JKFHYJ&:CVH!JH64UDVMT:;6P%/;&U?E-'O'U=C<"6[R
MNAY7<EX+U6Q4<U#-134/U7Q4"U MI+1N7-O:CJZL"UQ<3B;9LCK2%*53[39.
MHW02I[,FJ-%-(@ZUZ+:4^\)1DF0/\J="N\UR;9*+:5QJR6O;6K2ETVB[A!?M
MX*":C6H.JKFHYJ&:CVH!JH64U@UO6\;1U6V<ZSR;"#%M&CG50>*FX"ZWOVE6
MBN)%CGMCNMG+T(V^G=@K]8KL>[07U2Q4LU'-0347U3Q4\U$M0+60TKHQ;4L\
MNKK%8\9%O9'5Y%YP?PY7X\]>G@(_&@Q/Q^LI1"LXJ&:AFHUJ#JJYJ.:AFH]J
M :J%E-9-85O\T=7-G[=75_7-+LNP=V.)EG]0S4(U&]4<5'-1S4,U']4"5 LI
MK1O3MJRD;VDK=<I*VO4RG\RC0K1_GU9W(JZR61II:\4)>7L83T3:6?HW;8?^
MDWJ=]GZ_BC:@4,U"-1O5'%1S4<U#-1_5 E0+*:V;_[8+I;^3,I2.MJ%0S40U
M"]5L5'-0S44U#]5\5 M0+:2T;N;;8I2^I1D%G^E%ZU/Z9G_JM3.]:($*U6Q4
M<U#-134/U7Q4"U MI+3N50O:(I6A+E+]/J>.U)/N&]Y&V^'4$3JOA6HVJCFH
MYJ*:AVH^J@6H%E):-[QMN<I0EZO>>NK(V.P_O7+J2+TB^^X9HYJ%:C:J.:CF
MHIJ':CZJ!:@64EHWIFV;RE"WJ;:>.FK&;SUUI)YG[Q2B)2E4LU'-0347U3Q4
M\U$M0+60TKHI;$M2AKHD]?931\T$6T\=J5=D[YBB=2A4LU'-0347U3Q4\U$M
M0+60TKHQ;>M0AKH.U3UT'+4'ANM#2J5\<UH=).X<7>K-*MD]N6JT\4;R-]^!
MHJTH5+-1S4$U%]4\5/-1+4"UD-*Z:6U;4<:V:QL]I77'K*Z._MZ*7&YJY5)1
M,>]-+WK-(V/SNCROI1=M4Z&:C6H.JKFHYJ&:CVH!JH64UDUOVZ8RU&VJMUZ9
M3,WO'5.T<85J%JK9QN:UD/2STYX7) >=U]UY7@^=UT>U -5"2NM&L&U*&>JF
MU/.Q(;EIK [9;CMBBW:<4,U$-0O5;%1S4,UMM)>I/.G-)-I>0K4 U4)*ZV:R
M;2\9RJ;$VC7U\]7%!JM@9K,T_K7W>O.?U>3>P42+2*AFH9K=:*J+#Z(3NMLG
M]- )?50+4"VDM&[0VLJ0H:X,*:[CJ1ZY=YY(S40U"]5L8[/HM)$GM/>S?4(/
MG=!'M0#50DKK?GI#6^89JLL\7Y_W'>7;N-LHSK7[*)&;KJG<R4RR8IGW1DV-
M[ALU5#-1S4(U>]A32]+/^][%H?.Z.\_KH?/ZJ!:@6DAIW>"U19RANHCSN_^]
MB[SE*HF*0KN4XQ<+N5OZK:K9]L89O402JIFH9J&:C6H.JKFHYJ&:CVH!JH64
MUGU9:(L_PU6EX?_^9S!#]#I+J&:BFH5J-JHYJ.:BFH=J/JH%J!926C?S+SY"
M35TS:C;/S5_!U/O?O8EE/P)MLYDT[CNN;Z+36JAFHYJ#:BZJ>:CFHUJ :B&E
M=</8EHF&ZC)1?;7NYNK &]<$[KTDL!K<.Y<K[>4E@0='X_%Z*-'.$*K9J.:@
MFHMJ'JKYJ!:@6DAIW5"VG:&ANC/$OUFNE^U-,]HC0C43U2Q4LU'-0347U3Q4
M\U$M0+60TKJI;[M&PY-W\EX8+26AFHEJ%JK9J.:@FHMJ'JKYJ!:@6DAIW<RW
MY::ANMST-7N,DJI4V/E[<KD#'F>])0HUMW=TU2NG#[1'$>5]?[]NHBMBH9J-
M:@ZJN:CFH9J/:@&JA936S6E;>!KN7'A:WS;_IOGF5[LWK&CC"=5,5+-0S48U
M!]5<5/-0S4>U -5"2NOFM^U1#<_?R;XUVLI"-1/5+%2S4<U!-1?5/%3S42U
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MG?6.S4Q+SO(J"31()@HT9E$M8*HW3%"1,<K)%!?KG+Y=S;3+^GM;'I6 7KL
M^X^_U"7-8.B5]EUJ#5[Z\D4W#MZVI?./R/:RBIJLHF/LZ6BE%/HEI53;.++M
M1\9_?V1M&53$L2.V36J==B\2?[WK[&C)GMY>H[=W7&^+N X1V&:M\GTS;:(K
M]OZNHD$<OWFB^[FJ/>G]1GK_OTKO_QGF(![$3Z0_5U5)]W<ZE;TE/E*U8$(3
M#G/$!><72*.JSEM-C"Q=\YI)@ZW0#9=X68&R!;@_E])L)[8?-M=?^@M02P,$
M%     @ S(-I5]47Y6EN P  =PH  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&ULK59=;^,V$/PK"_50), EDN7$<5/;@.VT:(#F&IR1WD/1!UI:RT0D
M4D=2=MQ??TM24914%MJT+S:_9CDS7(H[V4OUJ+>(!IZ*7.AIL#6FO Y#G6RQ
M8/I<EBAH9B-5P0QU51;J4B%+':C(PSB*1F'!N AF$S=VKV8369F<"[Q7H*NB
M8.JPP%SNI\$@>![XS+.ML0/A;%*R#%=H'LI[1;VPB9+R H7F4H#"S328#ZZ7
M8[O>+?B=XUZWVF"5K*5\M)W;=!I$EA#FF!@;@='?#I>8YS80T?A:QPR:+2VP
MW7Z._K/33EK63.-2YE]X:K;38!Q BAM6Y>:SW/^"M9Y+&R^1N7:_L*_71@$D
ME3:RJ,'$H.#"_[.GVH<6(+X\ HAK0/P&,+@X AC6@*$3ZIDY63?,L-E$R3TH
MNYJBV8;SQJ%)#1?V%%=&T2PGG)FMMDSAV8*,2&$I"TH.S9R_9S!/4VZ;+(=;
MX?/%3IS<H&$\/Z45*R.31_BMK $/JQLX^7 *'R $;>-JX (>!#?Z(PU2^X[G
M.:W5D] 0=\L@3&J>"\\S/L+S![B3PFPU_"123%_C0]+<"(^?A2_BWH K+,]A
M&'V$.(J''7R6_QP>]] 9-N<P=/&&O>>P_OLYS)5B(D.Z. ;6!VBONV<'-SS?
M,Y7"'[]22+@U6.@_N_SU^U]T[V\_%M>Z9 E. _H::%0[#&;??S<813]VF?,_
M!7MEU45CU45?]-DG*<Z^5BSG&TXF:)>#TN<@LTYHV*$V7&10HN(R[3*C?X<A
M')"IKBQ=]@+?*?RR$7[Y'X7C4\F5SQN#JNA2WK_%(#HNO1?Y3NFC1OJHE]>#
M4)C(3/"_2'G2OA^)U(:>DYP9FC$2!)EDS]\ZU+HKKS#LY4YU?HH\ET'DR-AW
M<#<;G(\GX:YM1R_A=]IQU=AQU6O'%_<ZD2RV0T6/;9WI5G_C$U1MSXYZ8?WK
M\J"?0.S3!&(H_&=Y$$/*#IUYTQOIG4:-&Z/&_\ZHC$[>$%6#L&%<P8[E%8+<
MU!=)^P4$.*'GJM*I==:;=]KEDM_]JI4HT?G5Z$VF="T:O:23%Q:VWO "5>9*
M&TW'4PGC7[5FM*F>YJYH>#.^H*K*%T$O87Q)=L=4QDEBCAL*243I1BM?YOB.
MD:6K%-;24-WAFENJ#%'9!32_D=(\=^P&3:TY^P902P,$%     @ S(-I5TQG
M/?#: P  !@X  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULM9=MCYLX
M$,>_BL6=JE;:#9B$AVR32,EV>]<7[:T:]?K:@4F"%C!G.\FN=!_^QH9 MB$T
MJ+I]L6#"S/QF;,\?3PY</,DM@"+/69K+J;55JKBS;1EM(6-RP O(\9<U%QE3
M.!0;6Q8"6&R,LM1V'<>W,Y;DUFQBGCV*V83O5)KD\"B(W&49$R\+2/EA:E'K
M^.!KLMDJ_<">30JV@26H;\6CP)%=>XF3#'*9\)P(6$^M.;U;T% ;F#?^3N @
M3^Z)3F7%^9,>?(JGEJ.)((5(:1<,+WNXAS35GI#CG\JI5<?4AJ?W1^\?3?*8
MS(I)N.?I]R16VZD56B2&-=NEZBL__ E50I[V%_%4FO_D4+WK6"3:2<6SRA@)
MLB0OK^RY*L2)P="]8.!6!J[A+@,9R@],L=E$\ ,1^FWTIF],JL8:X9)<S\I2
M"?PU03LU6VZ9@-L%YA63>Y[A9$MFRG5+EN5$$;XF2\6C)S(_,!&3N:YCHEX(
M+@FBMD >020\)F\_@&))^FYB*^32WNVH8EB4#.X%AC'YS'.UE>0ACR%^;6]C
M/G52[C&IA=OI< G%@ R=&^(Z[I#\3FPB=9JRNG1$&-9E&YH(PPL1ONRR%0A3
MFA:7)6/I8=3N0>^V.UFP"*86;B<)8@_6[,UOU'?>=_"-:KY1E_>9F2I)<!M*
MQ?(XR3<W9 &;),_Q%I=QRO((R-LDKTKRCOS;6IPRDS*69V+I;;Z?A2,:>@&=
MV/L62*^&]#HA_Q L5[CNKL7PSC H#?S0#]LQ_!K#[\3 W;V&I ^(?P9RZSGX
MU\X1U!Q![SE[,-?>$Q:< 8Z]D3<:CML)PYHP["3\J]"M01)X!A$EDJW2ZY'"
M,R3/H:$3N.U(XQIIW!?IAAQ,+\8)97L0J"TH'UJ@="4C[#0"I6#'4J) 9&VH
MW1%]\@),2!*0K.Q:/HG92U=3H4[3C)VKLMF#-/AYC(D5*& X4-P\OKK@5:A7
MNY:&X6@T:J\X/9$,^JN4OSP'/T$(JDGPJTGHJK[;Y.5V-O7O1^1YA?Q0+BJ4
M.)%$T(KI_@]-GC8J1#M%I$>;W\F8%*A89KWHA=.H8FM>9=S@9/&X QI<6#F-
M*M%N63KM^'V)2L^4GB Y@_ 24J-!M%N$7G?_OE#>.10=N!?:+&T4B79+TI52
MT)?6/Z=U!\X%%:>-;M%NX;HD"WWQ@G.\X<"YU*X:T:+7J=;/FFI?W+!EB[@_
M%M,^^33/0&S, 41B"]SEJOQ*KY_6AYQY^6G?O%Z>D#XS@3M;DA36:.H, EQ\
MHCQTE /%"_.AO^(*CPWF=HL'-1#Z!?Q]S;DZ#G2 ^N@W^P]02P,$%     @
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MZ&PB^($(/1O9]$6A?H%&O5*F7Y07)?!IBC@U^PU094ENR4.2I-HZFI%/S+R
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MLO+YA[K 4Y9_63V<Z_\!4$L#!!0    ( ,R#:5=[F39B.0<  /$]   9
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ML.J>J'H1=*TO0A94")KKQX1@N2=3 /E]2:G8O:@*FMNZ\7]02P,$%     @
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M*]T$UH^Y[M-!& .]ON-:\'9@-K"=?_(?4$L#!!0    ( ,R#:5<>O6IO] 8
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M7PE9G\ADD;]5\9A(F43YX1SH!'@6H.Y/DT2^GF0O:I0OY@R_ U!+ P04
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ S(-I5YE<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #,@VE7OG M#V8&  "U)   &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ S(-I5^I(X@\A!@
M!AT  !@              ("!J X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( ,R#:5<][:5I)0,  "P/   8              " @?\4
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #,@VE71N?W
M!'H&  #5(P  &               @(%:&   >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ S(-I5T[5585[#P  F-$  !@
M ("!"A\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,R#
M:5???)9-3@<  &(B   8              " @;LN  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #,@VE7!/><#E,,  "9(   &
M        @($_-@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ S(-I5[ HWUEF$   JC   !@              ("!R$(  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,R#:5?LK$;A/A<  -I.   8
M              " @613  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #,@VE77X%7/^8$  "T"P  &0              @('8:@  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,R#:5>#=>4MF 4
M +$.   9              " @?5O  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ S(-I5_,/YJ"%!0  PPP  !D              ("!
MQ'4  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #,@VE7
MNVYIC0$%  #$"P  &0              @(& >P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,R#:5<<F3$G204  )\-   9
M      " @;B   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ S(-I5XM\-.\##   :"(  !D              ("!.(8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #,@VE7? 8 (A\+   6'P
M&0              @(%RD@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ,R#:5<A->V"@P0  )H*   9              " @<B=  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ S(-I5ZL$DT<-
M!0  :PP  !D              ("!@J(  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #,@VE77+TJ,[L'  !_%P  &0
M@('&IP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,R#
M:5?Z18R5; ,  ,<'   9              " @;BO  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ S(-I5ZD2=X1[ @  N <  !D
M         ("!6[,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #,@VE72#5%?D,"  "*!@  &0              @($-M@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,R#:5<OI9U*L \  !4P
M   9              " @8>X  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ S(-I5[M7-%*[ @  5P8  !D              ("!;L@
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #,@VE7"@$Y
M2^0#  !5"0  &0              @(%@RP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ,R#:5?@V1K0UP(  %\&   9
M  " @7O/  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MS(-I5SY \7VW @  !08  !D              ("!B=(  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #,@VE76%B0RRL#  !@!P  &0
M            @(%WU0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ,R#:5=AY0D+S00   (,   9              " @=G8  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ S(-I5Y9P@$LX!0
M<P\  !D              ("!W=T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #,@VE7G 06J@4%   =&@  &0              @(%,
MXP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,R#:5?8
MUSN9"0,  * ,   9              " @8CH  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ S(-I5]]*FF5_#P  4MP  !D
M     ("!R.L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,R#:5<"K=E?.@0  $L7   9              "
M@?,) 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ S(-I
M5U7YT"(= P  M0L  !D              ("!9 X! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " #,@VE7L!'6@(T#  !*$@  &0
M        @(&X$0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( ,R#:5=YE(<OPP,  !L0   9              " @7P5 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ S(-I5ZE2N:05 P  -@L
M !D              ("!=AD! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " #,@VE7U&[)X:@#  #<#@  &0              @('"' $
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,R#:5?%!1OZ
MA ,  /(*   9              " @:$@ 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ S(-I5V)\!7=T#P  G_4  !D
M ("!7"0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #,
M@VE7>YDV8CD'  #Q/0  &0              @($'- $ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,R#:5=^K@-G! ,  % ,   9
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M970U,2YX;6Q02P$"% ,4    " #,@VE7R&14L!H"  #*!   &0
M    @(&44P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M ,R#:5<#6!!(2 ,  *P4   -              "  >55 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ S(-I5Y>*NQS     $P(   L              ( !
M6%D! %]R96QS+RYR96QS4$L! A0#%     @ S(-I5[O(1MYL!   M2(   \
M             ( !05H! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,R#
M:5>*,79?SP$  #,?   :              "  =I> 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,R#:5<RX8'AQP$  !(?   3
M          "  >%@ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     \ #P
*6Q   -EB 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows - Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern</Role>
      <ShortName>Description of Business, Basis of Presentation and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Redeemable Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest</Role>
      <ShortName>Redeemable Noncontrolling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/CollaborationAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Redeemable Noncontrolling Interest (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables</Role>
      <ShortName>Redeemable Noncontrolling Interest (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/NetLossperShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail</Role>
      <ShortName>Description of Business, Basis of Presentation and Going Concern (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails</Role>
      <ShortName>Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail</Role>
      <ShortName>Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail</Role>
      <ShortName>Redeemable Noncontrolling Interest - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail</Role>
      <ShortName>Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Related-Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail</Role>
      <ShortName>Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail</Role>
      <ShortName>Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vtvt-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vtvtherapeutics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vtvtherapeutics.com/role/SubsequentEvents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vtvt-20230930.htm">vtvt-20230930.htm</File>
    <File>vtvt-20230930.xsd</File>
    <File>vtvt-20230930_cal.xml</File>
    <File>vtvt-20230930_def.xml</File>
    <File>vtvt-20230930_lab.xml</File>
    <File>vtvt-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtvt-20230930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="574">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vtvt-20230930.htm": {
   "nsprefix": "vtvt",
   "nsuri": "http://vtvtherapeutics.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "vtvt-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "vtvt-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vtvt-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtvt-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vtvt-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtvt-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 197,
   "keyCustom": 40,
   "axisStandard": 26,
   "axisCustom": 1,
   "memberStandard": 28,
   "memberCustom": 32,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://vtvtherapeutics.com/20230930": 1
   },
   "contextCount": 219,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 511,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 574,
    "http://xbrl.sec.gov/dei/2023": 31,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://vtvtherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited",
     "shortName": "Condensed Consolidated Statements of Operations - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
     "longName": "0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited",
     "shortName": "Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern",
     "longName": "0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern",
     "shortName": "Description of Business, Basis of Presentation and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreements",
     "longName": "0000009 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation",
     "longName": "0000010 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://vtvtherapeutics.com/role/Investments",
     "longName": "0000011 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://vtvtherapeutics.com/role/Leases",
     "longName": "0000013 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest",
     "longName": "0000014 - Disclosure - Redeemable Noncontrolling Interest",
     "shortName": "Redeemable Noncontrolling Interest",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://vtvtherapeutics.com/role/StockholdersDeficit",
     "longName": "0000015 - Disclosure - Stockholders' Deficit",
     "shortName": "Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions",
     "longName": "0000016 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://vtvtherapeutics.com/role/IncomeTaxes",
     "longName": "0000017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShare",
     "longName": "0000018 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments",
     "longName": "0000019 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://vtvtherapeutics.com/role/SubsequentEvents",
     "longName": "0000020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsTables",
     "longName": "9954472 - Disclosure - Collaboration Agreements (Tables)",
     "shortName": "Collaboration Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables",
     "longName": "9954473 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://vtvtherapeutics.com/role/InvestmentsTables",
     "longName": "9954474 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://vtvtherapeutics.com/role/LeasesTables",
     "longName": "9954475 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables",
     "longName": "9954476 - Disclosure - Redeemable Noncontrolling Interest (Tables)",
     "shortName": "Redeemable Noncontrolling Interest (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShareTables",
     "longName": "9954477 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables",
     "longName": "9954478 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
     "longName": "9954479 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)",
     "shortName": "Description of Business, Basis of Presentation and Going Concern (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-84",
      "name": "vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
     "longName": "9954481 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "vtvt:SaleOfStockConsiderationReceivedOnTransactionGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails",
     "longName": "9954482 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)",
     "shortName": "Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "longName": "9954483 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-113",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-113",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail",
     "longName": "9954484 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)",
     "shortName": "Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail",
     "longName": "9954485 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)",
     "shortName": "Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
     "longName": "9954486 - Disclosure - Investments - Additional Information (Detail)",
     "shortName": "Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
     "longName": "9954487 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)",
     "shortName": "Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "longName": "9954488 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-134",
      "name": "vtvt:PotentialMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "vtvt:PotentialMilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954489 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail",
     "longName": "9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
     "longName": "9954491 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)",
     "shortName": "Redeemable Noncontrolling Interest - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail",
     "longName": "9954492 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)",
     "shortName": "Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail",
     "longName": "9954493 - Disclosure - Stockholders' Deficit - Additional Information (Detail)",
     "shortName": "Stockholders' Deficit - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-147",
      "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-147",
      "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "9954494 - Disclosure - Related-Party Transactions - Additional Information (Detail)",
     "shortName": "Related-Party Transactions - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "vtvt:OwnershipPercentageOfMajorityOwner",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "9954495 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-177",
      "name": "vtvt:PercentageOfAmountOfCashSavings",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
     "longName": "9954496 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)",
     "shortName": "Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
     "longName": "9954497 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail",
     "longName": "9954498 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)",
     "shortName": "Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-198",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-198",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
     "longName": "9954499 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)",
     "shortName": "Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://vtvtherapeutics.com/role/SubsequentEventsDetails",
     "longName": "9954500 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtvt-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warranty liability, related party",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r136",
      "r137",
      "r153",
      "r176",
      "r177",
      "r184",
      "r186",
      "r192",
      "r193",
      "r250",
      "r269",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r282",
      "r283",
      "r286",
      "r289",
      "r296",
      "r408",
      "r515",
      "r516",
      "r517",
      "r518",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r549",
      "r570",
      "r594",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r742",
      "r759",
      "r766"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PercentageOfNonVotingEconomicInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PercentageOfNonVotingEconomicInterest",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC",
        "verboseLabel": "Noncontrolling interest ownership percentage",
        "label": "Percentage Of Non Voting Economic Interest",
        "documentation": "Percentage of non voting economic interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified stock option awards expiration term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased during period",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r99",
      "r525",
      "r594",
      "r617",
      "r664"
     ]
    },
    "vtvt_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "vtvt_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Customer",
        "label": "One Customer [Member]",
        "documentation": "One Customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r623",
      "r795",
      "r797",
      "r800"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r792"
     ]
    },
    "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Redeemable Non controlling Interest To Class A Common Stock",
        "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]",
        "documentation": "Exchange of redeemable non controlling interest to class A common stock."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]",
        "documentation": "Fair value of assets and liabilities measured on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r278",
      "r284",
      "r431",
      "r629",
      "r630"
     ]
    },
    "vtvt_NovoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "NovoLicenseAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novo License Agreement",
        "label": "Novo License Agreement [Member]",
        "documentation": "Novo license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_LicenseFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LicenseFeeReceived",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fee Received",
        "label": "License Fee Received",
        "documentation": "License Fee Received"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, contingent consideration",
        "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value",
        "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r122",
      "r170",
      "r171",
      "r199",
      "r366",
      "r373",
      "r497"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "vtvt_NotesReceivableDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "NotesReceivableDiscountRate",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Notes Receivable, Discount Rate",
        "documentation": "Notes Receivable, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r186"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ReneoPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "ReneoPharmaceuticalsIncMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reneo",
        "label": "Reneo Pharmaceuticals Inc [Member]",
        "documentation": "Reneo Pharmaceuticals Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r650"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment without readily determinable fair values assessed under the measurement alternative:",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "vtvt_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At the market offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Class A common stock and warrants, net of offering costs",
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r324"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "vtvt_CognaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CognaMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cogna",
        "label": "Cogna [Member]",
        "documentation": "Cogna"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, Beginning balance (in shares)",
        "periodEndLabel": "Awards outstanding, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r758"
     ]
    },
    "vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances",
        "label": "Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent",
        "documentation": "Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r130",
      "r153",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r380",
      "r383",
      "r384",
      "r408",
      "r651",
      "r777",
      "r793",
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Awards outstanding, Beginning balance (in usd per share)",
        "periodEndLabel": "Awards outstanding, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "vtvt_LicenseAgreementObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LicenseAgreementObligationsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement Obligations",
        "label": "License Agreement Obligations [Axis]",
        "documentation": "License agreement obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r439",
      "r440",
      "r441",
      "r637",
      "r638",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue recognized",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r784"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining available stock value",
        "label": "Remaining Availability Stock Issued During Period Value New Issues",
        "documentation": "Remaining availability under our controlled equity offering sales agreement"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement",
        "label": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]",
        "documentation": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r117",
      "r124"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestChangeInRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in redemption value of noncontrolling interest",
        "negatedTerseLabel": "Change in redemption value of noncontrolling interest",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r42",
      "r43",
      "r50"
     ]
    },
    "vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed",
        "label": "Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block]",
        "documentation": "Tabular disclosure of investment in equity security with and without readily determinable fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of days used to determine exchange value based on weighted average price of Class A common stock",
        "label": "Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock",
        "documentation": "Period used to determine exchange value based on weighted average price of Class A common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Receivable for Common Stock",
        "label": "Receivables from Stockholder [Member]",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock conversion ratio",
        "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio",
        "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r365",
      "r367",
      "r368",
      "r369",
      "r372",
      "r374",
      "r375",
      "r376",
      "r520"
     ]
    },
    "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Information",
        "label": "Unaudited Interim Financial Information Policy [Policy Text Block]",
        "documentation": "Unaudited interim financial information policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Technology Transfer Services of Chemistry and Manufacturing Know-How",
        "label": "License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member]",
        "documentation": "License and technology transfer services of chemistry and manufacturing know-how."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Deficit",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r152",
      "r281",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r298",
      "r392",
      "r597",
      "r599",
      "r619"
     ]
    },
    "vtvt_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash interest income",
        "label": "Interest Income, Operating",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r571",
      "r612",
      "r613",
      "r662",
      "r663",
      "r808"
     ]
    },
    "vtvt_TemporaryEquityChangeInRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "TemporaryEquityChangeInRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in redemption value of noncontrolling interest",
        "label": "Temporary Equity, Change In Redemption Value",
        "documentation": "Temporary Equity, Change In Redemption Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r153",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r380",
      "r383",
      "r384",
      "r408",
      "r547",
      "r632",
      "r665",
      "r777",
      "r793",
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r119"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales / Repurchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales",
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases / Issuance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r398",
      "r441",
      "r637",
      "r638",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants, term",
        "terseLabel": "Expected life of options in years",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r683",
      "r693",
      "r718"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r763",
      "r764",
      "r785",
      "r804",
      "r806"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, redeemable noncontrolling interest and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r105",
      "r488",
      "r651",
      "r760",
      "r772",
      "r789"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Deficit",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalent",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r131",
      "r626"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r685",
      "r695",
      "r720"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Compensation Expense Related to Grants of Stock Options",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to vTv Therapeutics Inc.",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r91",
      "r108",
      "r128",
      "r139",
      "r140",
      "r143",
      "r153",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r171",
      "r182",
      "r194",
      "r201",
      "r205",
      "r207",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r395",
      "r408",
      "r493",
      "r569",
      "r592",
      "r593",
      "r633",
      "r663",
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to vTv Therapeutics Inc. common shareholders",
        "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r174",
      "r183",
      "r186",
      "r194",
      "r201",
      "r205",
      "r207",
      "r633"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from G42 Promissory Note early redemption",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r37",
      "r38"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r682",
      "r692",
      "r717"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r321",
      "r466",
      "r504",
      "r539",
      "r540",
      "r602",
      "r606",
      "r607",
      "r608",
      "r610",
      "r622",
      "r623",
      "r635",
      "r639",
      "r645",
      "r653",
      "r779",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner",
        "label": "Proceeds from Repayment of Loans to Purchase Common Stock",
        "documentation": "Cash inflow from repayment of loans for purchasing common stock."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r313",
      "r321",
      "r349",
      "r350",
      "r351",
      "r442",
      "r466",
      "r504",
      "r539",
      "r540",
      "r602",
      "r606",
      "r607",
      "r608",
      "r610",
      "r622",
      "r623",
      "r635",
      "r639",
      "r645",
      "r653",
      "r656",
      "r773",
      "r779",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r361"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r133",
      "r153",
      "r194",
      "r202",
      "r206",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r379",
      "r383",
      "r408",
      "r484",
      "r561",
      "r651",
      "r665",
      "r777",
      "r778",
      "r793"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r321",
      "r466",
      "r504",
      "r539",
      "r540",
      "r602",
      "r606",
      "r607",
      "r608",
      "r610",
      "r622",
      "r623",
      "r635",
      "r639",
      "r645",
      "r653",
      "r779",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r313",
      "r321",
      "r349",
      "r350",
      "r351",
      "r442",
      "r466",
      "r504",
      "r539",
      "r540",
      "r602",
      "r606",
      "r607",
      "r608",
      "r610",
      "r622",
      "r623",
      "r635",
      "r639",
      "r645",
      "r653",
      "r656",
      "r773",
      "r779",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Class A common stock to collaboration partner, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r525",
      "r763",
      "r764",
      "r765",
      "r785",
      "r806"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption amount of noncontrolling interest",
        "label": "Redeemable Noncontrolling Interest Temporary Equity Redemption Value",
        "documentation": "Redeemable noncontrolling interest temporary equity redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r251",
      "r252",
      "r358",
      "r359",
      "r360",
      "r370",
      "r371",
      "r385",
      "r387",
      "r388",
      "r390",
      "r393",
      "r505",
      "r507",
      "r525",
      "r806"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r36"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r298",
      "r763",
      "r764",
      "r765",
      "r806"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_ProceedsFromInterestAndDividendsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromInterestAndDividendsReceived",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest received",
        "label": "Proceeds from Interest and Dividends Received",
        "documentation": "Cash received for dividends and interest on the entity's equity and debt investments during the current period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r149"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r658",
      "r659",
      "r660",
      "r661",
      "r804",
      "r806"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r434"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r434"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r434"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r109",
      "r144",
      "r198",
      "r416",
      "r579",
      "r663",
      "r805"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r127",
      "r141",
      "r142",
      "r143",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r191",
      "r251",
      "r252",
      "r298",
      "r358",
      "r359",
      "r360",
      "r370",
      "r371",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r424",
      "r505",
      "r506",
      "r507",
      "r525",
      "r594"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "vtvt_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Noncontrolling Interest",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PhaseTwoMultiRegionalClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PhaseTwoMultiRegionalClinicalTrialMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 2 MRCT",
        "label": "Phase Two Multi Regional Clinical Trial [Member]",
        "documentation": "Phase two multi-regional clinical trial."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "vtvt_CinRxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CinRxMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CinRx",
        "label": "CinRx [Member]",
        "documentation": "CinRx"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IncreaseInCommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "IncreaseInCommonStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in shares authorized (in shares)",
        "label": "Increase In Common Stock Shares Authorized",
        "documentation": "Increase in common stock shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r58",
      "r59",
      "r84"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair value",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r407",
      "r627"
     ]
    },
    "vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "MaximumFundingPercentageOfResearchAndDevelopmentMilestones",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding percentage of research and development milestones",
        "label": "Maximum Funding Percentage Of Research And Development Milestones",
        "documentation": "Maximum funding percentage of research and development milestones."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "vtvt_WarrantyLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "WarrantyLiability",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, related party",
        "label": "Warranty Liability",
        "documentation": "Warranty Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r97",
      "r98",
      "r99",
      "r135",
      "r136",
      "r137",
      "r192",
      "r282",
      "r283",
      "r284",
      "r286",
      "r289",
      "r294",
      "r296",
      "r515",
      "r516",
      "r517",
      "r518",
      "r639",
      "r742",
      "r759"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r192",
      "r282",
      "r283",
      "r284",
      "r286",
      "r289",
      "r294",
      "r296",
      "r515",
      "r516",
      "r517",
      "r518",
      "r639",
      "r742",
      "r759"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r326",
      "r354",
      "r355",
      "r357",
      "r646"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r641",
      "r781",
      "r802",
      "r803"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Table]",
        "label": "Equity Securities without Readily Determinable Fair Value [Table]",
        "documentation": "Disclosure of information about investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "vtvt_CinRxWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CinRxWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CinRx Warrants",
        "label": "CinRx Warrants [Member]",
        "documentation": "CinRx Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Line Items]",
        "label": "Equity Securities without Readily Determinable Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r197"
     ]
    },
    "vtvt_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "vtvt_MasterServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "MasterServiceAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master Service Agreement",
        "label": "Master Service Agreement [Member]",
        "documentation": "Master Service Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "vtvt_StockIssuedDuringPeriodValuePurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "StockIssuedDuringPeriodValuePurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock under CinRx purchase agreement, net of offering costs",
        "label": "Stock Issued During Period, Value, Purchase Agreement",
        "documentation": "Stock Issued During Period, Value, Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "vtvt_DueToRelatedPartiesMonthlyAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "DueToRelatedPartiesMonthlyAmount",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties, monthly amount",
        "label": "Due To Related Parties, Monthly Amount",
        "documentation": "Due To Related Parties, Monthly Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r136",
      "r137",
      "r153",
      "r176",
      "r177",
      "r184",
      "r186",
      "r192",
      "r193",
      "r250",
      "r269",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r282",
      "r283",
      "r286",
      "r289",
      "r296",
      "r408",
      "r515",
      "r516",
      "r517",
      "r518",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r549",
      "r570",
      "r594",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r742",
      "r759",
      "r766"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarizes the Conclusions Reached Regarding Fair Value Measurements",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares held by related party (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r603",
      "r609",
      "r611",
      "r656"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before noncontrolling interest",
        "terseLabel": "Net loss before noncontrolling interest",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r139",
      "r140",
      "r147",
      "r153",
      "r162",
      "r170",
      "r171",
      "r194",
      "r201",
      "r205",
      "r207",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r378",
      "r381",
      "r382",
      "r395",
      "r408",
      "r482",
      "r491",
      "r524",
      "r569",
      "r592",
      "r593",
      "r633",
      "r648",
      "r649",
      "r664",
      "r755",
      "r777"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r724"
     ]
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r101",
      "r102"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r116",
      "r118",
      "r120",
      "r121"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r64",
      "r65",
      "r210",
      "r620"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: net loss attributable to noncontrolling interest",
        "verboseLabel": "Less: Net loss attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r101",
      "r139",
      "r140",
      "r170",
      "r171",
      "r492",
      "r755"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r64",
      "r65",
      "r210",
      "r510",
      "r620"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average incremental borrowing rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r650"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of investments in Anteris Bio, Inc.",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r724"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r724"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable noncontrolling interest",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r724"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r434"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r716",
      "r724"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r176",
      "r184",
      "r185",
      "r186",
      "r190",
      "r394",
      "r395",
      "r481",
      "r495",
      "r631"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r783"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r724"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r314",
      "r319",
      "r398",
      "r439",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 (remaining three months)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities for Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r783"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r435"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r314",
      "r319",
      "r398",
      "r440",
      "r637",
      "r638",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Common Stock",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r486",
      "r651"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Change in fair value included in earnings",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r64",
      "r65",
      "r210",
      "r620"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r64",
      "r65",
      "r210",
      "r620",
      "r744"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants or rights (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r684",
      "r694",
      "r719"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r682",
      "r692",
      "r717"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r186"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails": {
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r311"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails": {
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r311"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r186"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contract liabilities, net of current portion",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r311"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining operating lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r650"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r658",
      "r659",
      "r660",
      "r661"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails",
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r191",
      "r468",
      "r511",
      "r536",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r572",
      "r573",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r657"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Abstract]",
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r187",
      "r188",
      "r189"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, fair value",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Contract Liabilities Related to Company's Collaboration Agreements",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r722"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r690",
      "r700",
      "r725"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r624"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r690",
      "r700",
      "r725"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r691",
      "r701",
      "r726"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r363",
      "r801"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Award Activity for the Period",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r53"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r511",
      "r512",
      "r513",
      "r514",
      "r604",
      "r605"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt issuance",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r64",
      "r65",
      "r210"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r151"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r398",
      "r439",
      "r440",
      "r441",
      "r637",
      "r638",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock to collaboration partner, net of offering cost",
        "verboseLabel": "Stock issued during period",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r99",
      "r525",
      "r594",
      "r615",
      "r664"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r428",
      "r429",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r566",
      "r568",
      "r601",
      "r792"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r400",
      "r401",
      "r404"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r110",
      "r111",
      "r126",
      "r213",
      "r214",
      "r405",
      "r406"
     ]
    },
    "vtvt_CinRxPharmaLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CinRxPharmaLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CinRx Pharma, LLC",
        "label": "CinRx Pharma, LLC [Member]",
        "documentation": "CinRx Pharma, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A Common Stock to Collaboration Partner (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r74",
      "r99",
      "r515",
      "r594",
      "r615"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of investments",
        "terseLabel": "Unrealized gain (loss) on investment",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r201",
      "r205",
      "r207",
      "r633"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r19",
      "r127",
      "r141",
      "r142",
      "r143",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171",
      "r191",
      "r251",
      "r252",
      "r298",
      "r358",
      "r359",
      "r360",
      "r370",
      "r371",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r424",
      "r505",
      "r506",
      "r507",
      "r525",
      "r594"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Income Attributable to Vtv Therapeutics Inc",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]",
        "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r61"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r263",
      "r264",
      "r621",
      "r774"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r278",
      "r284",
      "r431",
      "r628",
      "r630"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r578"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net",
        "documentation": "This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r50",
      "r61"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r578"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80",
      "r107",
      "r194",
      "r201",
      "r205",
      "r207",
      "r482",
      "r490",
      "r633"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r434"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of notes payable",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r69",
      "r485",
      "r548"
     ]
    },
    "vtvt_OperatingLeasesImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "OperatingLeasesImputedInterest",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Operating Leases Imputed Interest",
        "documentation": "Operating leases imputed interest."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonfinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Nonfinancial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inputs utilized in the valuation of warrants",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified stock option awards vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Retained earnings (accumulated deficit)",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r99",
      "r487",
      "r508",
      "r509",
      "r519",
      "r550",
      "r651"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r743"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r153",
      "r250",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r379",
      "r383",
      "r408",
      "r651",
      "r777",
      "r778",
      "r793"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r404"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r210"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r200",
      "r203",
      "r204",
      "r208",
      "r209",
      "r210",
      "r309",
      "r310",
      "r468"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/Cover",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Common Stock",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collection of notes receivable",
        "label": "Proceeds from Collection of Notes Receivable",
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r468",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r625",
      "r640",
      "r652",
      "r745",
      "r775",
      "r776",
      "r781",
      "r802"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per shares)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r549"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r468",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r625",
      "r640",
      "r652",
      "r745",
      "r775",
      "r776",
      "r781",
      "r802"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance, shares (in shares)",
        "periodEndLabel": "Ending balance, shares (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r74",
      "r549",
      "r567",
      "r806",
      "r807"
     ]
    },
    "vtvt_JDRFInternationalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "JDRFInternationalMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JDRF",
        "label": "J D R F International [Member]",
        "documentation": "JDRF international."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r573"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r549"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r428",
      "r429",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r566",
      "r568",
      "r601"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "vtvt_TypeOneDiabetesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "TypeOneDiabetesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type 1 Diabetes",
        "label": "Type One Diabetes [Member]",
        "documentation": "Type 1 diabetes."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_NotesReceivableFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "NotesReceivableFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes receivable recorded at fair value from collaboration partner",
        "verboseLabel": "Notes receivable for common stock from CinRx purchase agreement",
        "label": "Notes Receivable from Collaborators",
        "documentation": "Notes Receivable from Collaborators"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r191",
      "r468",
      "r511",
      "r536",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r572",
      "r573",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r657"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r689",
      "r699",
      "r716",
      "r724",
      "r728",
      "r736"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "vtvt_WarrantLiabilityRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "WarrantLiabilityRelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, related party",
        "label": "Warrant Liability Related Party [Member]",
        "documentation": "Warrant liability, related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "vtvt_VTvLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "VTvLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "vTv Therapeutics LLC",
        "label": "V Tv L L C [Member]",
        "documentation": "vTv LLC."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SatisfactionOfMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "SatisfactionOfMilestonePaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Satisfaction of Milestone Payment",
        "label": "Satisfaction Of Milestone Payment [Member]",
        "documentation": "Satisfaction of milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit attributable to vTv Therapeutics Inc.",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r94",
      "r551",
      "r567",
      "r595",
      "r596",
      "r651",
      "r665",
      "r760",
      "r772",
      "r789",
      "r806"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesPurchaseAgreement",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, Purchase Agreement",
        "documentation": "Issuance of Class A Common Stock under LPC agreement shares.."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r483",
      "r489",
      "r651"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r641",
      "r781",
      "r802",
      "r803"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business, Basis of Presentation and Going Concern",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r92",
      "r93"
     ]
    },
    "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developmental and Regulatory Milestone Payment",
        "label": "Developmental And Regulatory Milestone Payment [Member]",
        "documentation": "Developmental and regulatory milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_LicenseAgreementObligationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LicenseAgreementObligationsDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement Obligations",
        "label": "License Agreement Obligations [Domain]",
        "documentation": "License agreement obligations."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MaximumSponsoringContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "MaximumSponsoringContributionAmount",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contribution amount to clinical trial",
        "label": "Maximum Sponsoring Contribution Amount",
        "documentation": "Maximum sponsoring contribution amount."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CollaborativeArrangementNoteReceivableDiscountPaid",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount on note receivable",
        "label": "Collaborative Arrangement, Note Receivable, Discount Paid",
        "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "vtvt_AnterisBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "AnterisBioIncMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anteris Bio Inc",
        "label": "Anteris Bio Inc [Member]",
        "documentation": "Anteris Bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_TypeTwoDiabetesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "TypeTwoDiabetesMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type 2 Diabetes",
        "label": "Type Two Diabetes [Member]",
        "documentation": "Type 2 diabetes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction",
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r689",
      "r699",
      "r716",
      "r724",
      "r728",
      "r736"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and financing receivable, after allowance for credit loss",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r634"
     ]
    },
    "vtvt_AggregateOfferingPriceOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "AggregateOfferingPriceOfShares",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Aggregate Offering Price Of Shares",
        "documentation": "Aggregate offering price of shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_MFTTPHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "MFTTPHoldingsLLCMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "M&amp;F TTP Holdings LLC",
        "label": "M F T T P Holdings L L C [Member]",
        "documentation": "M&amp;F TTP Holdings LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]",
        "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]",
        "documentation": "Fair value of assets and liabilities measured on recurring basis table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r280",
      "r294",
      "r391",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r494",
      "r636",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "vtvt_MacAndrewsAndForbesIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "MacAndrewsAndForbesIncorporatedMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MacAndrews &amp; Forbes Incorporated",
        "label": "Mac Andrews And Forbes Incorporated [Member]",
        "documentation": "MacAndrews and Forbes Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail",
      "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Type",
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockConsiderationReceivableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "SaleOfStockConsiderationReceivableTerm",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration, receivables, payment term",
        "label": "Sale Of Stock, Consideration, Receivable, Term",
        "documentation": "Sale Of Stock, Consideration, Receivable, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "vtvt_ScheduleOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "ScheduleOfEarningsPerShareLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Earnings Per Share [Line Items]",
        "label": "Schedule Of Earnings Per Share [Line Items]",
        "documentation": "Schedule Of Earnings Per Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "vtvt_CinRxInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CinRxInvestmentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CinRx Investment",
        "label": "CinRx Investment [Member]",
        "documentation": "CinRx Investment"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PotentialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PotentialMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment",
        "label": "Potential Milestone Payment",
        "documentation": "Potential milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r685",
      "r695",
      "r720"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "vtvt_LPCPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LPCPurchaseAgreementMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LPC Purchase Agreement",
        "label": "L P C Purchase Agreement [Member]",
        "documentation": "LPC purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r740"
     ]
    },
    "vtvt_NotesReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "NotesReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G42 Promissory Note receivable",
        "label": "Notes Receivable, Current",
        "documentation": "Notes Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SalesBasedMilestonesPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "SalesBasedMilestonesPaymentMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based Milestones Payment",
        "label": "Sales Based Milestones Payment [Member]",
        "documentation": "Sales-based milestones payment."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ChangeInFairValueOfWarrantsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "ChangeInFairValueOfWarrantsRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrants, related party",
        "label": "Change In Fair Value Of Warrants Related Party",
        "documentation": "Change in fair value of warrants related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r173",
      "r176",
      "r184",
      "r185",
      "r186",
      "r190",
      "r394",
      "r395",
      "r481",
      "r495",
      "r631"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89"
     ]
    },
    "vtvt_LetterAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LetterAgreementWarrantsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter Agreement Warrants",
        "label": "Letter Agreement Warrants [Member]",
        "documentation": "Letter agreement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PercentageOfNonVotingEconomicInterestByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PercentageOfNonVotingEconomicInterestByParent",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC",
        "label": "Percentage Of Non Voting Economic Interest By Parent",
        "documentation": "Percentage of non voting economic interest by parent."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties receivable, period",
        "label": "Collaborative Arrangement, Royalties Receivable, Period",
        "documentation": "Collaborative Arrangement, Royalties Receivable, Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r740"
     ]
    },
    "vtvt_LesseeOperatingLeaseTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, termination period",
        "label": "Lessee, Operating Lease, Termination Period",
        "documentation": "Lessee, Operating Lease, Termination Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total cash and cash equivalents, beginning of period",
        "periodEndLabel": "Total cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r89",
      "r150"
     ]
    },
    "vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r428",
      "r429",
      "r430",
      "r431",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r566",
      "r568",
      "r601"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r740"
     ]
    },
    "vtvt_PercentageOfAmountOfCashSavings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PercentageOfAmountOfCashSavings",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of cash savings percentage",
        "label": "Percentage Of Amount Of Cash Savings",
        "documentation": "Percentage of amount of cash savings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "vtvt_OwnershipPercentageOfMajorityOwner": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "OwnershipPercentageOfMajorityOwner",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage of majority owner",
        "label": "Ownership Percentage Of Majority Owner",
        "documentation": "Ownership percentage of majority owner."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r721"
     ]
    },
    "vtvt_RedeemableNoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "RedeemableNoncontrollingInterestsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Noncontrolling Interest",
        "label": "Redeemable Noncontrolling Interests [Member]",
        "documentation": "Redeemable noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",
        "label": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member]",
        "documentation": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction, gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r574",
      "r575",
      "r578"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r280",
      "r294",
      "r391",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r494",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "vtvt_EquityInvestmentsWithReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "EquityInvestmentsWithReadilyDeterminableFairValue",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment with readily determinable fair value:",
        "label": "Equity Investments With Readily Determinable Fair Value",
        "documentation": "Equity investments with readily determinable fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail",
      "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "verboseLabel": "Common stock options granted under the Plan",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r429",
      "r432",
      "r521",
      "r522",
      "r523",
      "r576",
      "r577",
      "r578",
      "r598",
      "r600"
     ]
    },
    "vtvt_InvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "InvestmentOwnershipPercentage",
     "presentation": [
      "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments, ownership percentage",
        "label": "Investment Ownership Percentage",
        "documentation": "Investment ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_ScheduleOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "ScheduleOfEarningsPerShareTable",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Earnings Per Share [Table]",
        "label": "Schedule Of Earnings Per Share [Table]",
        "documentation": "Schedule Of Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CommonStockAndPreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CommonStockAndPreferredStockSharesAuthorized",
     "presentation": [
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital stock, shares authorized (in shares)",
        "label": "Common Stock And Preferred Stock Shares Authorized",
        "documentation": "Common stock and preferred stock shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_OtherIndicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "OtherIndicationMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Indication",
        "label": "Other Indication [Member]",
        "documentation": "Other indication."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development and regulatory milestone payments",
        "label": "Potential Development And Regulatory Milestone Payments Receivable",
        "documentation": "Potential development and regulatory milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_AdjustmentsToTransactionPriceForPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "AdjustmentsToTransactionPriceForPerformanceObligations",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to transaction price for performance obligations",
        "label": "Adjustments To Transaction Price For Performance Obligations",
        "documentation": "Adjustments to transaction price for performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r578"
     ]
    },
    "us-gaap_ReceivablesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, fair value disclosure",
        "label": "Receivables, Fair Value Disclosure",
        "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r788"
     ]
    },
    "vtvt_CantorFitzgeraldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CantorFitzgeraldMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cantor Fitzgerald",
        "label": "Cantor Fitzgerald [Member]",
        "documentation": "Cantor fitzgerald member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r688",
      "r698",
      "r723"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vtvtherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_G42InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "G42InvestmentsMember",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G42 Investments",
        "label": "G42 Investments [Member]",
        "documentation": "G42 Investments"
       }
      }
     },
     "auth_ref": []
    },
    "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vtvtherapeutics.com/20230930",
     "localname": "CollaborateArrangementContingentConsiderationTransferredCash",
     "crdr": "credit",
     "presentation": [
      "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborate arrangement, contingent consideration transferred, cash",
        "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash",
        "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(3)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "16(c)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001641489-23-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641489-23-000070-xbrl.zip
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ML[?N!DYN4V@$./D!YY$.5AG<A6L%./D#YY&.RAC<1:T%.+D$YS$.V+5$I%^
M,X]9/T:*6DOL/.P(SN_W5TM]T\O8!CG4>8"%F)&B--1<R_*%6W=#(7?[(V>
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M.]R&TV:X,?GU;_!$;/$Q_HY=*U8PY,8%^0O8'4I9D8VSA :W8;8RH*$*:.P
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M=)[Q@ C>C,7G+.);@80G0FQK58Z+]H%\S%S 5B(*PP% BH=<@@%UG!1#T@=
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ME1B_?C>=".ER&004_K.>R/M\J+1OOU.K\0?UO8PH::?68YMYZN=*%!TK*45
M2*"0P!D)5(XI@5TA@4("SUT"CRB ,%HA@4("SUT"U3V+X,8->T7&LSAU61;E
M;WD!T+0'#GT?X994<+HEY\0S]E*"KQIGT!YH0(EO#MA.HP6JSO%&N-4J3@#O
M$+:(27KI6E^G!+V.]4AATX!GS^J=W?,RQ>%?GB&U<1E0)J2T6D^KRP9/5;,$
MI Z^L"P347JMIRAUW>#I*+F U.%72F5BRJCU.G6MRU.?P[.J3O!7ZE),24;'
MD%A#V[6#T&?)PF=6I*!,WS A*DC(Y1Q)MQ42;')7-W2>>IB)X@2']@[+!A56
MY*NW- &JDP;583'5J?6Z]1+ZSPI,\8RI#0YBV:#J(J@ZN[?"YJ]Z"GNW:G#N
M(L9'ZKVE6+FHB[('UW&R)9%(2]$FBPJ\H&?4M599/< KL=<KH%>"@[D[]!2$
M7JM3C0U. 3UNW-#=D8?[)W*]W17MC 7TBGFKNV,/.P=VZJK<J@3VSBNOP_&"
M[?S4^:(8IR$VA>JG+3NJ*PJH38A]XYK>D'X'BA<6(7V5SUJX-B8?BKO$8,(9
M(W#):]@C HU5KJM X!DC\(  ;*WT8 4"SQB!2][K'B'89BVPE>YR?@=G$#R'
ML[5WX8#ZTH<DV/I1LAE?ZY)+SRUKLYC :'D%!NE[Z[G>O.!LN4FA=##;KE5&
M#>"*!A@J"*Q"N-I0J743G)81TZWU=)FGO"<!FO*U4=XJY.5J(U4&2UXWE%UZ
M30A@<0VLI<;;AP$6.\+6[>X2J.$O4[,"?F#L_<VX@^Q K_)98J5=J<5*RHY%
MRN9J@=G0A+RP_595\/CTY>[-(M.);] 44[-+S4^W5+/+\,'C.;PT@Q+(*5W=
M;&BM7!PO.BX7=MYB%*#A&#3JIMRPPJ QP%U3>;)1YQ"YNTF["L5.VYE%Z\I,
MAKQQ7X&.>+PL1GI*V2RH8VL;;6>HBU4OSW#9D$96!"ZXUV$L1VL%7$X(+N6A
M!:/['5&<X:31LB%/L A<NKB7SY-R.8= V<3M2F)D9Q8,VS&Y;Q'L,2U7+RTT
MF?5:$M&+T\3'1MNY$1]*K5=".J? !Y_XV!D>:JVW',P2\#@1>&STI3;B0ZOU
M2LC%%2&K?-S%=$'IF?8]GZ9;C2%Y3SJ3K6B:+8[_[O58Q32/,ZU):[L14&;:
M&.\+XU=\WQ-RZ_H]] E0UG:)/[X)Z3"XG6/==,E2;-=?T[%(D\%_@WMQKH['
MXQD\(9D=\]!W.F@DD'QR2*X@D/&XB%(WU%V.BP@DGQR2\QX7X0G*;79^NMU9
MSH7F#,KG$45-O7]IY'NO=@!\.+-(:KF!U$1^DJ7N%^K2OAT6Z-ZBE=?!3 1-
M>$;2QIC:SD@JKQ.70!+/2-HWD/3R&DH)(/$,I(UAW!5(6D:,4LJ.N(CJ%N+U
M+0U9 9PTLBL"N<<(Y-[['@C%-@?R=57$707PMHZ[[@ \381)!?"V#9/N@#M=
M1#4%\+:/:NZ /(,%(;LB",D#.K[3(+C 2C>Q^TK"T+>?HY \.U0*O5+]V.JN
MY/;CK<*:8;HW<#E#^">OG'"_C@=UZIV.R/XZ6:SE=13VCS7<6JJK<@D%S036
M^,0:-U#KU'IZO6WLXC\(J'$-M;Q>Z/ZQAJ7#ZD:+D_,79Q5*7?1%7Y]>I:<!
M]<F(1C#:0 +6-_>S8L@4*NXH]><]3?Z4-,E6SGA1+6'(M5ZKWC)** )7B5B*
M$#(A9#NO0@H+F8*F6&TM%YX00B:$[/2%[" RIK*ZY.VV*H1,"-D9"ME6"\_"
M4H9MK/2ZKNQR[%+L@!QEO0ED& X!1<& ^'3@.4#\I:Y7FZ@SPS,-&&-Y$;[Q
MY+5*P=F?DEK9;DOHE=A.',RZ8J![##WSMP1S7TA@FX45C[[[.K48%X\<5!62
M*"2QC VS\B71V'TQ*R112")7TS[ =F+Y@M@J8<4K)%%((E?3/L1N:_FBV"YA
M67P842QI'Y:]6]6:1H84L;]MUZ)N>-'HCOC"UV3-/*)^O!26O/Z*!?.50^#&
MR\G"&6%2EYX1(:SFD64[44BM'0(?YZ2F"LZ^PFKJGOJ/B*RETOUSGH.Z4EM=
M$]\%.@3I<[[&.)LH'GFJ>#KK#^N5/9)$.RZ/HUOKR4UY^2A(J6'"8[HFY47C
MA<R?E<RKY4I:2]Y2XK<<QVK=TU*8S"^?PA$R+V3^O&5>*UW6U"VE?LN1K-0^
M&LI\1K,@(?-"YL];YO62)4W?4N*W',<:W6,PF5^N+\"]S)>4 U#96,<_V1_4
MD@B,BKQ0R8V&S]0O/>!1Y !(PO*8+DM<WT5]\J=(5LHOBSL%ZQ?E\J+$IMR\
MC)EYRWAYUV?2&]Q%81 "BX!"!2*8,T+>.M!P$SVS-.K" V[7>AVEKG>T>BNC
M9E!)181*06N%CF<)Z5P-=_6(TKDNS%?F<$N3SBY(IUS7NW)=R;-:$-(II',W
MZ=2."??VNJ!<F0,N1YVT%6$[A70>4CKU(X)]7>BLS.&6IDRT6J^MUEMZMVYD
M]"H^!>ED"_-/+%T=_K7LU]XO\",=\Y#X+[8;'PQ0YR7!I'@:?G^@9T^\L$-X
MF[E>#%04 UA!2\2$U3*,9HQ5AEPOQ'Y(/GSLLI)#+SYQI!'Q0UQTAW![Y)+(
MLG%1#IBSL" J^XV=?B#X<=]VB6O:\#4 4$BQEV@P/2N^2*MD.(8.,QAY@8V(
MN/"I0T+[E7Y^LZUPD(KLS+<2KLO3KY!G& ' =^579IC2.BQ/UG+ F*?,[$\<
M/(J43?6^TM+ZQ% ZLMXV^UVC XZI81IJ6['4?O]?2K>6?FG@IS,8@6@WGGU*
M?FN0/DSP@CAO9!S4/LV3!6B2#$C'^%!Q\OT["D*[/UY-OWY_;_2+QP&JR(O[
M.5R GJ ^W@7#(=R,11KXJ)C_M)F3;9!)=@@&I W[5:#P_/*)]+)0PH?&22C2
MSD3W^KH1:V9Q'!'-GL351,]=S>JYQU2[,5X-B/L"K[1=Z8%:E X9$^<+H4B3
MWKT8BIS-V6-EQMN?I:^T;YMV*#6DGZF6K1JQ/@ %PH$7P3.LH"[1=Y."C9W&
M;6.'Y>.NT^K]\NQ_ZFWQE*FVB@^;30P*\Q> 2@X9!?0B_>6S90<CAXPO;)?-
ME7WI<_+XQ H9RU%S]L+X\E2C-N58JR8!_>3-R>4FN[3@_,375+G9TO65E^6F
MLO+:NL=VFKIL;/74]=<T=?4[#__4*E% C/7P8VTU.[I:D;%VFFJ[*G2MV%@[
M^?1KYH:LH4QB*VL.7\?FZS!!D/8F4\T,T3?/9RNZ$+Q3*@WA_D$@4?!UP#D!
MHTV9R=;DNJ3*JC:W/-^T+[WQ8/S*,!7'#\'M\L6G[/#\;H%!5@).Z=Y[?"0E
M]F]7;K27PJ(3)>&7 Y)0/*3$AVQ0BP5>7"G43A>\;%$VO^AE'Z4+WQQ8+D<O
ME\KC2C ACMKSHRPJ0;3+H1>Y^T%EU4DC\,0)GJI% !@KQKZ)P_3^/;&MANVR
MWZ_("+>ESIDXIAD-(X<%CY-([QE3X\D#-,Q%P?^2295*U]W.1XHOQ"&NB?NN
MH?1?D4NS%]VE5:0[\MF-?#0YL8J)^29=I'2$:JQO6SKURK/+\5__'MGA^(KX
M/F[\QY:K:-F(ML[Z277:RV4C4O;ME8K9N3T%\TFJ5#.UR#-V61Z=3*.V'>5N
M17I5:VUZU4Q-EMUSJ8P-F8Y"RD1E8F%F]VAF6^O-[*P#&YO4+#O90BG.*C0@
MQ%>T&SV6%6L?SHJU:SU5J\M=K=YI"2LFK)BP8@>V8NTRK%@'I7BY6*<07R&^
M0GSW*KZ=XN);,)+3!=DV]+HN0CE"OH5\ES#I0G6 U6[..L"[2WI'!DGOR/6.
MS'T+'"%I0M+*EC0M;S^8$B1-09M:5SN[=,NN4J^I6$(T7D1D??WL76I \1P;
M*J$JO;95@PCXS8F0+/>>CZ]8Z@GN;]B1+"Q?V#&QWNFT^&@07G;%AAS/V-<6
M7V5AS@Y2JI^WJRC (P@$EP27!)<$EP27!)<$E[ARD@_2K[BCE=8V5,"(1QAM
MUY^V,(S*ZS[+6P\OWN,-+'FB\4SB.EG#$74#5AYHJ_A#!AVJ(1/;&< U;#]V
M;M'Q$W %"(X. L$EP27!)<$EP:5*<ZG0LD];GXIS:6&%.5;T],F;'H?%D[ W
M;G(&EKF$S".\FG$('^COD1W8(7VD_JMMTGN8BV<]4--[<=E3_D&<B&8Y]]C0
M7EO>9!2HXQIU0C=4@4N[K>6/KQM:O.F&#6O_M-XF#):N!ZJX4]S)QYT"TN+.
M$[NSU(RP[J:^@WHSHX;R,:U^7,X;JWECTM)PQ$S_*]I8K&'MSI?UMC=5-Q.[
M'!LSRE[#U_#B"2CM^<0?)[4I&!-NW(<)"Q(OI^#>1QOW/M3V<B>2D]A"$VEB
M8CM><$EP27!)<$EP27!)<(FGD.!REMA\2/"'[7H^^+KI&8BR?-[.*I]78.MD
ML+4IW+PO;'7YP]:9%0G=T)XC_WG"S=TSS_5$[&Z4X43'[%YY0M./7V6T*]=Z
MBEQOJZ=3>F8G=/&RWWO\%,B]:;'JR&QV;3?-.%AMM^ZF7NQ"0CDM>"&,OS#^
MZXW_AA+CN:K&==73JGU:9<4@;&L9MO5PU;^[VDG63:VR" G;*FQK*;:UC+KB
M7?VT*K(*Q2 4P]DKABU*-1>,IQEQK=>N(C2'T!P<B8G0'#MF62Z5B=Y;;<MN
M"ZO(*G58WI=6W%+(L)#ALY?AI?VV_8EP.RY/FW$ZK%(2S/;^/[$RH_"O9;_V
M?H$?Z9"'Q'^Q7?;NUKSDX%D\NS].,-%C36HG\S[(8^ [;-@3\L9T M(Z9!30
MB_27S^D)#=MEZ&)?^IP\*Z%YQ@$*-LCX\N<WVPH'%]UN4],[Z) FN1+)B^.K
M2I/YJ@L\CZ^I<K/=::^\+#>5E=?6/;;=["CJ5D]=?TU3=8Z>NIX"LFJ(L98^
MUE:SW=+$6,\: V*L>QNKEN^IF7EY1GOB9Z_)O^.O8_DWSY?" 87_^Y1*0[A_
M$$C4M:BUG)"G%NIAOM$_RI.#P]M#LI)^=GA^M\ @*P&G*X<$@70IQ1N&$G/H
M5QXA+85%)TK"+P<DH7C(23YD@X(N\.)*R<\T>Y<M6^=3>-E'-YO.MF]%I%W2
M0HOPN!),B+-$^%%;E2!:G$F^%U16G30"3YS@J5($N/5"*CU0D]JO+"39A\5.
M0;?J5$DSK=3&3"*6:VO8+OL]*=IVSL0QS6@8.22$5?!7VK=-^YREZ,D#-$BS
M>S-_R:3*@<XK#FW+<NC!2:$NGE?\K\BEV9&1_'M+Y[PY6NGMST(9#$M]<(]P
MW+!3ZRE&O:LL]Q6L:G84W[D3_!TH/,=C#;I\N&,-W5JOW:YK:K<N&\ME!(24
MB2[8PLSNT\SJ&RJ'Y#E\H,HR2O%R\I 07TZ.[IVE%5,.9<5463G)PWE\BX&P
M8L**9<OZME9,/:TC=$)\.4&R$-]-XKNA-.*F#/>^_4ZMQA_4][+$6IM4TQ2B
M+41;B/9A15O;\QE65<:3[[I6;[>%Z1;R+>3[T*?4#G9,3979:76MKLGEG5,3
MDL8)Z(2D;92TI1IL^Y.T5JW7J1OJ\KXG9W)6:G,JC1<)R?8H;FDH.5ZP.I_O
M),N@%Q.1I5)**T0$:'GCFMZ0?@>"PF].A&2Y]WQ\Q648^O9SQ,[6/GFWGNMO
MR#4H+%[M6D^IPS^B#Y7H0R7Z?0@N"2X)+@DN"2X)+@DN"2Z=*I>*+666BC_F
M6<H47HET:CV]KK9.M".N@)&RJ=UR.3#J<@6CDL[45"(JQ)+7&L\DH#C7X8BZ
M 4'*;Q4ERJ!#-61B.P.XANW'SNT\_@$( 8*C@T!P27!)<$EP27!)<$EP:<]<
M*K0X7RJO/K^8NK2P%O"0NF'PY$V+1F"]B!LWJ13!''?FMU_-N.T/]/?(#NR0
M/E+_U3;I/<S%LQZHZ;VX]DRCYJ4EF"+7>IK6V;43LT"=T V"2SOU8M]P%N48
MND'A33><4][.31!$6/]$\OI26NG3C.LI!9BI!6B"=;QT9;L/[](H\LT!,%XB
M+SZEB)*ZY-(0O^OU^_!^]P6^'(1GE@5T<AL<(D>F1"V\X@!P-_, \&OX&L8I
MDBB8U/H:H5#%NC0^"7R?R.!E*H)%SP,K*H;#%4.O&WIW5ZW+,8C/"V59ZX 5
M18K688P9Z0R(+5MM#5"T?*9%P(=K^)R<I1)<$ERJPDZWL53)9F&G>QNE7&P;
M7-'1[@-)^-@&%Q@KV=P;*Y;V!T"64>MUZYJV?"!'J#"NX24,316X5$9\[P!*
MH%7K&76MO7,@C]=4JVY&((_];;L6T.NBH3<SFAL>$SA7 ^*^4,EV)3PC-APQ
M]+PBMS%BY\Z=%H.[-G30./O8^?+YO1G9>@+Z>C[QQTEI7T;Z&_=A0O@D_%U0
MJ-IH6?4N3]%QD4QV?-B*C3G!)<$EP27!)<$EP27!)<&ET^/2?@[D_;!=SX<%
M2EH=I*R%2F?50J5P31X!,!X!EONHWKX UN4*8"6EB/&1&99=_FNV,=:&ON$Y
MPGG)$CZ>T(4&9+>\"!OXY>RWO5*L>"-;_E)Q95*&$T6S>TE68T.UY0-TUE)5
M&8NV9I; JD[-UA+1Q<ONSO'3$O>FQ:HCL]GIC(9VL'XFJE+K=92ZWM'JK8QD
M!B&AAY=08?R%\2_%^&]1CWW9>JNH'PRA&#A0#,*VEF%;]</95NU$>H6=C@@)
MVRIL:RFV=:D5PC:V5:]Z%S*A&(1B.'W%4.QLPN%:-ZA&:6<0A 0+"3YA"2XD
MP"L24TN4VU;<W$C7E\]X"-LO-(?0'/R0I)CMSYLW4H(.:8,.:;7K<FMY_2"L
MOY!A(</;RO!2O;?]R7"GUE-:=:.U7#BD4B+,TG<^L1Y:\*]EO_9^@1_ID(?$
M?[%=]N[VO.B8%-,,RL:$(J>@8$^\P");MKG>_U$1)D\#*A$3"VL3%],=)-<+
M,6''AX]==J+KQ2>.-"(^J]$4PNV12R++#ED];CRW%E?F=AE]"7[<MUWBFC9\
M+0CA U8*K#GA[1I2*>H:6O5^>?8_]58^)IF5C@?H1E[ ZH5=^-0AH?U*/[_9
M5CA(_>*9;R70D:=?(<\PD2A<_969\;8.R]JUC&S-4V;V)PX>I<^F>E]I:7UB
M*!U9;YO]KM'1N[)A&FI;L=1^_U^X\95\:>"G,QB1%]IX]BGYK4'Z,,$+XKR1
M<5#[-$\6H$DR($.'$1<G'Y:-L_OCU?3K]_=&OW@<H+4\GY6BNV UR_ N& [A
M9BS2P$>%_:?-G 1/Z0EU$RO*AKK>Q9)JI)>%DBV$<7_H7K)F#-VO3Z\2J"J?
MC&@$.CF0;EPSETHYCHAF3^)JHBZO9M7E8ZHD&:]8KFN )VZG>6K2?**:E&:J
M@8K&KT]-,DO+;W^6OM*^;=JAU)!^ILJZ:L3Z !0(!UX$S[""ND3?30J6&OP+
M3"$%0L4;G1]S3@LFP4SU5.\SWP FXY!10"_27SY;=C!RR/C"=MF0V)<^)\]*
MC$7&$6U&M/CR5/$UY5CY)3F^R9N3RTUV:<'1B:^I<K.EZRLORTUEY;5UC^TT
M==G8ZJGKKVGJZG<>_JE5HH 8Z^''VFZV5*TB8ZT67?5N=>BJ&/GHFGE& ZLD
M35SCE6<Q8N/)4T3@F^>S]9L+5Z0AW#X() H>B;5\-D.;6XEO.JFR<9V=)QV;
MMX=DY7_O\/QN@4%6 DUII><X=RSV0E<6?BF%12=*PB\')*%X2(D/V: 6"[RX
M4JB=+DM90&Y^:<H^NME4!VHK(NUR+J<(CRO!A#A-EQ]E40FBQ4?Y]H+*JI,F
MQI,D '5T0%6+ )/V+DSQ8X^7ANVRWY-.+^=,'-.,AI'#8KQI0/:,R?'D 1SF
MHM5_R29+224W><Y7F"V,\)6:R=I;*5@78;ZTX7GE<12;.]>9&H42-58TY#AH
M;8-NG,'17L[@J$XB9R'\\%)#Z/AU3L_X#&5+/M@92DT^D?H$59(R86:%F<V6
M]2U/.FI*U:L(5$E\A17+9\64PUDQ]40J 51)#(05$U8L6]:WM6):U<_K"_$5
MXLO+I N)[X8ZEKN?Q='T^$QN6ZMRF4HAWT*^>9ETH5-WK:5:=7L[=:<9>'+6
MJ!NJOGOU:R%I0M*./NEBYUL/)VBM6D^1ZVU]E_HT!Y&SDNK/QP*B\2(AV1[%
M+0TEQPM6)TR=9-?/8L9HJ;C;"AD!6MZXIC>DWX&@\)L3(5GN/1]?<1F&OOT<
ML6-33]ZMY_H;-B0+RU<;RS^U#>TT6U ?OSYY]6 N6A ++@DN"2X)+@DN"2X)
M+NW32<Z[D)QSD@O[N'&)I':[A"IG D<\XBAO)[S=8-3E"T8EY757(N# DB<:
MSR2NC34<43=@M7RV"D!4MCWDR76)/7X"K@#!T4$@N"2X)+@DN"2X5&DN%5KW
M;2B/?VEA\4I6Z/3)FQZ*Q?.P-VYR$I:YA,PCO)IQ"!_H[Y$=V"%]I/ZK;=)[
MF(MG/5#3>W'MK5M=ZS*X_G6EO9Q\+D#)-2B%ZJ@"EW9:ZG.N.13^-,>&P$%:
MLA,&2]?#6-PI[N3C3@%I<>>)W5EJ/EDW([S+_K:QA'9XT=";&668C^D3Q(6[
ML6XWICP-1\PQ>$43C-6JW?D"WO:F"FEBBV1C/MIK^!I>/ &E/9_XXZ2P!6/"
MC?LP8<%V3I#*G"!YEUQICO??1)*9V,P77!)<$EP27!)<$EP27.(I8+B<8S8?
M,?QANYX/OFYZ@J(LGU=;Y?,*;)T,MC8$H_<%+9T_:)U9D=$-'3[R'T84O63W
M0QE.5,SN52NTI;C-X2N4ZD9\"%<]G;(U7+>IKD[ZY-ZT6'5D-KLNG&8<K"Z<
MWCK)ZJ95EE!A_(7Q+\7X;UB[YJHXI[=/JVYJE16#L*UEV-;6X6QKYR1KKE99
MA(1M%;:U%-NZ(0<]GVWMGE8U5Z$8A&(X>\70WG>=6$/&.K%ZO:L(S2$T!T=B
M(C3';DF66N=@A3$-!71(1ZDKW5W*40@9%C(L9'A.AO/6[2Q!A+&ABU%7M5V*
M;W(@P6SO_Q.K40K_6O9K[Q?XD0YY2/P7VV7O;F7U5$T@T6-=;B?37O\4^ Y[
MW80L\?R ) X9!?0B_>5S>K#"=ADJV)<^)\]*:)5Q[H&-,;[\^<VVP@'BJ"G'
MGF22Y)"\.;G<9)<6F!5?4^5F2]=77I:;RLIKZQ[;:>JRL=53UU_3U-7OW':L
MK6:WK8JQBK&*L8JQ5F>LG7:NIV:FOAGZQ)5=D^+&7U?Q;YXOA0,JN7!%&L+M
M@T"BKD6MY92W^<;:FQ( -WH@>;)<2GQ(5D;,#L_O%AAD)8!PY9 @D"ZE>#<M
M[C._\GAE*2PZ41)^.2 )Q4-.\B$;=&N!%U=*?J:IK6QM.)_?RCZZV73N.Y?:
M+Y5QE:!LG!?!CRZJ!-'BW.D<1#L_TL1XD@2@!*#*(<VM%U+I@9K4?F5QOCXL
M2PJZ4:=J%:=%S9@)Q,IF#=MEOR?US<Z9.*89#2.'A+!@_4K[MFF'>;32J9+C
MR0,X2+,[%7_))LN!CN\-;<MRZ,%IH2X>W_L*FB4.92@LE*'LJ>/C*>\75GI'
ML- !\@WY0(<X@6=@UWB]WFV=3L(0'^D$ASD?=XY9^JW.P;+T#;W6:[7J75VM
MM]NB]3I7"3?"1)Z#B5S*>]LBE]XP4(J[0GQY/8EVEE:L>S@KUCK)LV9\BX&P
M8L**9<OZME:L?5HGPH3X<H)D(;X;Q+<M[W9NJV^_4ZOQ!_6]++'N3&I#"M$6
MHBU$^["BO:'08@EG,=A![DY=Z2X?QA#R+>1;R/=>#UVUU8.=NFKAX6N]4^]H
MN[2C$)(F)(V721>3-.UPDJ;4>MUZ6U^.97$F9Z6V6M)XD9!LC^*6AI+C!:N3
M/T^RJ'<Q$<E[!!AH>>.:WI!^!X+";TZ$9+GW?'S%91CZ]G/$CIP^>;>>ZV_(
M$R@L7FJMI]>-5C6[*HF.2*+SA."2X)+@DN"2X)+@DN"2X-+)<ZG8,F2I^'>>
M94CA503VJ=+KNK*<>%6%983 T>8F57ECJ[OA2.<+1R6=:*E$3(>EGC6>24!Q
MKL,1=0."E-\JQI-!AVH(Q78F< W;JWWT0#"P"JFU@DN"2X)+@DN"2X)+@DN'
MZMO;WM#[X]+Z=Q2$0^J&P9,W+;B M19NW*3* G.ZF<]]->-R/]#?(SNP0_I(
M_5?;I/<P%\]ZH*;WXMHS'7^7UT]&K=?M*+NV]!6H$[I!<&FGGMY+X9+CZX86
M;[KAG#)F;H(@PLHADM>7TJJ89ER+*, <*2GTD 8.@04]X[,T(G[H4K\NN33$
M;WG]/KS9?8';@O#,,F^JMC$A\E)V.S#;;J\],,NR"E&BJ/4U0IF(E6!\>!8&
MS"[E##Y/C\ZVVJQ!N=9IU=7V<CY49< G$+;1<\_3G&L97\RRSL!KV<1V$$$"
M.A6#3M6LB^"2X)+@DN#2@8QEGK(\FXUEP42 +J:E=[66L*750I:0_RIPJ<Q0
MUE[DORW7>D9=SCCU=3QD[3T9B/UMNQ9UPXN&WLSH*<=U! MF3GWIRG8?WJ51
MY)L#$E")O/B48IRSS#A694/(50OTB^RBO<2Q7L/7<'T0ZSZ1G\M4?(H&L]H*
M.E"*H=<-?3F9LC( %"C;-I:U#F/,-F= ;-D,X^G0Y3)D CY<PZ=J5D9P27")
M5RX5.VRS5/MQX9#$-DJYX,))0[L/)-F]7(; &(_F?D4T[@#(TK$0B[9[2$[
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M"'^GDE)G8$H0SUR-]N?9MTX;X071<V!;-O%A=&\#VQP4D0_JOL#5B1@"_DT
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M<KLP$W)ILAY%&+0EL(0;+#.I4&,6E:Y.>VNPV3CF(.MI)2:&B\^JWV/"N!=
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M7#:]<(T+SWWPS'D26Y5,(%C0D>AMX^[NIM5O'Z3*KBGIY9D+HCT,Y5)*QC2
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MCB$_=,MH1L7D%9.OQ^0Y\<:79_(NMC'L#K8N#3D )E\CH?3(DP-B>3%(8)Z
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ML  O.T!@Q-XIA1'"PJF /0B'+]COR%[*+G7P)XP/8^-,IL 4PB%O"7Y;7.&
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MHU!;)5^=SR@Y"R:F_B45>6D,FV:O5U@^&@$E$,BQS XM$X")1%\7$2?;M<8
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MKYNVLCM&WCER<,7(%2-7C+QN5DQY\[E_*N9S&=2EES_J%A[U_Q;]+WX#>="
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MX<('(2A",J((!)I0(K9(G%X(5$Q7"^C'=T9 0"%82Z X<2P+2'L$XX]@9DA
M7F3YH*;O(]NDL>'7!@_T1L#0[X6,($E&"_3LL6+WA]20*5P5A-R@PAI[8X'K
MPV<''C DV-U]UW=0Q1@A_QR%/I@-0,1ZJ?@NX"7ZWZ0%N!C#QUL(;[H$!N.#
MVH6^SKO(&6%^MSKSS;#17 ?W^([0>0-K[_;VJM7MOE_Q'.?."!4EX&;$E)P^
MGGI,3G2[< PV'6T$K_'1'PHG>.>G+C(G\G3C1TA$.HCQY9_'VGN.L*MHG/X)
MTI5^BMJU,YX@G8%QF?H87I'A5Z+3D41G329C836 +IV>P#"J&ORV<:H&G^9J
MBS*N]N8RKFNN7#@UK+F9O&L&9YK%U:=KQC:'Q=415>TRR.H?K%Q8[[<0?3=D
MK]XC@5(V!<J\$2,-EP?P"N$YU%03GX,D&-LC6A3H#I$#V]:]YU@/D9> 5HLJ
M6$PJ'8YQC"\BVI2QF!-,PL&*#U9$S@,WC,;2C8G/J)(1F";<G5C.S(J!@>H,
M! ]4$@Q1DLZG<Y*L$V*%Q_FH$64@T!>_Y;ZP4<=Q+'HQQ7=@H0]8AF-QMI12
M!"*"4H8'&OMPW_8;=9PD_WU0+T3#>,(</+O!":L;9W,DA P:?B,,TA-F39 \
M!S3$(V$&2>41PC*R,630B0?A'>,AZ%NJL\$?((^W4>U!(PPL BM?AH2&EGX!
MOC#"TB-6TXJ@9BT0%2:5-5HFF1F$XX#*]B=8>5GY$9 ,&;CA@X@*I*45VADG
M*C&)Y5'.HL/<*9PP];&K,J/IC+'*NR C5U-'AKN"/CFYF )1<TE4[(R$/$>T
MM/ 02&=8@'Q[H8R(S236[,L\P?*KRV9,<T#S0^)^2^NLQ]OMI* S1U11E056
M2]\.)U_^XMDQM<5YXM8RUUM]188.Y4E9$Y&8URBSJP)ID[)Q,WW^=%"AZZ)-
M'$GN D0T;X/??-"R70%D5_''#8DNS55 T9*ZBL)^"NS_2EIJVV\]4WESZ/OA
M Y4L<RUL"M8O2I0X\RQG-J4MS5_L!!$ "QQZ8W+%I-J]Z)$O;"QM(K+&22@9
MWNG9);NEY^V-[JPX<O_Q[CZY3[ S5*O>;=7_[ZY1^W-\]PYTG^0?[]296+'O
M]<E;1'$!#MIA;L_D_S#&^]5J-/;K31J$?YWGQ*UN:_QSF<K>PVYW_!,YTI.M
MKLXC5M?&78-;MD%/E0UZ)7T+JEG(NAP,LV+?\QP,VWUUE0F'J@M-DDPQG9;U
M^?28'5T8,.H+[)>J(IZHJL0I!9?0$R'0&8_>*8Q$ISX[O\9.,@0YBWJO>A2^
M]2C>)2V8RI<T?T8OY^A!"P4=4>;YDDJ4#",*Z:N!^9SYA.XH7*%-0:0'"OUR
MT(OG  HD:K=QDO8IP!-;<8BIN+&.B;)IHGZ<Y.@.O9B<8BEK-,#$'&&>B0CZ
MX]"#V:K5&2]@!1I%*:6S!@639C@9AW?^!"Q4SR77/DQ590]2H*<7TDRV@?A6
M/<FY4R*"@J/!4J#Q3O1;.L\R5T&"-SB"%00A!BG[%IM#][F0O0/F/AK.<'>
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MZ$P5*VI'"KP.\7ZDL)*Z(>I-\A/5[X$-JHH"7I$"I U;0,"20'O52:SO+HH
M@>2S5E%>4 9V5IW0*\LU _.3\#C'VA8M0;I<&'BQ.IT7OS^Q<%/"/=7ME%W0
M+Q+I"R'C7D/9F5AL#OE3"#&0?4@^"JX>H[/*G@X2;533 :&42B=!!DQ*4*P(
M\A</)@IW'"<9#\,HV<=^#0PD#.8@1CCPWW):B%0H,I!<UI#HNP!1BL%P3!0
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M4$&7E9;K]&'.,88W'=;8=?.N>7.K6:<YAJ)BGC V2@JY)T9'6^"'^M;8<II
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M,Q9=D""4OTTI*U@U*S%3'B)TBP;<=%39#&,%R@3_5C ^U$ M4]BPG963>/&
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MPR04J E,LLBYKMT1]!Y(F]#$_<G"HII:ZJL/P^(8]JCT8^8^6F*Y122Z=(3
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M[#:(6KTZG<UHJ<M+KZIV9**?SD?9HE7!68A%5$LM)?+'B@+);"Z6ZTR@&YC
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M!BE=A.2DIBQ,TW__]CG,<'YTNJB5,]7?&\GD;=#>D[)%3RZ[HSV'_ !P.?'
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MUYSW%>L QMQR=:/L##-9"^#)ACHIPY*^<0$Y<HU,1*EM<V^]>_)WS><#A#>
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M12U:2G[(3@_K18\T\E0\DE6-KFHJ_>$S.G+,-;,F)3*U6^<\W@!Q*.3WD^X
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M$G"=M33*2F%;'WQ-%_"'OCZB0K0N_5Z7AY[C/"K_"+-9(%%?;A@_"B9@D4D
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M@ABD=;69,1A,M;!52O">1?+?N0K,"JNNAQ^_/]78W<087#-V$?L0&K&*YMR
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MNQX[DG4DM5 &C&>Y3@+ NETP((DYQVO_4)6W<JMV?O1W%J3?18VNN&?#<C*
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M9_P=T_5L4OFQKZ:UA'QYG6OSQC>=&]L[-IIUR?3%UZ479D21-II.^XQ YGL
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MM"8 !  ,AQG^[0+^>C$<HL^1F>7(458V>H=R+N 0 R/C(2;&/V9-_]2/_CG
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M//3VL8V( GN58-O/G7P>L@;AGD#J3G;ZB6&)ZEZNMH++PSRA _<N7!EAJU0
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M* OYY$W2]>] <-8I35R5)G#$Y4.@=YO,N.?"CLE8F=>(Q/-*%@54PCBOS],
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MD.01F6[ R["I_&# #5RZPV99F&X?=ZZC4JV[G^,BT6S1_C]W)H+7&@O!C2J
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M;49658T!+Q['3*-KJ%JY)/16#P5^L+%+M]^0><("Y1!,8V\/WEI& [RH]'5
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M55[:6*9QKBCWN)JS-Y[W5.X[L!^UDE4;4OA<FYN"(/OBNIB/V5_I]9_\W/E
M<OI998S&@WP>I/@C-?&H)MOH\I_0K$9U1)#G2JWP@PJ2=(Y3_=/03G.5^$^A
MG=EY5>)!L286P0:<I]OCO_=I-BKG'K[C$1\Q6IZU_VO/[;] (_E_"'N)7C#\
M3^FDATM'=K"OD=U%J?_"U6CE\YU-,P"+Y==?!+? <O2A9:X'*V.P5)>)X:67
ML>WW2J)*RZM."YQF">KAK0T6'D]\6)[Z]*:<4W9!];86^G](@ZB%!D3I1@S9
M#4/R<[O:JSW^^:&K0M=NQTM)&;ZG8_W,QT/N*.JK%=TD-?A\3I3.X]OF_C7A
M6%0R,6[UT(#W1PGNR;/Z[*J-=^R >/H1Y7/1HC62478Q78_X+ETWU/I8N?(Y
M]/O_H*W6_AN$&!9">*&6]_!/RU42"L8HT50I RBJ&2;SQ5/C7:PK:[&FV [$
M+,OW119H[5E]D9O3JB_R?P)>AC],"0^NH< NA5WVDA96G5U, IP!DIXG;+(N
MJ3(.LMM'SB.&%FG F227]T9.!7OP_RJ_AOR)9?_8/O*MJ.-B:JC4?H-^E+;0
M&&[M:,44C+LDN1U<1P,L0\'R_77^?\;#/^/AOW@\_!>P1N<LHC')T=#%FSD9
M)ZH^/'W]QS6WLE^SDRR9UR,[S2FFS_756')@.?_.*ONA%K*6[ZKL'Q -C<8J
ME_V_.5J4)WW/K??+G=3SM5=?CX:**%[8/54X,I_; (ZVEB""\XXJ+=6-Y/S\
M,;'DQ0[+"W5?KC081SYWW@ '(P1A&@0/ X%4Y>[Q+X-^^2;O7VN5>K%_IQB
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M%\55]X5>TV#()/W_&3N^8_JOPN+_]T* 4TZ4'MINIB84413M3(FH0=2(8Z@
M0:R#% :FIP*KV?:H S'L"U6SW9^';ZB30P4*#S'3'-AW@PKDUU !$\ITKI_<
M7R\23Z"J%4CQ%B)D""GT G$:3E;O.$#MDL4QB+_</$$&T9%8 @Q:X1L;_0R_
M^@N_5!8+W:'_HOG:O_KO?[-&D.:8)BX+'GP CRA1XQ7Z-+%">SL.7+W^#J-F
M.:NF^*V%^)8A%F4>4D!4Z<J:M&SRQ1[COX@5]S_RO8B3J)?R"3N[$5U^;,P,
M^9Q>TW0NN2/:&X<<_5*8UUHD%[MV(;]+T3 IMGNS\SQ=!E+G22.D W16$N&!
M>,7%4I<8W%JGC-8MG)+\9F@6WM+^UOYUHOV 8OMM0<:.%$SE;56^O2VU1+V3
MX7D]!M(>FM;9A?U3(SO[,FEXD]4-^X_V ?QP)L+7P=8#5&C>V653:_G8DQK!
M7_?#YB,:O\PJ+FIQ+J7I,0=T^:0'8>J)^3OASG*-:M^F)NVIP)C"V?%]ARL_
MQ<M4:J6 I2AFMR\KNH1<?+=>Y9"?8R[,L 7ME.K]:;KK$%2&/7-"/_9EUF[S
MRR46R+C</<XX.G@6AMK-JL%[A3H5S_4CBN7J"YW+=>#.6/$?:Y\U."2SKK0+
M"X O=/99M$0D[H0DDYBD5VHKDHPX=96AN;5K]2N%C<7DP1B"IO/,Q'(Y(56W
M#B^<5R7J'LMDVB4!AKZ;/F5Z>U3<);OJ^M5\-7F8\W5<7NNDGC9N2V'73_C2
M]W=^_4=SK\>?WU<N82VC$5&-N=UC1KB*-]0FF,D7NOIB0D:=I?DW^6MB#1P5
MJF]P*!K?EY!Z('_\7O'+)IY1\5E>*XV1RH6&[^[G,#VJB:Z/G"TW3JEM><?0
M^G]([\@K*'F5NV8VTI%PU>#@#7_* NIIBNGZ6C'9O:RL<6Q;HWX&%0S%NU(X
MF>@FEDP4CL4U84]"+>U/N:GPJSN+W3#YUK6LI;B ;D ]()@]_DAP_E(V[>"I
M9+J\E[P[JA1H.M'-OR]S])21!:FK3WV,BR>>6[''_0"Q=OG#)"P%POJ#=+6Z
M"O\R2L*TN+=8LEFC^3)'*S>K"BX;<(&CBZ2/4[X/PIXRT64O.N8KA$93@53!
MT5MR/^J>?3XJ;%4#,NXU^^B8?KF8I2AC>H[L\V/'8:A[67=+6QZ*[K<7ZN$6
ML6&;K$7U+AAD4WI]C$/QXE^,J]%!A-@6)#_Q+MO/7G_Y.VV<5ZV?,A]_?G_]
M:SRMB_*6$FJ5R#H?D^&+86*SIUR,\#>2=4Q\8#F]6LWX/;!U WY@WP[#(J37
M!&P=BV%*ZQU-^#%3V%/LNJ.OW)#E=;&[-9?KZV2X7XP]T;HZT8)T.%Q$-S2A
M>?8CZ6=Q,1F86Z'W=1U6K/O<=E,3%[-=N$&4=UOC*?E$WX]40 ],X.88\786
MCX(Z;O]$]J/)TCUX]Q^C^.K5JJDS_3;##.%"-16?TSDJ36KZG:#!#4Z84[BD
MSMHXK>6WG1T\$4-XV]6^[&D_]7+<7K#'N[8*+NUIA_@>&XF^(R]JWAEY)V%O
MC)WX\.ATFLPWDCXY"X5Y;&<B+X^6I"2XPC31'Q-:O:HO)?;.\GC.)PFFGG^L
M7:7LR;])&?PYW3:B1$:$1%>VV&>,I7P2+A CUUUB$=4PHC\9+/[%_#WS<96S
M\JVF9(^U.:?<Q(N;%;7^D_Y40'G\TQ(\K>ZL0T89>2<O6D4RQ\S1;+OOC#=2
M(],_K]M6,.#>^NO*A@S%FHY)<"N-RI.:C(CIT]N'YLLG-S<WIMJU\)V5-/^4
MW1[7L]+T2YYWU.QC8(_<FCIY;-W:05Q%*A98*-ON0HN)"9?:^^-*3W.QRBM5
MGHK$<MD7'2Z7+K'8ENBX1DRSJ\F(M/;(W!I8DS7NWYX4_V:7M**?K/^^?%9\
M05OAN$;_JP5.E?3+1:J(*S_'YURP:IFK"ZO0'G\UD8^IEEV2>_5+/[TS_H4N
MM;!]!?IU8^N7"OB?TNC#WJP731$@@#\==^]"#G^\_=?[=N]"72D]_3N\L$Y5
M\8V,8 B;K%[D%"]EN#_EEEU8S/* 1VO2P-FTZ!\9F:0ZDRX4+=RZ4:_CI',Q
MK.!I_[8P#:92 -HS$/=ZCL\*;K*L>;T7LYL7ZJ?P$:9W.TBG?S5S</4\Q^W'
MYDS/]>YIS95VB<0[MK1K)WC&M@8DMU3@^X.7ZPT7TZF 5/>!3D&N.HO)6_\/
M_^@+6?]/,08'48$YDT'P2B 5$/M1!&>@ IV(C_!1.LK]OP30T?Q1>4 Y307B
M-&]2 00'>-MTI,V*H$Q1YV6B-#RB OV.U[A_"]5S@7!2CL-,9CN"YG![$47(
M?OJ-*U/+_&R^#R]'XZL4U3[,G6VB1YX91LVDHSB1K"LRDWZ7\&7FIC(V=]@'
M[$<%/4]_6%7DW0M@/7BH[G@B/B32JK=U1O1)ROOAG+IBSOU,*)&.Y$<HA1\C
M1,]Z5 \.O[3R+^C.OXU<XE!VBZ("9Q#52!I*+Y*9G$:20IN$K*'-ZJ.+?3^9
MSTQ87%JJB8FXVAQ#[QNOM<,EFOA0]^&JA!KD)J,4K+"[?CC])!81&"".%VGO
M8R/$M[2BDX/="]=.?&WG="]WZO&2@+I8"#XT^!K,+'6LW8L/AI#"_>:)XR$M
M!Z$O^=.7*>*2(KH#:UF4[F&K",FK&)$U+4&;TO,)M4;^7V;GO\CM6K D:D0F
MG7B?(3=M@O+7BT1A;OF9CNQT[R,JJ$"IW4%T6]&>C]E*CQ=G$N\]SE?YUG%A
M:C>0Q]"^4$LZR^\HFS4?M*KRS80;=9_+R_&1#EY<K9;\<3W#D3KNLU^CD(L/
M!$L++Z'GDN9V$)\7/^V67;#91GB.$U&=^PHW"0IXD.:PK/5HD8<>NYT\GS\R
MU98APG) 5YE]0,7P&[&IAGZBM2'9YL?]@EY';@A!&I]MC!<)EY;=J(0%3-_7
MR1<T@Y]5J1]?TV]L6+2\6;'_Y.[+R_'UKE'D9'5INW:<++I:A@16-M^WZI@&
M2&Y0/+N.\\EEGUF"Z90XO%1%";/U3,IOU_?=QZV)=[=>(&QG6-'9K#NJ+/>U
M[QK7#FI'V=4J[AR"YYS%OR#HS$([KJ>-N^ U5?E! R+K5TM3<@E=<F>:3-G]
MB=.CYN\OS5G/#!^(TJ:G8J:#I3P*=KP;+F=W%^I=,>\.V#W+.9?(;W=/XW4)
MMOM<P^/P3@V;Q=MY8P2&%BX_)7=Y),\ -'.P:/IN60PW1QP4:BX*XZ<)N/V#
MWX;]A*>4YI'J_ ^G60-H2;(0IG$['=Q&<]"MRGJB'Y==OR2RA[7W\D*.KWQ1
MQMK+#)_J#R0I'.J57&2CH<ZA NZ<&UC;SB@=-VMC+)+_+%L2]XG_!;L,F.'\
MZ1=NZ<@:5#0?#QX4I<9"*+R.2YS_F(KEO==LQJTS/NH>,=$I+_LJJ_1KH0S
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MO,=#Z U6M<S*7F,L7"GJ5>_$5D3;X^=+EE^5G$LZLE4V(NU%K_9^6B XLV]
MJU+6J];K,VY2@5^9WO^[V5I>*N*\>?HZ)TLE:M?S',4_^]LA'M[:.#B9O+/Y
M1_S&IQ1^<M!?W+TRV9O,K,YWI:IJP/SV\VM8Q>&W.ZNGE;9S-DE<)N[]!M@)
M"E1#L:"*"I1TU,#_X'VNG+XF9V(T+%FA*W5(X^2N\HK@A13=W*JLP&\N-"(
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M9X>4\#:\%MO4DVUQ)@-%&3#<?3I#!;K!J*5#6EI&3"FJF8!])M"+Q=/^%E2
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M$%4RT(P $[5 N"*$,!FXVQ!) 4% $E(.VB-0,*.#]"G;X_0@,I!^G0PT&1V
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M$!+/R<M?(<GCO#)FJF'2X9[CABF+HJCRGQW[X11QY"?''=5]\!9H8$)OC9\
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M1&'^EI^U0^$'A3^V&Y;]_!60"OM:3.9E^(OO>783DE\2#D+."'P6&#9Z"Q?
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MXX%:1NHFV? ^2.!OC:CCIB_UVZ!.:5 @V,[UNAOTUVG;?5H=K<S5T%+XI3F
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MU@+3*&]^$_W[$J<Z$FF2(N*J,/A-CX-$F?*M5PWR0SM*;H=#:+W5,2\R<%$
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MGRJ7/.'CL 1O"CO,/M"/T@V]#ZU+U-;379U^:S#9:CW;.#7&--R;ZFM]&>\
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MEVN_B$"I?B5P+XZC8W6[9D)J,YT;IB49X-O?7^V,*+,_ZAY@WS3J!=GQ!UE
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M:W5R;4QXQ*9H%9N3M,E8U9OJUT[/) ><M"A?<[._ +'0M3R_1/>2QO_]3L!
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M.CX$I)1G;R(\E(]P+>I$L E]-/V4XEC_O>;)FE>R(;?7UNME]OV%NR>%U93
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M")QF&NZWY$+GR.J_\(ZZ)G>QF'"7WJR?JV&NB?C$ZU+(!=Q$L!8BK"7L5SK
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M]?H*[_H,4FNAK-UHTR RTPL[EB03#)DM 5]R D'N!T^QM7$@432'.MP)\7Y
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MQ>3\O"D[E%@O(Z[S=EN-'0,TLU]YK;:%'W&D^G7%,/&Y25>1I:E#?-EA_/Z
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M7+9P3$&:@+=Z$%2^'HQ-72H6LC&\AKCM[<.=?/ZE?,85RW<I[R !/_K66*Z
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M_?,PU4F/G9V"[V4;5$T66995YS@<;X@+FDHPL4<78CM1V;=Q8W$=("<RX+O
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M-6;3%+M6$(H-;T:.FYC'>3H;<\.VX[.G;CY]WS0$Y;]#4CLK!$-PRR16H?(
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MH;&RFG/T$SXV=XDI#>! T/&:4[:@HU4JV?,[92$31$BP@MK^G:<X9'(R,:.
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MK^C2_N28W=\-HU$^*O"2+VKOJ7'7KZI+P/:/6C3\=NA[!-%$;-9-!1;Z)?8
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M:B$"WQ61SR!&K@M1$F(8NYX#>4B\T'.]!#%DPC_&$LR-CS[SLOQ[O4=;2@T
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M9F,U\DJV.TR7W6':J@9V= ,=Y2[ 1KUFL3,V]=D=20,SX)N-Z$0FPHE'ULR
M. KXO<9%NSU.9W@<!:D=H^0X/0Q:JK,R7Z:L[J;-&/G[@Y3NY?I;QMG7%9%2
MI+AXN9&]997Z85$^I$_K.BGM*S=R!CW(S<>U6/_B7?O&0N @I%$00I_32!Z(
M@P0FH2L@80SCF"<.(R;+]\CBSFU)7Z<E_/G'=:+".MWDJSHJ\K=_ YA*EELU
MR9X8%RE-J_K&^JE55[D:MV4VP&]9JC*"RO^7)^=RM:S]D&G^^"@IJ4F;D+;U
MPDTRX(S_.6GM&V;TD8R^E^CH"M8I7QMM0:TNV.H+&O'!1N-MU;+UFVNEP;78
M_O+=^LU9?0E&^XX9?1&3[46Z7P9MQ_=;\V7D]9=1;K^,I^;+R#=?QJ8<VOK-
M+HEL?DG6;]JZY9QLI$YL7,:68LK-S$2([FUPINK5W 7P5C;3AG"H6-/+[VFI
MZ_IWX-6Y[1@Z(FZOW&H.4!)K.N$<@ZE_];6 T,C+93\XX \EKB4_OAX@!OGO
M'6IO,K^]'F6Z_GI]CYD'<'^E#YRMEG+ROPX%K:,<C@2(UE^J0P3!0IXX"/4)
M1*&'84)0!&,68NPXPHEPHAO>?8X@<Z.'U_',_=^\W5'IYX\IL1Z9:$QA-@H:
MMX'1&2'E9W4_6<"Y#9"ZX>A6VAOFQW EC^5IX[QVF;&-C8BFO%QXE'H)B2AD
MKNM"1!P,XXAYT%&)P@F/B,^,ZIWT]#4W*NN(6@?^T*ZP9I?^?0CK7<Y;PFUT
M<\$N9%=:D!G?;FN 8>D6NJ^G26^+-53>O]75>648870*?7[*GE9-S8)_Y$NY
MU5W6)%67-/4)IW(K)+=(;LQ4N":%"2<A#)GOA"QF&#,MRZQ1KW,C$14J2Y7!
M]'DCJ!EUZ&&M1R+6$1R93KH%96N!+]H")5N93U>X-F87(Y0L\8Q>GY,RCA$,
M^]QC]O* BZ4O><7+6TYY^JS<3E045[[*JEMY+%RXB<<BZGF0Q!&"*!$.C!/$
M88@B%C#BQ81JG<U.=30WKEG+!@KMO'HGL=2X#[&$T,A<4DL)MF)>@ U<M_;@
M,K@TL 3;1.;^H?"9F><U,.DUK/>]/YU)7$.+'6.VSO/F9NA/S07_78&9W/?5
MN3KDSN^FR.EGS1 2S59F-,E;:4$K+EC+6Q]&E-#RB%VHC V?;<:$&.(TR#RK
MT_YDYEH#9;OF6Y/71LJ2?BRW[VM'UB^K>F/M4=>+HB!1AET*4>0)2#SB0L;#
M*"&,44&PU13IIA+.;1-R()H"_)AFH%1:E3]93IIN/)YZ!Z4W':61.7*T0(=&
MTPE3KP\=A*GRKAO+-Z^DZT/A-<ZX/KBC 7?SJR5W'1*XLON[XC&KF$EFGL-O
MSXV!E91 B0G=G3E]UUY'\^/E;'3QTKBG/QNJL:_J3Z)D->U./Q[#;NP/-SG=
MI7VO2COW]OU/#O$K3K/;[ZWM$WD!\UW/@82Z&"+7=6 21 3*?SD<T23R/*U$
MI?L-SVU>UZ*9N$AV,-(PXPS4?.P;)275:2-OO_8FKIS#4)C*Z;+W$S!TA7RM
M:;_38N?Y"=T+7TNYZPAXX/?GN>SEO/R25[?\GZNTX+><YL^\>%&I:>O,M$,\
M^?I;G!O-='W8F!0=9'D%BD9XL)9^F)O?"6@U=A6CH#KV3J/K%*@ E6*#VSU
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MCJ_*'L8!@3%B"&+/=>,X0"+0B[@R[7AV;-(U?IV.?*SO1KO:_??_%GMN]#_
M>RY2FAH&:6N/EK&5T=H83&=[K*%M!!V[#+,6.O;-D_W=OI714@N,'E.FWOMG
M&CB_\.H]+]+GYI)8$FBUEN"EW7:QZ^R6*PN_G*[O<)F6W2QO388L^7N)CGRI
M=GY:Y\#^E-'EBG'V*5O7.EA$E'D!8K'<8#D>1(Z((0Y] 5WE0A0X41(X\2#3
MZ:1JS(UJU67AP:H&:2NZ^C%OA1]HH)WV.S$T_<YV]"<S*E\ ]1%L00 U"N#'
M#0X_K<^F3-4-V& !:C N#F9NW 7D8J?VP*?.E_7AU)<UW(+])@-KVS8^K1)O
M8W5_DX$Z:L]_&VD&NN2J)?Z6/TE.>% ^PN]72J;&';@).? 9BV/*0^@[40 1
M\UR8N,*%U'5IX(6,.-C(]>=DCW-;WVJ!0;&5&+!:9*/:Z?IXZRT^5E$<>9UH
M .P("QII-W$5ML,F=+&QY3QZLK]I?4%UU7_EVJG]XH#"WU_RBG<RVG^48F\=
M2/.B7(1>3#&*&<1.[$(4J[\AGLAM>L)BX84^][1X1JNWN7%,+6^GE(7ZJX*6
M 5QUM]1JM$''LU9NIIYP464].24'#(7OJPKJ-(81H1PB$44P"80'77E(8H(Q
M[M!P\<P+DD\^&-U>)QP.51VC6^>Q&8BK-+O]#M;S!>#[@G/]>F)Z8]&_'%C'
M=^2EH 'VM@-LC6-76IO@&=0BMPGB1%7&SP'3K(BX+CB]Y<%/-C)=X6]=?79*
M>FN_-&PGWJG8]BE[STEUF;%?<?$GK[WZ&_/;5W5H6%OGKGA1R6/!NM:$.F>4
M6U>B[2T8IC$*W="'7DP01 GA$!./RJT\=R/B4!)3HUK?8PDZMS59I[KAM".I
M=S28P_B,O(QT5%0F(*5D?<VP57-]X[!5%/RHGFAU!9M*.+6V/W6\(D>Z31U[
M5"R=9483<](CT-A@[Y^<1N_O#./.X9M'XH0>B0B!-(PP1$B5\(CD:4ON]3E-
M'"\DH5')H+_.S?"A6U[6W/+^?8 MYYR+W;_$5>XZ)?#E7HSA#:Z#;L:XTIWL
M$G<NU[;F%[6C7<U>*8FSJC$NW*;EG^]X1A\>)9F]SQ\E92W".(E"AD-59\R'
MR*4>C$/7@[[G>:$7^IY+C2Y13W4X-_[8D1<H@<%&8C/^. FU'HO8!'!D+NG#
M#OS1B&N11W21L<0F)[N;E%-TE=]G%NWW!O-+35._I]7#U:JL\D=>;*['%@YR
M&/8"#TJ68:JB,8$D$0P2[-$H3ES"0M<DA+6W-R-FF2":=2UL-Y#U F2\4IG+
MUD&N3WFA!L:8:7I UZ89.U".SS$-BM^DH& MZ078R&J57TY#8H]<>OJ:FEE.
MJWV 5C1>&G"Q=(4S.4H?T^I?][S 2]96Z0PC-W*2Q(5^H&Q=22(@(=R'-(I$
MB'&,>.1I7R<=[F-V.Y-:2K 5T\"4?@1%C=N'\[$9FQ#V83E=V50;'X,+AO-Q
MFNA:H<5+;/%ZK$4]GD#&[#*A'XC>*X0CKTYW<= O^\YUP8E'A^V>]DU)BDWS
M577+,4N7+^^YI)G'-*NO)S959!^?Y%_5=Z,<B"ZS;(67;=FCQ(]]05P?NH0C
MB+CP8)*@1.4/X0@%D=QO:7'D*-+-C5VWDJKM6+IK@;Y4<01I"=ZE^<6 9$MV
MAU5O/_=F@S6)O:IK^/_6: 9:U4!7-]!U8NT,L5+P C0J6B^"-0KTEO:9=F6;
M=%\Z"JS[^]AQ.CDWG^K:&_2&%^M\KRF]S-C[=+FJ.*OS[&WO$6/JN2'A+I1;
M8[DWEE0/,141=(*8.2X+0L&U LG/E&-N#+_K<JM8OGK@JF0OKR_XZQO&]SS+
MU?BJ?_]6-A[HZJDKO*2KY>;%6N_FA4;SVD%>#7^=:KS&1CUWM<3R1Y<J5[7R
M+:JMND.3J)I] YHW%../[,C+P2;=K41[K8-R/&W&X.+ 2#793\$HM\!GXFD]
MVZF9%&^4TG005,?SE@YK;N+"$O5__B&WF!L/7'=!/)\YG,709=R!R'4$)-1-
MH,-)$!(GC(+(S!/?HG!SXW)5T>R?<IU-12JG=..SV11_ %A)7X+G1OYA7OPV
MAU63B=]HL,:FY_,+-M1_@%;#-J9@!C48>G!_ZP(+AT3[:U1/Z '56FF$OC[,
MLS1]^"Z/"BH0[ I7_#XO7BZ_IZ5NEJ:#+\^-:C="@K64FGXTQ^'IIT0KR(QM
MA7@%"OA#B6@INUJO^H/R,AUN<;*\3+T*=?,R]3\X]$Y:G;[JL]B[UK#O>KZ0
MYV " ZZ<IJ/$AU@@"M6YV>&>@Q(_-/-RV>]B;M.X.8J^.^,H>@!&W:OE<\ 9
M_3ZYQF,-S\F[HP&WR,>TMW9U_*J#B>^+CRGX^I+XZ).#0@Z?\\\IE4L_OUR'
M9K7?)0K\T$?4AT'H<RC_$D/B>@(*AT1$_8I'6C5I3_0SMSFN) 6MJ.!R4+C:
M44@UKHKM #7R?#^,T9 [XQZPC +3;( V64B:!&_9@K>)A[1U<WP:BA,!:$=?
MGS+T[)0.>T%G)Q\?:)E*[[-4I!3+4P^EZC)"'7=R.79I-X4B]=V0QV$$,1<4
M(BR),D9<.>0YOI>XE&-JM _2ZW9NO/EU]?B(Y18^%Z"C -AJ -8J&-J1] 9!
MTT)D'=JQ;3_]4(X4B&4&DRU3C5ZGTQIAC(!X95XQ>_O,/'%-3IS/_)DOW78)
MI9[ #L&A9":'0!0X5)[0A(!^0L,P\7W/C9-!R=Q>]S4W.OK?JUQ=5-65KQOW
M$UJ;&IJ0L[+.5O")R95"#L^R#7$$/]8: =>PPG'?$.CQDB5@1R:C'3^06M +
MT"(VPIE/ Q/;>< .]/0VR;J.JWPTHU;/*^86V0'9\F><(]\L%;Y9 OQYIKVW
MG^7>5F[[-\EH?R*/_?G9ZU4K'Z5D><:5A\PS+UX^9<QD^AQ^^Z\]DXX@<GI2
MG0_&V"MA(R!82ZC60Y8^ITRY0MJ;=/TX#)I_1YJ<;"KVJ]2=E2>>'!KNCZO:
M0-#X**IK3]F'*LBK[M1\[%(G<@3$'I(G^4!5QHT%D@@FGNLX(0J08<1_3V]S
MF]NM4_!62--(_SYD-8_GMO :>?J_@LK:Q:41$M8B_/OZFCC(7T/MUW'^.B\-
MXXNZ$K>0LT^E>N?%LSRZ9_?7XF.:X8RF>/DI*ZNBMAJ7=[*'\O"OVEAUDKB8
M!\*!S%>&0C=",(E9" /&0B_VHH!AK1N5,82;&QMM) 4=4<T8R>K8Z1'86XW(
MV-N=0X,Q0C*",>"S1))619N44\< =9^"1^ECH*.*NAF_%K]CY<5671>WZ?U#
M]>$[+VA:\MH<N/EEV?ZV=!<X#BB+$P?2 +M-*'3B8 2%*UPW=CAR0F'DRS)$
MBKEQ\%I>\*0$5C<[WUJ1Y8B HA8:_)AF8%6R.F:C5,Z"AL;38>.E1\>CC\+(
MO-LXU$C<6R$5[+64%V S-C?KL?F],S:-*A;];\X!TI:+SB 9IO7B.0>F5XX^
M9S5F;K^Z9"Q5G@]XB1SO^5!N34U3ULF&YL9S6X&!E/C'YVZJ2WUKUVG\3AN^
MK$(W,CGUH39"L61M: :9Q4ZW/IF%3%O1KK%,_Z4!3H+;VH"[I0'7E0'+]74S
M$PY!&$,WCCA$8>)!XOI8(NU0@D(J-U&.ML>@9J=SXY+3=10-O.-T@>\GEK'@
M')E?3B-9#O$XU,74P/UP!&PG\D7L8)SM8IRN9;?EF&@(4J^7HFY;T[DL&FJW
MX[]H^NX !K]1Q3?NON6_KI95>LOOZY7B2CZMO%_N"GD,;[]Z'SF8)IQ(T$6L
MXF=#2>$(0\YH0B+D^HQ1;0K7[75N'%[+#3SPZ^W5G0&S:(.L0==C0#<R7S>H
M29E!+3182PW68H-:[B&<K8VL 6F/@?!$K-T@74FD'Y7PL%@C3==(5TI^6\QM
MBE0O=6LW-AUWF^JW0][&+T^<).&Z#N@O?ZG-!)^R)ECWER(ORT4<) ''$54E
MT .(HCK%#6?09V[B!G'B,&YD\QQ!QKFM#+6(G-5&S]K861I:.\<81\V[];<=
MG9$7'PLY$EH]+T"CJ?(97A=?K+6=0;Z$TT/QUFD3>B3\:V1/. VQM20*&ET-
ML.*JEG_+6+%\N>^44WFLM*VWQQJ8&Q=+&;D44AU6MW(:F&N/ J5AIK6!T=CF
MV3KERT&0K"5KU,)BF#WV:*O3V6%/*;9C?SWYL-E49CQ=?,@JE4;Q$2^7[U9E
MFG&YU@M"8S?@(0R#6)4=E2=U3$,.B1.&?A(@CPHM#\4C[<]MCC<B@EI&L!92
M;XX?0[!_=EO 9>1Y;0:)]E0^H7C/))9O-I-8_F4[B8^U-\GT/:',>N*>>LQ\
MRGZ6^"YO'O*,?UG5!@F'41Q&K@,1$A&4TY-#G#@$QDY $.=8N+Y6^NA#C<]M
MLM;R@5I T$BH/U-? 7=ZFIX#Q\ASU  )HPEZ3.5!L_-58Y--S6-J=.?ET6>&
M5HZE!9<;\/>\^?-3UD;D=JK5+CCFR/4\!_*8AA#%80ACY@KHA"Z5JZS/<.@M
M,GZ/*\[T3"(ZW6I]MTGSW78['W'KV,K8J>YM6MU5 VT]LX4U!*>JNMJ("7Y<
M"_Q3$WS<(GI[&M$!95/U(;)6 E6CRXG+F>J#\+HTJ<&[YD?R=033M?A0%,I&
ML'7/^"PW')\J_JB3SD^GF1G-A+6X=5+IHI!$GJ_*Y4MC;=NWTG4]AY0RH-;&
MDN>0"7"##JM:'4QV;C51MWN$-7KOC&@:3-60MV$5/O,)Y3B!8>S%$$4\@)BX
M"(9)XKC<38AP7..0F&X/<]LD=P0<$,VR@YW> GH6(B-S1$>VL:))#FEN,R1D
MI_WIXSH.J7<P../@@V=FG'GWTD;.*Y/VQX+_<\4SVF2G#;V$AAYR(8E\N946
M;B*/O"R"A'@D%C%CG!O-:XT^YS;3.W*"C: #$\OT(*W' I;Q&YD7#D)G/<;6
M !/;B69Z>GR;A#.G(3B:>$;CU6$\TP8WM*X]'A-NY'#)*#R2C(+=$!**?1B&
MV/."@$0X3A9R_T)R74[9:=_DZ^_V,MXD:)/J-G49UH%79ORQBZ >4PQ&961.
M6(= V4\T=5!C2S-^M^U)Y_9!M?9G\>&'ALW7ZR=5!"K-[C^K0_2F<*UR:FT*
M,R\0<8C<U'N0Q#R"B(4"$C].(/&HP)$(!7&-JK.<['%N>X*-P&!96XFL5[$^
M/09Z+& 5V9&980MJ+6RGC/4%V ILCR^TL;'$(:?[FY17M-7?YQK]%\].OO5^
MQ>_R?Z1Y4VWN6ORO_)%?*8M>\?(9?S/PAC%M=VZ$LY^H"K 5!U4.-CHHQE%:
M@%8-(/6X..4@<C[\I\V=8R(_,B&- _HYF<.TT;.14^QT9V^5;4P;AIX\9/IM
MG&E=:7+27F;L\W:3T)ZTV'5VJYR,"DFF\@')H,7ZGZI27ZG>K\6[X_0A2^6)
MK*Q+]BU\X0>1%SIRQ\5]B *&("880_D_&@181+YGM $;4]C94>DF^^TZ7;#4
M!G3T!6N%P74&-BK73W65KLMIEF"C-MCJW=;5U R-F>2+,30OO?%W,#:Q;S^!
MKHFJ2;U;%T@=-*K#+5<CPFW;Y#6&J&]C*QL1]*-&MC'['+9.O>=/LI^F#O0B
M)AB%)!(P\#"#*,$)Q#YR88"8") K7(RTW-P.-3ZW=: K&^#?U26VH7O,#G1Z
M!#L4D)$)L2N6/7H[I*PE.MII>E+Z.*34_G0_^,RPZ7E3Y)1S5GZ4@MSRIR;L
MY%I\SG%6WN4W\@-0@8N-C;FN8[>(F.]Y",DY''$7(C^*(:8>AV'@Q5$<"<^)
MC)+?&DLPMXF^5@"HP02_( _(GSRF9:DJ57[)*PXX+I8O0%(P?VSJ)A=\J?SS
MU&&OQ,N=\O6T:\Z7OZ?Y4J*5%PV//.&BRG0=9H>/L1[9C#IR(S/2[J!MI%<C
M4<NOH%]KH%?'T9B^!L-GB>/,^Y^4" ?#L\^6PQLZ\V3>OP>K-UV_93DI>5&[
M#M;' V4^R*A\JY[O5WA)5XT%X5;RP,>\4%YQ"\3<(/8Q@1%7$=DBBB")0P:#
M1) PX5@@SR@B>W2)YT;9W0HU!T_F>?=D7NM] ;J:-V<YL*O[!>AH#_Y0^H,6
M@*%']=$^(</S^AP^C,D.[6_^30P_Z(\]3K9/^Z/)^S9'_K'A/WKN'[WCLQUY
M53[GQN4OP9%'$@*9'Q&(4$0ACAF!+DUHA 01L:=5#:>GC[DM-UW_527C8(_>
M#8AZ]'TF-",3[CXJUAWW>M2W[]J[Z>&MG'OW5>QQ[WWUZ.!@N?R1;\IJJ%"\
M.J6%^D!Q0H2@ 84^30)5%9S )$$">F&<N!@G.'"9R2SOZ6MNL[T1%6QD!6MA
MC8/CCJ*K-_TM838R#1R%RSH?:.!A+^[M:$]3A[N=4OE E-O)5X;Q12?73=G<
M0.#M3SKTM$ZMZL2((M_%,/1"!)&/&8S#V($4LS#F"7-1;!0<8-C_W'CE:FL)
M?.8[":O4C6+WW]?5 R] ]8 SL/.2&0&9#I<>*8TX"",3U?GXCQ"\-!!.2SQG
MVONDW#<0FGT^'-K," G4[_CCD_R4BI>F@MGMYD*A/@,N(AK')$H<B)TPAHAA
M#V(D^=)U(M^C?H #)[*65[U?EKEQYU8\@&OW.67H/Y+*VF*2\!,#UL^8$P_#
MR.QY.DT[V.@"VL*)G5&KU9EN9"QF=;<W0K-)]@ZJS4CQ9J0Z=YO/2JVILL'K
M@7M6DO@37<PG=[P>%D8IY36;''8<^,S+DO,CWOZ_XDHEQWNI79"VI7$8"@/J
M> E$KAM"Y" ?DB2A, B)XS$18.P;.:8.D&%N2]M7^L#9JG$B:"56UQ;J(KN.
M'>K>98B\ 'MA,(:A@D,&3>]@,/)0C+R\-=)?[*.[$V14Y8!P<(-3=K$>J9?6
MZ1-8K8-D 5)+!X0A$DQZ2#@#HOV#PCE-#:QAB<L'>211?RB"EBNO.J3<Y,N4
MOFRG'_)BQJE+(7$8A2AAB?+C9]#G'DY\ZC@Q28QJ5NKT.C>65-+6Y_3Z+QVY
M#:M0:B&N1WC6<1S;_G$,P@O0" W^:/\<A<R,X+)52U*KSVEK1YK \*I6I-'+
M TM0R$:O1>U(U:1DE/^H2R!\*LL59Y^RCLUDX?MNB(,DA+'+Y:8.$0*30+C0
M%:[OAQA3&ACMYTPZGQM%-8*",E^>4SC"!'T]GAH+TY'IZFOK6%L+?M'F5ZU_
MT.#<2*^R+NKDVC(OWC  -5M5&4RZGK;<P@!07M51&-+&,"KK!&\U'C-I^>?'
M@O/U\?@65[R]_(A8$H=REP6Q<%4"YU 2F>OX, D]+@(:.!AA$R+3[WIN-*8D
MA4**NC47R0VQX=V3 ?)Z)#8.GB-3V*O@P0N@Y%:YKOC6;*I$'R'=C3EBENC+
MH.-)R<L<D'WJ&M""&7&51:7<W=F*UG=57WGQG%)>MHD@ T=X#I:D%#!$(')9
MI&Z*0BB8%^.8!8%D*1V.ZNUE;G34"EH?7%I)]:BH'\M^UK&&T,@$<P <BW?4
M6BCTD89LH$,8\E];LNAO>Q)>T%)O30%Z#P\\<;46X&MQF54I2Y<KY6RP+2_S
MX3M=KAAG*@!&)>Q=56U.B@^XR-+LOKSA1;V%VEHP!.74]QP*D>/&$%&5?(NR
M&,H]#F$1]^27%1J=RZR+.#>>Z9KA;_)*4GR*E\L7\+[5M5M7*<O5>MYHK X@
MW1 !^7K]BOS-%ZZ<X<H2/,F#2ZV]X5G0_G>A>6)\T]$>^US9&>BN>MT!7BO8
M1!=V5*RSG+=*JK*!S;".>@DPWF#8.J[:%W#:0^UH +\Z^H[7DWDJM=K)338H
MVEVM0;:T Z_.C<X;%SXE8UX\8OD=K./ S).>'0*JGT<M8#0R"0Z'QR@]60\(
M@S*0'6IOLB1C/<IT\XCU/68^2^\*=ED4G5*#]_>7SSA=&LS6GB;F-FNE:$5=
M^@C4$NI7)#H%U>GY:@FED>?M78%9G6QLZ\)ZL5/Q\S6 5B>T!DJ#)G9?NY--
M< WENA-=Y_%A!\);7G+YDKKJ>\^?^3)_4@/]H<E!M VNB)R .Y#$E,ACGJ?"
M,&,')C1P" \IQ8Y1*B:-/N?&%FN1:_,'VPIM=LK2 5OOV&09PI&I9 >]CKR@
M%7@$D[0!0);.)CH]3GK8,(!@__1@\NHPWOG"*^5:<%/DSZD\AKQ[^:U4%W*?
MLF=>*I>H2RK/*PW7D;(J,*T6"1$19B2!PG60LC;Y,$Z( T44<8\DONL'U(2&
MS$68&RO5WC5BF7]K<Q.E:]$!WLC^=S.*&C N>HPU+MHC$Y@RK]5@K\4'Y 7\
MJ#20F/\$-DJ K1;@C[4>%EEM.(B62&Z  )-RWG" ]BGPC);,CUZ?LE)V4LAM
M7NU@)1M5F:B^Y-4ERY\JSK965<V#F':#<Z.T5G"P/GVLQ:^W#G5Z+K92+CE2
M%=#JHG]LTX?Y]"%N%(1'IK$!X((_K%J:!R$WZ)BGW\MDASYCQ;M'0/.7!T25
M=ARFKO*FPR;-3UVT5B4*ZGA,_5+D9;EP P\3UQ50.8ZK<IL>Q$*>%1T<QC'U
M/1$)K>P= _N?&W^M70G+QI60=K5HBU\W^<&JK2(7X%ZI8A"R.&"<^AEM O3'
MOFO;]>'<40#<=H"_ZP+_R_C &\2'CCL $\6$CC$09I&@PV'LC?X<T.QT$9_#
M==Z)\CRCF8&)7LZ[G6P,SHO0CVB /0>Z(74@\B(.22@83+P0N2*( H\993FU
M(M7<EJ:NJ\G&$Z'<=35).ZXF=-?59/.**BJW7/N:U)$'PV,0[ R_G@5B\D$=
M><6SY%%B[QIV%*!MI9^Q(M.T26ELPO@J58W5Q@=ROTH;NLE325U"7)8@*!@6
M$ E&(:8.AFY$4<B8@WP6&W%XM_6Y<7$MW( $G[N0:?+>4"#&YJ\-!M;3]QU4
MV1:3[+0]+2,<4NO5S#[XD-D,93Q=O&^/"_][A0LY)98OMUS5CUUX'HE([%'H
M$8+5/ UA3%V522I"0G@T$8&C,T][^IC;;%V+"39R@D90O<G;AV;_%+:$T<@3
MV1P>[0FM 4"/=5"^W<QH^9?M1.YK<Y+IK*'4>E+K/#K4\>.99RO>K/2=Q(,=
M=Y]F-R"7_9UGL_JRX_>T>KA:E57^R(L%Y22*241A2'VJLF\&,':""-+0<TF"
M@L2C1B$ %F6;&Y5T]*D-@K7PRC"8WV?IOW0O,\881+W-Q!L-S<@,UDJZ/C$=
M2=YY 3:J@;TW&NW -ZD>6.MGTYG%.NC6G%[L23:Q<XQU2%\[T=CO8FCV]29H
MM'7@63C4HSP)*4P8\R'R*(:$^P12C_N(HBC D;O(:N=.IL?8>SUH3>VDF=K=
M?L:\^FQ#H >55]P'4(\KAX RU45PB\:'$V@,2)Q^4&=KR=)W6Y\X0?I!U5XG
M13_\V)D5PCH!X>7FA_\KY87RTWMI0XT%]UB0,&7])@@B[C(HCV,"QJZ+7>0P
M$6*C@HM&O<]MJ]4IK;R1M/9T^'+YCX$UMK0&08\<1H-V9.KH0W6$I.6#8+)=
M>DJK[[<I(V4"R]&24$:-#..Q7V03I8I0YN5U]N&[\J!;I>5#4U_Q/2?5@H9N
M'"5,P# @JM@3(Y+%N ]%[$4>#_T(>?YZ4W*G3V$G.QZP5[F;@+WJ:&[M,K%F
M?'9Z,/0XS ZVT_"6DA7\J(3]23D?[$I;A])+>>WQEC8TEKCJ='^3\I.V^ON<
MI/_B0![BF:2UY67&+MECFJ7*=5<=RG:#< +!&2))J!*?R@,2813&.&20)2[R
M./6\(#0J2:75Z]SV3ZW0]>*.=\0V9!LMR#49QS:08[-.!\-=B4>,?3("R1;_
M:/4Y+0>9P/"*AXQ>'A)L7;M@7Q9%?9.K'5_=?6MNA'$@8E@S^N@ (OU\<!X8
M(T_Z SA8N^$^KOC 8.B=IB:,?SZDPF[(\\$GAEYV+=6^_087U4NW#M/[M*3+
M7)U]MJ$?@<^CQ(TP1#20YQ 6($AB),\A 8TB#PD>N4;I.0WZGMN$;D6'M>Q=
M?UW#5.@F\.M>0XT"ZNC73+74X#6>8"NXY8B;,Q"S=D>DW_/$=T#&D+R^XS%O
M8AB%_5;R:_&AK-)'V6&Y\+"'7$X#R)V80LE* B9Q$,*(>U[D!;Y/N987SN'F
MYT9$4KK:>74MGQG][$&GQS## 1F91/:QF*:DPF$X+#'$7N.3DL!AQ?;G^9&G
MS/?]-SR_I-5*.>&KZC[*R=8@O]+AM^<V6V\^7(.UF'4-H]H)71Z;&J<7TZ1H
M1R [?4 X'ZV1I_)Y0!F=&?JQ&'1V.-+D9&>(?I6Z9XD33PX(E-VK=G?UH YZ
MG[)7M2$CW_&9\&%$0KE*LS"&&+L!I!AYB&,11T(K98E!GW,C@T9,%4^T7_C1
M3EU5S9'H9XN1\!W;SK!7!/4"M&!_RLZIAZK[;>O'M=I'=J)85BL(FP6OFF'5
M&["JV=1T0:IFNNT$IAJ^:A[N\"&K9+L?TR5O2L4LPC!VB,,C2!+J0^0(R=UQ
M2* O(N5BXW-'+Z;T4.-S(^E&/J $;*L?Z4<VO *NGVK/A6-D3C5 PBB(X9C*
M@Z(77C4V6=C",36Z\0I'GWGKD@4J1>D")Y%#D1="Y,;R/P%+8,(="HDO$HR9
M%T;$*)FE7?'F1@R;#/;7&AGL/^['&U_W9+ _;IN8XBO0LP&]W=B.S'+C%2:8
M936"+OJSJT10"_<7K4+0!7:\"@0[O0Q;1(Z46KY:%84\12R(2W"$70&=0*@
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MO^_P=U[>J1W (G00XX[GP,1/$HA\RE2T*(=.Z',4AQYVB5:N_H.MSXUG&OE
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MK8Y(].,";C-_R;+=XQNVI7"IJF)>_9$!8I$X-Y54)S-5UGSZ!Y#,3.9& DB
M8L?KI4J62>"<'XB#@[/>K9]DC=#GYZ*)]V^#P;(D]], IY QCT$D+H4PC5@*
M29#'-/"XO";JW!#/3S,UN593"3IDZEWP+F"I=G&['B''$NX$' >A=?T@6+I8
M79ADU M3/Z/'%Z&!I_5V?K5:SW_(:_3-SZ*:QRGG-/0(3-)8;/0XB6'&0@HS
MY*4TRKE'<Z5:WP>C3FU?RZI;1;466N "?&-8WBC5NTL=XM6_F8U1<&U,.0\
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MFD>IJS7+VFW$\8Z+JJ%GO^/BCJ1TMXOL:N_^W9(F[F@A>M5RVW..IZ,[0NM
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MH)_GU ^PGR54JV6BWO13DPPM]?4N>%P6TAJG:VS00E_5\. *4^=&B 9.N5'
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MARJ5MG>]G!H7GG=;UI$N2(+ S0*O "TJLBBE/T3NVOUU75:O8@?U)=Y.-_!
MI0E;MRPG:]%[*[,[XWBW."=('=SZW,SP/FETOXMOG5%!O51ZB6R'5LI???HI
MKK%%)2G]@\F&XN*95[82M]KV;]C]2F@X<Y_R.$JB!(9>S"!B*8=9FD20A30/
M24C]/-"Z5+XO.U-3)EJFP&O-52UV6,M7G;4N*Q=?6_'SG3\@M<OHO\YG,>+=
M]=IDP-_W7]6GSE?U>]TUKP/-#&S! 2TZV[]EH,9G.KF#=M9Y(CF&5S+S+Y6+
M:&?A;.<L6J+*5B. ^Q5[P07]R#A;K1AMS52"O+OU$UO)B^*ZFGN1G_,X8!#[
M/(4H]@*8>8$O8W#"C$<,>Y1M^Z^JG<EFA"@)S<-.K(Y/TY;J^@@5Y%:UY"LE
MQ0#7)%];]E]I?=0./(>8OVLK@.T:M.372U S &[ZE\!"+P =!)UU!5 BXIW[
M ^@ -=PI0&LT_0@GLX3-:6=I6L_,U$['G&P.YJAYEQ:3+=\KPW(XK=)J+N7.
MTM$),/Z\8O_<L"5Y:T/:P\@C/F8I]$+D0<1RH:%$60C## 4XC&,O##,=FX'"
MG%/;X-U0^!VI>NJ'"M)JNH9E_!P+@+/0.4@BT$#%DK*@,N.HFH$&!,=J@,ZK
M5_<):EWT3>FJ'ZQBJU=&/Y>KSYNUF/I+56VPX'>>,H^1C'$8D(! E'@Q3#%-
M8!P'7A@E:1[IY7-K4S U*=3M(30#I.&A,2)68-5R 7BY KSF Q0M([71L7G.
MO+^0XJJIR3"G:^%8HAWV'FK);PNQ@1_=96A8 %L>G'0BTH//?E\BQ?G?JTN1
M'CP]/8LT!S*X&"T6GWXRLI'%<FZ%POQ8K@I6M46;5*])/6-,39H)6L&.6+"G
M5N.6U(>8PIW)$EBN;U 7<+)8WTH5#;.;5-_ X]VK%-@[N&6I/&_<8WJ]PF0M
M_<_;:N.[0ABRX6G3RF&><G&U2C,&(Z'Q0!2P#.9AG$/BD8AY682YIZG_*,T[
M-3FQ);N;K3D#2[:6P1\MS>"E7$EK@G8[:J6%4%5IK,/K7)%ID:V#9+8T=PKB
MS,">;JL=JW6 LM>]6FG6L3M9ZT!QIJNUUNL&<:F[B^$=;TR_-TO:275MKXOT
M;OE#AM>LBN6C+#9=U3$S<R^/>1;&&/IUN^N <(A1EL((H]2/D?@E4@]#O8:2
MJ<FT3L#A'6]=*7688H<AL.4(W"W!CJ>Z3'O5!BCJ1"5>M9#]$G#4Y7$L$__5
M5D8C/'2L%1HI&O3S+F93*@*-1[CV3W;T!/"\72EQ85_M5BJO5ZIN3V$KWM,&
MN+WAG5=-,%XTIPT<#H(WK0RH?QL7I^>/S8+Y7A[Y-ZO5#2U?UN*^O\"/JG?Q
MRR-,[302E$))*I"T0O\@-JTE6_U2W@/<\)7<#F:.CP@%N,"?DF9+-_-A4(SN
MY3W#CG8K'V:M>R=7>-KL1OZ#+60\TSU>K=\>Q&)6LO-UN=SVXPM8$E!*8.3)
M1%R>AC"G*(21+_38+ XP0UKW\-[9IB8;6F)!32WHD*O9J$\-:K6;MC4 '0N*
M*[#3OE0K86+I*MT_UZ@7:"6VCZ_-:B\95@' JZ700:I[MJI=!3=Y55_1YUF>
MA0GW&,PYRB#*<@*QYWN08![S,,]IEFM)D4L334V ;.F4V?5M3OZ?6UIU$^LO
M8:LF-FP@YEABF(&EG[D^@(2M%/1+TXR;2S[ [$E2^-#SAHE?F[RJXRG6GU[%
M/[[NRCO$:9"%E$40Y4D(413&$%/"("-AP!'**:=*1K*AB:8F&/9T@IK0*RIN
M7,1633#80,RQ8# #2S^?9P )6YDVEZ89-P=F@-F3[)2AYZ\.C*KM''/D>ZF7
M1AS2//0ABB,&LQA'D/L!"@,_"GRJU/_[T@13$P3=L*;&H&<<H]0 J.JO,X?%
MN6.N&V%44S>KHXAZ##'7Q! =\&\_1*@9_KTB@ Z8ZPGP.7S.;"__@RW9"B]N
MEO2&/A?+0FH.,H*@3:*8BR,^XHSX,& ,093@!.+(2R'UD\#W\X2F::RSM0?F
MF]I.;\FMK?3X@&"]'3\$LYH L B>8WG0Q>V0UFUBECVQH(B*)2DQ--NH0D.1
M]6,9HOK:-:UM/K)7MBA?ZH37)?W!'C<+N8YOQQTCJA^,L.*U=@U&0>R'4<!A
MQKFX7= \%Q>+-((IS5B$0Q*&5*FU\M643$T,[5N8T#TS]>9:[=@Y[6ZB&)AX
M_;KU2Z]15\.Q7-LO1(>/VMN^Y^2T.X\,LMXR,]::F#3S<;PVH_?[T=HLTMO>
M,F6]+= 5P*IU#C*9X!V:"UV!P_G^0]<,:-C+<?6(E\7_U-_P;;FLRD5!FZ(/
M2]HV-FQ++WXNEGA)!)&_BM\T;9%W]E_D90@AFD).60Z1QQG$,48PX$&"XSCC
MB/M:G1]M4#6U4Z_+U P<L%5OYRYC,J)FQQK8\V9LNK>SSFIZ_>BKY_B4'&OA
M]+M<V@3:5D],*S2-VT'3)HPG_3:M#FZ0U23+\U2WB[)B#^6WY4OQL:C(48E+
MU>2FX:&F)G,;DD%-LRRG\E \,UFSZ]OW^R_@XZZ,935KZHYJI#XIP-HO+1T@
MZE@.JH*I4[U5+T5*'2ZS3"F%\<=+F%)G]B!O2N,U,Y6QB0*];7-S,&.AYS,&
M\R2+(?)E^^\T3&&4!('GDRP+$D^G9]W!Z%KB9+2N==N<)Y,B6(?@J>E3QI"X
ME@<U74(CLIV@=)9A2_K)X=BCZAEGV3K6%\X_9+93A7[1U)"J_2MM7FZ,/)KC
M/()>0L1=#>,08N+GD(L_XI31--.[JYV;9&IJP([&QJ6GMV7/HJBV<Z_%QK7Y
M[Q 6BPG-*@!8VM!GIQAU7_<Q>;R]>Y\UJEGP94F+UX)N\$*_5L')NU/;N#+W
MOD.D5FF"4V 4%/(K,7%]XA["8;\"P47F32L/G XX9L6!B^P<51JX_)R!S_!7
M<9^O>!/2?,>/3;?MIYCY"8H\3B#Q<A^B(.4P#S&":4AP@L.<I2A0]@VJS#BU
MG=VE61K-3KQ,&IXE)<05O'JV<70L#0X@O#L#X;!\,,12PQMG&].1O&['G^>)
M@\V64TT'GU[GF=) XSG)=/@Z<(9IO6@@GF_+A?BY;$)$.JF#W\LUV[O5I-5$
MUD6]QP6=!U&",A90*.Y.1 9R$)@F80!Q%&.21WF:8?7&O/KS3TUT;VF3.=U+
M077'U:PA: S604&$NT77L4 _(/ZPQ:*DOQ-V,0.[19 \N(5=0]J[A7\DV6]_
M&?2.!',0>P\(@V''.R[,>3XX/*X8QJB=.RF?V0/^R3K=8GF \C0A&4Q3H=0C
MS$.8I3&&,:-)6)?=P:E&%_?3&:9V'#0T@II(@QRBRT@JB/MK\7$LT)U!H]6%
M_3J(1FN^7D.UEG3:Z[1^F?6!!NMG7ARSK_IENH_:J?<\:!@0)IM,?"^7Y0N3
M4G3YV,RQC>P/X@@'2<PA21)9$YH)Z4:$/IQ1['M"N%&>:F51]T\W-5'7=%XI
MFD_UE[8OCF9%YP& U1P+]F!S+ $;Q+J4@G:G__)I"#[]>"@E5&P%.O5/-FX$
MDQ+C)Z%):F_IR1'*BOFGY;I8OWT65_=56[KU;>[1(,#4\Z$?)#Y$F="-L"]T
M(Y[3("*^1X(\5Q$<%\:?FJ1H2 0UC=N:P8H-*RXAV"\9+.#B6!3H0:*\^0<8
M[W%<B#>;C2Y^V._O2^.-LJ$'F-GNX*''C,JMW;/R.RMO7A_K*!?-_E"7WI_:
MOI2UP^X_W8'OXO_;YIQ-5,]5_:(NPM>_:6TAYWCGV@%-M^9:+RJF%=?.#SIF
MO;5>MHZJK?4_:U@'91M=W-0OY:$X?HFLII;F 41^2L6YC!E,8IJD'O$RDBB=
MR^>'G]KVWU&G5R;V G9JNKHY(HZWM3H8^G5,SO)LJWK)X>#CUBPYR]A)I9+S
M3^EKTFT<X.>B(GCQ7PRO/BWI1S'V/&!A0@,O@MA#]3T<22LC@5Y$XBB/8Q)A
MHJI.7YID:INWI1,TA ))*1"D DFKNFI]$=)A_=H&4*Y=2"88:>G:0R 8*=P7
M!QU-ZQYBJZMZ#SYK$C4DXP&;$C,?-[**\CU;%25MVAW=B\_C"5?LYG'%:KDR
M1YQF88P"&.8I$M=IWX,I#A)($>>$AFF*<G4O@][<4Q,+V]9/,DSC=H&K"MP
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MI*F>)72UIW(AWJ@^_7,C8U_C)"8^SH0NE7@<HHCG4"RE!^,TH)'X'<U9K!.
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MM]Z(P92F"(89"B.?!)RC1*]+G];\4SM%MN2#7[8,_$U&^G1Y^-^@O2'_*?D
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MU_P2\];\Y"<3C.P9O\3@J2_\XI,&D8W?<"4V3%M;X>9QQ5@G4(RAC$1>$L*
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ME[_27EO%->&H>/+< ;<J;,H%G0ZA[JV9I<R]O.G['HR@!PGJP5EN J%V8N\
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MR3!*ZMA*;4:3?0K?]TO<7/WS=L=V]Y#4[-CN[/EW)/V4*5)J'VC'\8SV'E6
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M4"(F8Y$033W6-;)P;XP*OG5Y^KW$C&M'FN#@5NJWB>"[MA_;W)0=_NKO2%>
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M7J53M10ZU*&.AEQ,8TA8FM@JQ:+7K4\EMB)LW%[*0Z&KN4HZP-GE):2;C-C
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MH4#ID$A@.@)CA>FHC4\W\_<MH7F-EG&+OWN$X?ZJ&COY<86)>L5W2KK;M.S
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M8FNS]P17QN@\!A 3@SCA'&D>$TK8\2BP5206[\NWCYC*-Z E5'T</@/DWAZ
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M'R[-%B"P02X1Q'MF+" _/WRC6B.M@D8X,,\D#9B*7L\Q^H"@II-RAK*VU3U
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M#V$O*,=?3/B- VD5/>M@.*$I(LJB!>]51.0$X\B&("E7-LA0VHX=HZD?H%Y
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M;X8E,1Q#SA)$;9X3EL/;_/(.::\I,<1X:6/AC7!>![IQ/+NB^N[=:.X4X3>
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MB8S&64S.XN153+1TBF47'97?YQ73\O:3@'-%W@!LUIMN1]7.I161R9P"\E$
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M7B-*J]OR:+R@[+#,_]T$Z=]-D,XI(ECO?_C+1S;-D"*"QVO7#99[[:*#0FE
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M1:I*L5;C[N#5=QMXU%L,Z]OW_G"FHO/>*4_#M<CEE(2AJ:(9&,CERHK?&VD
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M8PO_R10-+2WI[TF\MG(730 ZJ-).D X6NL$V)2"#6?*#:=/.U@N]9RX+]O#
M]1;9/S,@EPZ00)X2@25_J=Z"KA.2IZJFNI@29]!*WK;O!DS+HE36A9X3:F>Y
M#KPI'T :$/Q3Y$7O*][/MC#X3HO^#M/HZ52\QZ#*F,R+P^AE?W+>\2_S=W]-
MZ_R1LZV-L</(=#&(0M:6QHLO$Z2KNI#SL:I\*+[1I/45:^=T.>97^%-.>U!0
M[13YV0K5J[?[O7YXP^\,_J>+GMOJGJ\Z<>EFW<M^;Q2=/EG=[T5/UGW*[:!W
M?OYT[==Z'0Y[@_/=@CWQ$Q$F _-M:UF]/A@>+!JT^VO<%Y[4E_X^83JH[\4C
MSN+=N;$ZNO[VX(U&&/B/\X=*X!D,Z<7A"(SC/Q_]!.'!*/_\Q=[!M-W5O.=A
M*_QEJ. IF7SA](:M_.UGV!/&OLWJ7VKN#/0<"Q4OE2YS19FXNJ>DX?L:\7,X
MH6Q.Z8GG^2U99/UG6[6V_N7F.-S(3VGCAUPK'/I$T5\UD3' V+C-)I_Y[5?[
M&7Z&=N)__O9?4$L#!!0    ( ,V#:5<\H!FP=@<  -HG   8    =G1V="TR
M,#(S,#DS,'AE>'@S,3(N:'1M[5K=;ALW$[WO4[ VOM0!)%FKGR26' .IXP"^
M2='$0"\+[G)6R\]<<DMR):M/WQER]6?)B9RVB>HV0&0M.1S.< [/#+DZ+WRI
M+LX+X.+BN_/OVVWVUF1U"=JSS +W(%CMI)ZP7P2X6]9N-U*7III;.2D\ZW5[
M??:+L;=RRF._EU[!Q4+/^6E\/C\-DYRG1LPOSH6<,BE>'\D>[W:S5SW1[^?9
MX$6OF_*LG^<I3[+\5:_7SW]-CG HBL<QSL\5O#XJI6X70/./!L/*CV=2^&*4
M=+O_.PIR%^>YT1XGLS@X?HTZMC5Q.T%EWE2C%ZC(PYUO<R4G>A3<.XJ:%M*9
M4<:.CKOAWYAZVCDOI9J/?KB1)3CV'F;L@RFY_J'EN'9M!U;F4=#)WP%-Q$G"
MXRR:_Q+U**EAX4[2(Q^N[@J92L_Z2:>WZ<!>IF>X[F#_=ML'.VW_>'5Y<_W3
M>];O]MCEU8>;ZW?7EV^H94]'OI'9URWVT<,4-+NILZ+%,K!>YG/F"^Z?'0]?
MC?>-0\6%P!W35I#[T7"P&9G_UXZTQB:I!09JU.Z]_&9>)YV%6U]_]LV52LXZ
M0UJ&:U;P*3 +4PDSI!]?2,=^J[E%1*LYME?&>F8T>V=LR9)N^V=F<C:]F;*;
M BROH/8R<^Q:9QUVX@M@SXZ12+IC"Q/IO.7:AX9D_!RC>O8TH]H[N*C^R!W&
M$J-6SMFM-C,%8@*M&-PFI,*@"=I@XL$9N-2,ZSFKM;<UH >8BD)6PEAS5N*3
ME5RQG&?89)DID2R]B7); AHR<([;.8F4_!88X6*ITV&;0&-P2A52&LY! IFT
MF,)03.-PM$2 9;-"9@5S-7VLQL_ 0J.$'"BE4YCK*&W.I"_005=!%@PDO16:
M9@2Z.<5A@J7S]65XNJ#L_W- "2R7&L-."%J%N86(1''LMFO]4N=(1-Q+U"-U
MIFJ!.A%*:S%M(0PED5>%2" 0$[B56J&T 8B[-S5N!"%)<8LD:H4""$V#^ G3
MN6!/QEW!<F5F;H';%=,Q3HW1;K2RM08_MS!FR]JGB\#!P2'P9B-<E)B2EV/7
M8*RI0(A&3)Y+?#QQST,LKQFW$%"#*)"I HHN X1JJJ0K: 2)E<BBQ*3T+*3+
ME'$UCB-^M49%^%369""PV;$31(L A%^$Q-5=5G ] ?8&J>M#K5 BZ?-V,CR!
M:$4R%/$I/DJJ.76$+>EGQ&]K:([H(EON3?01LMHBSG&"A^?,-^;,<4YR^3[<
M48*JAR^OUUXEAPWA$_[\8# \[)PEM!!OP>%282Q#6OP\T%J4L3->N_V'4.I,
M 4'3S!23L:DM*D ^FTH76!*E0 <]5+6O^'6=HRTH'E#89.,5?%H-?U.G1*Y%
M6YQ14H13L*M3)X7D5I(#,M8,(6MHTE0[RN-AW[J0] .G&@=HD _8;K$*:UB9
MU8I3*D"W@A&K>@!'Q.IBO2C";RF0(+(UC@?QY>Q\\-!.#PG:_<$VM/=FN"V$
M[\^->P,=-\=4"L(O=T9S2@+<(?:I6B50<RL6 $/(2YY*)?V<:H1=T])V"U@,
M,(L[94-TK=H-N>:N<:BJ;84P=Z&FR3)C13 @U+T3T%BJ*$0[]D!%VXA$L*:/
MB,;M)BOD^">,Z>R0,!WI^FK*51TXC0(.>8Z5IYQBJ-R."G)9DNS!T?%Q=U$9
M((P#D5]=+%U34_N'+=@GB_"E-%!=GG_^<,721<4?=B7$E4![ @)I@J>)0G%(
M*&R8-09X&RATZF^*P-"S$XV/X%,J!$R&%2;!82WK[M!:&N>QG6Y/49?+4%%S
M\135%-PM:PHBM0!<$('M@P,-$\^9DK>@FNN&>_*M/^W3GP/KH1_2AD_GD!8N
M,L4"Z*T5^Q 9KH-M141$8X\H,[9JV*5U'.M8;ZQ;9O;0@"K+4GH/\ FJ3PW6
M#M0O)-H7E)P@PI%9'3$W_J5J>K&/X+=:HOEAS]0Z"Q<3S_\[@'W-C/Y&87V&
MBR41?W0,IK-U)@'1TF3EY4%H!OR6TFRLUT*B#95FN$-=W"L]"H/-F27>1^S@
M/RYPH(,E_3V(UZ8^Q2$(.BPC6S'7.TSTKBX1,KA*P9DF3^R\@7OB>?P 3TAO
M,%WG%LFEA4B 0(F(I7 +WH"N%9.GU%.CID 95/-)<YEO&Q:%LE)F#M@[*TSD
M3;X!:83@7U(/= [[)>1;7+/ G>P]>E"F8)\=)R^ZX[-6>,^^O_$^' B;WA2W
M$]@V.J%XY6"T^#+&W%0I/A])'4P)@\:-KM1X;\H1O5V?4H[#:JC9%F$[Q.[5
MB_=.-[Y\]Q;_B\7,37<G=)UZL=WWHML9),,'N[N=Y,&^3ZGM=<[.'N[]4JW]
M?J=WMI^QIV$AXF+@>KN*Z]='_:/%@&8SC;HL,/A2WR=$>]4=NT=0M!6WHF.J
MKP_>9("._SC?3/M/P*5GQP.DE_"Y_NN #1?_A9&.I+1'H!OF(5Y"AUBX3F5D
MW_B1OD:Z^4;N_A?YQT?^GQ3?RT)"SMXMJX6?XD%N.]:G(4/NR+_KOT6KC LO
M;4?Q3<,4MGZ=MMH=(<5V5T-XBEND]MM#/O.#MN8S_K;N-/RF[P]02P,$%
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M.3,P+FAT;5!+ 0(4 Q0    ( ,V#:5==NX*V(1(  #V\   1
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M '9T=G0M,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( ,V#:5?(NU1/A(P
M -)I!@ 5              "  6 B! !V='9T+3(P,C,P.3,P7W!R92YX;6Q0
M2P$"% ,4    " #-@VE7>YM\%Z8'   %)P  &               @ $7KP0
M=G1V="TR,#(S,#DS,'AE>'@S,3$N:'1M4$L! A0#%     @ S8-I5SR@&;!V
M!P  VB<  !@              ( !\[8$ '9T=G0M,C R,S Y,S!X97AX,S$R
M+FAT;5!+ 0(4 Q0    ( ,V#:5> D"N9E@0  +T2   8              "
M 9^^! !V='9T+3(P,C,P.3,P>&5X>#,R,2YH=&U02P$"% ,4    " #-@VE7
MY3(,,7@$  "<$@  &               @ %KPP0 =G1V="TR,#(S,#DS,'AE
?>'@S,C(N:'1M4$L%!@     +  L Y (  !G(!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
